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Abstract
Threonine synthase (TS, EC 4.2.99.2), catalyses a ^-replacement reaction to convert (2S')-0- 
phosphohomoserine (32) into (2S,3/?)-threonine (33). Although threonine as an essential amino 
acid is vital to all lifeforms, the enzyme is not expressed in mammals. This makes it an ideal 
target enzyme for herbicides, fungicides and bactericides, and several inhibitors of the enzyme 
have been produced with this in mind. In particular, the enzyme from Escherichia coli has 
previously been the subject of inhibition studies, and the reaction mechanism of this particular TS 
has also been partially elucidated. However, no product inhibition studies have been carried out 
on TS from E. coli. In order to carry out such studies, a [U-14C]-labelled version of the substrate 
(32b) was synthesised in this work, starting from [U-14C]-(25)-aspartate (28b), via a route 
previously developed for producing the unlabelled substrate. Various analogues of the substrate 
have been synthesised and these were also to be tested with the enzyme, either as potential 
inhibitors, or to elucidate further the reaction mechanism and active-site structure of TS.
The mutant E. coli strain K-12 TirS, which had been used previously as a source of TS, appeared 
to have reverted to wild-type, no longer over-expressing the enzymes of the thr operon. 
Therefore, the thrC gene from E. coli, coding for TS, was cloned into a pET-expression system. 
In a host cell containing such a construct TS could amount to 50% of total cell protein. ThrC was 
amplified via PCR and inserted into a cloning vector, pGEM-T, and then subcloned into pET-3a, 
pET-3b and pET-16b, pET-16b constructs produce a His-tagged version of the recombinant 
protein. Sequencing of the recombinant gene in two pGEM-T constructs revealed one deletion 
and two mutations in the thrC sequence, which probably occurred during the PCR-amplification 
of the gene. These alterations were confirmed in sequences obtained for the pET-constmcts.
V,V-diisopropyldichlorophosphamidite (78), a precursor to a reagent used originally for the 
phosphorylation of oc-isopropyl-Al-trifluoroacetyl-(2iS')~homoserine (75), proved difficult to 
synthesise. Instead, dipentafluorophenyl phosphorochloridate (81) was used for the 
phosphorylation reaction, as it was easier to synthesise and gave a good yield of the phosphate 
ester. Deprotection of dipentafluorophenyl phosphates has, however, only been achieved 
previously on the solid-phase. The solid-phase synthesis of the substrate was therefore attempted 
using Wang, p-hydroxymethyl polystyrene and Merrifield resins. A new linker was attached to 
Merrifield, to produce the novel resin, polystyrene-4-oxymethyl-2-phenylethanol (97). Although 
selective opening of the V-trifhioroacetyl-(2S)-aspairtic anhydride (73) was successfully 
accomplished to attach the a-carboxyl group to these resins, subsequent reduction of the (P-acid 
has not been achieved. a-p-Eenzyloxybenzylpolystyrene-V-trifluoroacetyl-^S^aspartate (87) 
proved unstable towards reducing agents and bases. It is hoped that compounds attached to 97 
will prove more stable towards reducing agents.
ii
List of Figures
Figure 1.1: Dermatitis caused by pellagra.
Figure 1.2: Sequence homology between various eukaryotic and prokaryotic AspATs.close to
the active-site lysine residue.
Figure 1.3: A summary of the reactions carried out by enzymes of the (-family of PLP- 
dependent enzymes.
Figure 1.4: Sequence homology of (-family enzymes around the lysine motif and the glycine- 
rich turn.
Figure 1.5: Complex between cobalt (III) and PLP-glycine Schiffs base.
Figure 1.6: Active-site structures of the (-subunit of wild-type and (K87T TrS.
Figure 1.7: Casal's necklace - a common symptom of pellagra.
Figure 1.8: Route for the biosynthesis of threonine from aspartic acid postulated in the 1950s. 
Figure 1.9: Sequence homology of amino acid residues around the active-site (underlined) of 
threonine synthase from various microorganisms.
Figure 1.10: Genetic map of the threonine operon of E. coli K-12.
Figure 1.11: Regulatory region of the thr operon.
Figure 1.12: Model for a typical repression mechanism of gene regulation.
Figure 1.13: The thr regulatory region from -71 to -27, which forms the termination structure. 
Figure 1.14: Internal phosphate complex formed prior to elimination of phosphoric acid.
Figure 1.15: Inhibitors of PLP-enzymes.
Figure 1.16: Amino acid inhibitors of threonine synthase.
Figure 1.17: General structure of pET-vectors used in cloning experiments
Figure 2.1: Graphic map of the restriction sites on thrC used during cloning experiments.
Figure 2.2: DNA sequences of the primers used in the first PCR reaction.
Figure 2.3: 1% agarose gel electrophoresis of amplified thrC,
Figure 2.4: Primers complementary to the centre of thrC.
Figure 2.5: Results of overlap PCR experiments on thrC.
Figure 2.6: Ndel digest of pGEM-TTSa and pGEM-TTSg ,
Figure 2.7: SP6 and T7 primer sequences.
Figure 2.8: Orientation of thrC in pGEM-TTSg.
Figure 2.9: Left: primers used for the third PCR experiment to amplify thrC. Right: result of 
PCR using primers TS5 and TS6.
Figure 2.10: Results of ligations of thirC into pGEM-T.
Figure 2.11: Sequences obtained for pGEM-TTSj and pGEM-TTSn.
Figure 2.12: Vector maps of pTN-TS constructs.
Figure 2.13: Gels of restriction digests of pTN-TS constructs.
4
9
12
13
18
20
29
37
41
45
46
46
47
51
57
58
68
80
80
81
83
84
85
86
87
89
91
93
95
96
iii
Figure 2,14: Restriction analyses of pTN-TS constructs derived from pET-16b. 97
Figure 2.15: DNA sequence of the two termini of the f^-imet^lrylaspartase gene and the primers 98
used in the PCR reaction.
Figure 2.16: Graphic map of the restriction sites on the gene for P-methylaspartase used during 99
cloning work.
Figure 2,17: Result of the first PCR experiment to amplify the gene for (-methylaspartase. 99
Figure 2.18: Primers complementary to the centre of the gene for p-methylaspartase. 100
Figure 2.19: Results of overlap PCR experiments. 100
Figure 2.20: Ndel restriction digest of pGEM-TMAj ( 1) and pGEM-TMAn (2). 101
Figure 2.21: Left: primers used in the third set of PCR reactions for ^--m^tll^^dl^^.sJ^artase, right: 102
the result of PCR using these primers.
Figure 2.22: Ndel restriction digest of several putative pGEM-TMA constructs. 102
Figure 2.23: Restriction digests on maxiprep DNA produced from samples shown in Fig. 2.22. 103
Figure 2.24: Alternative phosphorylating agents tried in the synthesis of (ZSS-O- 106
phosphohomoserine.
Figure 2.25: NMR spectra of A-trifhioroacetyl-(25')-6)-phosphohomoserine diphenyl ester (83). 109
Figure 2.26: Examples of NMR spectra comparing ratios of a- vs ^-substitution of 86 on 119
Wang.
Figure 2.27: I3C gel-phase NMR spectra of top: Wang resin, bottom: 87, both in DMSO. 120
Figure 2.28: Hindered reducing agents. 130
Figure 2.29: ‘H-NMR spectrum of material cleaved from Wang resin after an attempted 131
reduction of 87 using LiBH4
Figure 2.30: 13C gel-phase NMR spectra of top: Menifield resin, middle: 97 and bottom: 99 138
Figure 2.31: 19F NMR spectra referred to in Table 2.14 139
iv
List of Schemes
Scheme 1.1: Some types of reaction catalysed by PLP-dependent enzymes.
Scheme 1.2: The metabolism of vitamin Eg.
Scheme 1.3: Snell's "Shuttle Mechanism" for enzymic transamination.
Scheme 1.4: Conversion of bound cofactor to pyridoxamine phosphate - a process common to 
many PLP-enzymes.
Scheme 1.5: Condensation between e-lysine residue and PLP at the enzyme active-site followed 
by transaldimination.
Scheme 1.6: Preferential cleavage of the bond orthogonal to the plane of the pyridinium ring as 
predicted by the Dunathan hypothesis.
Scheme 1.7: Formation of the a-aminoacrylate intermediate.
Scheme 1.8: The aspartate pathway.
Scheme 1.9: The reaction catalysed by threonine synthase.
Scheme 1.10: (2S)-0-phosphohomoserine deaminase reaction.
Scheme 1.11: Alternative metabolic pathways for phosphohomoserine.
Scheme 1.12: Transaldimination reaction involving (2S)-0-phosphohomoserine (32)
Scheme 1.13: Labilisation of H“ by an enzyme-bound base.
Scheme 1.14: p,y-elimination of phosphoric acid.
Scheme 1.15: Labilisation of the 3-pro-S hydrogen atom.
Scheme 1.16: Comparison of proposed mechanisms for the elimination of phosphate.
Scheme 1.17: Resaturation of vinylglycine intermediate and release of threonine.
Scheme 1.18: Protocol for the purification of His-tagged TS
Scheme 2.1: Route A: Fickel and Gilvarg's synthesis of (25)-(?-phosphohomoserine, Route E: 
Schnyder and Rottenberg's method.
Scheme 2.2: The biomimetic synthesis of (25')-C--p^hosphohomoserine (32) from (2S)-aspartic 
acid (28).
Scheme 2.3: Synthesis of N,N-diisopropyl(bis)benzyl phosphoramidate (78).
Scheme 2.4: Final cloning procedure adopted for thrC.
Scheme 2.5: Plan for the ligation of thrC into pET-3a derived from a pTC construct.
Scheme 2.6: Synthesis of dipentafluorophenylphosphorochloridate (81).
Scheme 2.7: Attempted methods of phosphorylating N-trifluoroacetyl-a-isopropyl-^S)- 
homoserine (75).
Scheme 2.8: The proposed solid-phase synthesis of (25’)-0-phosphohomoserine (32) on Wang 
resin.
Scheme 2.9: Selective reduction of a carboxylic group in the presence of N-trifluoroacetyl and 
methyl ester functionalities.
V
2
3
5
6
16
17
22
36
37
38
38
49
49
51
52
53
54
68
70
72
73
78
90
107
108
113
123
Scheme 2.10: Proposed scheme for the reaction of' 87 with NMM and IBCF. 126
Scheme 2.11: Proposed mechanism for the diborane-mduced cl^ea^va^C5 of 8(5 from Wang resin. 127
Scheme 2.12: Coupling reactions with dietliylamine. 128
Scheme 2.13: The K(^]^^-^in?-:^ia^t^-i loading of 95 onto Memfield. 134
Scheme 2.14: McKillop's ether synthesis. 135
Scheme 2.15: Mechanism for the reaction earned out by Davis and Muchowski. 136
vI
List of Tables
Table 1.1: PLP-dependent enzymes belonging to the a-family.
Table 1.2: Enzymes of the y-family.
Table 1.3: Minimal requirements of humans for some of the essential amino acids (mg kg" 4 
day"4).
Table 1.4: Threonine synthase from microbial sources.
Table 1.5: Kinetic properties of threonine synthase from various higher plants.
Table 1.6: inhibition of TS from different sources by various anions and salts.
Table 1.7: inhibitors of threonine synthase.
Table 2,1: The results of ligations using thrC and pGEM-T.
Table 2.2: Results of ligations of new rh/'C fragment into pGEM-T.
Table 2.3: pTN-TS constructs produced from various pET-vectors and pGEM-TTS constructs. 
Table 2.4: Description of primers used in sequencing experiments.
Table 2,5: Loading of Wang resin with Y-TFA-asp under various conditions.
Table 2.6: The racemisation effects of varying amounts of DMAP.
Table 2.7: Effects of varying reaction conditions on the regioselectiviely of Wang loading.
Table 2.8: Conditions for loading p-hydroxymethylpolystyrene resin.
Table 2.9: Conditions for attempted reductions of a-p-benzyloxybenzylpolystyrene-Y- 
trifluoroacetyl-(25)-aspartate (87).
Table 2.10: Experiments to find reagent(s) responsible for cleavage of 86 from the resin.
Table 2.11: Reagents tried for the reduction of the activated (-carboxyl group on 87.
Table 2.12: Conditions used in experiments to load 95 onto Merrifield resin.
Table 2.13: Optimisation of the conditions for the loading of 95 onto Merrifield using 
potassium hydroxide.
Table 2.14: Comparison of the regioselectivity of substitution reactions of 73 onto 98.
Table 3.1: Oligonucleotides used for amplification of gene fragments.
Table 3.2: Oligonucleotides used in sequencing experiments.
8
14
39
40
43
59
61
86
91
94
104
115
117
118
121
124
125
130
133
137
140
175
176
YU
List of Compounds
73
74
75
78
79
76
32
74b
75b
76b
32b
81
86
87
101
9 4
102
97
103
99
7-Trifiuoroacetyl~(25)-aspartic anhydride
a-Isopropyl-Y-tri•tluoroacetyi-(2S)iOsportote
a4sopropylV-trifiuoroacetyli(2£)ihomoserine
Y,Y-Diisopropyldichlorophosphamidile
A,V-Diisopropylbis(benzyl)phosphoramidate
ai-IsopropyliY-tritluoroacetyl-(2S)-pl•losphohomoserinebis(benzyl) ester 
(25)-0-phosphohomoserine
[U-^4C]•-(XiIsopropyliY-tritluoroacetyli(25,)iaspartate
[U-14C]-iaiIsopropyl-Vitl•ifluoroacetyli(215)-homoserine
[U-14C]-a-Isopropyl-.Yitrifluoroacetyl-(215)-phosphohomoserinebis(benzyl) ester
[Ui14C]--(S))i9-phosphohomoserine
Dipentafluorophenylphosphorochloridate
V-Trifluoroacetyl-(2S)-aspartate
ni■pi-Benzyloxybetlzylpolysty^ene-V-tritiuoroocetyl-(2,S')-osportate
Oi-h?-Benzyloxybenzylpolystyrene-.7h-trit'uoroacetyl-(2>Sl)-asportoteip-methyl ester 
Oi•p?-Benzyloxybenzylpolysyr^ene-Y-irifluoroacetyl“(215')iasportate-P-diethyi amide 
o-p-Methylpolystyrene-Y-trifluoroacetyl-^Syaspartate
Polystyrene-4ioxymethyl-2iphenylethanol
a-[2-(4MIetiloxyphenyl)-ethyl]Y4rifluoroocetyl-(25')-ospai’tote
ai-(Polystyrene-4-oxymethyl-2-phetlylethyl)-7h-tri:tluoroocetyl-(215)-aspartate
152
153
154
155
156
157
158
159
159
159
159
160
161
162
163
164
165
166
166
167
Viii
Abbreviations
AMP adenosine monophosphate
AmpR ampicillin resistance gene
AIDS Acquired immune deficiency syndrome
AlaAT alanine aminotransferase
AK aspartokinase
APS ammonium persulphate
AspAT Aspartate aminotransferase
ATP adenosine 5'-triphosphate
Boc tert-butoxycarbonyl
bp base pairs
Br. flavum Brevibacterium flavum
Br. lactofermentum, Brevibacterium lactofermentum
BSA bovine serum albumin
B. stearothermophilus Bacillus stearothermophilus
B. subtilis Bacillus subtilis
cAspAT cytosolic aspartate aminotransferase
Cbz (Z) benzyloxycarbonyl
CD circular dichroism
C. glutamicum Corynebacterium glutamicum
CIAP calf intestinal alkaline phosphatase
CNS central nervous system
mCPBA m-chloroperoxybenzoic acid
CS cysteine synthase (D-acetylserine sulfhydrolase)
Da Dalton
DCM dichloromethane
DDC DOPA decarboxylase
ix
ddNTP chain terminating dideoxyribonucleotide triphosphates
DEA diethylamine
DIPEA diisopropylethylamine
DMAP 4-dimethylamino pyridine
DME 1,2-dimethoxyethane
DMF A,A-dimethylformamide
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
dNTP deoxyribonucleotide triphosphates
DOPA 3,4-dihydroxyphenylalanine
dsDNA double-stranded DNA
DSDHT D-serine dehydratase
DTP dithiothreitol
EC Enzyme Catalogue
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
eq equivalents
Et3N triethylamine
Etp diethyl ether
GAEA y-aminobutyric acid
GAEA-T y-aminobutyric acid transaminase
HDC histidine decarboxylase
HEPES (/V--2-hydroxyethyl]piper£azne--V'-[2-etha.nesulfonic acid])
H. influenzae Hermophilus influenzae
HK homoserine kinase
HRMS high resolution mass spectrometry
HSD homoserine dehydrogenase
IECF isobutylchloroformate
IPTG isopropyl-P-D-thiogalactopyranoside
X
IR infrared
LMP low-melting point
kb kilobases
Kd dissocation constant
kDa kilo Dalton
K enzymic inhibition constant
Km Michaelis constant
KOH potassium hydroxide
lacZ gene for P-galactosidase
LB Luria-Bertani medium
LSDHT L-serine dehydratase
mAspAT mitochondrial aspartate aminotransferase
M. glycogenes Methylobacillus glycogenes
M. leprae Mycobacterium leprae
Mr relative atomic mass
mRNA messenger RNA
M. tuberculosis Mycobacterium tuberculosis
NAD nicotinamide adenine dinucleotide
NADP nicotinamide adenine dinucleotide phosphate
N. crassa Neurospora crassa
Ni-NTA nickel-nitrilo-tri-acetic acid
NMDA A-methyl-D-aspartate
NMM N-methylmorpholine
NMR nuclear magnetic resonance
OASS D-acetylserine sulfhydrylase (cysteine synthase)
ODC ornithine decarboxylase
ompT outer membrane protease
0/N overnight
ORF open reading frame
xi
ORI replication origin
P. aeruginosa Pseudomonas aeruginosa
PBS phosphate buffered saline
PCR polymerase chain reaction
pET plasmid for expression by T7 RNA polymerase
32P-y-ATP adenosine triphosphate, at the gamma phosphate
P/ inorganic orthophosphate
PLP pyridoxal-5'-phosphate
PMP pyridoxamine-5'-phosphate
PyBOP benzotriazolyloxy-tris[pyrrolidino]-phosphonium
hexafluorophosphate
RBS ribosomal binding site
RNA ribonucleic acid
SAM 5-adenosylmethionine
S. cerevisiae Saccharomyces cerevisiae (yeast)
SDS sodium dodecyl sulfate
SDS-PAGE SDS-polyacrylamide gel electrophoresis
S. marcescens Serratia marcescens
S. pombe Schizosaccharomyces pombe (fission yeast)
ssDNA single-stranded DNA
STET sodium-tris-EDTA-triton buffer
TAE Tris-acetate-EDTA buffer
T. aquaticus Thermus aquaticus
TBE Tris-boric-EDTA buffer
TBS Tris buffered saline
TE Tris-EDTA buffer
TEMED A,A^,.A',A'-tetramethyiethyienediamme
TES triethylsilane
TFAA trifluoroacetic anhydride
xii
TFA trifluoroacetic acid
THF tetrahydrofuran
thr threonine operon
thrA aspartate kinase I- homoserine dehydrogenase I
thrB gene for homoserine kinase
thrC gene for threonine synthase
tic thin layer chromatography
T4 PNK T4 polynucleotide kinase
tRNA transfer ribonucleic acid
TrS tryptophan synthase
TS threonine synthase
UV ultraviolet
DV Vh/Vd
DV/K (VhWd)/(Kh/Kd)
X-gal 5-bromo-4-chloro-3-indolyl“P-D-galactopyranoside
Z-APPA (25,)-2-ammo-5-phosphono-3-cw-pentenoic acid
3D 3-dimensional
xill
Contents
Acknowledgements i
Abstract il
List of Figures iii
List of Schemes v
List of Tables vii
List of Compounds viii
Abbreviations ix
1.0 Introduction 1
1.1 An Introduction to Pyridoxal-5'-Phosphate Dependent Enzymes 1
1.1.1 The Scope of Pyridoxal-5’-Phosphate Dependent Enzymes 1
1.1.2 The Discovery ot Py^rTi^o^^^l-l^'-l^lic^^i^li^l^ 2
1.2 The Classification 0! PLL Enzymee 6
1.2.1 The Evolutton of PL^I^-I^^t^^tlt^e^t^t Enzymes 6
1.2.2 Thh PILLlXn^^y^y^^ Famiiies 7
1.2.2.1 The a-Family of ILL-Dependent Enzymes 8
1.2.2.2 The (-Family of LLL-Deprzdrzt Enzymes 11
1.2.2.3 The y-Family of LLL-Depezdrzt Enzymes 13
1.2.2.4 Other ILL Enzymes 14
1.2.2.- Exceptions to the Family Rule 14
1.3 The Structure and Mechanism of ILL Enzymes 15
1.3.1 A General Mechanism of PLI-Enzyme Action 1 5
1.3.2 Recent Structural and Mechanistic Studies on P-Family Enzymes 19
1.3.2.1 Recently Published Crystallographic Data on LLP Enzymes 19
1.3.2.2 Structure-Activity Studies on O-Acety-serize Sulfhydrolase 21
1.3.2.3 Structure-Activity Studies on Tryptophan Synthase 24
1.4 The Metabolic Roles of Various Lrridfxal-5'-Lhfsphatr Dependent Enzymes 277
1.4.1 Niacin (Nicotinic Acid) Synthesis From Tryptophan 27
1.4.1.1 Lrllagra and Related Diseases 28
1.4.2 Decarboxylases 30
1.4.2.1 Glutamate Decarboxylase and r-Amizfbutyric Acid Transaminase 30
1.4.2.2 Ornithine Decarboxylase (ODC) 31
1.4.2.3 Histidine Decarboxylase (HDC) 33
1.4.2.4 DOLA Decarboxylase (DDC) 34
1.4.3 Amino Acid Racemases 35
1.4.4 The Aspartate Pathway
1.5 Introduction to Threonine Synthase
1.5.1 The Discovery of Threonine Synthase
1.5.2 The Associated Deaminase Activity of Threonine Synthase
1.5.3 The Regulation of Threonine Synthase
1.6 The Structure and Character of Threonine Synthase from Various Organisms
1.6.1 Microbial Sources of Threonine Synthase
1.6.2 Threonine Synthase from Plant Sources
1.6.3 Threonine Synthase Expression in Mammalian Systems
1.6.4 Threonine Synthase as a Potential Target Enzyme for Herbicides
1.7 The Threonine Operon of Escherichia coli
1.7.1 The Structure of the Operon
1.7.2 The Regulation of Thr Expression
1.7.3 Cloning of 77zr
1.8 The Mechanism of (25,37?)-Threonine Synthesis
1.8.1 Introduction
1.8.2 Reaction Mechanism
1.8.3 Unanswered Questions Concerning the Threonine Synthase Reaction
1.9 Inhibitors of Threonine Synthase
1.9.1 Functional Groups Which Inhibit PLP-Enzymes
1.9.2 Amino Acid Inhibitors of Threonine Synthase
1.9.3 Inhibition of Threonine Synthase by Various Anions
1.9.4 Phosphonic Acid Analogues of (2S)-(9-Phosphohomoserine
1.9.5 Phosphate Analogues
1.10 The Aims of This Project
1.10.1 Testing New Substrate Analogues as Inhibitors of Threonine Synthase
1.10.2 Product Inhibition Assays
1.10.3 Further Assessment of the Allosteric Activation of TS by SAM
1.10.4 Structure-Activity Studies on Threonine Synthase
1.11 pET Expression Vectors
1.11.1 Introduction
1.11.2 T7 RNA Polymerase
1.11.3 Expression of Target Genes
1.11.4 Vectors Selected For Expressing Wild-Type and Mutant ThrC
36
37
37
38
39
40
40
42
44
44
45
45
46
47
48
48
48
55
56
56
57
59
60
62
63
63
64
65
65
66
66
66
67
68
2.0 Results and Discussion 69
2.1 Substrate Synthesis 69
2.1.1 A Survey of the Literature Methods for Synthesising (2S)-0- 
Phosphohomoserine.
69
2.1.2 The Biomimetic Synthesis of -2S))“6-Phosphohomoserine. 71
2.1.3 Syn^ies^ of [[B14CC^(-(2)^<2^-IPlo.sihlc^lh<^Im^^i^trin^. 74
2.2 The Growth of Threonine Synthase 76
2.3 Cloning of ThrC and the Gene for p-Methylaspartase 77
2.3.1 The General Clonnng Strategy 77
2.3.2 Cloning oo ThrC 79
2.3.2.1 Amplification of ThrC 79
2.3.2.1.1 Iehiaiihn of C0rhmhehmal DNA 79
2.3.2.1.2 Polymerase Chain Reaction on 7/zrC 79
2.3.2.2 Attempted Ligation of ThrC Into Cloning Vectors 81
2.3.2.3 Overlap Polymerase Chain Reaction Experiments. 83
2.3.2.4 Ligation of ThrC into pGEM-T. 84
2.3.2.5 Attempted Ligation of ThrC Into Expression Vectors. 87
2.3.2.5.1 pET-SaandpET-^b. 87
2.3.2.5.2 pKK223-3 87
2.3.2.6 New PCR Fragment. 88
23.21 Attempted Ligation of ThrC into pET-3a. 89
2.3.2.8 Liggtioo oo New Geee Fraamoet IntepGEM-T. 90
2.3.2.8.1 Amolificctioh cd TTirC 90
2.3.2.9 Sequencing of ThrC in hEEM-TT8i and hEEM-TTSIi. 92
2.3.2.10 Ligation of ThrC Into hET-Exhrreeioe Vectors. 94
2.3.3 donmg oo -he p-Methylalpafiase Gene 98
2.3.3.1 Cloning the Gene Into hEEM-T 98
2.3.3.1.1 Gene Amplification 98
2.3.3.1.2 Overlap PCR Exhrrimreii 99
2.3.3.1.3 hEEM-T 100
2.3.3.1.4 A New Erer Fragment 101
2.3.3.1.5 New hEEM-TMA Cheetrucie 102
2.3.3.2 Further Work on the Erer for h-MrtOylaehariasr 103
2.4 Sequencing of the ThrC Gene Fragment in Recombinant Plasmids 104
2.5 Attempted Solid-Phase Synthesis of (2S)-0-Phosphohomoserine 106
2.5.1 Aitsrnstivs Pefepefryisting Agents 106
2.5.2 19F Gel-phsee NMR Spectroscopy 111
2.5.3 p-Bsnzyifxyibsnzyi Alcohol (Wang) Resin 112
2.5.3.1 The Loading of Wang Resin With i^-"^TiSfiu^l•ifs^<^t^h^li^((^.^')-^i^^<spsI•tsts 114
2.5.3.2 p-Hydroxymsthyipoiyetyrsns Resin 121
2.5.3.3 Attempted Reduction of a,-/;-Benzyloxylbsnzylpoiystyrene-N- 122
trifisorfscetyl-(25--aspsrtate
2.5.3.4 Experiments to Confirm the Activation of the Carboxylic Group on 87 128
2.5.3.5 Reduction of a-t?-Benzyloxylbenzylpolyetyrsns-W-Trifisorfscstyl-(2.5-- 129
aspartate
2.5.4 A New Solid Support 132
2.5.4.1 Attachment of 2-(p-Hydroxypesnyi--stesnoi to Merrifield Resin 132
2.5.4.2 Loading of the New Resin With Y-trifisfroscstyi-(25)-separtsts 137
2.6 Conclusions and Future Work 142
3.0 Experimental 149
3.1 Synthesis 149
3.1.1 General Experimental Procedures 149
3.1.1.1 Compound Characterisation 149
3.1.1.2 Reagent and Solvent Preparation 150
3.1.1.3 Suppliers 151
3.1.2 Synthetic Procedures and Characterisations 152
3.2 Moleeutas Clonmg 169
3.2.1 Cloning Techniques 169
3.2.2 Polymerase Chain Reaction 173
3.2.3 Oligonucleotides 175
3.2.4 Expression in E. coli 176
References 179
Appendices 191
CHAPTER ONE
INTRODUCTION
Introduction to PLP Enzymes -Scope of PLP Enzymes
1.1 An Introduction to Pyridoxai-5’-Phosphate Dependent Enzymes
1.1.1 The Scope of Pyridoxal-5’-Phosphate Dependent Enzymes
A wide variety of enzymes responsible for amino acid metabolism utilise pyridoxal 5'- 
phosphate (PLP, 1) as their cofactor. The enzymes dependent on PLP include the 
transaminases1 (or aminotransferases), through whose action the Ca-N bonds of most amino 
acids are formed, the racemases,2 many of which are involved in the biosynthesis of 
peptidoglycan in bacterial cell walls, and the decarboxylases which convert amino acids to 
amines (Scheme 1.1).2 The latter function is one of the most important physiological roles of 
PLP.
Pyridoxal-5'-phosphate (1).
There are over 66 known transaminases altogether as well as 50 different decarboxylases. All 
the aformentioned enzymes alter a substituent at the opposition on the substrate. Many other 
enzymes which are PLP-dependent, in addition to first removing the a-proton of the amino 
acid, also eliminate or replace groups which are in a P- or a y-position. The numerous 
examples of PLP-dependent enzymes indicate that PLP is one of nature’s most versatile 
coenzymes; playing a crucial role in amino acid metabolism/ connecting the carbon and 
nitrogen cycles and providing entry into the ‘one-carbon pool’. PLP also participates in the 
formation of biogenic amines as well as a number of other important processes/ The 
versatility of this coenzyme is reflected in the fact that PLP-dependent enzymes occur
1
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in four of the six EC classes of enzymes.'
NH2
H/J
{OCX
PLP
■ “ — -1'
NH2
decarboxylases
NH2
H/J
HChC^X
PLP
X
HCfcC^X
aminotransferases
NH2
H/J
HO2C*^X
PLP NH2
HA
HChC^X
racemases
nh2
HO2C>VcO2H
PLP nh2
1
serine hydroxy methyl 
transferase
HOzC^
Scheme 1.1: Some types of reaction catalysed by PLP-dependent enzymes.
1.1.2 The Discovery of PLP
PLP is a metabolite of vitamin Bg (or pyridoxol (2), see Scheme 1.2), a nutritional factor which 
was first identified in 1934 by Paul Gyorgy.7 In the early 1930s, when purified preparations 
of thiamine (Bj) and riboflavin (B2) first became available, it became appareer that a separate 
heat-stable vitamin, later found to be vitamin Bg, could arrest the development of a pellagra-like 
dermatitis (similar to acrodynia) in rats (Fig. 1.1).7 In fact, as early as 1926, Goldberger and 
Lille had noted that rats given a diet deficient in a so-caned 'pellagra-preventative factor' 
developed this condition^ In 1932 Ohdake isolated a eitrhgenhus compound from rice 
polishings, but no vitamin significance was attached to it at the time.7 It was only later that it 
was shown to be identical with vitamin B7. Birch and Gyhrgy studied the properties of the 
vitamin in 193677 and subsequent to this the compound was isolated independently by five
2
Introduction to PLP Enzymes -Bq Metabolism
OH
CH, IV
H
pyridoxine (pyridoxol) pyridoxine-5 '-phosphate 
(5)
OH
ch3
I
pyridoxamine (4) pyridoxamine-5 '-phosphate (PMP) 
(6)
Key to enzymes involved in the above steps:
I: pyridoxal phosphate oxidase
II: sminotransfsi'ssss 
III: pyridoxal kinase 
IV: pyridoxal phosphatases 
V: pyridoxal dehydrogsnasse
Scheme 1.2: The metabolism, of vitamin Bq
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laboratories in 1938 and its structure and synthesis were reported in 1939 when it was named 
pyridoxine.1114
■
fa.
•. •-
■ ■■S;>v\s-:4V,t /:■
wo
Figure 1.1: Dermatitis caused by pellagra.*
Originally the cofactor was named 'cfdecsrbfxyisee' by many research workers as a result of 
its ability to reactivate the resolved inactive apoenzyme of (25--lysine decarboxylase.15 It was 
not until Bellamy and Gunsalus were investigating the prfpsrtiss of tyrosine decarboxylase that 
the link between the nutritional factor Bfi and 'cfdecsrbfxylsse' was made.'6 In their 
experiments media containing larger amounts of pyridoxine (2- and nicotinic acid than were 
necessary for growth of bacteria, were found to give high yields of the active enzyme. A 
couple of years later Snell realised that vitamin B£ occurs in multiple free forms, and by 
studying the non-enzymic transaminations between pyridoxal (3- and amino acids he provided 
the first clues to the function of the vitamin. 16 The reaction shown in Scheme 1.3 was shown 
to occur in the case of ^--glutamic acid, and the data suggested that a similar reaction could
a reproduced from wsb-eits: http://www.mc.vandei'bilt.edu/bioiib/el/pd4.htmi
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take place between pyridoxal (3) and certain other amino acids. It is now known that most 
amino acids are biosynthesised in this manner from (25)-glutamic acid and the corresponding 
a-keto acid via the action of transaminases.
Scheme 1,3: Snell's "Shuttle Mechanism" for enzymic transamination.
The next decade witnessed the identification of tryptophanase, (2/?)-serine dehydratase and 
cysteine desulfhydrase as PLP-enzymes.2 The availability of further enzymes for study meant 
that much stereochemical, kinetic and primary structural information about PLP enzymes could 
be gained, providing insights into the general mechanisms of such enzymes and the role of 
PLP. 3D structures of most PLP enzymes and their enzyme-substrate complexes are, 
however, still scarce, except in the case of the transaminase group of enzymes.
5
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1.2 The Classification of PLP Enzymes
1.2.1 The Evolution of PLP-Dependent Enzymes
Ail the PLP enzymes studied to date share certain similarities in the preliminary stages of their 
reaction mechanisms (see also Section 1.3). In 1974, Dueathae and Voet also noted that 
several PEP-dependent enzymes convert the bound cofactor to hyridhxamiee phosphate (6) 
during normal or abortive rraesamiearihe reactions and that this proceeds sterehspecifically, 
with the same absolute stereochemistry in seven quite different PLP-enzymes.18 The key step 
in this reaction is the prhthearihe of the bound substrate-pyridoxal phosphate Schiff base (7) at 
the C-4' carbon of the cofactor, from the A-si face, after loss of one of the groups at the 
substrate Ca (Scheme 1.4). They inferred that this demonstrated a remarkable regularity in the 
geometry of the binding of the cofactor to the apoenzyme in all PLP enzymes, and interpreted 
this as evidence for the evolution of this entire family of enzymes from a common progenitor. 
Jensen's hypothesis supports this theory, as it suggests that ancestral organisms produced a 
relatively small number of enzymes with flexible substrate specificity, which gradually mutated 
into more selective enzymes.19
Scheme 1.4; Conversion of bound cofactor to pyridoxamine phosphate- a process common 
to many PLP-enzymes. Ha-elimination is illustrated here.
6
Classification of PLP Enzymes- ■Homologies
However, not only do PLP enzymes share many mechanistic similarities, they also demonstrate 
definite sequence and structural homologies. Mehta et ai found that most aminotransferases 
formed a group of homologous proteins, which could then be divided further into distinct 
evolutionary subgroups on the basis of their sequence similarities (see Section 1.2.2.1).20 
Subsequent profile analysis to detect distant relationships between amino acid sequences of 
various enzymes showed that the evolutionary relationships included other Be enzymes.21-23 
In 1994 Christen and co-workers carried out a comprehensive analysis of the amino acid 
sequences of PLP enzymes and of their 3D structures and, as a result, proposed that most of 
the enzymes could be assigned to one of three different families of homologous proteins; the 
a-, p- or y-families.20 Although the sequence similarity is too low in some cases to allow 
meaningful alignments by standard programmes, hydropathy plots and secondary structure 
predictions do indicate evolutionary relationships between PLP enzymes.25 Their affiliation 
with one ' of these structurally defined families also correlates in most cases with their 
regiospecificity.24 The folding pattern of the polypeptide chain of the y-family enzyme is 
similar to that of aspartate aminotransferase (AspAT), further suggesting an evolutionary 
relationship between the a- and y-families.24 Christen et. al also cited various reports of the 
side reactions catalysed by Be enzymes as further evidence for a common ancestral enzyme 
with broad substrate specificity.22 Decarboxylases catalyse transamination, aminotransferases 
cause racemisation, tryptophan synthase (TrS) produces racemisation and transamination and 
glycine hydroxymethyltransferase also initiates a-decarboxylation, transamination and 
racemisation.
1.2.2 The PLP-Enzyme Families
The largest family of PLP-dependent enzymes, the a-family, contains enzymes catalysing 
reaction at Ca of the substrate. Similarly, the P-family contains those acting at CP and the y- 
family those acting at CY. There are, however, some exceptions to this general rule, and some 
PLP-dependent enzymes do not seem to belong to any of the groups.
7
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1.2.2.1 The a-Family of PLP-Dependent Enzymes24
I
i The a-family is the largest of all the PLP-dependent groups and includes the aminotransferases
(ATs) and the group II decarboxylases (DCs). In spite of the low level of sequence similarity 
between members of the a-family, (only two residues are conserved throughout the a-family; 
the lysine and aspartate residues which bind PLP),25 many of these enzymes have 3D 
structures available for comparison and the conformational similarities between different types 
of enzyme can clearly be seen. John reviews these similarities in more detail, but they include 
eight or nine a-helices packed around a seven-stranded (3-sheet in the large domain.25 In the 
a-family the PLP-binding lysine residue occurs between residues 209 and 256 of the various 
members of this family, which are listed in Table 1.1.
Table 1.1: PLP-dependent enzymes belonging to the a-family.
Most aminotransferases (excluding branched chain and D-amino acid) 20> 2^ 
Group II amino acid decarboxylases 
Tryptophanase 
Tyrosine phenol-lyase^
Glycine hydroxymethyltransferase 
I -aminocyclopropane-1 -carboxylate synthase^ 
2-amino-6-caprolactam racemase 
Glutamate-1 -semialdehyde 2,1 -aminomutase 
Isopenicillin N-epimerase 
2,2-dial/cyl decarboxylase^ 
4-amino-4-deoxychorismate synthase^' 
Glycine-C-acetyltransferase 
5-Aminolevulinate synthase 
8-Amino-7-oxononanoate synthase 
The gene product of cobC (cobalamin synthesis)
The gene product o/nifS (nitrogen fixation)
The gene product ofmsXY (abolishes induction of the maltose system)
The most intensely studied members of this family are the ATs. In their studies on the 
evolutionary relationship between ATs, Mehta and co-workers discovered 107 invariant
8
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residues between the cAspAT and mAspAT sequences from, vertebrates, which have an average 
length of around 400 amino acids.26 Their average pairwise identity was 41%. The active-site 
sequences of AspATs from both prokaryotic and eukaryotic sources have been aligned here 
showing the conservation of various motifs, including the lysine residue for binding PLP (Fig. 
1.2).
I
******** * * * * ** * * * * *******
A ----------- HHIGISQSYA1MMGLYGQR
B OAHnPTCT^EPIlLIQkTSI^RQ^a^RDK^-i^lU^PFFDSAYQDFASDSIjDADAQPVDLFVADD---------- DILLVAQSYAKNMDLYDID
C aAHffPR3TT^DTn^l^^QQIAA^tRRR^I^I^I^I^]FDSAYQDlFASDSI^DKDAWAVRYF^^]I3----------- FILFCAQSFSKNFDLYNED
D <CAHN^T^-V)Pl^BOWB^II^C^ILMRS-f^]L^]^^FDSAYQCa^2^1^<DSLDjAD^C^fSVDC;FVA]D3----------DICLAAQSYAKNMDLYeED
I CAAHJPTCIDPTPIQWQIASSVKRR-FFLPFFDSAYQGFASDLERDAWAIRYYVSEG-----------FEFFCFQSFSQNFGLYNED
I CIFHTP^TCV>PTLDQIAIIRRILMPS-.-FJLPFFDSF.YQGFFSDSLDQDFQSVPMIVFD----------DILLMAQSY7Q3SMGLYDIP.
e CIAHJPPG,TDPTPIQWAQIA£SVKQRpFLFPFFDSAYQGFASDNLIQDAWAIRYFVSEG-----------FILFCAQSFSQNFGLYNED
H CEFHNP1GLDPTSEQWAQIVVAFASK~NHIALFIT^AYIGFFTD;DLDQDAYAVRLGVEIQJSTV SPVFVCQSFAQNADMYGER
I <CFHN>TGmPRQEQI^JQ:AIFSAQKp3NLGYFEMFYQFASGDIAPDAFAALPHIE$G---------- IDAGSSSSFQKMGLYGER
J CIAHPPGDOTRPEQWKEIATTAQRpIMiLAFFFMAY$3FASGID3DKDDAA\VD^FILIQ----------- INVCIJCQSYA^NMGLYGEP
Q CIAH'IPPGIDPTPEQAEKIADVIQI—-SIH^IP'FFDVFYQGFASDSLDI'DFFSVDLFVF.DG---------- LEVLVF.QSYSQNLGLYFED
L CIFHIP1AVDPPIQQWIIMFTLVQQN-MLFFF'FDMAYQGFFSGEGNQDFWAFVRHIE<I3---------- I^VICLCQSYA!SMGLYGEP
M CCHOTTILDPTQIQL'raKIIDTIYLL-TJYPPIVDVYQDGISSGlLuLlDAYLLRLLLVVQKYSIASNGILCQQSFAISMGLYGER
* ** * . . **. *.***
N PS-NPTGVMY^EEELS]FGeICCLIHDILIVSDIIYEQLTYDGK-QH/SIFQLSDDL:------------ IQTVIlNGSSKSHSITDAD
O P.S-N]PSGPFYSHEELIAG7TD\IMMPHVAV1L^DDMMYIHLYGDF-RFATPVEVEPGLY----------- IDTL^MNGVSKFYFMDA^P
P PS-NPTGMVYRDELLIIAF-M.,LN-INILIVSDIIYE-GLYNGA-EHFSIF.QISEEVC---------- AQTIVnflVSQKHHMTrcAD
Q PS-NPGMIYTFI:ELKALGIVC]GA^-G\VJIVSDEIYIQLTY(D3A-QEH/SIAELSPELQ---------- AQTVIINCVSS-SSHSMDAD
D <CCHNPI3IDPTLEQAQlGFQLSVK-GDAPLLDFAFY^eFF3-A-EIHSSAQISEEVK---------- AQTIVINGV-KSHSITDAD
S CCIHN)TCIDPTPIQWAQILFFLSKQ-GGALPLFFAFYG:IDLFG-AFFQHSSIF;LSPELK----------AQTVTNDVS-KHSSITKAD
T P-HNPTCTLFSPNDVKQTOISPDN-QIILLSDEIYDIFVYffiGQ---------- MRSTLEDSD ADOFLIYVNDFSKTF]M^DAJR
** * * * * *
A - Arabidopsis thaliana (mouse-ear cress), 277; B - Medicago sativa (alfalfa), 264; C - cAspAT Callus 
gallus (chicken), 257; D - cAspAT Daucus carota (carrot), 251; E - cAspAT Homo sapiens (human), 258; 
F - cAspAT Oryza sativa (rice), 253; G - cAspAT Sus scrofa (pig), 258; H - cAspAT S. cerevisiae 
(baker's yeast), 254; I - mAspAT G. gallus, 272; J - mAspAT H. sapiens, 279; K - mAspAT Lupinus 
angustifolius (narrow-leaved blue lupine), 299; L - mAspAT S. scrofa, 279; M - mAspAT S. cerevisiae, 
286; N - Bacillus suhtilis, 237; O - Rhizobium meliloti, 239; P - Bacillus sp. (strain ym-2), 239; Q - 
B. stearothermophilus, 237; R - E. coli, 246; S - H. influenzae, 246; T - Sulfolobus solfataricus, 241.
Sequences A - M are eukaryotic, sequences N - T are from prokaryotes. Residue number of the active-site 
lysine is shown in blue. Asterisks denote identical residues, periods denote conservative replacements (e.g. I-V- 
L-M-F, D-E, R-K, S-T). For the eukaryotic sequences, identical residues are highlighted in red. For the 
prokaryotic sequences, identical residues are highlighted in blue. The homology of each set of sequences is also 
indicated- by asterisks and periods above the sequences. The overall homology between all the AspATs aligned 
here are indicated by the asterisks and periods underneath both sets of sequences. The lysine residue responsible 
for binding to PLP is indicated by an arrow. The alignment was performed using Clustalw (1.60).
Figure 1.2: Sequence homology between various eukaryotic and prokaryotic AspATs. close 
to the active-site lysine residue.
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When the various vertebrate ATs were aligned the percentage identity ranged from as low as 
5% up to 75%, whereas the percentage similarity (which accounts for conservative 
replacements- ranged from 25% to as high as 87%.20 Four residues were conserved 
throughout the sequences: G197 which participates in a p-turn at the domain interface, D/E222 
which forms a esit-bridgs or hydrogen bond to N1 of PLP, K258 which forms a Schiff base 
with PLP and R386 which forms a hydrogen bond with the a-csi'hfxylate of the substrate.20 
Mehta reviews various site-directed mutagenesis experiments to replace these residues in E. coli 
AspAT which resulted in significant reductions in the catalytic activity of the enzyme. 20
On the basis of sequence similarities the ATs could be divided into four subgroups. 11 
residues were invariant in subgroup I, 19 in subgroup II, 82 in subgroup III and 25 in 
subgroup IV.20 Jensen and Gu have subsequently reviewed the evolutionary relationship 
between 47 group I ATs and proposed seven new subfamilies on the basis of sequence 
alignments.20 They suggested that these originate from a single ancestral broad specificity AT. 
Another study has demonstrated structural homology between serine eydroxymethylti•ansfsrase 
(SHMT- and AspAT, with 66% of aligned residues around the central and C-terminal regions 
predicted to share the same conformation^1 Bossa also cited a previous observation of weak 
sequence similarity between the active-site regions of decarboxylases and various PLP 
enzymes, including SHMT.31 In addition to this, the NifS group of proteins (responsible for 
nitrogen fixation in bacteria- appears homologous to a new class of PLP-snzymes, which 
includes various aminftranefsrsses and isopenicillin N epim^i's^i^s^52 although they all have very 
different functions. The sequence identity between distant members within this class is below 
25%, but secondary structure predictions indicate that this class of enzymes might have an 
overall a-p topology. Sander and Ouzounis also reported sequence similarities of around 30% 
between mammalian peroxisomal serine-pyruvate aminotransferases and the small subunit of 
soluble hydrogenases.32 Most recently Babbitt and Gerlt have observed sequence similarities 
between 5-ksto-4-defxyglucarate dehydratase/decarboxylase and various dehydratases and 
aldflases.33 In a separate study on decarboxylases Kang and Joh have demonstrated significant 
homologies between porcine and bovine L-amino acid decarboxylases and feline glutamic acid
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decarboxylase and tyrosine decarboxylase from C. roseus (31% identity beween all 
sequences).34 Christen et al. have more recently compared sequences from nine different DCs 
and divided them into four subgroups:.35 However, only group II demonstrated a distant 
relationship with the ATs. No evidence was obtained that the other DCs were in any way 
related to other PLP enzymes and profile analysis suggests that the decarboxylases have 
evolved along multiple lineages, even if they have the same substrate specificity.
1.2.2.2 The P-Family of PLP-Dependent Enzymes24
This family has seven members including threonine synthase (TS), which are shown in Fig. 
1.3. Although few crystal structures are available for the comparison of the tertiary stmctures 
of these enzymes, their sequences do show significant homology. Parsot has demonstrated 
extensive - homology between the TS enzymes of E. coli and B. subtilis, threonine dehydratase 
(TD) from S. cerevisiae and D-serine dehydratase (DSDHT) from E.coli.^ There are 72 
conserved amino acid residues (21%) and 40 conservative replacements between TS from B. 
subtilis and TD from yeast; an overall homology of 33%. Similar results were noted between 
the sequences of yeast TD and DSDHT of E. coli. As a result he postulated the evolutionary 
connection of these enzymes. Bork and Rohde also aligned various p-family enzymes from a 
number of microorganisms and identified three regions of significant homology in the 
sequences including a lysine motif and a glycine-rich turn, which are illustrated in Fig. 1.4.56 
They proposed a new alignment, which revealed a similar folding topology in long segments of 
the enzymes studied. The pairwise identities ranged from 15% to 19%. They also found that 
the sequences of TrS and D-acetylhomoserine thiolyase, a y-family enzyme, had an amino acid 
identity of 11% and suggested that there could exist an evolutionary relationship between these 
two families, although the findings of Christen et al. refute this.24 Appendix 1 shows a more 
extensive alignment of p-family enzymes from B. subtilis, E. coli and yeast whose pairwise 
identities ranged from as low as 4% between DSDHT and TD of B. subtilis to 100% between 
TD and TS from this source. The average pairwise identity was 15.7%, which increased to 
24.9% around the active-site.
11
Classification of PLP Enzymes- ■p-Family Enzymes
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Figure 1.3: A summary of the reactions carried out by enzymes of the P-family of PLP-
dependent enzymes
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cs__ bacill 39
♦
----- PG-SJVKDRI-GLAMIEAAE- ----- K 58 167 DD-^QLDGFVGGIG-TGG^ITGGG^rLK E 199
cs__ e_coli 36 —ps-fvkkcrIiGAMUWDGE- -----K 55 165 dg-qvdvfiggvg-tggtltgvsryikg-tk 183
cs__ yeast 81 -----PG-ISGKDRV-GLNIIKTGE- ----- E 100 219 -KGNIDGFGGCG-GGTIrGVGKFL.JKERGK 248
dsdht__ bac 111 HELPISGSIKRGGirEVLKYGENLGLQ 136 266 SLETPLFVYhPCGvVCGSGPIGVGFGLKLLYG 296
lsdht -yea 34 -----pg-gsfksrg-ighlirksn- ---Q 53 171 SLPRVKGLVCJSVI-GGGLFSII IKGLDR-NH 200
td__ bacill 54 ----- PT,-<SFKD^^MVMGVGKGK- ----- E 73 174 -GEGPDVLAIPVG-GGGNIGYWK<GFKEYHE 203
td__ e_coli 57 ----- PV-HSKLRGG-AY7MMGGLT- ----- E 76 178 —~GHLDRWFVVG-GGIGAA(GWVLKKQMP 206
td__ yeast 104 ----- PV-FSKRG-AYIMIGKLD- ----- D 123 225 TGNKIGAVFVPVG-GGGLIGGIGAYLKRVAP 256
trs__ bac11 85 ----- HT-GSHKINN--LGQGLL-K~ ----- K 104 223 EGTM>D]KWACVG-GGSN-MCGM'QQ-?ILJ-ED 252
trs e col 81 ----- HG-GGHKTNQ-VLGQALLGK- ----- R 100 219 EGRLPDAVIA<CVG-<G3S1N-I(GMF-)DFN-ET 248
ts__ bacill 54 ----- PT'-CSFKKRG^-VMGVGKGI^C- ----- E 73 174 -GE-PDVLAIPVG-GGGNI-YWKGFKEYHE 203
ts e coli 102 FHGPT-UFKDFG-GIFMGQMLI?- -----H 121 236 ETRNQLWSVPSGNFGDLTGGL]LG<SILI-LP 266
ts__ yeast 119 ^^PT^TG^KDVG^LQFV^BLra-
*
----- Y 138 265 KDSKKVKFWP^^^F^D^^IG
*
296
The lysine residue responsible for binding to PLP is indicated by an arrow. The consensus sequence is given 
below the other sequences. Homologous residues are indicated by a period, identical residues by an asterisk.
Figure 1.4: Sequence homology of p-family enzymes around the lysine motif and the 
— glycine-rich turn,.
Further evidence of the evolutionary relationship between the P-family enzymes is found in 
their ability to catalyse similar reactions and produce similar intermediates, suggesting a similar 
active-site conformation. TS from B. subtilis and E. coli still exhibit some TD activity both in 
vivo and in vitro and both TD and TS produce a-aminocrotonate as an intermediata.19 TrS 
can catalyse the conversion of vinylglycine to a-ketobutyrate, a reaction normally carried out 
by TS.37 TS also catalyses various side-reactions (Appendix 2).
In contrast to members of the a-family, in the P-enzymes the PLP-binding lysine is positioned 
in the NF^-Terminal segment of the polypeptide chain between residues 41 and 118.24 This 
difference may reflect the alternative PLP arrangement needed for the enzymes to carry out 
reactions at the Ca-centre rather than at the cP-atom.
1.2.2.3 The y-Family of PLP-Dependent Enzymes24
The y-family contains four members and is therefore the smallest group of PLP enzymes (Table
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1.2 ). Belfaiza et al. noted an overall homology of 36% (31% identiiy) between the two 
cystathionase enzymes.38
Alexander et al. found that the PLP-binding lysine residue is in the same sequence segment as 
in the a-family suggesting a possible evolutionary relationship between these two families.24 
As stated earlier, significant sequence similarities between TrS (of the P-family) and O- 
acetylhomoserine sulfliydrolase of this family have also been shown.36
Table 1.2: Enzymes of the y-family .
O-succrnylhomostrrme (thiolylyase (cystathionine-y^-synthase)
O-acetylhomoserine (thiol)-lyase (methionine synthase)
Cystathronine-y-l,yast (y-cystathromast)
- - Cystathionine-f-lyase (f-cystathromase)
1.2.2.4 Other PLP Enzymes
A few of the PLP-dependent enzymes studied by Alexander et al. proved to be unrelated to any 
of the three family groups. These are alanine racemase, selenocysieine synthase and many 
amino acid decarboxylases which are not in group 1124
1.2.2.5 Exceptions to the "Family Rule"
As already mentioned a few PLP-dependent enzymes do not belong to the family that would be 
suggested by their regioselectivity. Tryptophanase, tyrosine phenol lyase and 4-amino-4- 
deoxychorismate synthase are all members of the a-family by virtue of their sequences, yet 
they catalyse P-elimination reactions.24 1-aminocyclopropane-1-carboxylate synthase, also an 
a-family enzyme, catalyses an ay-replacement reaction. Similarly, TS, which is a member of 
the p-family, catalyses a p,y-replacement and cystathionine p-lyase, supposedly a y-family 
enzyme, catalyses a P-elimination reaction .24
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1.3 The Structure and Mechanism of PLP Enzymes
1.3.1 A General Mechanism of PLP-Enzyme Action
Much of the information concerning the general mechanism of PLP-mediated amino acid 
reactions and the structure of PLP enzymes has been gleaned from studies of the PLP- 
dependent transaminases. In particular the action of aspartate aminotransferase (AspAT- has 
received much attention. Between 1954 and 1955 two independent workers, Braunstein and 
Snell, developed a general theory for the mechanism of PLP enzymes.39- 40 The following 
section gives a detailed discussion of this mechanism, and examines the experimental data that 
was used to prove it.
For all known PEP-enzymes the first reaction step involves the formation of the Michaelis 
complex (10- otherwise known as the holoenzyme sidimine or internal aldimine between the e­
amino group of a specific enzyme-bound lysine residue and the C-4' carbonyl group of PLP 
(1, Scheme 1.5).4> 5
Upon formation of the hfioenzyme the amino acid substrate can bind to give the Schiff's base 
substrate aldimine (or external aldimine, 7-41 This involves the condensation of the amino 
acid substrate with the internal aldimine (a process known as transaldimination4 or 
transiminstiotl3) with the simultaneous release of the enzyme-bound lysine residue (Scheme 
1.5-.42 This occurs via the formation of a tetrahedral transition complex. Formation of the 
external aldimine was originally observed for AspAT by a change to an absorption maximum at 
430 nm in the UV-visible spectrum and a decrease in the positive CD value .43-45
The structure of this external aldimine at the active-site has not been rigorously established, but 
a rra«5-configuration at the imine double bond (C-4'-N) is most likely on steric groundsP as 
unfavourable interactions would occur if the 4'-N substituent were in the czy-coplanar 
conformation.46 This structure would also allow hydrogen bonding between the imine
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nitrogen and the hydroxyl group on the pyridine ring,5 helping to hold the imine double bond 
in the plane of the pyridinium ring. Braunstein and Snell first postulated the formation of the 
external aldimine as a solution to the mechanistic problem of C°5bond cleavage leading to an 
intermediate carbanion which is too basic to be kinetically competent.59 40 They suggested that 
the developing negative charge is stabilised by the delocalisation of electrons mesomerically 
with the positively charged pyridinium nitrogen atom47
R = Enz-Lys-NHi
1
400 - 430 nm
Enz
H
External aldimine (7)
®o
320 »340 nm
H
13
H
12
Scheme 1.5; Condensation between lysine residue and PLP (1) at the enzyme active-site followed, 
by transaldimination. hmax absorbance values are given for various intermediates.
Dunathan's postulate states that, in the external aldimine, rotation about the Ca-N bond is 
controlled by the enzyme, so that the bond to be cleaved at Ca is held orthogonal to the plane of 
the pyridinium ring, thus allowing maximum orbital overlap between the developing
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negative charge and the conjugated electron-deficient 71-system (Scheme 1.6).4> 5 The Ca- 
CO2H bond is broken by the a-decarboxylases whereas the amino acid transaminases and 
racemases cleave the Ca-H bond.4 These enzymes will be discussed further in Section 1.4. 
The formation of the conjugated enamine (or quinonoid intermediate, 14) in Asp ATs is 
accompanied by a characteristic absorption band at 502 nm and a sharp negative CD.43'45
IB-Enz
400 - 430 nm
External aldimine (7)
z
= N'C©wco2‘
;,„.H U H
N CH3 
H
Quinonoid intermediate (14)
H
Scheme 1.6: Preferential cleavage of the bond orthogonal to the plane of the pyridinium ring as 
predicted by the Dunathan hypothesis. This example shows Ca-H cleavage but Ca-CO2 and 
Ca-R bond cleavage can also occur. The diagram also shows the hydrogen bond between the 
PLP hydroxyl group and the nitrogen on the substrate, which helps to hold the imine bond in the 
plane of the pyridinium ring.
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Quantum mechanical calculations have indeed implied that the strength of a a-bond between Ca 
of the Schiffs base and the electrofuge is at its weakest when the bond lies perpendicular to the 
pyridinium ring.88 Floss and Vederas suggest that, if an enzyme were to bind the relatively 
rigid PLP-cofactor at the pyridine nitrogen and at the phosphate, attachment of a single distal 
group on the substrate, which in most cases would probably be the carboxyl group, would 
result in a three-point binding of the complex fixing a particular conformation of the C“-N 
bond. 5 There is little actual evidence to support this suggestion however plausible it may
seem.
Abbot has provided experimental support for Dunathan's hypothesis by demonstrating that in a 
complex between cobalt (III) and PLP-glycine Schiffs base the two C--hydrogens are held in 
distinct conformations relative to the 7-system and apparently exchange at different rates, as 
measured by -H-NMR spectroscopy (see Fig. 1.5).-9
Figure 1.5: Complex between cobalt (III) and PLP-glytine Schiffs base
Karpeisky and Ivanov proposed a model for the mechanism of enzyme-catalysed 
transamination, suggesting that the transaldimination step requires reorientation of the 
coenzyme by rotatory dislocation round an axis passing through its 2-methyl and 5'-phosphaie 
groups (indicated on structure 10, Scheme 1.5).8f’ 5i The reversal to the original frientaiifn 
of the coenzyme ring would be linked with the transition from the PMP ketimine to the free 
PMP-enzyme and keto acid.
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A large number of reaction pathways are available to a PLP-amino acid, and it is the enzyme 
present which determines which of the Ca bonds are broken by orienting the Ca-R bond and 
which determines the reaction specificity by the positioning of specific binding sites and 
catalytically active residues. Snell and Metzler postulated that the catalytic abilities of PLP- 
dependent systems are, to an exaggerated degree, those of the coenzyme and that enzymic and 
non-enzymic reactions proceed by similar mechanisms.40 It has also been postulated that the 
reactions of PLP-enzymes all take place only on one face of the planar PLP-substrate complex 
(the ‘exposed’ or ‘solvent’ face) the other being covered by the protein. It has been noted that 
the ‘exposed’ face is always the si -face at C-4’ of the cofactor (below the plane of the page in 
all structures shown).5
1.3.2 Recent Structural and Mechanistic Studies on p-Family Enzymes
1.3.2.1 Recently Published Crystallographic Data on PLP Enzymes
The first X-Ray stmctures of cytosolic chicken heart AspAT became available in 1975.52 The 
most recent studies on AspATs include that on a R292D mutant complexed with PLP and 
sulfate at 2.8A resolution in 1993, and a K259H mutant complexed with PLP at 2.1A 
resolution in 1995.53,54 Arg292 is responsible for substrate charge specificity in the wild-type 
enzyme and Lys259 is the residue which forms a Schiff base with PLP in the active-site. The 
R292D mutant preferred arginine to aspartate as a substrate, but had a lower catalytic efficiency 
than the wild-type enzyme. This was attributed to small side-chain and main chain 
reorientations. The catalytic competence of the K259H mutant in the forward half-reaction was 
only 0.1% that of the wild-type enzyme. The most recently obtained structure was produced in 
1997 of wild-type pig cAspAT refined to 1.6A resolution.55 However, for most of the a- and 
y-family enzymes there are few representative 3" stmctures available.
Of the p-family enzymes only crystal structures for TrS are available (Fig 1.6). Complexes of 
wild-type TrS with PLP in the presence of Cs+ and K+ ions have been resolved to 2.3 and
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Wild-type TrS complexed with PLP
-A
Gln1I4/""^
dy303
Lys382
Glu350
Ala348
Lys8,
Thrl90
Ser:
er377
Cys230
Ser351
Alal91 Gly23 Val231
Asn2
Ala237
PK87T TrS complexed with PLP and (2S)-serine
lyl 16
Ala23
Thrll O
Leu 16'
Leu304
AIa302
Figure 1.6: Active-site structures of the (i-subunit of wild-type and (5K87T TrS.aa< 58> 59
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2.0A respectively.60 Substitution of these monovalent cations for Na+ induce local and long- 
range changes in the 3D structure of the enzyme. A crystal structure of the wild-type 
holoenzyme is also available without cations at 2.5A resolution (Fig. 1.6, top).56 A mutant 
form of TrS ((3K87T), lacking the PLP-binding lysine residue in the P-subunit, has been 
crystallised recently in two forms, complexed with PLP and the natural substrate, (2S)-serine 
(Fig. 1.6, bottom), or with PLP and the product, (25')-tryptophan.57 These structures were 
refined to 1.9A resolution.
1.3.2.2 Structure-Activity Studies on O-Acetylserine Sulfhydrylase
In 1994 McClure and Cook carried out fluorescence studies on OASS to attempt to determine 
the effect of product and substrate binding on the structure of the enzyme.61 Previously the 
emissions of both enzymic and synthetic PLP Schiff bases in both aqueous and non-aqueous 
buffers had been studied and these results were used for comparison. An emission maximum 
was observed at 497 nm with OASS, consistent with the presence of a PLP-Schiff base in an 
aqueous environment. In addition, emissions attributed to the presence of tryptophan residues 
in the enzyme were considerably quenched by the formation of the holoenzyme, consistent 
with a model in which energy transfer occurs between at least one Trp residue and the PLP 
Schiff base during transaldmination. A similar phenomenon had been observed with TrS and 
this was attributed either to singlet-singlet or triplet-singlet energy transfer from an excited Trp 
residue to the PLP Schiff base in the holoenzyme.62-63
Other results with OASS indicated that product binding does not affect the equilibrium between 
tautomers of PLP that might be present in the enzyme. An enhanced fluorescence observed 
upon the binding of (25)-cysteine to OASS was thought to indicate a conformational change 
that occurs upon transaldimination to increase the efficiency of energy transfer from a Trp 
residue. The presence of a Trp residue, namely Trp 163, in the active-site was therefore 
postulated. More recent studies on Trp luminescence have produced further evidence that such 
a conformational change takes place.64 Addition of O-acetylserine (OAS) to OASS led to
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a splitting of the 0,0 vibronic band in the phosphorescence spectrum of Trp 163 yielding poorly 
resolved peaks at 406 and 408.5 nm. This indicated that the polarity of the environment of the 
Trp residue had changed as the internal Schiff base was converted to a^^e^n^j^r^c^a^ctylate (Scheme 
1.7). The distance between Trpl63 and PLP was estimated to be about 25A which is 
comparable to the distance between Trp 177 and PLP in TrS.55
Scheme 1.7; Formation of the a-aminoacrylate intermediate. R’ = OAc for OASS or OH
for TrS.
Studies by Cook et al. confirmed that transaldimination produces a conformational change in 
the enzyme, but their data indicated that this is reversed by the formation of the a- 
aminoacrylate intermediate 15.55 They studied the characteristics of OASS with various 
substrate analogues. With (2S)-serine and (2S)-cysteine the enzyme was trapped in the 
external aldimine form, whereas with the natural substrate, OAS, the a^-^aminoacrylate 15 was 
formed. UV-CD spectra recorded for OASS in the presence or absence of the three amino 
acids revealed a significant increase in the ac-helical content of the enzyme in the external Schiff 
base as compared to the internal aldimine. This was interpreted as the closing of the active-site 
into a catalytic conformation. No difference was observed, however, between the 2“ structures 
of the internal aldimine and species 15, evidence which was later refuted by investigations on 
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the phosphorescence of Trp 163 (see earlier discussion).64 The formation of the external 
aldimine from the holoenzyme aldimine was observed by a shift in the Xmax value from 
412 nm, for OASS and PLP, to 418 nm. The absorption band at 412 nm indicates that the 
Schiff base between the enzyme lysine and PLP is protonated. Cook et al. also suggest that the 
pyridinium nitrogen is protonated in the internal aldimine66 The external aldimine formed with 
(2S)-serine also produced a second absorbance band at 320 nm suggestive of the establishment 
of an equilibrium between different tautomeric forms of the Schiffs base. In the presence of 
OAS, absorbance at 481 nm increased, concomitant with a decrease in the absorbance at 412 
nm, indicating concerted formation of 15. No quinonoid intermediate was detected for OASS, 
whereas for TrS a quinonoidal species has been detected as a fleeting transient, before an 
equilibrium is established between the a-aminoacrylate and the external Schiff base.67
The 31p NMR spectra for the reactions of OASS with (25)-serine and (2S)-cysteine were also 
evaluated.65 The internal aldimine has a relatively high 5p value, indicative of a strong salt 
bridge formed between the 5’-phosphate group in the dianionic form and an enzyme residue, 
which is excluded from solvent. Similar findings for TrS and D-serine dehydratase (DSDHT) 
were also cited.68 The line widths of the 31p NMR signals for the external aldimines formed 
were considerably increased, indicating the presence of different tautomeric forms of the Schiff 
bases. ,
Initial velocity studies on the basis of pH indicated that in the internal aldimine an enzyme 
residue with a pK of 6.7 - 7 must be protonated for maximum activity.66 This residue is 
thought to hydrogen bond to the O-acetyl group on the substrate to hold it in the correct 
conformation for p-elimination to occur. A similar mechanism may operate for TS to hold the 
y-phosphate group of O-PHse orthogonal to the PLP ring prior to elimination. Additional data 
suggested that the enzyme lysine (Lys42) that forms the internal Schiff base with PLP also acts 
as a general base to accept a proton from the a-carbon of the external Schiff base. A K42A 
mutant was also found to be incapable of forming 15. The protonated lysine is thought to 
donate a proton back to the a-carbon of 15 to form the product external Schiff base.
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At the start of the second half-reaction, in which 15 undergoes nucleophilic attack by HS\ the 
lysine residue is protonated and the enzyme group with a pK of 6.7 - 7 is unprotonated.66 The 
latter hydrogen-bonds to the incoming nucleophile. A similar mechanism may operate in other 
p-family enzymes. Nucleophilic attack at C-3 of 15 is accompanied by protonation of the a- 
carbon. The unprotonated lysine residue then attacks C-4’ of the product external aldimine to 
regenerate the interal aldimine.
More recent studies on OASS have involved stopped-flow and single wavelength absorbance 
stopped-flow experiments and kinetic isotope studies.67-69 These implied that the first half­
reaction (formation of 15) was limiting to the overall reaction. The external Schiff base formed 
rapidly, but its conversion to 15 was slower and quasi-irreversible.
1.3.2.3 Structure-Activity Studies on Tryptophan Synthase
TrS exists as an a2p2 tetramer of which the a-subunits catalyse the formation of indole and the 
P-subunits utilise PLP in catalysing the formation of (25)-tryptophan. Various studies on TrS 
have attempted to elucidate the functions of a number of amino acid residues by using mutated 
enzymes. In one such study the role of PGlu35O was investigated.70 Crystal structures had 
already revealed that this residue is located near the protonated pyridinium nitrogen of PLP and 
stacked parallel to the plane of the coenzyme in a geometry that might not favour strong 
interaction (Fig. 1.6 and Appendix 3). Comparisons of the wild-type, PE350A and PE350Q 
mutants indicated that although E350 is not essential for catalysis it may serve a role in 
stabilising an optimal conformation of the active-site. Mutation of this residue did not induce 
gross conformational change, however, as all the enzymes had many similarities in their 
spectroscopic properties and substrate specificities. A reduced intensity of the 412 nm peak for 
the internal Schiff base did suggest, that the orientation of PLP was altered in the mutants. The 
mutant enzymes also appeared incapable of a-proton removal, or of catalysing P-elimination to 
form 15. This may be attributed to an alteration of the positions of catalytic groups in the 
active-site relative to the p-hydroxyl group of (25)-serine. Later studies on mutants PE109A, 
pE306A and pD3O5A showed similar alterations in their reaction specificities, indicating that
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the active-site conformation of the wild-type enzyme is readily altered and that these changes 
affect the selectivity of the enzyme.70
A pK167T TrS mutant was observed to have a drastically reduced specific activity in its 
p-reaction (4% of wild-type) although the a-reaction was unaffected! 1 The substrate and 
reaction specificities were also altered from the wild-type enzyme. The K167T a2p2 complex, 
like the wild-type P-subunit, was more active with P-chloro-^Sj-alanine than with (2S)-serine 
and had similar activities in the p-replacement and p-elimination reactions. This differed from 
the wild-type a%p2 complex. The spectroscopic properties of the K167T a%p2 complex also 
differed from that of the wild-type tetramer. In the presence of the substrate, (2S)-serine, the 
major intermediate for the mutant enzyme had a dominant absorbance at 420 nm, ascribed to 
the external aldimine. The wild-type Ot2p2 complex produced a major absorbance at 340 nm 
with the substrate, ascribed to 15. Interestingly, upon binding of a-subunit ligands, the 
properties of the mutant enzyme became closely similar to those of the wild-type enzyme. 
These results were seen to imply that the interaction of PK167 with aD56 is important for 
promoting intersubunit communications in the tetramer.
Luminescence studies of TrS revealed a number of details concerning the allosteric activation of 
the CK2P2 tetramer63 . The binding of a-subunit ligands caused a reduction in the thermal 
quenching of the fluorescence of Trp 177 and slower triplet decay kinetics. (See earlier 
discussion on Trp fluorescence in OASS). From this it was inferred that there was a 
considerable tightening of the active-site region and N-domain. However, the constancy of 
Trp 177 fluorescence and phosphorescence in the various complexes of the native enzyme 
suggested that the structural changes observed in phosphorescence do not involve a different 
distance or orientation of the PLP moiety relative to Trp 177. This would indicate that the PLP 
ring does not tilt during transaldimination in TrS. Reorientation of the coenzyme has been 
observed, however, during the tcansaldinination reactions of a-family enzymes 42 In addition 
the internal Schiff base at K87 of the p-subunit was clearly demonstrated to exist in two 
tautomeric forms, that of a ketoenamine and an enolimine fluorescing at around 490-510 and 
361-380 nm respectively.
25
PLP Enzymes - Structure and Mechanism- Tryptophan Synthase
Although studies have been carried out on the roles of the PLP-binding lysine residue of 
various a-family enzymes, it was not until 1993 that the altered properties of a PK87T mutant 
TrS were investigated by E. W. Miles et al..11 Spectroscopic and kinetic studies revealed that 
the mutant enzyme formed external aldimines much more slowly than the wild-type and only 
carried out two slow partial P-elimination reactions: the conversion of P-chloro-(25)-alanine 
and (2S)-serine to 15. The latter reaction was catalysed by ammonia, which partially replaced 
the deleted e-amino group. These results highlighted the role of K87 in facilitating the 
formation of external aldimines by transaldimination and its importance for substrate and 
product release, because (25)-serine, (25)-tryptophan and aminoacrylate dissociated very 
slowly from the mutant (X2P2 complex. The residue does not play an essential role in cofactor 
binding, which is in agreement with results observed for other PLP enzymes.
One of the most recent studies on the p-subunit of TrS involved the construction of 4 
C-terminal deletion proteins and 11 point mutant proteins.73 Multiple sequence alignments had 
revealed that residues 384 - 397 are variable, whereas residues 378 - 383 are conserved (see 
Appendix 3 for the positioning of these residues relative to PLP). Residues 383 - 393 form 
helix 13. Deletion of the variable region (A384 - 397) resulted in 80% inactivation of the 
enzyme, whereas the additional deletion of one or two conserved residues (A383 - 397 or 
A382 - 397) resulted in greater inactivation. Point mutants at the conserved residues R379, 
D381 or K382 exhibit significant activities (2 - 40%). The authors concluded that the C- 
terminal conserved and variable regions and helix 13 play no essential functional roles, but may 
serve structural roles.
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1.4 The Metabolic Roles of Pyridoxal 5'-Phosphate Dependent Enzymes
In Section 1.1 introducing PLP-enzymes some of their metabolic functions were alluded to. 
This section describes the roles of various important PLP-dependent enzymes and some 
reference is also made to the biochemical effects of pyridoxine deficiency to further illustrate its
physiological function.
1.4.1 Niacin (Nicotinic Acid) Synthesis From Tryptophan
The tryptophan-kynurenine-nicotinic acid metabolic pathway in most animal species is under 
the control of four Bg-dependent enzymes. If a deficiency of pyridoxine (Bg) occurs then 
kynurenine (16) is diverted away from its further conversion to niacin to become involved 
instead in the formation of xanthurenic acid. Excretion levels of this acid are therefore used as 
an indicator of the levels of Bg deficiency.74
Kynurenine (16), xanthurenic acid (17) and niacin (18).
Niacin is an essential component of the two cofactors, nicotinamide adenine dinucleotide 
(NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+), which are involved in a 
number of processes: tissue respiration, glycolysis, the hydrogen transport series, the 
formation of high energy phosphate bonds, pyruvate metabolism, pentose biosynthesis, lipid 
metabolism, amino acid and protein metabolism and photosynthesis. In fact more than forty
27
Metabolic Role of PLP Enzymes Pellagra
reactions are known to be dependent on these two cofactors. Niacin is therefore required by all 
living cells.
1.4.1.1 Pellagra and Related Diseases
In man, if niacin is not obtained through the diet, this can result in a condition called pellagra. 
The name of this disease is derived from two italian words: "pelle" meaning skin and "agra” 
meaning rough or unsightly.75 Although pyridoxine deficiency rarely leads to the disease in 
adults, in infants the lack of pyridoxine is much more likely to be a factor in niacin deficiency.
In the 1940’s a liquid baby formula in which a considerable portion of vitamin Bg had been 
destroyed by heat sterilisation produced convulsions in infa^ts7^ Prompt administration of the 
vitamin to -affected babies produced quick recovery. Similar symptoms were observed by 
Hawkins and Barsky when they attempted to produce experimental pyridoxine deficiency in 
human subjects, although one child developed hyper chromic anaemia instead^7
Pellagra has often been referred to as the disease of the four 'D's: dermatitis, diarrhoea, 
dementia and death.55 Early signs of the disease include lassitude, anorexia, weakness, 
digestive disturbances (such as heartburn and nausea) and various psychic and emotional 
changes such as anxiety, depression and irritability 78 One main indicator for the disease is an 
affection of the skin resembling severe sunburn, which is usually symmetrically disposed on 
those parts of the body which have been exposed to the sun (Fig. 1.7).55 (In cases of chronic 
pellagra skin changes include thickening, scaling, hypdrkdratinization and pigmentation). The 
mouth can also become sore, especially the tongue, and the gastrointestinal tract inflamed, 
leading to diarrhoea.70 If the disease progresses to an advanced state the patient may 
experience delirium, hallucinations, disorientation, confusion and stupor.85 Fortunately 
treatment of the disease with the administration of a B vitamin complex is swift to reverse the 
effects of the disease, with recovery sometimes produced within 24 hours.
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Figure 1.7: Casal's necklace - a common symptom of pellagra.
As described in Section 1.1 rats fed a diet similar to that which caused pellagra in humans 
developed a dermatitis similar to a human disease known as acrodynia.75 There was reddening 
and scaliness of the snout, the paws and the tail. It was because riboflavin (vitamin B2) and 
niacin (nicotinic acid) failed to cure the condition that Bg was first identified as a new vitamin, 
which restored the rats to normal health? The lack of pyridoxine also causes rats to lose 
hunger, thus aggravating any inherent problems of nutritional deficiency, with ensuing weight 
loss and a decrease in fat storage. There was also oedema, growth retardation, anaemia, 
proteinuria, nerve degeneration and abnormal reproductive performances in rats maintained on 
the pyridoxine-deficient diet?0
Various other animal species have also been tested for their response to pyridoxine deficiency 
in the diet. The vitamin is essential for the growth of chicks, dogs, pigs, mice and infant 
humans as well as for a number of microorganisms?? In dogs, as in several other animals, 
microcytic anaemia results from a lack of Bg.?? In monkeys Rinehart and Greenberg
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demonstrated that a lack of Bg caused atherosclerosis and hypercholesterolemia.83 This was 
attributed to the role of PLP in essential fatty acid synthesis. In chicks there was poor growth 
and feathering, inflammation of the mouth and diarrhoea as a result of Bg deficiency, whereas 
rabbits suffered from subnormal weight gain, leukopemia and terminal diarrhoea..78 
Pyridoxine deficiency has also been implicated in kidney stone formation due to the 
accumulation of calcium oxalate caused by a lack of transaminase activity necessary for the 
conversion of oxalate to glycine. A loss of conditional reflex performance and some 
impairment of the immune response in various Bg-deficient animals has also been found.84
1.4.2 Decarboxylases.
PLP-dependent decarboxylases control the formation of a number of important amines. These 
include GABA (19), putrescine (20), histamine (21) and dopamine (22)
1.4.2.1 y-Aminobutyric Acid Transaminase (GABA-T)
Glycine and y-amino butyrate (GABA, 19) increase the permeability of postsynaptic 
membranes towards chloride ions.74 This results in an improved chloride conductance causing 
membrane hyper polarisation. It is this effect which increases the threshold for the triggering 
of an action potential and thus effectively inhibits neurotransmission in the central nervous 
system (CNS). In a therapeutic capacity high cerebral concentrations of GAB A have been 
shown to prevent convulsions by depressing the firing of neurons throughout the CNS.
y-aminobutyrate (19) and glutamate (23).
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GABA is formed via the decarboxylation of glutamate (23), a reaction which is catalysed by 
glutamate decarboxylase in the mammalian brain. Both the decarboxylase and y-amino butyric 
acid transaminase (GABA-T) are PLP-dependent enzymes involved in the regulation of the 
GABA-ergic system. The inhibition of GABA-T, the first enzyme on this catabolic pathway, 
may be important in anti-convulsive therapy. Several factors indicated the role of GABA in 
causing convulsions: its abundance in the brain, its ability to produce hyperpolarizing 
inhibition of almost all neurons, its association with benzodiazepines and the discovery that 
many convulsants inhibited its synthesis.85 One anti-epileptic drug, y-vinyl GABA (GVG), 
also known as vigabatrin, is a selective irreversible suicide inhibitor of GABA-T and increases 
brain and cerebrospinal fluid GABA levels, without a deleterious effect on cognitive 
function.86-87 This drug has been widely tested for side-effects and tolerance development, 
with encouraging results and is the only GABA-T inhibitor in clinical use.86-94 Patients 
suffering from chronic epilepsy when treated with this drug maintained a 54.7% reduction of 
seizure frequency compared with an 18.6% increase for those on placebo.86 GVG and 
ethanolamine 6>-sulfate have been shown to reduce rat brain GABA-T activity in vitro by 65 - 
79% and increase GABA content by 40 - 99% compared with control values.95 Other 
GABA-T inhibitors include gabaculine, y-acetylenic GABA and aminooxyacetic acid 
(AOAA).91’96 AOAA has been shown to dose-dependently increase spinal GABA content and 
markedly surpress procaine-induced convulsions in rat spinal cord.97 Pyridoxine has also 
been used as a treatment of epilepsy in infants.98- 99 A treatment for migraine prophylaxis, 
valproic acid, is believed to act by inhibiting GABA-T and the antidepressant phenelzine also 
reduced GABA-T activity in rat brains.100-101
1.4.2.2 Ornithine Decarboxylase (ODC)
Ornithine decarboxylase (ODC) is the first, rate limiting enzyme in the biosynthetic pathway to 
putrescine (20) and higher polyamines.102 Both spermine and spermidine (24) are 
synthesised from putrescine. These two positively-charged polyamines help to counteract the 
charge repulsion effects of negatively charged phosphate groups on DNA, thus ensuring that
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chromosomal DNA is sufficiently compacted to fit inside a cell.
Putrescine (20) and spermidine (24).
The activity of ODC in vivo increases dramatically in response to cellular stimulation which 
promotes regeneration and replication. Cellular levels of the enzyme are therefore high during 
growth and protein synthesis and very low in growth arrested cells.103 ODC activity has been 
shown to increase markedly in cells undergoing apoptosis followed by a paradoxical decrease 
of the intracellular content of poly amines.104 Liver sepsis and traumatic brain injury in rats is 
also accompanied by increased ODC activity.105-107
The association of high polyamine levels with rapid cellular proliferation and protein 
biosynthesis led to the idea that polyamines may be required for RNA and DNA
i
biosynthesis.108 For this reason the enzyme has been identified as a target for cancer 
chemotherapy .4 Many tumour promoters have been shown to increase ODC activity and a 
recent study confirms the potential role of ODC in causing tumor growth. 109’111 Constitutive 
expression of epidermal ODC in transgenic mice led to several abnormalities, including the 
development of dermal follicular cysts, excessive skin wrinkling, enhanced nail growth, 
alopecia and spontaneous tumor development. 111 The tumors themselves were analysed for 
ODC activity and the absolute values of ODC-specific activity were extremely high in all 
tumors. ODC activity has also been reported to be high in human neoplastic lesions from 
breast, stomach and colon.H2 Tamori and co-workers compared the nucleotide sequence of 
ODC cDNA with that of non-tumorous tissue in the same patients and discovered three point 
mutations in hepatoma ODC cDNA, which led to a change in two amino acids and the 
replacement of codon 415 (CAA) with TAA, a stop coddn.112 The truncated ODC from
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hepatoma tissue is stabilised, thus increasing its half-life compared to that of wild-type ODC. 
Studies have indicated that a high level of tumor ODC expression predicts a favourable 
prognosis in humn colorectal carcinoma but not in breast cancer.1 13«114
Many highly specific and potent inhibitors of ODC are based on the lead compound 
a-dhfluoromethylonnthme, an enzyme-activated irreversible inhibitor. W9- H5’ H6 p-carotene 
and DL-<o-tocopherylacetote oIso effect a reduction in ODC activity in human atrophic stomach 
mucosa and intestinal metaplasia, by 50% and 18% respectively.117 Unfortunately p-carotene 
appears to increase the incidence of some types of canccr.Hi Some green tea polyphenols 
inhibit ODC induction dose-dependently and crude extracts of lowbush blueberry, cranberry 
and lingonberry are active inhibitors of ODC activity in vitro.U9< 120 Wilms' tumor surpressor 
has been shown to function by binding to multiple sites within the human ODC promoter.^1
1.4.2.3 Histidine Decarboxylase (HDC)
Histidine decarboxylase (HDC) catalyses the decarboxylation of histidine (25) to give 
histamine (21). In mammals histamine is important as a major receptor agonist and regulatory 
factor for peripheral blood circulation. 122 The overproduction of histamine is associated with 
many biological responses such as gastric secretion and various allergic and hypersensitivity 
reactions. 123 The development of antihistamines; antagonists for Hj and H2 receptors, is an 
important area in medicinal chemistry. An alternative, more recent approach to the problem, 
has been to evaluate methods for controlling the biosynthesis of histamine in vivo through the 
use of specific histidine decarboxylase inhibitors 4 In vivo and in vitro experiments using the 
HDC irreversible inhibitor, ac^^'luoIO^m^r^t^hlylhistidine, produced virtually complete inactivation 
of HDC activity in the rat hypothalamus, similar to results obtained with mice. 124 i8-O-p- 
glycyrrhetinic acid has been shown to inhibit HDC activity in vitro in cultured mast cells. 125 
Somastatin also inhibits HDC in cells isolated from rabbit gastric mucosa by a dual mechanism 
involving a decrease in the affinity of the enzyme for (25)-histidine and a reduction in the 
number of functional HDC molecules. 126 HDC activity in rat oxyntic mucosa has been
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shown to be surpressed by the administration of the prostaglandin I derivative, beraprost
sodium. 127
H h
25 21
Histidine (25) and histamine (21).
1.4.2.4 DOPA Decarboxylase (DDC)
DOPA decarboxylase (DDC) is part of a family of aromatic acid decarboxylases which catalyse 
the formation of many pharmacologically important amines including catecholamines and 
indolamines.74 These enzymes proliferate in bacteria, plants and animals. DOPA 
decarboxylase itself is found in mammals, and is broadly specific for a number of aromatic 
amino acid substrates.
Amines synthesised via the action of DDC include dopamine (22) and serotonin (26). 
Dopamine is a precursor in adrenaline biosynthesis. Both adrenaline (27) and serotonin are 
catecholamine neurotransmitters and act on smooth muscle tissue and the cardiovascular 
system. These two catecholamines are synthesised from tyrosine in sympathetic nerve 
terminals and in the medulla of the adrenal gland. Adrenaline causes an increase in blood 
pressure, strengthening of the heart-rate and widening of the passages of the lungs. Serotonin 
is also thought to be important in maintaining stable mental processes and schizophrenia has 
been attributed to abnormalities in the metabolism of this amine. Two non-dopaminergic 
psychotogenic drugs, lysergic acid diethylamide (LSD) and phencyclidine (PCP) significantly 
up-regulate DDC mRNA levels in rat brains, producing useful models of schizophrenia. ' 28 
Amphetamine and vigabatrin, which act as dopaminergic system agonists, cause a down­
regulation of DDC mRNA levels. The antipsychotic drugs, haloperidol and clozapine, relieved
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the symptoms of PCP-treated animals. Evidence exists that the excess amounts of 2- 
phenylethylamine (2PE) and tryptamine produced by overactive DDC are associated with 
schizopprenia.128 These compounds are modulators of all the neuroreceptors known to play a
role in the disease.
The headache, chronic pain and depression associated with serotonin deficiency are often 
alleviated by administering Bg supplements to the patient. DOPA and various inhibitors of the 
decarboxylase are used in the treatment of Parkinson's disease, a neurological disorder 
characterised by tremor, rigidity and disturbances of posture.74
3,4-dihydroxyphenylalanine (dopamine, 22), serotonin (26) and adrenaline (27).
Serotonin has recently been shown to be a mechanism-based inactivator of DDC in both a time- 
and concentration-dependent manner, 729 This occurs via a decarboxylation-dependent 
transamination. Other substrates such as DOPA and m-tyrosine and their a-methyl derivatives 
also undergo this minor reaction and it is thought that his could be the basis of a control 
mechanism. 129 Two quaternary benzophenanthridine alkaloids, sanguinarine and 
chelerythrine, have oIso exhibited strong inhibition of the enzyme from rat liver in vitro J30
1.4.3 Amino Acid Racemases
The racemases, which catalyse the interconversion of (2S)- and (2/?)-amino acids, are 
extremely common in prokaryotes where they play a crucial role in the biosynthesis of 
peptidoglycan in bacterial cell walls. 731 These enzymes are therefore a possible target for
chemotherapy.
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1.4.4 The Aspartate Pathway
In both plants and bacteria, threonine synthase (TS) is the last of five enzymes involved in the 
biosynthesis of (25,3/?)-threonine (37) from (25)-aspartic acid (32)54 The first two steps of 
this biosynthetic pathway, known as the aspartate pathway, are common to lysine, threonine, 
isoleucine and methionine biosynthesis (see Scheme 1.8).132’133 (25,3T?)-threonine is one of 
the twenty common, nutritionally essential amino acids and as such is vital to all life forms41
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Scheme 1.8: The aspartate pathway.
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1.5 Introduction to Threonine Synthase
1.5.1 The Discovery of Threonine Synthase
The existence of the enzyme threonine synthase (EC 4.2.99.2)1 was first suggested by H. J. 
Teas et al. in 1947 1 34 Jn studies on mutant strains of both Neurospora crassa and Bacillus 
subtilis, which had a requirement of threonine (33) for growth, he demonstrated that 
homoserine (31) was a precursor to both threonine and methionine. During the early 1950s a 
number of other authors reported on work with various other species of bacteria which led 
them to assume that the pathway for threonine biosynthesis in all bacteria was as 
follows:535'139
aspartic acid ----------- *- homoserine ------------ ► threonine
Figure 1.8: Route for the biosynthesis of threonine from aspartic acid postulated in the 1950s.
However, the enzyme was not properly identified in bacteria until 1960 when Flavin and 
Slaughter reported a pyridoxal phosphate-dependent enzyme, "which will be called threonine 
synthetase, [and which] catalyzed an elimination of orthophosphate coupled to isomerisation 
from y- to p- hydroxy compound, to yield threonine from P-homoserine."140 The conversion 
of (2.5)-0>-phosphohomoserine to threonine actually takes place stereospecifically via a p,y- 
replacement, and a side-product of the reaction is inorganic phosphate (Scheme 1.9). It was 
not until 1975 that the enzyme was first isolated from plants. 141
+
H-3N,
H"
o C
OH
H
+ Pi
Inorganic
phosphate33
Scheme 1.9: The reaction catalysed by threonine synthase.
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1.5.2 Associated Deaminase Activity of Threonine Synthase
TS is very selective for the substrate, and is only known to catalyse a few other reactions, often
with substrates similar to (2S)-0>-phosphohomoserine (see Appendix 2). In addition to 
catalysing the dephosphorylation of (2S)-0-phosphohomoserine, TS in B, subtilis and E. coli 
has also been shown to catalyse its subsequent deamination; a step usually carried out by the 
enzyme threonine deaminase (Scheme 1.10)442 This reaction yields a-ketobutyrate (34).
+ 
NH3
H"JL n
QzC
.O'
O'
32
----------~ rJ^CH3 + HOPO32' + NH3
34
o
Scheme 1.10: (2S)-O-phosphohomoserine deaminase reaction..
Mutation events affecting TS activity also affected the deaminase activity suggesting that both 
activities were produced by the same enzyme.142’ 143 In contrast to the reaction involving 
threonine deaminase, the deaminase activity of TS has been shown not to pass through a 
threonine intermediate (Scheme 1.11).142 This activity of TS was therefore 'named 
phosphohomoserine deaminase. This associated phosphohomoserine deaminase activity was 
shown to be a lesser activity of threonine synthase, as the two activities co-purified, were of the 
same molecular weight, co-inactivated upon heating and also displayed the same value for 
the substrate, phosphohomoserine. 144 This associated deaminase activity appears unique to the 
TS enzymes of B. subtilis and E. coli.
phosphohomoserine
■... . ■■ ' ■ ■’
phosphohomoserine / 
deaminase /
-NH3 -PO43- ' \ threonine synthase
isoleucine -
h-------------------
r
*---------- a-ketobutyrate
threonine deaminase,
threonine ;
-NH’
Scheme 1.11: Alternative metabolic pathways for phosphohomoserine
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1.5.3 Regulation of Threonine Synthase
As mentioned in Section 1.4.4 threonine synthase (TS) is the last of five enzymes involved in 
the biosynthesis of (25,3/?)-threonine (33) from (2S)-aspartic acid (28, Scheme 1.8).54 Table
1.3 compares the human requirement for some of the common amino acids. Interestingly 
threonine is also one of only two essential amino acids containing two chiral centres, the other 
being isoleucine, itself synthesised from threonine. Threonine has also been found to play a 
role in the regulation of the aspartate pathway in a number of microorganisms by feedback 
inhibition of three of the enzymes involved. 145 Depending on the organism concerned it has 
been shown to inhibit aspartokinase, 146-151 homoserine dehydrogenase, 152-155 or homoserine 
kinase. 140, 142, 156-160 jn plants TS does not generally appear to be subject to feedback 
inhibition by amino acids, but levels of TS activity are repressed by supplementation of the 
growth medium with mettionine.161 In wheat seedlings threonine almost completely inhibits 
its own synthesis without affecting methionine biocsntntsi6.1i1 An inadequate supply of 
threonine results in a negative nitrogen balance by inhibiting protein synthesis due to stalling of 
the ribosome at codons for threonine (see Section 1.7). Other amino acids then accumulate and 
are transfeiTed into degradative metabolic pathways causing a net loss in nitrogen.
Table 1.3: Minimal requirements of human beings for some of the essential amino acids (mg 
kg-1 daylf'2
lie Leu Lys Phe Met Cys Thr Trp Vai
Child 90.0 - 90.0 90.0 85.0 - 60.0 30.0 85.0
Man 10.4 9.9 8.8 4.3 1.3 11.6 6.5 2.9 8.8
Woman 5.2 7.1 3.3 3.1 4.7 0.5 3.5 2.1 9.2
WHO* 3.0 3.4 3.0 2.0 1.6 1.4 2.0 3.0 -
*World Health Organisation norms
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1.6 Tlte StmcCtire and Character of Threonine from V:ar.<ou;
Organisms
Until fairly recently little was known about the structure of threonine synthase (TS). Within the
last ten years, however, the gene encoding the TS protein has been isolated and sequenced 
from a number of organisms, as has the enzyme itself. No 3D structures of the enzyme are 
available as yet. In all cases the enzyme has proved to be dependent on pyridoxal-5'-phosphate 
(PLP, 1).
1.6.1 Microbial Sources of Threornne Synthase
The gene for TS has been isolated and sequenced from B. subtilis,162 Brevibacterium 
lactofermentumP^^' 163 Corynebacterium glutamicumP22 E. colli65 Pseudomonas 
aeruginnsaa66 Seraatia maecsssn.s222 md Saccharomyces cerevisiae (yeast). 168> 169 The 
enzyme has been isolated and characterised from these sources and also from Nsurdspora 
crassa.222 Table 1.4 shows the various masses of the enzyme from different sources.
Table 1.4. Thrednins synthase from microbial sources
Species Molecular Mass
(Mr) of TS (Da)
Number of Amino
Acid Residues
Literature
Reference
B. subtilis - 351 19
Br. lactofseosntso 52, 807 481 170
C. glutamicum 54, 481 481 164
56, 000 - 133
E. coli 47, 060 428 165
( " 36, 000 - 171 )
M. glycogenes 52, 167 475 172
S. cseevisiae 58, 000 514 169
40
TS Structure and Character -Microbial Enzyme
Depending on the species in question, the TS protein has a molecular weight ranging from 
36 to 58 kDa. As Fig. 1.9 shows, it is an enzyme which shows significant homology 
particularly in the amino acid residues in and around the active site (see also Appendix 6).173 
The average pairwise identity around the active-site is 41.8%. The lysine residue (indicated by 
an arrow) is thought by analogy with (27?)-serine dehydratase to be the residue responsible for 
binding pyridoxal phosphate to the enzyme by formation of the internal aldimine.19 This idea 
is supported by the conservation of this residue and much of the surrounding sequence, such as 
the phenylalanine and aspartic acid residues to either side (underlined), in all of the microbes 
studied. As mentioned in Section 1.2.3, TS also shows significant sequence homology with 
and a similar active-site structure to other enzymes from the p-family of PLP-dependent 
enzymes, of which it is a member (see Figs. 1.3 and 1.4 and Appendix l).24
B. subtilis
{
--------- TEGVN- PTGSFKDRG-----MVMAVAKAKEEGN-------- ----------- DTIMCASTGNTSAA
B. lactofermentum --------- YEGAN-PTGSFKDRG----- MVMAVAKAKEEGS------- ----------- EAIICASTGNTSAS
C. glutamicum --IYLGHLSEGPTAAFKDMAMQLLGELFEYELRRRN------- ------- ETINILGATSGDT-GS
E. coli —VGCLELFHGPTLAFKDFGGRFMAQMLTHIAGDKP------- ----------- VTILTATSGDT-GA
H. influenzae - -I YALELFHGPTLAFKDFGGRFMAQALAAVRGDGK------- ----------- ITILTATSGDT-GA
M. glycogenes - -LYLLSLSNGPTLAFKDMAMQLLGNLFEYVLAQKG------- ------- ETINILGATSGDT-GS
M. leprae --------- VEGLN-PTGSFKDRG----- MTMAVTDALARGQ------- ----------- RAVLCASTGNTSAS
M. tuberculosis --------- VEGLN- PTGSFKDRG----- MTMAVTDALAHGQ------- ----------- RAVLCASTGNTSAS
P. aeruginosa ------- CVELFHGPTLAFKDFALQLLGRLLDHVLAKRG------- ------- ERWIMGATSGDT-GS
S. pombe —LNVLELFHGPTFAFKDVALQFLGNLFEFFLTRKNGNKPEDERDHLTWGATSGDT-GS
S. marcescens --VSCLELFHGPTLAFKDFGGRFMAQMLAEVAGEQP------- ----------- VTILTATSGDT-GA
S. cerevisiae ENLHILELFHGPTYAFKDVALQFVGNLFEYFLQRTNANLPEGEKKQITWGATSGDT-GS 
** **** . * * *
Arrow indicates the lysine residue thought to be responsible for binding to PLP. Asterisks indicate conserved 
residues (highlighted in blue); homologous residues are shown by a period.^ Note the conserved PT--FKD 
motif at the active-site in all enzymes. (Appendix 6 shows the alignment of full TS sequences and gives values 
for the similarity between each sequence). Multiple alignment was performed using Clustal W 1.60.
Figure 1.9: Sequence homology of amino acid residues around the active-site of threonine 
synthase from various microorganisms.
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The first reported purification of threonine synthase was a 500-fold purification from 
Neurospora in 1960 through a series of acetone and ammonium sulfate fractionations followed 
by ion-exchange chromotography4 37 A crude preparation was obtained from Brevibacterium 
flavum by Miyajima et al. in 1968,45 and a purified preparation from C. glutamicum by Han 
and co-workers in 1990464 However, there were no reports of the enzyme being purified to 
homogeneity until Parsot and his co-workers described a preparation of the enzyme from E. 
coli K-12 strain Tir 8 (strain Tir 8 is a constitutive mutant for the enzymes on the threonine 
operon)465> 1?4 They carried out a 35-fold purification of the enzyme to 100% homogeneity in 
a protocol which has been adopted in subsequent experiments involving TS from this strain. 
Szczesiul and Wampler have since found TS from the same strain to have a pH optimum of 8.0 
- 8.5411 and the same enzyme has an apparent Km of 0.053 mM for phosphohomoserine475
1.6.2 Threonine Synthase from Plant Sources
The study of the aspartate pathway in plants has aroused interest for two main reasons. Firstly, 
as a result of man's desire to improve the nutritional qualities of various crop plants and 
secondly, because an understanding of the aspartate pathway in plant tissues may aid in the 
design and synthesis of effective and selective herbicides. Cereals are deficient in the 
nutritionally essential amino acids lysine and methionine and legume seeds exhibit low 
quantities of methionine.1”76 increasing the efficiency of aspartate metabolism in plants would 
lead to improved levels of a number of amino acids in fccdstoiks.
Although there have been relatively few studies on TS in plants a number of groups have 
successfully isolated and purified threonine synthase from plant sources. The enzyme was first 
detected in 1975 by Schnyder et al. in the homogenates of pea seedlings and Lemna minor. 14i 
The following year Madison and Thompson identified the enzyme in sugar beet and radish 
leaves,177 and it has since been partially purified from Lemna pausicostata,118 barley 
seedlings,!79 pea seedlings, 180 soybean plants481 Wallsgrove and ^workers have also
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shown that the enzymes of the aspartate pathway are confined to the chloroplasts of plants.182 
In all plants studied to date threonine synthase demonstrates an almost absolute requirement for 
S-adenosylmethionine (SAM, or AdoMet, 35).132 SAM acts as a potent allosteric activator of 
the enzyme, stimulating its activity as much as twenty-fold with a Hill coefficient of 2.0-2.5 
(Table 1.5).177- 183
S-adenosylmethionine (35).
Table 1.5: Kinetic properties of threonine synthase from various higher plants.
Plant Source SAM (mM) vr max
Hill
Coefficient
Literature
Reference
Sugar Beet X 2.7 38.2 nmol h“l - 165
11 J 2.2 534.3 nmol h"^ - 165
Pea Seedlings X 2.2 - 2.1 168
tl y 0.67 4-fold increase - 168
Barley Seedlings y 0.05 - - 167
Lemna pausicostata y 2.2-6.9 70.8 pmol h"l 2.5 166
The Hill Coefficient is a measure of cooperativity, where the binding of a ligand (in this case SAM) to protein 
is at 50% saturation
Half-maximal activation of TS occurs at concentrations of between 40 and 200 (iM SAM.180 
Aarnes has found TS to have a pH optimum of around 8-9 in barley seedlings.179 No 
isoenzymes of TS have been detected.132
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1.6.3 Threonine Synthase Expression in Mammalian Systems
«
In order to improve the diet of non-ruminants it is necessary to supplement their feed with the 
essential amino acids, especially lysine and threonine (33). If the genes encoding the enzymes 
used in the biosynthesis of these amino acids could be expressed in animal cells, the need for 
supplementation of the diet would be eliminated. 184 Rees and Hay recently achieved the 
expression of aspartokinase and threonine synthase in mouse 3T3 cells. 185 These were then 
able to grow successfully on medium lacking threonine but containing (25)-homoserln6 (31), 
the precursor to pHospHchomos6rin6 (32).
Threonine synthase and Homcserine kinase have never been shown to occur naturally in 
mammals. It has, however, been noted that (25)-C^-^phosphohomcs6rine is an antagonist of 
N-methyl-D-aspartate (NMDA) in the rat brain. 1 86.187 (NMDA is an excitatory amino acid in 
the mammalian CNS). Phosphohomcserice has also been the subject of a patent for its use, 
together with the drug levemopamil, in the treatment of patients suffering from damage to 
neurons as a result of AIDS-related dementia, myelopathy, peripheral neuropathy and vision 
loss. This is caused by a reduction of the gp 176 responsive rise in calcium ions. 188
1.6.4 Threonine Synthase as a Potential Target Enzyme for Herbicides
Because of its high substrate specificity (see Section 1.5) and the range of organisms in which 
it is found, TS is an ideal target enzyme for herbicides, bactericides and fungicides. Selective 
inhibitors of the enzyme should not have adverse effects on animal species, which do not 
express TS. It is also known that blocking amino acid biosynthesis is a highly effective 
method of inhibiting growth in plants and bacteria.41 Any structural and mechanistic 
information obtained about TS can be used in the rational design of potential inhibitors of the 
enzyme Many inhibitors of TS have already been synthesised and tested and provide insight 
into the active-site structure of the enzyme. These are discussed fully in Section 1.9.
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1.7 The Threonine Operon of Escherichia coli
1.7.1 The Structure of the Operon
The thr operon is at 0 min on the genetic map of E. coli and contains three structural genes, 
thrA, thrB and f/zrC.^9-190 Transcription of the thr operon proceeds from thrA to thrC (Fig. 
1.10) as established by analysis of phage Mu insertions and nonsense mutations in the thr 
cluster, and by analysis of a phage X insertion into the thr regulatory region, which 
pleitropically affected the expression of both thrA and r/zrB.191-193 The bi-cistronic thrA gene 
encodes the threonine-sensitive bifunctional enzyme complex aspartate kinase I - homoserine 
dehydrogenase I (AKI-HDHI, Scheme 1.8).194- 195 E. coli strain K-12 contains two 
additional aspartate kinases (AKII and AKIII) and one additional homoserine dehydrogenase 
(HDHII), controlled by methionine and lysine respectively.196- '97 The thrB gene encodes 
homoserine kinase (HK), which is inhibited by threonine. 19 PhrC, a gene of 1287 bp, 
encodes TS (Appendices 7 and 8).
Direction of translation
thrA
A
serB C thrA .
—...
thr A2 9 thr B thrC pyrA
K
AKI
1 {
HDHI HK
I
TS
Figure 1.10: Genetic map of the threonine operon of E. coli K-72. ’85. 190
The promoter for the operon has been localised approximately 230 nucleotides upstream of 
thrA, between a BstE II site at position -254 and a Hha I site at -184.'99 An operator region 
has been located between the promoter region and the structural genes. 190 Positions -147 to 
-82 upstream of thrAj on the operon encode a putative leader peptide of 21 amino acids 
(Fig. 1.11), containing eight threonine and four isoleucine residues, eleven of which occur 
consecutively.
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Regulatory Region
Structural Genes
thrA
_____ A_______
thrA i thr Ai ' thr li thrC
3k,
Figure 1.11: Regulatory region of the thr operon.
1.7.2 The Regulation of Thr Expression
At first the expression of the thr operon was thought to be under the control of a multivalent 
repression system dependent on the concentration of free threonine and iso^crne (Fig. 
1.12).200 However, Samt-Girons and Margarita were unable to detect the presence of any 
repressor bound to the operator and further research has shown that factors affecting threonyl 
tRNA synthase also affect thr expression, no, 172 a model has therefore been proposed for the 
multivalent regulation of thr operon expression involving coupled transcription and translation 
of the leader region. *1 This is a comon regulatory mechanism in phage and bacteria.
Regulatory gene Control sites 
,---------A---------v-—
thrA
Structural genes
I thrB 1 thrC I
I i mRNA
I _
(121 Repressor
Repressor binds to operator (O) and prevents 
transcription of structural genes. If an inducer 
molecule is present, this forms a complex with 
the repressor. The repressor then cannot bind to 
the operator and the structural genes are expressed.
Figure 1.12: Model for a typical repression mechanism of gene regulation.™
If the intracellular levels of He and Thr are sufficient, RNA encoded by the thr regulatory region
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from bases -71 to -27 folds to form a termination structure (Fig. 1.13).172> 201> 202 This 
signals RNA polymerase to terminate transcription at a site (attenuator site) upstream from the 
structural genes. Under conditions of threonine and isoleucine deficiency, translation of the 
leader RNA sequence is stopped due to a shortage of threonyl- and isoleucinyl-tRNA 
molecules. This pre-empts the termination structure, allowing transcription of the structural 
genes. A region of overlapping rotational symmetry from bases -93 to -49 overlaps the 
attenuator and can form of a structure which blocks the attenuator region.203 a G-C rich 
region of dyad symmetry followed by a stretch of six uridine residues occurs 21 base pairs 
after the stop codon of thrC, which is thought to be a rho-dependent transcription termination 
she.204
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Figure 1.13: The thr regulatory region from -71 to -27, which forms the termination structure.
1.7.3 Cloning of Thr
Amplification of the thr operon has been carried out by various groups205-207 and has also been 
the subject of patents.208-209 The thrC gene has been cloned from C. glutamicum by Follettie 
and coworkers,si0 and from Br. lactofermentum by Malumbres et al..}1° A constitutive 
mutant E. coli K-12 Tir8 has also been produced, which over-expresses the enzymes of the thr
operon.165
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1.8 The Mechanism of (2S,3R)-Threonine Synthesis
1.8.1 Introduction
Although there is a wide interest in PLP-dependent enzymes, relatively few studies have been 
carried out on the mechanism of the TS reaction.
The first few steps in the conversion of (25)-(^-^f^h^c^s^phohomoserine (32) to (2S,3/?)-threonine 
(33) are assumed to follow the same general mechanism as the reactions of other PLP- 
dependent enzymes acting at C-4 of the substrate. Most of the mechanistic information for 
such enzymes has been acquired from studies using cystathionine y-synthase from 
Salmonella^ The reaction has been demonstrated to be essentially irreversible by Rognes. ia2 
He determined that no [iacj-O-phosphohomoserine was formed when N. crassa TS was 
incubated with [i4C]-threonine and inorganic phosphate (Pj), and that no enzymic exchange of 
a2pf. into phosphohomoserine occurred.
1.8.2 Reaction Mechanism
The first two steps in the TS reaction are described in more detail in Section 1.3.2. They 
involve the formation of a holoenzyme aldimine (10) between the e-amino group of a specific 
enzyme-bound lysine residue and the C-4’ carbonyl group of PLP (Scheme 1.5)4- 5. 42 The 
condensation of (2,S)-^i^ -phosphohomoserine with the internal aldimine (10) then leads to the 
formation of a Schiff’s base substrate aldimine (36, Scheme 1.12), with the release of the 
enzyme-bound lysine residue.4 42 Farrington et al. found that substrate analogues, which 
were capable only of binding to PLP and undergoing C" proton abstraction, exhibit rapidly 
reversible binding, suggesting that transaldimination is a fast step. J25
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Scheme 1.12: Transaldimination reaction involving (2S)-O-phosphohomoserine (32) .
The next stage in the reaction is labilisation of the Ca-H bond to form the quinonoid 
intermediate (37, Scheme 1.13). As described in Section 1.3.2, Dunathan's postulate states 
that in the external aldimine the bond to be cleaved at Ca is held orthogonal to the plane of the 
pyridinium ring, thus allowing maximum orbital overlap between the developing negative 
charge and the conjugated electron-deficient rc-system.4-5
Scheme 1.13: Labilisation of Ha by an enzyme-bound base.
Fuganti suggests that not only the Ca-H, but also the Cp-H and CY-OPO3H a bonds in the 
Schiff’s base, all of which are broken in the course of the TS reaction, must be held 
perpendicular to the extended rc-system, in order to optimize orbital interactions in the bond
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breaking and making probi6ses.612 It has been demonstrated that the known reactions of PLP- 
enzymes all take place only on the ‘exposed’, i.e. the si -face at C-4’ of the cofactor (below the 
plane of the page in all structures shown here).1 It is therefore assumed that TS follows this
general pattern.
The cleavage of Ha is further facilitated by an enzyme-bound base, probably the ucprotocated 
lysine residue originally involved in binding the enzyme to the coenzyme, PLP.1 This has 
certainly been suggested by data produced in studies on OASS (Section 1.3.3.1)11 The e­
amino group of this lysine residue stabilizes the positive charge as it forms on the 
electrofuge.11 The removal of Ha forms a carbarnon at C“, which is resonance stabilised as a 
pyridcxal-ketimine-p-quiccnoid (37). In this intermediate the acidity of the protons at C-3 is 
increased through being adjacent to a conjugated system of double bonds, and they become 
more labile. OASS, another p-family enzyme, does not appear to form a quinon^d 
intermediate, whereas for TrS such a species has been fleetingly detected.11 When F, Barclay 
incubated (25))[2-2Hl]-<0-phcsphchomoserice with the enzyme from E. coli, isotope effects of
1.2 andd 1.0 weee obtainnd for DV and D1V/K) rr6peeiivety. Tins i ndicctte t hat the rrmooal oo 
C"-H from the substrate is kindtiially significant but not ente-limtt1ng.l1 The fact that the value 
of DV is small, but larger than the value of D1V/K) for the C^-demer^ted compound, strongly 
suggests that the high forward commitment to the C“-H proton removal step occurs because 
teansaldiminatibn in the reverse reaction dir6ctibc ncd/oe dissociation of the substrate from the 
enzyme is very slow. Farrington et al. also proposed that immediately after Cl-elimicatloc, the 
phenolic oxygen and C-4’ of PLP me prbtbcated (as shown in Scheme 1.14).H5 7S has been 
shown to produce PMP in half-teacsamicatioc renctiocs with a number of amino acid substrates 
which do not possess a leaving group in the p-position.21 1
In 1979 Fuganti first demonstrated, using yeast TS, that it was the 3-pro-S rather tenc the 3- 
pro-R proton which was eliminated in the next stage of the reaction, using (3/?)- and (35)- 
[3-1H; U-llCJ-(25)-O-phosphbaomoserine as substrates.111 This is unusual, as most other 
PLP-depecdent enzymes acting at C-4 of the substrate catalyse the removal of the 3-pro-R 
hydrogen.4 This was also observed for the E. coli enzyme. The (2S,35'--[3-2Hl]-lsotbpom6r 
of the substrate displayed isotope effects of 1.74 and 1.0 for DV and D(V/K) respectively
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whereas the (2S,3/1)-[3^2]Hi]-isotopomer produced no kinetic isotope effectJi The value of 
D(V/K) for both the (2S)-[2-2Hi] and the (2S,3S)-[3-2Hi]-isotopomers was unity, indicating 
that - the first two reaction steps provide a large forward reaction commitment. The substrate can 
therefore not readily debind from the enzyme via reverse steps once the quinonoid intermediate 
(37) has formed. Laber et al. observed the accumulation of the quinonoid (observed as a 448 - 
453nm chromophore) which implied that the elimination of the p-substituent is rate-limiting as 
for tryptophanase.21 1 F. Barclay also noted that hydrogen elimination was slow compared to 
other steps in the reaction, suggesting that the steady-state concentration of 37 is quite high.aa
Scheme 1.14: py-Elimination of phosphoric acid.
Loss of the 3-pro-S hydrogen could occur in a concerted manner with elimination of the 
phosphate group, via the formation of an internal phosphate complex (Fig. 1.17 and Scheme 
1.14). If this were the case, it is most likely that the p, y-elimination of phosphoric acid would 
occur in a jyn-fashion, although normally an ««fLperiplanar elimination would be assumed to 
be energetically more favourable, due to the enzyme covering the ra-face of the coenzyme. 
This would produce an enzyme-bound vinylglycine intermediate.
------- ,
CO?"
Figure 1.14: Internal phosphate complex formed prior to elimination of phosphoric acid..
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Another postulate for the elimination of the phosphate group involves a sequential reaction, 
whereby the 3-pro-S hydrogen is removed first by a base approaching from the 4-si -face to 
form a resonance stabilised CP carbanion (39, Scheme 1.15). Subsequent elimination of the 
phosphate group (the nucleofuge), also positioned on the 4'-si -face of the coenzyme, from CY 
then generates the vinylglycine intermediate, as shown before (38, Scheme 1.15). 
Phosphorylation of homoserine to replace a hydroxyl group with the more electronegative 
phosphate group facilitates this y-elimination.
OPO32'
H
39
Scheme 1.15: Labilisation of the 5-pro-S hydrogen atom,.
Laber et al. observed that vinylglycine was converted to threonine upon incubation with TS, 
confirming that the pyridoxal p-quinonoid of vinylglycine 38 is an intermediate in the 
reaction.2^ The initial absence of any long-wavelength chromophore was seen to argue 
against the transient accumulation of 38.
Although it is not yet known which of the aforementioned y-elimination mechanisms are
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preferred, it has been shown that inorganic phosphate is formed by nonhydrolytic elimination 
rather than by hydrolysis of the phosphate group at C7 {i.e. the C7-O rather than the P-O bond 
is broken). This was discovered by Flavin and Slaughter in studies carried out in 18O-labelled 
water, where 18O was incorporated into (25,3/?)-threonine but not into phosphate.213 They 
also proved, using 3H-labelling, that it was the vinylglycine that was formed, rather than the 
reaction proceeding via a hydride-shift mechanism (see Scheme 1.16).
Scheme 1.16: Comparison of proposed mechanisms for the elimination of phosphate.
The terminal alkene (or vinylglycine intermediate, 38) produced by the removal of the 
phosphate group is re-saturated by a hydrogen atom, which may come from the solvent, or 
from a protonated base on the enzyme, again probably from the 4'-fi -face (40, Scheme 1.17). 
Farrington et al. propose that, immediately prior to this step, the phenolic oxygen and C-4' of 
PLP are deprotonated again. 175
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38 40
10 42 41
Scheme 1.17: Resaturation of vinylglycine intermediate and release of threonine.
It is known from incubations conducted in deuterium oxide that threonine synthase introduces 
two atoms of deuterium into the product, one at C-2 and one at C-4, leading to the assumption 
that no significant internal proton transfer takes place.4
The TS reaction is then completed by a hydroxyl group or water attacking at C-3 of the 
substrate4 As the absolute configuration of threonine is {2S,SR) this process must occur via a 
retentive mode.4 (2S,3/?)-threonine can now be released from the coenzyme via reverse 
transaldimination, which regenerates the holoenzyme aldimine.
The mechanism of this p/y—replacement requires a completely different conformation at the 
active site compared with p-replacement systems. This difference in the stereochemical courses 
of the two types of reaction can be explained either by the transient quinonoid intermediate 
described earlier or by a two-base system4
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1.8.3 Unanswered Questions Cbdierdidg the THeebdide Synthase Reaction
• The removal of the C-3 proton and the elimination of phosphate from the quinonoid 
intermediate (37) may be sequential or concerted (Section 1.8.2). The concerted elimination 
should occur in a 1yn-fashion, if the enzyme covers the e6-faie of PLP, but it is not yet certain 
from which face of the coenzyme the phosphate group leaves. It also not clear whether the 
phosphate group or the e-amido group of the tradsaldimidated lysine residue would act as the 
base removing the C-3 proton (Scheme 1.15).
• It is not yet know whether the eeprotonation of the enamine (38) to give the imino acid 
moiety (40) occurs with retention or inversion of configuration, whether the protonation occurs 
from the 4'-s‘-face as assumed and whether internal proton transfer from C-3 to C-4 occurs. 
Flavin and Slaughter saw no internal proton transfer when they assessed tritium transfer from 
the substrate to the prod.uct.211 However, if the proton in the conjugate acid is readily 
exchangeable with solvent protons, then very few tritium atoms would be transferred back to 
the substrate in this type of assay. More careful analysis of the isotope content of the threonine 
methyl group from very short-time experiments is required. The reprotocatioc step may also 
be reversible.
• The attack of water at C-3 of 40 is defined by the stereochemistry at C-3 of threonine (33) 
{i.e. 3R) but the geometry of the attack is not known with respect to the coenzyme.
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1.9 Inhibitors of Threonine Synthase
1.9.1 Functional Groups Which Inhibit PLP-Enzymes
In section 1.4 the metabolic role of various PLP-enzymes was discussed, demonstrating the 
wide scope of action of such enzymes. As a result of their varied functions the inhibition of 
PLP-enzymes has potential phamiacological and therapeutic utility. Generally PLP-enzymes 
are inhibited by carbonyl attacking reagents such as hydroxyl amines and hydrazines, and 
substrate analogues which bind at the active-si te but cannot undergo further reaction^ In the 
absence of endogenous coenzyme many PLP-dependent enzymes are also inhibited by the 
production of PMP in abortive transaminase side reactions. The development of mechanism- 
based, suicide inhibitors of PLP-enzymes which are substrate analogues has been widely 
studied, both for their inhibitory properties and as a means of elucidating the mechanism of 
specific enzyme.2.4'... As the role of PLP is to stabilise carbanionic intermediates that form 
during the catalytic process (Section 1.3.1), inhibitors possessing functional groups which 
become activated by their close proximity to an enzyme-generated carbanion can break down to 
yield a reactive species. This may react with an active-site amino acid side-chain, or with 
tightly bound PLP-coenzyme. Either of these processes will lead to the inactivation of the 
enzyme, in the first instance blocking the active-site with an unreactive species, or in the second 
case causing the coenzyme to become unavailable to bind substrate.
Functional groups commonly used in the design of such inhibitors include acetylenic, olefinic, 
p-halo substituents and other leaving groups, nitriles, aryl sulfoxides, dihydroaromatics and 
phosphonamino acids.214- 217 A number of olefinic substrate analogues such as 
vinylglycine.2. 6- 218 (E)-methoxy vinylglycine (43)717 and p-methylene aspartate (44)22° 
have been demonstrated to inhibit AspAT. Acetylenic analogues such as (25)-propargyl 
glycine (45) inhibit a range of PLP-enzymes including the transaminases AspAT and co­
ornithine aminotransferase and both y-cystathionase and cystationine-y-synthetase.22h 222
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Some of the most common suicide substrates for transaminases are those which possess a good 
leaving-group at CP, as they can undergo a facile elimination to generate an olefinic 
intermediate. (25)-3-chloroalanine (46)223* 224 inhibits AlaAT and various halogenated 
alanines are suicide substrates for tryptophan synthase (Ti'5*)^^2^5 (25)-s<^ir^r^<^-^(0-sulfate (47) 
also acts as an inhibitor of varous PLP-enzymes including AspAT, and glutamate 
decarboxylase.226 GABA-T is inhibited by various acetylenic, olefinic and halogenated 
substrate analogues227’ 228 4nd a number of carbonyl attacking reagents such as 
hydroxylamine, aminooxyacetic acid, hydrazines and carbazides4
och3
44 45
NH2
CO2H
43
NH2
II"A^C1
co2h
nh2
H"|k^OSO3H
co2h
46 47
Figure 1.15: Inhibitors of PLP-enzymes.
1.9.2 Amino Acid Inhibitors of Threonine Synthase
Various studies have been carried out on the inhibitory properties of both biogenic and 
exogenous amino acids on enzymes of the aspartate pathway, some of which are proven 
inhibitors of threonine synthase. In 1967 Miyajima et al. found that TS from Br.flavum was 
scarcely inhibited by amino acids of the aspartate family suggesting that the enzyme may only 
be subject to weak feedback inhibition or repression in vzvo.2^29 Lysine, threonine and 
isoleucine only showed approximately 15 - 20% inhibition of the enzyme, and the presence of 
methionine negated the effects of lysine and isoleucine. However, cysteine (48) and
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glutathione (49) showed 100% inhibition and alanine (50) showed 44% inhibition of TS. In
Lemna pausicostata cysteine has also been shown to inhibit the stimulation of TS by SAM480 «
As cysteine and phosphohomoseeine are converted to cystathionine by another enzyme it has 
been suggested that the conversion of (2S)-(9-phosphohomoserine to either threonine or 
cystathionine is regulated by the relative amounts of SAM and cysteine present. 180 in 1984 
Giovanelli and coworkers carried out a separate study on the activity of TS in Lemna 
pausicostata with mechanism-based inhibitors of PLP enzymes. Although DL-vinylglycine and 
cysteine both irreversibly inhibited TS to a small extent (22 and 17% respectively) both (25)- 
propargyl glycine (PAG) and gabaculine failed to act as suicide substrates for the enzyme. 118 
In a later study by Rognes et al. the TS activity in pea seedlings was reduced by up to one half 
in the presence of excess methionine (51)1160 Aarnes also tested a number of amino acids on 
TS from barley seedlings, but only (25)-orni1hide (52) and 2,4-diamino butyrate had any 
significant effect (75 and 77% of control activity respectively). The latter was also found to 
inhibit the enzyme in Lathyras sylvestris. 119
Figure 1.16: Amino acid inhibitors of threonine synthase.
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1.9.3 Inhibition of Threonine Synthase by Various Anions
«
Aarnes found that conditions of high ionic strength appeared to inhibit threonine synthase in 
barley seedlings. 179 The addition of 100 mmol of NaCl, KCl and (NH.^O. reduced the 
activity of the enzyme by approximately 25%, although NaF had no effect. As shown 
previously (see Scheme 1.9) inorganic phosphate is produced as a side-product of the threonine 
synthase reaction and it has also been shown to strongly inhibit threonine synthase in Lemna 
pausicostata in a reversible manner. 183 Other anions tested for their effects on TS were less 
inhibitory (see Table 1.6). Adenosine monophosphate (AMP, 53) is also an extremely potent 
and structurally specific inhibitor of threonine synthase, each inhibition progressively 
decreasing with increasing concentrations of (2.5)-0-phosphohomoserine {i.e. competitive 
inhibition). 183 Most analogues of AMP do not share its inhibitory properties, and only the N6- 
subtstituted derivatives resulted in inhibitions even approaching that of the parent compound.
Table 1.6. Inhibition of TS from different sources by various anions and salts.
Barley Seedlings L. pausicostata
Salt Concentration Inhibition Aniona Concentration Inhibition
NaCl 100 mmol 25% P. 1 mmol 50%
KCl It 25% PP. 15%
(NH4)S04 25% SO42- 30%
NaF ♦1 none Cl- 44 none
a - cations are not specified in the reference.
Adenosine monophosphate {AMP, 53)
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1.9.4 Phospho^c Acid Analogues of (2S’)-<0-Phiispabhiimoserlne
Phosphonic acid structural analogues often exhibit high affinities (and are therefore potent 
inhibitors) for enzymes which catalyze phosphoryl transfer or phosphate hydrolysis reactibcs 
and theeonicd synthase is no exception. This is due to the fact that these ncnlbgues do not 
undergo complete catalysis due to the chemically inert nature of the C-P bond. 115 Ash et al. 
first explored the suitability of various sulfide analogues as inhibitors of E. coli TS, finding teal 
2-amido-3-[(phbsphbdomethyl)thio]pebpionic acid (55, see Table 1.7) was a slow-binding 
potent inhibitor of the enzyme.230 The efficacy of this compound probably lies in the fact tenl 
it cannot proceed past the formation of the quiconbld intermediate (37, Scheme 1.14), but is 
already committed to the catalytic process. In 1993 Fareicglon et al. carried out further studies 
on phosphornc acid inhibitors ofTS from E. coli K-12 Tir-8,m in particular analogues 55-58 
and 61.125 The results of similar studies by Pohlenz and his group were published in 1994. 
They describe the synthesis of a number of analogues of the natural substrate (55, 59, 60 and 
64-68) which they later tested on TS along with analogues 61 63.23f 232
Although the sulfide analogue 55 is a good inhibitor, the p-sulfoxide and p-oxo-analogues of 
the substrate (56 and 60)have a significantly reduced potency (one order of magnitude). In the 
case of the sulfoxide analogue this is probably due to steric aindeacce on the active-site 
preventing it from effectively binding to TS. The oxo-ncalogue 60 may be inert as an inhibitor 
due to the less nucleophilic nature of oxygen relative to sulfur. This may have some 
significance for the binding of substrates to TS. Taibetaers also have the ndanctng6 lanl the 
sulfur atom, which is more readily polarised, will stabilise adjacent carbnnlocs. This renders 
the a-protons much more acidic taac is the case for ethers. Thus, in the case for teloeleer the 
quinonbid intermediate is more readily formed (Scheme 1.15). The P-amino analogue 59 on 
the other ancd demonstrates a K\ value (59 jiM) comparable with the Km of the substrate 
(53ji,M).175 Analogues with a cHiIc length of teee6 carbons are, generally speaking, more 
potent inhibitors, with the potency decreasing as the number of carbons along the cHiIc 
increases, indicating that larger compounds anve difficulty fitting imo active-site of the enzyme. 
This also has implications for the positioning of the phosphate group in the nctlae-slte (see later
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Structure No. (mM) Type of Inhibition
H2O3P
Z\ZK>C02H
nh2
5 4 0.031 competitive
h2o3p
x\s^>co2h
nh2
55 0.011 slow-binding
h2o3p S 1
O nh2
56 0.194 competitivg
h2o3p
C,C
xxsX^co2h
nh2
57 0.225 competitive
H3C
^>co2h
nh2
58 0.330 competitive
H2O3P
^^CO2HN y* 2
H NH2
59 0.059 enzyme-activated
irreversible inhibition
h203p z^o^>CO2H
nh2
60 none
h2o3p
CH
xO^A^CO2H
nh2
61 0.05
competitive
H2O3Px o^^^oo2h
NH2
62 0.01 competitive
h2o3p"°^Z\Z\zc°2H
nh2
63 none
h£>3p>
nh2
6 4 0.10 irreversible
^o3p-'XX=<xCO2H
NH2
65 0.40 irreversible
h203p
nh2
66 0.54 reversible competiive
H2O3P 4x==x^>OO2H
NH2
6 7 none
H2O 3P
4^ 1
NH2
68 none
Table 1.7: Inhibitors of threonine synthase.
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discussion). Replacement of Ha with a methyl group also hinders the binding of the substrate 
to the enzyme both sterically and because this precludes any reaction beyond the formation of 
the holoenzyme aldimine. These substrates are therefore less committed to the catalytic 
pathway.1.5 Olefinic and acetylenic amino acids are well known inactivators of various PLP- 
dependent enzymes (Section 1.4.1). Indeed the olefinic analogues 64 and 65 do inhibit TS in 
E. coli, but the olefinic analogue 67 and the acetylenic analogue 68 both fail to inactivate TS. 
The most likely explanation for the lack of reactivity of these compounds is that the phosphate 
group is held too rigidly in a conformation which prevents it from interacting with specific 
residues on the enzyme. In a study by Giovanelli et. al. the importance of the y-phosphate 
group on (25)-0-phosphohomoserine for binding was clearly demonstrated. 1?8 A variety of 
0-acyl homoserine esters had a binding affinity for TS at least 2 orders of magnitude smaller 
than that of the natural substrate. Also the poor binding affinity of O-phosphoserine and O- 
phosphothreonine indicated that the optimal position for the phosphate group was at the y- 
position. Analogue 64, [(25')-2-amrno-5-phosphono-3-cz£-pentenorc acid (Z-APPA)], has 
been shown to be the active component of plumtemycins233’ 234 and rhrzocticms,277 which are 
di- and tripeptides that posess bactericidal, fungicidal or acaricidal activity according to the 
nature of the peptide. The acid has been shown to decrease the activity of threonine synthase by 
acting as a suicide inhibitor and is also known to have herbicidal activity.
1.9.5 Phosphate Analogues
The use of naturally occuring antimetabolites as bacteriocidal agents has received much 
attention. In 1984 Shames et al. carried out studies on the action of aspartate-derived 
antimetabolites on the enzymes of the threonine biosynthetic pathway, and found that 
(25,)-eAre<?-3-hydroxyhomoseriie phosphate (61) was a potent inhibitor of threonine 
synnhasa,236 a finding confirmed by Laber et al.-32 They also investigated the properties of 
cyclopropyl analogues 62 and 63 and showed that the first of these was a potent inhibitor of 
TS, but the latter showed no inhibition under standard assay conditions. This is probably due 
to the extended length of the compound, causing the phosphate group to be in the wrong 
position for binding.
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1.10 The Aims of This Project
1.10.1 Testing New Substrate Analogues as Inhibitors of Threonine Synthase
Previous inhibition studies on TS indicate the following about potent inhibitors of the enzyme:
• The should be 3 i3a^T^c?c^s in length.
• A phosphate (or phosphonate) group should be n the y--fD^^lttic^n for optimum binding.
• The inhibitor should undergo both C1-H cleavage and 3-pro-S proton I^^mc^azlll, 
exhibiting a high forward reaction commitment, but remain inert to further reaction.
Potential inhibitors of TS were therefore designed which should promote the removal of a 
proton in the C-3 position; (2R,3S)- and (2/?,3/?)-3-fluorophosphohomoserine. P-fluoro- 
amino acids have previously been shown to be good inhibitors of certain PLP-ddpendent 
enzymes. It was assumed laat the small size of fluorine would allow these compounds to fit 
easily into the active site, but that the electronegativity of fluoridd would cause perturbation of 
the enzyme mechanism. The analogues (25,35), (2S,3R)-, (25,45)- and (25,4R)-methyl--0- 
phbsphbhomoseelne were also designed to aid in the elucidation of the geometry of bound 
reaction intermediates at bbla C-3 and C-4. These substrate analogues have been synthesised 
by G. Allan (unpublished results). The aim of this work was to assay all laese analogues with 
TS from E. coli K-12 Tir8 and determine their effectiveness as substrates or inhibitors of the 
enzyme. The rate of turnover of these analogues and the substrate was to be mocilor6d using 
malachite green assays, which detect even nadomolae quantities of the side-product, inorganic 
phos^j>li£it<e.4h 238-241 values can be determined by measuring the initial reaction velocity
(d) for a series of different analogue codcentra1iods [S]. This data can then be represented on a 
Lineweaver-Burk plot (1/3) against 1/[S]). The slope of this plot is KMAjm1X, the y intercept is 
1/Vnmx and the x intercept is -l/KM.142 Alternatively the Eadie-Hbfstee plot (i) vs. 3/(8]) is 
more accurate and gives a slope of -A^M, a y intercept of Vj^ and an x intercept of Vmax/ArM. 
Different types of inhibition can also be determined using these types of plot. Values of i) are 
determined for a constant inhibitor ibdcenteation ([I]) over a range of [S] values (in this case S 
is the natural substrate). This data is determined for several values of [I] and the separate 
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lines for each [I] value are drawn on the same graph. Competitive inhibition is indicated by a 
family of lines with a common y intercept on both Eadie and Lineweaver plots. Uncompetitive 
inhibition (where I binds to the enzyme-substrate complex only) is indicated on a Lineweaver- 
Burk plot by parallel lines or on an Eadie plot by lines with a common x intercept. 
Noncompetitve inhibition (where I and S bind simultaneously) is shown on an Eadie plot by 
parallel lines and on a Lineweaver-Burk plot by a set of lines with a common, negative x 
intercept. K[ can be calculated once Vmax and and the type of inhibition are known.
The (2i?,3(5)-3-fluoro- and (2S,3/?)-3-methyl- analogues are not expected to undergo reaction 
beyond formation of the quinonoid intermediate, as there is no 3-pro-S proton available. These 
substrates may therefore undergo abortive transamination reactions to produce PMP (6), which 
can be monitored by UV-Vis studies. The removal of the 3-pro-S proton in the {2R,3R)-3- 
fluoro- analogue may proceed more quickly than is the case for the natural substrate, due to the 
electron-withdrawing effects of the fluorine atom. This analogue may therefore prove to be an 
enzyme-activated irreversible inhibitor ofTS. The analogues methylated at C-4 will indicate 
how constrained the y-phosphate group is normally in the TS active-site, as they cannot bind 
effectively if there is too much steric hindrance.
1.10.2 Product Inhibition Assays
Inorganic phosphate (Pj) is produced as a side-product of the TS reaction (Scheme 1.9) and has 
been shown to strongly inhibit the enzyme from Lemna pausicostata at 1 mmol concentration in 
a reversible manner. Threonine has also been shown to inhibit the enzyme from Br. flavum 
but only by 15 - 20%. It was considered of value to carry out product inhibition studies on the 
enzyme from E. coli, but malachite green cannot be used to monitor substrate turnover in this 
case. Therefore it was envisaged that part of this work would involve the synthesis of [U- 
14C]]-22>))t9-phosphohomoserine (32b, Section 2.1.3). The substrate turnover in the presence 
of various starting concentrations of P, or threonine was to be monitored by quenching the 
assays after a given time, separating the (33b) produced from 32b
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via ion-exchange chromatography and determining the quantity of 33b present in solution by 
scintillation counting.
1.10.3 Further Assessment of the Allosteric Activation of TS by SAM
The effect of SAM on TS from E. coli K-12 Tir8 has been investigated by F. Barclay for 
comparison with its effect on plant TS enzymes-H The value of Xm for TS was almost trebled 
in the presence of SAM (115.1 jiM compared to a value of 43.5 pM without SAM), and the 
Vmax value was increased almost two-fold (7.34 pM mim7 compared to 4.18 jtM mind without 
SAM). More kinetic data is needed in order to determine the Hill coefficient, h, which at the 
upper limit is equal to the number of allosteric binding sites. The value of h can be determined 
from the slope of the following equation in the region of 50% saturation:
log —7------ = /ilog[S]-logK
fax " 7
It was also hoped that some of the other unanswered questions concerning the TS mechanism
(see Section 1.8.3) could be addressed in this work.
1.10.4 Structure-Activity Studies on Threonine Synthase
No crystal structure of TS from any source has yet been produced. It was hoped that an X-ray 
structure of the enzyme complexed with PLP could be produced during this work, either using 
TS isolated from the Tir8 strain, or from thrC cloned into an expression system, such as the 
pET system (Section 1.11). This would elucidate the active-site geometry and provide 
information on how substrates bind to the enzyme. In Section 1.3.3 the altered properties of a 
number of mutant TrS enzymes were described. It was hoped that similar site-directed 
mutagenesis experiments could be carried out on TS to elucidate the exact role of key residues, 
such as Lys 107 (responsible for binding PLP), which are conserved in all the known microbial 
TS sequences (Appendix 6). Mutant enzymes were to be expressed in pET vectors.
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1.11 pET Expression Vectors
1.11.1 Introduction243’ 244
The pET system is one of the most powerful systems to date for the cloning and expression of 
recombinant proteins in E. coli. Expression of target genes in pET plasmids is under the 
control of strong bacteriophage T7 1ranscrip1ibd and translation signals and is therefore only 
induced by the presence of T7 RNA polymerase provided by the host cell. This polymerase is 
so selective and active that it can direct almost all the cell's resources towards expression of the 
target gene. Recombinant protein can amount to up to 50% of total cell protein.
1.11.2 T7 RNA Polymerase245
The RNA polymerase of bacteriophage T7 has a stringent specificity for its own promoters and 
active T7 promoters have never been found in DNAs unrelated to T7 DNA.246 No T7 
promoters exist on E. coli chromosomal DNA (a natural host for T7). Once an E. coli cell 
becomes infected with T7, the bacteriophage can use its highly selective RNA polymerase to 
direct gene tradsieiptibc away from the host's DNA to its own. Transcription by T7 RNA 
polymerase is very active as well as selective, elongating RNA chains about five times faster 
taan E. coli RNA polymerase.2662248 77 rna polymerase also appears not be subject to the 
factors that cause termination of transcription by E. coli RNA polymerase.249 The one 
terminator specifically for the polymerase in T7 DNA is also not entirely efficient.^ Studier 
and co-workers therefore concluded that T7 RNA polymerase should be capable of efficiently 
producing complete transcripts from almost any DNA linked to a T7 promoter. Since T7 
promoters are never utilized by E. coli RNA polymerase the presence of this promoter in the 
cell should have little effect on Host gene expression. However, once T7 RNA polymerase is 
introduced into tie host cell this induces active and selective transcription from the T7 
promoter.
66
pET Expression Vectors Expression of Target Genes
Rosenberg and co-workers first reported the construction of pET vectors (plasmid for 
Expression by T7 RNA polymerase) based on the plasmid pBR322.251-253 T7 gene 1 is 
contained in the expression host; the plasmid containing both the T7 promoters and terminators 
either side of the cloning site.
1.11.3 Expression of Target Genes243
The target genes are initially cloned in hosts which do not contain the T7 RNA polymerase 
gene. Background expression of the gene product is minimal in the absence of T7 RNA 
polymerase helping to establish stable recombinants. This is particularly advantageous in cases 
where the gene product would be toxic to the cell.
For protein expression the recombinant plasmid is transferred to a host containing a 
chromosomal copy of T7 gene 1. These are lysogens of the bacteriophage XDE3. Of the two 
lysogenic strains suitable for gene expression, BL21(DE3) and HMS174(DE3), the former
lacks the ompT outer membrane protease which can degrade some proteins during purification.
1
Both strains contain the polymerase gene under the control of the inducible lacUVS promoter. 
Expression of target genes can therefore be halted until the growing culture has reached a 
suitable stage. Upon the addition of the inducer isopropyl-p-D-thiogalactoside (IPTG) T7 
RNA polymerase is expressed and the gene contained on the plasmid is transcribed. Some pET 
vectors also contain a Tllac promoter operator system. This means that they contain a lac 
operator sequence just downstream of the T7 promoter, and also the natural promoter and 
coding sequence for the lac repressor (lacI). The latter is oriented so that the Tllac and lad 
promoters diverge. In DE3 lysogens the lac repressor acts at the lacUVS promoter to repress 
background transcription of the T7 RNA polymerase gene by the hosts RNA polymerase. The 
lac repressor also acts at the Tllac promoter to block transcription of the target gene by any T7 
RNA polymerase that is made.
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1.11.4 Vectors Selected For Expressing Wild-Type and Mutant ThrC
The three vectors chosen for expressing thrC, pET-3a. pET-3b and pET-16b (Fig. 1.17), are 
translation vectors containing efficient translation initiation signals. 243 All these vectors 
carry the strong ribosome binding site of the T7 gene 10 protein (the major capsid protein of 
phage T7). pET-16b also contains the Tllac promoter operator system and produces 
recombinant protein with a His» Tag™ affinity handle at the N-temrinus.243 This permits 
one-step purification of expressed proteins by metal chelation chromatography on Ni-NTA 
resin (see Scheme. 1.18). 254
T7 Terminator
Ampr Jk . BamV I-site
[ ORI
'f-'Nde I-site 
|| Ribosomal Binding Site
pET-vector TT T7 Transcription
Control Region
Figure 1.17: General structure of pET-vectors to be used in cloning experiments.
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His-tagged protein binds to Ni-NTA resin
1. Contaminating proteins flow through column.
2. Tagged protein eluted in imidazole gradient.
3. His-tag may be cleaved by Factor Xa.
Resin
Purified enzyme
Scheme 1.18: Protocol for the purification ofHis-tagged TS.
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RESULTS AND DISCUSSION
Results and Discussion- Substrate Synthesis
2.1 Substrate Synthesis
A protocol for the synthesis of (SS)-0-phosphohomoserine (32) had previously been 
developed by F. Barclay.41- 255 This approach was adapted for the solution-phase synthesis of 
both the unlabelled and [U-^CJ-labelled substrate in these studies, with a view to continuing 
the elucidation of the TS reaction mechanism. Several other approaches to the compound had 
been reported in the literature, but none of these were very efficient, and many of them relied 
on enzymic synthesis.
2.1.1 A Survey of the Methods for Synthesising (2S)-<0-Phosphohomoserine
Agren reported the isolation of phosphohomoserine from trichloroacetic acid extracts of 
Lactobacillus casei in 1962, obtaining 55 mg of substrate from 650 g (dry weight) of cells.256 
A few years later Watanabe et al. reported the production of phosphohomoserine by the 
treatment of homoserine with a yeast-derived preparation of homoserine kinase.257 Skarstedt 
and Greer also phosphorylated (25)-homoserine (31) enzymically, using aspartokinase 
purified from a threonine-deficient strain of B. subtilis.143 Contaminating phosphate- 
containing side-products were completely removed by ion-exchange chromatography.
The first chemical synthesis of the compound was in 1973 by Fickel and Gilvarg, starting from 
(25)-homoserine (Scheme 2.1, Route A).258 The starting material was A-protected with 
t-butoxycarbonylazide, esterified with benzyl 3-p-tolytriazine and phosphorylated with 
diphenylchlorophosphate. The protecting groups were then removed using boron trifluoride 
and hydrogenolysis. This synthetic route unfortunately led to 20% racemisation of the end 
product. Schnyder and Rottenberg developed this route further, synthesising the substrate via 
a-p-nitrobenzyl-Ar-benzyloxycarbonyl-(25)-homoserine (72) instead, (Scheme 2.1, Route 
B).i42 This was again phosphorylated with diphenylchlorophosphate, and deprotected by
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hydrogenolysis, producing the substrate (32) in 49% overall yield. F. Barclay developed the 
first biomimetic synthesis of the substrate, starting from (25)-aspartic acid (32) ,41-255
Scheme 2.1: Route A: Fickel and Gilvarg’s synthesis of (2S)-Ophosphohomoserine, 
Route B: Schnyder and Rottenberg's method.
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2.1.2 The Biomimetic Synthesis of (254) ~O-pHosphoHomossrine
The biomimetic synthesis of the substrate developed by F. Barclay41- 255 was repeated in this 
study of TS as follows:
(25)-aspartic acid (28) was N-protected using trifluoroacetic anhydride in tetrahydIofuIar, 
giving the /V-trifluoroocetyl cyclic anhydride (73) in excellent yield (99%, Scheme 2.3). Other 
N-protecting groups tried previously in this laboratory by F. Barclay such as 4-butoxy carbonyl 
and benzyloxycarbonyl gave much poorer yields.4i The IR spectrum of 73 confirmed the 
presence of anhydride carbonyl groups {1886 m (C=O, anhydride) and 1722 s (C=0, 
anhydride)} and of a secondary amide carbonyl group {1556 m (C=O, 2° amide)}, as well as 
various peaks corresponding to C-F bonds. The 13C-NMR spectrum confirmed the presence
of two new anhydride carbonyl groups {169.28 (“C=0) and 167.61 (PC=O)} and two quartets 
corresponding to the N--rifluoroacetyl protecting group {157.43 (q, 7 p^C 39, F3CCO) and 
115.34 (q,/F,c285, F3C)}.
The anhydride was regioselectively opened using isopropanol to give the a-isopropyl ester (3- 
acid (74) in quantitative yield after one recrystollisation from ether and light petroleum. Other 
alcohols used by F. Barclay were less selective in opening the anhydride to gain the a-ester
due to their higher nucleophilicity. The 4H-NMR spectrum of 74 produced new signals 
corresponding to the a-isopropyl ester {5.11 (1 H, sept, 7 ch3,h 6.25, ' PrCH) and 1.26 and 
1.23 (6 H, d, 7cH2, h 6.25, 2 x ( PrCH3)} and IR spectroscopy confirmed the presence of ester
and acid carbonyl groups {1738 s (C=O, ester), 1709 s (C=O, carboxylic)}. In the r,(^-lNMR 
spectrum the signals for the carbonyl groups had shifted downfield {175.54 (PCO2H) and 
168.56 (oCO^Pi)}.
Reduction of the free p-acid was performed using mixed anhydride methodology. The mixed 
P-aspartic isobutylcarbonic anhydride was formed from the acid by treatment with 1.1 
equivalents each of N-methyl morpholine and isobutylchloroformate ot -20 °C. The
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32
ho2c
NH2 —
H"K/CO2H 
ho2c
NH2
32
Reagents and conditions: (1) TFAA, THF, 0 °C, 4 h; (ii) 'PrOH, 0 OC, 24 h; (iii) NMM, 
‘BuOCOCl, THF, -20 ”C, 20 min; (iv) NaBH4, THF, -20 °C, 2 h then rt 2 h; (v) 
‘Pr2NP(OBn)2, 1-W tetrazole, CH2Cl2, 20 OC, 4.5 h; (vi) m-CPBA, CH2Cl2, 0 °C, 45 
min; (vii) Pd/C, H2, MeOH, 20 °C, 96 h; (viii) KOH, EtOH, 20 °C, 18 h.
Scheme 2.2: The biomimetic synthesis of (2S)S0-phosphohomoserine (32) from (2S)- 
aspartic acid (28).
precipitated salts were then removed, and the mixed anhydride treated with sodium 
borohydride in THF. This is a problematic reaction, and yields varied widely depending on the 
equivalents of NMM and 1BCF and of sodium borohydride used. N-selectride was also tested 
as a reducing agent for this reaction by G. Allan (unpublished results), but although this 
produced a much cleaner product, the yield was significantly lower (20% crude). The results 
using this reducing agent were also not easily reproducible. The best yield of
trifluoroacetyl-(2S)-homoserine (75) obtained after purification by flash silica 
chromatography, eluting with 3% ethanol in DCM gave 75 as a yellow oil in a yield of 35%. 
The 13C-NMR spectrum revealed the loss of the signal at 175.54 ppm corresponding to the 
PCO4H group of 74, and the appearance of a new signal at 58.58 ppm, corresponding to the 
7CH2OH of 75. The carboxylic C=O signal (1709) had disappeared from the 1R spectrum. F. 
Barclay reported that the deprotection of this compound to give (25)-homoserine (31) showed
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that no racemisation had occurred even during saponification, the [a]o being the same as that 
obtained for an authentic sample of 31. .
Phosphorylation of 75 was achieved using a reagent which was first developed for the
synthesis of myo-inositol phosphates; A,ANdiisopropyl dibenzyl phosphoramidite (79, 
Scheme 2.3).259 This compound is produced from Aa^^-f^i-diisoDpy^iyicidorophosp^iK^rrn^iidite 
(78, Scheme 2.3). 78 was synthesised by the addition of two equivalents of
Ciisohropyiamine (77) to phosphorous trichloride in diethyl ether under a nitrogen atmosphere 
(HRMS: Found: M+ 201.0235, Calc, for CgH^NPC^ 201.0241). Although this reaction 
worked well in some cases (up to 81% yield was achieved) it was very moisture sensitive, and 
the product had a tendency to hydrolyse whilst the contaminating hydrochloride salts were 
being removed by filtration, prior to solvent removal and distillation of the product. Although 
this problem was originally overcome by the use of cannula filtration under nitrogen to syphon 
off the product in solution, later experiments to reproduce this method were unsuccessful, and 
a new phosphorating reagent had to be selected (see Section 2.6). G. Allan has since 
successfully perfomied this reaction under argon, suggesting that the nitrogen source used here
Scheme 2.3: Synthesis of 'Hf}-diisopropyl(bis)benzyl phosphoramidate (79).
Esterification of 78 via nucleophilic displacement of chloride with excess benzyl alcohol in the 
presence of triethylamine yielded the p0osp0oramiCate (79), which was purified by silica
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column chromatography using 25% ethyl acetate-light petroleum as the eluant, in 84% yield. 
(HRMS: Found: [M + H]+346.1600, Calc, for C20H29NO2P 346.1936). The ^CCNMR 
spectrum showed the presence of aromatic carbons, some of which were coupled to 
phosphorous: 138.11 and 138.01 (2 C, d, J 4.89, Ar-C quaternary), 128.31, 127.41 and 
126.87 (10 C, Ar-CH) and 64.41 and 64.19 (2 C, d,/CH2,OP 10-88, 2 x OCHiPh).
The alcohol, 75 was treated with 79 and the intermediate was oxidised with m-CPBA as 
described by Yu and coworkers.259 Only one equivalent of phosphoramidote was necessary to 
produce the phosphate triester (76) in 63% yield. The nC-NMR spectrum revealed two new 
signals corresponding to the benzyl groups {127.93 ppm (10 x Ar-C) and 69.46 ppm 
( -C^pty} ond 31p-NMR spectroscopy produced o single signal at -1.07 ppm. Deprotection 
of this to give the substrate (32) was achieved by catalytic hydrogenolysis of the benzyl 
protecting groups ond base-cotalysed hydrolysis of the A-trifluoroacetyl and A-isopropyl 
groups. This proceeded in excellent yield (91%) after purification by cation-exchange 
chromotography (Dowex 50-W, H+), eluting with water, mp 167-169 0C (lit., 41 170 °C); 
Oh(2OO MHz; 2^0) 3.97 (H, dq, 7ox 7.6, JBX 4.8, H«), 3.93 (H, dq, Jqx 116, 7Dx 5.4, 
HY) and 2.09 (2 H, m, HP); 0c(50.31 MHz; 2H2O) 175.09 (aCO2H), 64.67 («C), 54.19 and 
54.03 (d, /c,op 8.14, YC) and 33.40 and 33.25 (d, /c,cop 7.63, PC)) 5p(121.42 MHz; 2H2O) 
0.59; m/z (El) 200 (5%, [M + H]+), 199 (5, M+), 181 (9, M - 110]+), 119 (17, [M - 
H3p0>3]+) and 104 (23, [M - PO4P). The overall yield of 32 achieved here by this method 
was 20%, although F. Barclay reported a yield of 66% from (25)-aspartic acid (28),44 on 
improvement on the previous best yield of 49% reported by Schnyder and Rottenberg. '42
2.1.3 Synthesis of [U-14C]-(2S)--0-PhospHoHomoserine
Previous methods for studying the kinetics of the reactions of TS from E, coli in this group 
involved the use of malachite green assays to detect inorganic phosphate, which is produced as 
a side-producS.238224I Lonzetto et al. first reported the detection of nanomolar quantities of
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phosphate by measuring the absorption at 660 nm of a sample treated with malachite-molybdate 
complex.241 Although this has proved a very accurate method for monitoring the progress of
the TS reaction, it precludes product inhibition studies.
In order to avoid using malachite green as an indicator of product concentration, an assay was 
designed using [U-14C]-labelled substrate, 32b. In the case of malachite green assays, the 
colorimetric dye was also used to quench the reaction. For these assays it was envisaged that 
the reactions would be quenched using trichloroacetic acid as reported by Rognes. 132 The 
product, [U-^CC-^W/O-threonine (33b), could then be isolated by passing the reaction 
mixture down an anion-exchange column {e.g. Dowex 50-W, Cl -), which would bind 
unreacted labelled phosphohomoserine. The amount of radioactivity still present in the eluted 
solution could then be determined by scintillation counting to monitor turnover of the substrate. 
To attempt such an assay 32b was synthesised from [U^CP^^-aspartic acid (28b), using 
the protocol described for the synthesis of the unlabelled substrate, in 32% overall yield.
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2.2 The Growth of Threonine Synthase
In her work on threonine synthase, F. Barclay used an E. coli constitutive mutant for the 
enzymes encoded by the thr operon.165 The use of this mutant, in which the enzymes of the 
thr operon are continually expressed, was necessary because threonine synthase is normally 
only expressed under conditions where threonine and isoleucine become limiting for growth, 
as described in Section 1.7.
Attempts to isolate the enzyme from the E. coli strain K-12 Tir8 in this work, using the 
protocol developed by F. Barclay, were unsuccessful. No TS activity could be detected after 
just a few purification steps and malachite green assays on cmde cell-free extracts were not 
possible due to the high background levels of phosphate. The radiolabelled substrate was 
prohibitively expensive for use during these enzyme purification experiments. The reason for 
the lack of enzyme activity was not fully investigated at the time, but it was thought possible 
that the mutant had reverted to wild-type. It has been reported that such constitutive mutants do 
revert readily to wild-type and that wild-type cells will rapidly overtake a growing culture.174 
It is also possible that excessive cell lysis or lengthy purification procedures may have 
inactivated the enzyme. After a few abortive attempts to purify the enzyme from Tir8 cells 
grown from fresh frozen glycerol stocks, attempts were made to clone the gene for threonine 
synthase (thrC) into a pET expression vector.
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2.3 Cloning of ThrC and the Gene for P-Methylaspartase
2.3.1 The General doning Strategy
Experiments were undertaken to attempt the cloning of both thrC and the gene for p- 
methylaspartase into expression vectors. The latter had already been cloned into a different 
expression system, which was no longer producing sufficient enzyme.
Amplified genes were not cloned directly into pET vectors, because previous research in the 
group had indicated that the ligation of gene fragments with these vectors was problematic. 
The intention was that each gene be cloned into a pGEM cloning vector so that large 
quantities of DNA could be produced relatively easily, removing the need for repeated PCR 
experiments. The stategy for cloning thrC and the gene for p-methylaspartase into a pET™ 
expression vector was therefore as follows (see Scheme 2.4):
• Amplification of thrC (from E. coii chromosomal DNA) and of the gene for (—- 
methylaspartase [from plasmid pSG4 contained in E.coli TGl {K-12 A [lac-pro] supE 
thi hsdR5 /F'-traD36 proA+ B+ lac] Q lacZ A M15 )],260 adding specified restriction 
sites at each terminus. These were chosen such that the restricted gene fragment 
could be ligated to a similarly restricted vector.
• Insertion of the gene fragmeni into a doning vector ) in this case hie pGEM™ series of 
vectors was chosen.
• Maxiprep purification of the recombmani paasmid produced m the above seep.
• Ex^ston of the gene fragmeni usmg the resrriction sUes at) each Urrmn^us of the gene.
• Subdonmg of the gene fragmeni mto a pET expression vecto) cu) with) the same
enzymes.
77
Results and Discussion- Cloning Experiments
\ Primer 1
Primer 2
Chromosomal DNA
Amplification of thrC via PCR
i Direct ligation 
I into pGEM-T
ThrC gene fragment
Ampr
fl ori
T7(l)+
Nde I (82)
-VP6 Promoter T7 Promoterwobbt f SP6(126)— pGEM-TTS construct
Nde I - site contained in vector
1. Transformation of E. coli XLl-Blue with 
recombinant plasmid
2, Maxiprep of plasmid pGEM-TTS
▼ 3. Excision of gene fragment using Nde I onD BamH I
2 base 5'-overhang
RBS
4 base 5'- overhang
Ligation into pET-
Ampr f ”
Ba^Hl (319)
ST" Nde I (330) 
> tacZ
16b pre-cut with ■ pET-16b
▼ Nde I and BamH I
\ 5,711 bp
fl ori^"
iBomH I - site
EH3
Nde I - site 
T7 Promoter
pET16b- TS Construct 
T7 Terminator
Scheme 2.4: Final cloning procedure adopted for thrC. A similar strategy was applied to 
the gene for f-mnethylaspartase and other expression vectors were also used..
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2.3.2 Cloning of ThrC
2.3.2.1 Amplification of ThrC •
2.3.2.1.1 Isolation of Chromosomal DNA.
Preliminary attempts to isolate chromosomal DNA from E. coli JM109 using freeze-thaw and 
sonication methods for lysing cells were unsuccessful. The freeze-thaw method appeared not 
to be harsh enough to disrupt the cell walls and sonication led to fragmentation of the DNA 
making it unsuitable for use in PCR experiments. However, in an experiment for the 
minipreparation of pSG4 for the cloning of p-methylaspartase a small amount of 
chromosomal DNA also remained, which was a suitable template for amplifying thrC.
DNA was isolated using a variation of the alkaline lysis method of miniprep plasmid 
purification. 26 O 262 p minipreps were carried out in this manner. Cells were harvested from 
an overnight culture in LB and ampicillin and lysed with lysozyme in STET buffer. Cells 
were then incubated on ice with SDS to denature bacterial proteins and potassium acetate to
precipitate insoluble cell debris, such as genomic DNA and protein, leaving the plasmid in
1
solution. The supernatant was treated with RNAse. The aqueous DNA solution was further 
purified by repeated extraction with phenol/cOloroform. DNA was precipitated with cold 
absolute ethanol, allowed to dry briefly and stored in water at -20 °C.
2.3.2.1.2 Polymerase Chain Reaction on ThrC
The ligation of cohesive termini is known to be more efficient than blunt-end ligation, as 
indicated by the shorter incubation time and much smaller amount of ligase (50 times less to 
achieve the same extent of ligation) necessary for the former. 263 264 The pET vectors chosen 
for the expression of thrC each contain a unique Nde I-site (see Appendix 9 and Fig. 1.17) in 
the multi-cloning region. As thrC does not contain this site (Fig. 2.1 and Appendix 8), the 
first primers for PCR experiments were designed to produce Nde I-sites on either side of the
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termini of thrC (Fig. 2.2). The gene was amplified via 20 cycles of PCR (annealing temp. 
42 °C, polymerisation step 2 min) using the AmpliTaq™ form of Taq DNA polymerase. This 
thermophilic polymerase lacks a 3' - 5' exonuclease proofreading activity, and therefore has a 
high error rate per nucleotide polymerized ( 110 x KF4 at lOmM MgCh and ImM dNTPs).265 
This results in a base substitution rate of one in 9 000 and a frameshift rate of one in 41 (XX) 
nucleotides.26-5 Taq was, however, readily available and had previously provided satisfactory 
results in the group, so it was used again during these experiments. The enzyme does possess 
a 5' - 3' structure specific nuclease activity, which means that it will degrade any DNA 
annealed to the template strand while adding on bases to the 3' end of another annealed 
primer264 In addition the presence of a 3’ - 5’ exonuclease activity can sometimes cause- 
some degradation of primers from the 3' end, although this has only been observed to be a 
problem with primers of a length greater than 30 basest4
228 BjsH II 
109 £coRI
717 PvuII
M3 Pvu n
1159 Xmn I 
1086 Bel I
I I
Threonine Synthase - (E.coli) 1287 base pairs
Figure 2.1: Graphic map of the restriction sites on thrC used during cloning experiments.
Met Lys Leu Tyr Asn Leu gji 25mrr. Forward
5 • -tttt CAT aaa ctc tac aat ctg primer from N-Urmunus
Nde I
Met Lys Leu Tyr Asn Leu / Met Met Asn His Glu *
5' - ATG AAA CTC TAC AAT CTG / ATG ATG AAT CAT CAG TAA - 3
3‘ - TAC TTT GAG ATG TTA GAG / TAC TAG TTA GTA GTC ATT - 5
TS2. 28mer. Reverse Met Met Asn His Glu * Met
primer from C-terminus tag tag tta gta gtc att GTA TACAaa-5
Nde I
Figure 2.2: DNA sequences of the primers used in the first PCR reaction. Nde I-sites are 
underlined. The middle sequences show the two termini of thrC.
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PCR produced a DNA fragment of approximately 1300 bp, consistent with an amplified gene 
fragment (1287 bp) with 17 additional bases added at the termini by primers. This was 
determined by agarose gel electrophoresis, staining with the fluorescent dye ethidium 
bromide and using a 1 kb DNA ladder molecular weight marker for comparison (Fig. 2.3). 
The amplified gene was gel-isolated by running the band of DNA into a section of low- 
melting agarose, which was cut out and incubated at 70°C in phenol/acetate. The DNA was 
then purified and extracted from the aqueous layer in the usual manner.
1904 bp-----
1584 bp-----
1375 bp-----
947 bp-----
564 bp-----
amplified 
thrC fragment
Figure 2.3: 1% agarose gel electrophoresis of amplified thrC (left lane contains a X DNA 
ladder-).
2.3.2,2 Attempted Ligation of ThrC Into Cloning Vectors.
For all cloning work, competent E. coli cells were prepared using the CaCl] method,266’ 267 
and blue-white screening for a-complementation was used to test for the presence of putative 
recombinant plasmids in individual colonies.266, 268, 269 pjl maxipreps of recombinant 
plasmids were performed using theQIAGEN™ maxiprep plasmid purification protocol, 
using strain XLl-Blue. This slow-growing strain of E. coli is known to produce a very high 
quality of DNA, which works well for sequencing. Other strains (TGI and the JM1OO series 
for example) release large amounts of carbohydrate during lysis and have high endonuclease 
activities.
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The restriction endonuclease, Nde I, has a very short half-life (15 minutes) and can often be 
inefficient at Digesting DNA.264 Nde I is also particularly sensitive to impurities present in 
some DNA preparations; for example, DNA purified by standard miniprep procedures is 
reportedly cleoveD ot lower rates,264 Some ligations corried out prior to the results reported 
here, using Nde I-restricteD DNA, hove produced o high vector background, which may in 
part be Attributed to this inefficiency. Remnants of undigested plasmid DNA are frequently 
undetected by routine agarose gel electrophoresis and this can lead to o significant proportion 
of cells transfected with the undigested vector as opposed to recombinants^63 In addition to 
having a short holf-life, Nde I has been reported to require a segment of ot least 8 DNA bases 
before the Nde I-site in order to function correctly .264 As the thrC PCR fragment had been 
designed with just 4 bases before the restriction site at each terminus (Fig. 2.2) it was thought 
that the enzyme would not, in ony cose, cleave the termini of the PCR product. Some 
apparent disruption of the lacZ region of cloning vectors after Nde I Digestion has also been 
noted, cousing even self-ligateD plosmiDs to produce white colonies. For these reasons the 
use of Nde I was avoided in the preliminary cloning work in favour of blunt-end ligations, in 
spite of their reduced efficiency.
pGEM-3Zf(+) (3199 bp, Appendix 9) contains a unique site for Sma I in its multi-cloning 
region, an enzyme which produces blunt-enDeD DNA fragments. The first experiments 
involving Sma I-digesteD vector ond the thrC PCR fragment (uncut) produced few white 
colonies onD control experiments indicated o significant background of self-ligoted vectors 
with disrupted lacZ regions. In order to Decrease the vector background in ligation 
experiments, the 5'-phospHate groups on the linearised vector could have been removed using 
calf intestinal alkaline phosphatase (CIAP). However, the use of CIAP in previous ligation 
experiments with other vectors hod failed to produce successful recombinant plasmids. CIAP 
is very difficult to remove from DNA and the continued presence of the enzyme will impede 
subsequent ligotion reactions. Even if great care is taken to remove CIAP, organic 
contaminonts or particles of ogarose from DNA preparations, any of these may contribute to 
the failure of ligotion reactions. The use of CIAP in this case would also have necessitated
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use of T4 polynucleotide kinase to add 5'-phosphate groups onto the PCR product and this 
was considered too inefficient. Increasing the ratio of PCR product to vector did produce 
several putative recombinants, of which three were selected for maxiprep plasmid 
purification. These plasmid preparations were subjected to restriction analyses using the 
enzymes BamH I, EcoK I, Hpa I, Hind III, and double restrictions using BamH I and Kpn I, 
EcoK I and Hind III, EcoK I and BamH I and Hind III and BamH I. Only the restriction using 
BamH I produced the predicted size of DNA fragment (corresponding to the linearised 
recombinant plasmid). This suggested a possible mutation of the gene insert or that the 
wrong gene or segment of chromosomal DNA had been amplified during the original PCR 
experiment.
2.3.2.3 Overlap Polymerase Chain Reaction Experiments
To quickly confirm that the original PCR experiments had produced the desired thrC 
fragment, overlap PCR experiments were carried out using the original chromosomal DNA 
preparation as a template. Two experiments were performed to produce half-gene fragments 
originating from either terminus of the gene. This was achieved using the original external 
primers (Fig. 2.2) and two new primers complementary to the centre of the gene (Fig. 2.4) 
The two half-gene fragments were then subjected to overlap PCR in a reaction containing the 
half-gene fragments as templates and the outside primers TS 1 and TS2.
5' - AAC ATC AGC COT TTC CTG - 3'
TS4 I8mer Reverse primer 
from base 660 on thrC
TS3 18mer Forward primer 
from base 643 on thrC
y - TTG TAG TCG GCA AAC GAC - 5'
Figure 2.4: Primers complementary to the centre of thrC.
Both sets of experiments successfully produced DNA fragments of the correct apparent sizes 
as visualised on agarose gels (Fig. 2.5). The new PCR gene fragment was purified more 
stringently on this occasion, using Wizard Prep™ DNA purification columns, to rule out the
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possibility of contamination by agarose or organic solvents, which could have been a 
contributing factor to the previous failure of ligation experiments.
Figure 2.5: Results of overlap PCR experiments on thrC( 1287 bp). Gel A shows the two 
different half-gene fragments produced from TSl and TS4 (lane 1) or TS2 and TS3 (lane 2). 
Gel B shows the results of PCR reactions with the half-gene fragments and forward and 
reverse oligonucleotides TSl and TS2.
2.3.2.4 Ligation <rf ThrC into pGEM-T
Once it was confirmed that thrC had been amplified in PCR experiments, a new vector, 
pGEM-T (see Scheme 2.4) was chosen for ligation experiments. pGEM-T is formed by 
linearising pGEM-5Zf(+) with EcoR V and has one thymidine overhang added at each end. 
These single thymidine overhangs greatly improve the efficiency of ligation of PCR products 
because of the nontemplate dependent addition of a single deoxyadenosine to the 3' end of 
PCR product by thermostable polymerases. Taq i^ know to produce predominantly two 
kinds of ends on DNA fragments, some of which are blunt ends, some of which are single 
base 3' overhangs.264 Proofreading polymerases, such as Vent, on the other hand, generate 
95% blunt-ended fragments.26^ if the proportion of blunt-ended fragments generated by Taq 
was too low, this may account for the apparent failure of blunt-end ligations attempted 
between thrC and pGEM-3Zf-+). pGEM-T is also supplied with a control sample of DNA of 
known concentration for inserting into the vector, giving an accurate guide to the
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overall efficiency of ligations and transformations using the pGEM-T system. Ligations were 
carried out using various ratios of insert: vector and incubated at room temperature overnight, 
as summarised in Table 2.1. Competent JM83 were used for transformations. Colonies taken 
from experiment 4 produced a number of putative recombinants which were subjected to 
restriction analyses using Apa I, BssH II, EcoR I, Sea I, Ssp I and Xmn I. Two of these 
plasmids produced the predicted results with all enzymes. Maxiprep plasmid preparations 
were made of these two recombinants (denoted pGEM-TTSa and pGEM-TTSs)and restricted 
with Nde I (expected fragments 31, 1287 and 2973 bp). This indicated that pGEM-TTSa had 
lost one of its Nde I-sites as no thrC PCR fragment was excised (Fig. 2.6).
4486 bp---- >
2973 bp---- >
1287 bp---- >
-----  4500 bp
-----  3003 bp
-----  1904 bp
-----  1099 bp
Figure 2.6: Nde I-digest of pGEM-TTSa and pGEM-TTSb.
In previous ligation experiments the digested vectors had been purified by phenol/chloroform 
extraction and ethanol precipitation, rather than gel-isolation. Although this should have 
removed any enzyme and buffer components from the DNA solution, undigested vectors may 
have remained, which are smaller and more likely to be taken up by competent cells. As 
pGEM-T is provided in a linear form, such vector background is eliminated. Linear DNA is 
taken up 50 times more slowly than supercoiled circular DNA molecules by E. coli cells2263
An attempt was made to sequence the gene from pGEM-TTSe, the plasmid which had 
retained both Nde I-sites, and from which the gene could therefore be subcloned, using the 
fmol™ cycle sequencing protocol. SP6 and T7 primers (Fig. 2.7) were used for this purpose 
as these promoter sites are found on all pGEM™ plasmids (Appendix 9). A successful
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sequence was obtained for just the first 317 bases at the C-terminus of the gene (slightly
downstream of the SP6 promoter). This confirmed that the C-terminal Nde I-site was still
intact.
Table 2.1: The results of ligations using thrC and pGEM-T,
No. Ratio of Insert: Vector
Amount of
Transformed
Cells per Plate
Number
of
Colonies
% Whites
A Vector + control insert - - 45%
B Vector only control lOOpl 10 10%
1 1:1 50jxl 20 40%
2 1:1 lOOpl 50 20%
3 2:1 50pl 20 0%
4 2:1 mm 50 20%
5 4:1 50pl 20 15%
6 4:1 ioopI 50 60%
7 20:1 50pl 15 80%
8 20:1 IOOpI 25 60%
10 200:1 ioopI 10 70%
9 200:1 50fPl 2 100%
Highlighted row indicates ligation. experiment from, which recombinant plasmids were isolated.
SP6 Promoter Primer: 5' - d(GATTTAGGTGACACTATAG) - 3' 
T7 Promoter Primer: 5' - d(TAATACGACTCACTATAGGG) - 3'
Figure 2.7: SP6 and T7 primer sequences
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BssH n (278)
Mte 1(50)1 
T1 promoter ( 1)
i| thrC insert
Xmn 1 (3281) Ssp I (3695) 
Af 1(1337) 1
SF6 Promoter (1483) Ssp I (3486)
J____ 1___________i______ L_l_____ __
N I
Apa. I (14)
EcoR I (159)
n i 1
SflcI (1381) 5ca 1(3162) $spl (3671)
4
PGEM-TTSb Graphic map 4291 base pairs
Figure 2,8: Orientation of thrC in pGEM-TTSg. Restriction sites used in analysis of the 
construct are also shown..
2.3.2.S Attempted Ligation of ThrC Into Expression Vectors
2.3.2.5.1 pET-3a and pET-16b
The recombinant thrC gene was excised from maxipreps of pGEM-TTSg using Nde I and 
purified using the phenol/acetate method of gel-isolation described earlier, or the Wizard™ 
Prep DNA Purification System, according to the manufacturer's instructions. The pET- 
vectors named above were restricted with Nde I, gel-purified and treated with CIAP prior to 
ligations to try to eliminate the self-ligation of plasmids. Although numerous ligations were 
attempted with varying ratios of insertrvector, and a number of white colonies were obtained 
when selecting for the lac+ phentotype, no recombinants were isolated. Unphosphalased 
linear plasmids also failed to produce successful recombinants, indicating that CIAP was not 
the sole causative factor in the failure of ligation experiments. Various putative recombinants 
failed to produce the expected fragments on digestion with Nde I and EcoR I. As many of 
these produced fragments corresponding to the linear vector, but not an excised thrC 
fragment, this suggested that the plasmids were self-ligating, as had been observed earlier in 
ligations experiments involving cloning vectors.
2.3.2.5.2 pKK223-3
Once again, in an attempt to avoid using Nde I where possible, in case the enzyme was 
contributing to the failure of ligations, blunt-end ligation of the excised thrC fragment into an
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expression vector was attempted. The vector chosen for these experiments, pKK223-3, 
contains a Sma /-site in the multiple-cloning region (Appendix 9).
The pKK223-3 vector contains the strong tac promoter, which in an appropriate host is 
regulated by the lac repressor. Expression of gene inserts can be induced by the use of IPTG 
as is the case for pET-vectors. Immediately downstream of the tac promoter is the pUC8 
multiple-cloning site (MCS) and the strong rrn ribosomal terminator which stabilises this 
vector-host system by inhibiting transcription initiated from the tac promoter in the parent 
plasmid. The linearised vector was dephosphatased and purified in the usual manner to 
remove CIAP. The thrC gene fragment was excised from pGEM-TTSg using Nde I and 
incubated with T4 DNA polymerase to flush the 5'(protruding ends with dNTPs. Ligations 
(at room temperature) and transformations were carried out in-gel using SeaPlaque™ GTG 
agarose gel in low EDTA TAE buffer, as recommended by the manufacturer. This was to 
prevent any loss of the thrC fragment during purification procedures.. After two attempts at 
using this protocol without success a new strategy for cloning was proposed.
2.3.2.6 New PCR Fragme^
For some reason the ligation of gene fragments with Nde I-sites at each terminus into pET- 
vectors is very problematic. This may be due to Nde I non-specifically digesting the ends of 
restricted DNA, as observed by the disruption of the lacZ region of cloning vectors digested 
with the enzyme. It may also be due, in part, to the inefficiency of the enzyme in restricting 
DNA. In addition, the orientation of such thrC fragments in pET-vectors cannot be 
controlled, further decreasing the efficency of ligations. The use of CIAP also presents a 
problem. It is beneficial to hinder the self-ligation of the expression vector in order to 
increase the efficiency of ligation reactions. However, because CIAP is difficult to remove, 
the enzyme may also inhibit ligations between DNA fragments and dephosphatased vectors.
Some success had been achieved previously in the group ligating gene fragments with 
different restriction sites at each terminus to pET-vectors. For this reason two new primers
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were designed for PCR experiments (Fig. 2.9). The forward primer (TS5) contains an Nde I- 
site directly before the gene start codon. As a minimum of 8 bases are needed before the site 
for the enzyme to function efficently, a ten base sequence was also added before this 
restriction site. The reverse primer (TS6) contains a BamH I-site, which is found on all the 
pET-vectors that had been used previously (see Fig. 1.17).
ThrC was amplified via PCR as before, from the original chromosomal DNA preparation, 
gel-isolated, restricted with Nde I and BamH I and gel-purified, using the Wizard™ protocol, 
before carrying out further ligation reactions.
TS5 3l mer. Forward primer
Met Lys Leu Tyr Asn Leu 
5' - GTC AGT CAGT CAT ATG AAA CTC TAC AAT CTG 
Nde I
TS6 2Hmer. Reverse primer
Met Met. Asn His Glu * Met 
TAC TAC TTA GTA GTC ATT CCT AGG CGTA - 5‘ 
BarH I
4072 bp 
3054 bp 
2036 bp 
1636 bp 
1018 bp 
517 bp
_ ThrC 
fragment
Figure 2.9: Left: primers used for the third PCR experiment to amplify thrC. Right: result 
of PCR using primers TS5 and TS6.
2.3.2.7 Attempted Ligation of ThrC into pET-3a
Attempts were made to ligate the doubly-restricted PCR product directly into pET-3a. In 
order to monitor the progress of the restriction of pET-3a, the original vector was not used in 
digestion experiments. Instead, constructs made previously in the group, from pET-3a and 
various gene inserts, were restricted with Nde I and BamH I. These had been produced using 
the same protocol now being applied to thrC, the gene insert having an Nde I-site at one end 
and a BamH I-site at the other. The progress of the restrictions could be monitored by the 
observation of a gene insert and linearised vector on agarose gels (Scheme 2.5).
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Gene insert
pTC construct
linearised pET-Sa
Ligation
x Nde I x BamH I
thrC x Nde I x BamH I
Gene insert♦ +
pTN-TS construct
Scheme 2.5: Plan for the ligation q/thrC into pET-Sa derived from a pTC construct.
A number of different pTC constructs were linearised using Nde I. Subsequent 
BamH I-digests produced an observable gene fragment and linearised pET-3a vector (4640 
bp). The linearised vector was then isolated from Nusieve™ agarose gel. Two sets of 
ligations were attempted, using CIAP-treated vector only in the second case, but no 
recombinants were identified.
2)3)2)8 Ligation of New Gene Into p<GEIM-T
2.3.2.81 Amplification of ThrC
It appeared that, even if the termini of the thrC gene fragment contained 2 different restriction 
sites, ligation of the gene into a pET-vector would prove difficult. In order to prevent the 
need to perform repeated PCR experiments the gene was cloned as before into pGEM-T. At 
this stage the original chromosomal DNA preparation (also containing pSG4) from TGI 
became ineffective as a template for PCR. Chromosomal DNA was therefore isolated from 
XLl-Blue using the SDS-Proteinase K protocol.2™ PCR experiments were carried out using 
either this chromosomal DNA preparation or pGEM-TTSe as a template. The first set of 
these experiments produced fragments of DNA too small to be thrC, but the use of freshly 
synthesised primers and a lower annealing temperature (40 °C) achieved the desired result.
ThrC fragments from PCR were gel-isolated and purified using the Wizard™ PCR Preps 
DNA Purification System. Direct ligation experiments produced the recombinant plasmids
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pGEM-TTSi and pGEM-TTSn (see Table 2.2). QIAGEN maxiprep plasmid purifications of 
these vectors were subjected to Nde I- and BamW I-digestion, with the predicted results (Fig 
2.10).
Table 2.2: Results of ligations of the new thrC fragment into pGEM-T.
No. Vector: PCR product ratio Number of Colonies % Whites
1 1:0.8 49 80%
2 1:0.8 37 81%
3 1:1 Lawn 95%
4 1:1 Lawn 95%
5 1:1.5 Lawn 95%
6 1:1.5 Lawn 95%
7 1:2 11 55%
8 1:2 8 63%
9 1:3 15 67%
10 1:3 11 55%
Figure 2.10: Results of ligations of thrC into pGEM-T. Left: plasmid miniprep DNA 
preparations pGEM-TTSi and //, taken from ligation experiments 9 and 10 respectively, 
showing they are putative recombinants. Right: restriction digests of these recombinants 
using Nde / and Bam// I. Lanes 2 and 4 contain restricted pGEM-TTSi, 1 and 3 pGEM- 
TTSu. The Nde I-restriction indicates that the gene is oriented differently in the two vectors.
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23.2.9 Sequencing of ThrC in pGEM-TTSi and pGEM-TTSu.
c
Sequences were obtained of the termini of the recombinant gene in both vectors. This was 
achieved using the fmol™ protocol for cycle sequencing with SP6 and T7 primers (Fig. 2.7). 
Both primers were at the 5'-terminus by incubation with 32P-y-ATP and T4 PNK.
PCR experiments were performed with each reaction containing one of the primers and one 
of four chain-terminating ddNTPs. The radiolabelled DNA fragments obtained in this 
manner were separated by high-resolution denaturing polyacrylamide gel electrophoresis 
using different lanes for each reaction. The sequences obtained are shown in Fig. 2.11, 
confirming that the genes are oriented in different ways in either vector. Attempts were also 
made to sequence the middle of the recombinant genes at this time, using primers TS3 and 
TS4 (Fig. 2.5), but without success. This could be due to the plasmid DNA being too dilute, 
the primer solutions having deteriorated during storage, or their concentration having altered 
since last being calculated. There could also have been some residual contaminants in the 
plasmid DNA preparation, which made the polymerase reaction too inefficient. Whilst 
further attempts were made to obtain fuller sequence information on the two recombinant 
genes, experiments were carried out to subclone the genes into pET vectors.
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dGEM-TTSl x SP6 I.st 120 bases of gene from N-terminus
TT gga gct CTC CAT atg gtc cgg CTC TCT gca ggc ggc cgc ACT cag tga TTG
TCA gtc agt CATIaTG AAA CTC TAC AAT ctg AAA gat CAC AAC gag cag gtc agc
Nde I
TTT gcg CAA gcc gta ACC CAG ggg TTG ggc AAA AAT CAG ggg ctg TTT TTT ccg
CAC gac ctg ccg gaa TTC agc ctg
pGEM-TTS, x T7 1st 170 bases of gene from C-terminus
CC cgg ccg CCA
|-----------►
TGG cgg gat TTA TGC GGaITCC TTA ctg atg ATT CAT CAT CAA
TTT ACG CAA CGC
BamH I
AGC AAA ATC GGC GGG CAC ATT ATG TGA ACT TTT GGC AGA TCC
AAC GTT TCA CCG AGA ATC GCT TCC ACG CTC TCT TTA AAT TTC GCC GGA TGC GCG
gtg ccg A
pGEM-TTSj  x SP6 1 st 80 bases of gene from C-terminus
gga gct CTC CAT ATT ggc gac ATC tgc agg cgg ccg CAC tag tga TTA tgc GGA
Bam
Itcc 
h i 
ATT
tta ctg atg ATT CAT CAT CAA TTT acg CAA cgc agc AAA ATC ggc ggg cag
atg tga aag cag CAC gtt ctg CCA gct CA
pGEM-TTS i 1X T7 1st 200 bases of gene from N-terminus
AT tgt ACA gtc agt cat)
Nde
Iatg
I
AAA CTC TAC AAT ctg AAA gat CAC AAC gag cag
gtc agc TTT gcg CAA gcc gta ACC cag ggg TTG ggc AAA AAT cag ggg ctg TTT
TTT ccg CAC gac ctg ccg gaa TTC agc ctg ACT gaa ATT gat gag atg ctg aag
ctg gat TTT gtc ACC cgc agt gcg aag ATC CTC tcg cgc TTT ATT ggt gat gaa
AT
Figure 2.11: Sequences obtained for pGEM-TTSi and pGEM-TTSu. Primer sequences are 
shown in red except for the Nde I and Bam// I-restriction sites which are shown in blue and 
underlined. The first base, of the thrC gene is indicated by the arrow.
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2.3.2.10: Ligation of ThrC Into pET-Expression Vectors.
Once the thrC gene had been cloned into pGEM-T it was a simple procedure to excise the
gene fragment using Nde I and BamH I and gel-purify it for use in ligations. The pET- 
vectors pET-3a, -3b and -16b were also restricted with these enzymes, but not treated with 
CIAP as the enzyme was thought to be inhibiting ligations. Various ligation experiments 
were carried out using different ratios of insert : vector and a number produced successful 
recombinants. This could not be determined from the plasmid minipreps, as the DNA was 
smeared when run on a gel. Therefore maxiprep plasmid DNA was produced, as previously 
described, from 8 putative recombinants (see Table 2.3).
Table 2.3: pTN-TS constructs produced from various pET-vectors and pGEM-TTS
constructs.
No. pET-vector Source o»ThrC Number of
Colonies^
pTN-TS construct(s) obtained
1 pET-3a pGEM-TTS! 8 -
2 ft pGEM-TTSu 8 pTN-TSl and pTN-TS2
3 pET-3b pGEM-TTSi 11 pTN-TS3 '
4 t! pGEM-TTSii 18 pTN-TS4
5 pET-16b pGEM-TTSi 30 pTN-TS5 and pTN-TS6
6 pGEM-TTSn 45 pTN~TS7 and pTN-TS8
a - only white colonies were produced.
The recombinant vectors derived from pET-3a and -3b were subjected to restriction analyses 
using Nde I, BamH I, EcoR I, Pvu II and Xmn I and produced the predicted fragments in all 
cases. The vectors derived from pET-16b were also restricted using these enzymes and Bel I, 
producing the predicted fragment sizes in all cases. Fig. 2.12 shows the graphic maps of the 
pTN-TS constructs. The gels for each restriction digest are shown in Figs. 2.13 and 2.14.
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Figure 2.12: Vector map ofpTN-TS constructs Restriction sites for pTN-TS3 and 4 are 
similar to those in pTN-TSl and 2 but orientated in the reverse direction..
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r
7126 bp^_ 
6108 bp----
4072 bp----
3054 bp----
2036 bp----
1636 bp----
Nde I-digest
■6987 bp 
5888 bp
4198 bp
1690 bp
x EcoR I
.6108 bp 5090 bp 
4072 bp 
3054 bp
------2036 bp
------1636 bp
------1018 bp
3379 bp 
2485 bp
xPvu II
.6108 bp ■5090 bp 
4072 bp 
3054 bp
■ 2036 bp 
1636 bp
------1018 bp
2916 bp —♦ 
1934 bp—*
1038 bp—»
xXmn I
6108 bp 5090 bp 
4072 bp 
3054 bp
------2036 bp
------1636 bp
------1018 bp
Figure 2.13: Gels of restriction digests of'pTN-TS constructs. Lanes are marked 1 - 8 
denoting the pTN-TS constructs 1 - 8. The EcoR I-digest ofpTN-TSl and 2 produced the 
same fragment sizes as shown for pTN-TS3 and 4.
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x Bcl I
6108 bp 
5090 bp — 
4072 bp — 
3054 bp-----
2036 bp-----
1636 bp-----
1018 bp-----
x Xmn I
4206 bp —►
1933 bp—*
848 bp—►
____5090 bp
------4072 bp
------3054 bp
------2036 bp
------1636 bp
------1018 bp
------506 bp
X Pvu II
3172 bp-----*
2274 bp-----*
1502 bp----- ►
7 8
-----5590 Ip
-----4072 bp
-----3054 bp
-----2036 bp
----  1636 bp
-----1018 bp
----- 506 bp
5487 bp
X EcoR I
1500 bp----- ♦
^6108 bp
-----5090 bp
-----4072 bp
-----3054 bp
-----2036 bp
-----1636 bp
-----1018 bp
-----506 bp
Figure 2.14: Restriction analyses of pTN-TS constructs derived from pET-16b.
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2.3.3 Cloning of the p-Methylaspartase Gene
Much of the work carried out during attempts to clone the gene for p-methylaspartase into 
pET-vectors was similar to that already described for thrC, as the two sets of experiments 
were performed simultaneously. Cloning experiments will therefore not be discussed in as 
much detail in this section.
2.3.3.1 Cloning the Gene into pGEM-T
2.3.3.1.1 Gene Amplification
The plasmid pGG4 was isolated from E. coli. strain TGI (K-12 flac-prol supE thi hsdRS / 
F'-traD36 proA + B+ lad £ lacZ M15 )26° using the alkaline lysis method (Section 
2.3.2.l.l).26i. 262 The p-methylaspartase gene was originally amplified using primers which 
incorporated Nde I-sites into each terminus of the gene fragment (Fig. 2.15) as for thrC. 
These sites are not contained on the gene (Fig. 2.16 and Appendix 10). The PCR product 
was then gel-isolated.
Met Lys lie Val Asp Val MAl. 25mer Forward 
5 . -tttt cat atg aaa att gtt gac gta primer from N-terminus 
Nde I
Met Lys lie Val Asp Val / Val Gly Arg Arg Lys *
5' - ATG AAA ATT GTT GAC GTA / GTA GGA AGA AGA AAA TAA - 3
3' - TAC TTT TAA CAA CTG CAT / CAT CCT TCT TCT TTT ATT - 5
MA2. 28mer Reverse Val Gly Arg Arg Lys * Met
primer from C-terminus cat cct tct tct ttt att gta tac aaaa-5'
Nde I
Figure 2.15: DNA sequence of the two termini of the p-methylaspartase gene (centre) and 
the primers (top and bottom) used in the PCR reaction. Nde I-sites on the primers are 
underlined.
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343 EcoR I
218 Seal
699 Ssp I
625 Xmn I 1012 Hpal
Methyl Aspartase 1242 base pairs
Figure 2.16: Graphic map of the restriction sites on the gene for p-methyl-aspartase used
during cloning work..
1904 bp___
1584 bp___
1375 bp — 
947 bp —
564 bp-----
1 2
S
Gene fragment 
"----  (1242 bp)
Figure 2.17: Result of the first PCR experiment to amplify the gene for p-methylaspartase
(1242 bp). Lane 1 contains a X DNA ladder-, lane 2 a portion of the PCR reaction mixture
after 20 cycles.
2.3.3.1.2 Overlap PCR Experiments
As was the case with thrC, preliminary attempts to ligate the amplified gene into cloning 
vectors were unsuccessful and overlap PCR was performed to confirm that the correct gene 
had been produced, as for thrC (Section 2.3.2.3). Two DNA fragments were produced using 
the two external primers MAI and MA2, and two new primers complementary to the centre 
of the gene (Fig. 2.18), which were of the correct size to be half-gene fragments. These were 
used as a template in overlap PCR experiments, producing cloned DNA of approximately 
1300 bp, consistent with an amplified gene fragment of 1259 bp (1242 bp for the gene plus 
17 additional bases produced by the primers, Fig. 2.19).
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51 - TAC GTT AAA TGG TTA AGA - 3'
MA4 18 mer Reverse
primer from base 657 3 ' -
MA 3 18mer Forward 
primer from base 640
ATG CAA TTT ACC AAT TCT - 5
Figure 2.18: Primers complementary to the centre of the gene for fi—methylaspartase.
Figure 2.19: Results of overlap PCR experiments. A: Lanes land 2: half gene fragments 
produced using MA2 & MA3 or MAI & MA4 respectively, lane 3 whole gene from PCR 
using MAI and MA2. B: amplified gene (1242 bp) produced from either half-gene fragment 
(see text for details).
2.3.3.1.3 pGEM-T
The gene fragment produced from overlap PCR experiments was directly ligated to pGEM-T 
using similar vector:insert ratios to those described for thrC (Table 2.1). Competent JM83 
cells were used for the subsequent transformations. Seven putative recombinants were 
identified and subjected to restriction analyses using Apa I, BssH II, EcoR I, Sea I, Ssp I and 
Xmn I, which suggested that five of them contained the desired DNA insert. Two of these 
(denoted pGEM-TMAi and pGEM-TMAn) were used to prepare maxiprep plasmid DNA. 
Upon restriction of these vectors with Nde I it became apparent that pGEM-TMAj had lost 
one Nde I-site, as no gene fragment was excised from this construct (Fig 2.20).
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Nde I-digest
Figure 2.20: Nde I-restriction digest of pGEM-TMAi( 1) and pGEM-TMAu(2.)
It was confirmed that the gene insert in pGEM-TMAj had only retained one Nde /-site by 
sequencing of the gene insert in each recombinant plasmid, using the fmol™ protocol, with 
the GP6 and T7 promoter primers (Fig. 2.7). The correct sequence for the first 120 bases of 
the gene from the GP6 promoter (the C-terminus of the gene) and the first 120 bases from the 
T7 promoter (the N-terminus) were obtained from pGEM-TMAn-
The p-methylaspartase gene fragment was excised from maxipreps of pGEM-TMAn using 
Nde I and purified by agarose gel electrophoresis. As with thrC, attempts to ligate this into 
various expression vectors were unsuccessful.
2.3.3.1.4 A New Gene Fragment
After several failed attempts at cloning the gene fragment into various expression vectors, a 
new gene fragment was produced with an Nde I-site at the N-terminus and a BamW I-site at 
the C-terminus (Fig. 2.21). The PCR product was gel-isolated in the usual manner and 
attempts were made to clone this directly into pGEM-T.
101
MA5 3lmer Forward primer
Met Lys lie Val Asp Val 
5' - GTCA GTC AGT CAT ATG AAA ATT GTT GAC GTA 
Nde I
MA6 28mer Reverse primer
Val Gly Arg Arg Lys * Met 
CAT CCT TCT TCT TTT ATT CCT AGG CGTA - 5 
BamH I
3054 bp
1018 bp 
506 bp
gene
fragment
Figure 2.21: Left: primers used in the third set of PCR reactions for p-methylaspartase, 
right: result of PCR using these primers.
2.3.3.1.5 New pGEM-TMA Constructs
Ligation of the new gene fragment into pGEM-T produced several putative recombinants. A 
number of these were digested with Nde I to produce linearised constructs (samples 4, 6 and 
8, 4245 bp, Fig. 2.22). DNA inserts were also excised from recombinants 3 and 5 (Fig. 2.22). 
However, some of the putative recombinants produced fragments which did not correspond to 
any of the expected Nde I-restriction products. The putative recombinants shown in lanes 4, 
6 and 8 of Fig. 2.22 were used to produce maxiprep plasmid DNA which was subjected to 
restriction with Nde I and BanM I (Fig. 2.23). Only sample 4 appeared of the correct size for 
a recombinant and subsequent restriction with BamH I apparently excised a cloned DNA 
insert. However the remaining DNA fragment is too small to be pGEM-T (3003 bp), 
indicating that more than just the desired gene insert was excised from the plasmid, when 
digested with Nde I.
5090 bp 
4072 bp 
3054 bp 
2036 bp 
1636 bp
1018 bp
*------gene /augment
construct
(linear)
pGEM-T
pGEM-TMA
Figure 2.22: Nde I-restriction digest of several putative pGEM-TMA constructs. 
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x Nde I
a ■
5090 bp 
_4072 bp
------3054 bp
------2036 bp
------ 1636 bp
-------1018 bp
- ------ 506 bp
x Nde I x BamH I
5090 bp 
4072 bp _
3054 bp-------
2036 bp-------
1636 bp-------
Figure 2.23: Restriction digests on maxiprep DNA produced from samples shown in 
Fig. 2.22.
2.3.2.3 Further Work on the Gene for p-Methylaspartase
Further ligation experiments were attempted to produce successful pGEM-TMA constructs, 
and several more putative recombinants were identified. However, at this stage efforts were 
focused on the work to clone the thrC gene into pET-vectors and further work to clone the 
gene for P-methylaspartase into pGEM-T and then into expression vectors was continued by 
other researchers. Successful pGEM-TMA constructs were indeed obtained and the gene 
fragment excised from these was inserted into pET-5a. Unfortunately, although some success 
was achieved in purifying the recombinant enzyme from this source, efforts made by 
S. McMahon of J. Naismith's group to produce crystals in order to obtain a 3D-structure of 
the enzyme were without success. This was thought to be due to the presence of the 
His • Tag, which could not be cleaved with Factor Xa as expected. The gene was therefore 
excised and cloned into a new pET-vector to prevent the formation of a His#Tag. However 
crystals could not be obtained of the enzyme from this source either. Sequencing 
experiments later revealed that the stop codon at the end of the gene had mutated and further 
amino acid residues were being added to the end of the protein. The gene then had to be 
cloned directly from C. tetanomorphum.
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2.4 Sequencing of The ThrC Gene Fragment in Recombinant Plasmids
Sequencing of each vector was carried out by the University of St. Andrews DNA 
Sequencing Unit. They produce sequence data using the ABI PRISM™ DNA Sequencer, 
which uses a different fluorescent dye for each DNA extension reaction: A, C, G and T. 
They also use AmpliTaq FS, a mutant form of Taq DNA polymerase, which is reported to 
read easily sequences which are otherwise difficult. The fluorescent dye is incorporated on 
each dideoxy terminator, although it is also possible to use dye primers which are 
fluorescently labelled instead. All four extension reactions are then loaded onto a single lane 
on a polyacrylamide gel. Perkin-Elmer software is used to read the sequence directly from 
the gel by scanning for the four fluorescent dyes.
Table 2.4: Description of primers used in sequencing experiments.
Sequence
SP6
SP6 Promoter Primer: External primer
complementary to the SP6 promoter on
pGEM vectors.
5' - d(GATTTAGGTGACACTATAG>- 3'
TS3 Internal primer producing sense strand of
thrC (starting base 643).
5' - d(AAC ATC AGG CGT TTG CTG) - 3'
TS4 Internal primer producing anti-sense strand
o/thrC (starting base 660).
5' - d(CAG CAA AGG GCT GAT GTT) - 3'
TS6 External primer producing sense strand of
thrC from N-terminus of gene.
5' - d(ATGG GGA TCT TTA CTG ATG
ATT GAT GAT) - 3'
T7
T7 Promoter Primer: External primer
complementary to the T7 promoter on pET
and pGEM vectors.
5' - d(TAATACCACTCACTATACCG) - 3'
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The constructs pGEM-TTSi and pGEM-TTSu were submitted for sequencing using the
vector promoter primers SP6 and T7 and the gene internal primers TS3 and TS4 (Table 2.4).
«
Full sequences were obtained of the gene inserts (Appendix 11). The following changes from 
the wild-type thrC DNA sequence were observed:
■ In pGEM-TTSi base base 320 (adenosine) of thrC had been deleted, disrupting the 
reading frame of most of the gene. Base 944 was also mutated from thymidine to 
cytidine. Bases 340 and 716 were also mutated (A to G in both cases).
■ In pGEM-TTSn the mutations described for pGEM-TTSi were found, except that base 
340 (A) remained unaltered.
Each pTN-TS vector was also sequenced using the T7 promoter primer, TS6, which is 
complementary to the sense strand at the N-terminus of the gene and the two internal primers, 
TS3 and TS4. The data obtained from these constructs confirmed the findings for the 
pGEM-TTS constructs (Appendix 12). It should be noted that the gene inserts in pTN-TS3, 
pTN-TS5 and pTN-TS6 were subcloned from pGEM-TTSi and all others were subcloned 
from pGEM-TTSn (Section 2.3.2.10). Some additional mutations were observed in 
sequences of the pTN-TS constructs as follows :
■ In pTN-TS2 base 1051 was mutated (G to A).
■ In the construct pTN-TS5 base 278 was mutated (T to A).
The deletion of base 320 of thrC will produce a truncated protein, as this leads to a stop 
codon (TGA) after a further sequence of 19 amino acids. In fact, the frameshift caused by 
this deletion leads to a total of 18 stop codons along the DNA sequence.
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2.5 Solid-Phase Synthesis of (2£)-0-Phosphohomoserine
2.5.1 Alternative Phosphorylating Agents
Due to the difficulties encountered in the synthesis of AJ^-c^j^isopnrpyhlicl'^c^rc^j^lK l^s]^lianiidite 
(78), a key reagent for the phosphorylation of A-trifluoroac(^i^;yl-^^-isoproyyl-(25)-homoserine 
(75) in the solution-phase protocol for substrate synthesis (Section 2.2.2), it was necessary to 
find some new means of attaching the phosphate group to 75. To this end a few readily 
available phosphory^ting agents were tried: diyhenylyhosyhorpchloridate (80), 
diyentafluorophenylpCosyhorocClocidate (81) and A,/Addsopropyl methyl yhosyhpnamidic 
chloride (82, Fig. 2.24).
Figure 2.24: Alternative phosphorylating agents tried in the synthesis of(2S)-O- 
phosphohomoserine.
Both the phosphonamidic chloride (82) and diyhenylyhooyhorochloridate (80) are 
commercially available. There are many reported uses of 80, with different methods for the 
subsequent deprotection of the phenyl protecting groups.271-283 The main method for the 
removal of the phenyl groups involves hydrogenolysis using platinum dioxide (Adams
catalyst) or platinum/ activated carbon.
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81 was first patented in 1967, as a reagent in the synthesis of base stocks for hydraulic fluids, 
as heat transfer media and lubricants in aircraft systems.284-285 The compound was developed 
in this group as a phosphorylating agent for peptide synthesis by P. Hormozdiari.286 gl is 
synthesised by refluxing phosphorous oxychloride and 1.8 equivalents of pentafluorophenol at 
140 °C under nitrogen for at least 20 h.287, 288 The method was repeated here, continuing the 
reaction for 48 h (Scheme 2.6) The undesired side-products of this reaction were readily 
removed by distillation under reduced pressure, giving a pale brown oil, which solidified on 
cooling, in quantitative yield. The i4C-NMR spectrum showed signals between 136.77 - 
142,91 ppm corresponding to aromatic carbons; 31p-NMR spectroscopy showed one main 
signal at -15.14 ppm and the 194F-NMR spectrum showed signals at -154.89 and -154.96 ppm 
(4 F, d 7 19.75, ortho Ar-CF), -157.96 ppm (2 F, dt, J 3.95, J 21.73, para Ar-CF) and 
-162.38 ppm (4 F, t, meta Ar-CF).
Scheme 2.6: Synthesis of dipentafluorophenylphosphorochloridate (81).
Phosphorylation reactions carried out using 80 and 81 were successful, but 82 failed to 
produce the desired phosphate methyl ester (84, Scheme 2.7).
The phosphorylation reaction using 80 produced the diphenylphosphate ester (83) in 82% 
yield. This was purified by silica column chromatography, eluting with ethyl acetate-light 
petroleum (1:1) (Rf 0.42). LRMS gave a peak corresponding to the mass ion [m/z (El) 489 
(M+)]. The 4H-NMR spectrum showed new aromatic signals between 7.35 and 7.17 ppm, 
and the 13C-NMR spectrum indicated phosphorous coupling to PC and YC and one of the
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aromatic carbons (Fig. 2.25). The YC signal was also shifted downfield by 6.6 ppm:
5c(50.31 MHz; C2HC13) 169.49 (CO2*Pr), 150.56 and 150.42 (d, 7 7.04, Ar-C), 130.11 (Ar­
C), 124.80 (Ar-C), 120.21 and 120.13 (d, 7 17.21, Ar-C), 70.88 (*PrCH), 65.17 and 65.06 
(d, 7ptc 5.49, YC), 50.40 («C), 31.82 and 31.68 (d., 7 6.71, PC), 21.79 (fPrCH3). 31P-NMR 
spectroscopy produced just one signal at -11.57 ppm.
O
Reagents and conditions: (i) diphenyl chlorophosphorate (80), DMAP, EtgN, 
DCM, r.t., 17 h.; (ii) dipentafluorophenyl chlorophosphorate (81), EtjN, 
DCM, r.t., 21 h; (iii) A,A-diisopropyl methyl phosphonamidic chloride (82), 
DMAP, DIPEA, THE, r.t., 18.5 h.; (iv) MeOH, r.t., 60 h.; (v) m-CPBA, 
DCM, r.t., 12 h.
Scheme 2.7; Attempted methods of phosphorylating N-trifluoroacetyl-a-isopropyl-(2S)- 
homoserine (75).
The phosphorylation using 81 also proceeded in good yield. The 13C-NMR spectrum of 84 
showed a downfield shift of the YC signal and phosphorous coupling to PC and
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Aromatic Cs CDCI3
Figure 2.25: NMR spectra ofNotrifluoroacetyl-(2S)-phosphohomoserine diphenyl ester 
(S3). Top: 1H-NMR spectrum, bottom: ,3C-NMR spectrum.
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YC. {0c(50.31 MHz; CiHClg) 169.46 (CO2*Pr), 157.82 (F3CCO), 138.46 (Ar-C), 71.19 
(*PrCH), 67.44 and 67.32 (d., 5.90, YC), 50.23 («C), 32.03 and 31.88 (d., Jp^-e 7.32,
PC), 21.69 (^PrCHg)- The 4ip-NMR spectrum gave a new signal at -10.77 ppm, and 19F- 
NMR spectroscopy of the crude material showed new multiplet signals at 189.99, 188.27, 
187.25 and 185.45 ppm. 19F signals for 81 in this spectral window appeared at 198.10, 
195.06 and 190.60 ppm.
Having established two new methods for the phosphorylation of 75, attempts were made to 
deprotect the phosphate esters 83 and 84 using base-catalysed hydrolysis. If this were 
successful then the removal of all protecting groups could be performed in one step to give the 
substrate (32), a major advantage over the previous route (Scheme 2.3).
Although 83 was subjected to hydrolysis in IM sodium hydroxide, for several days, the 
deprotection appeared to be incomplete. The 1 H-NMR spectrum still showed aromatic signals 
at between 7.28 and 7.00 ppm, and although 2ip-NMR spectroscopy showed one signal at 
0.67 ppm, which possibly indicated the presence of the desired product {8p( 121.42 MHz; 
4HOH) 0.59 for (32)}, a number of other 31P signals were also present. P. Hormozdiari 
found, whilst using this phosphorylating agent, that hydrogenolysis of diphenyl phosphates at 
atmospheric pressure, using either Adams catalyst or platinum/ activated carbon, failed to 
produce complete removal of the phenyl protecting groups.^6 Reports in the literature, 
however, state that complete deprotection can be effected using this method within 30 min to 3 
h.271-283 84
84 was subjected to overnight hydrolysis in IM sodium hydroxide. A white precipitate was 
formed, and tic on cellulose [eluant ‘PrOH/H2O/NH3 (20:5:6), developing with ninhydrin] 
showed a band with a similar Rf value to that of the target compound. The 1 H-NMR spectrum 
was, however, inconclusive, and the 4PrCH3 signal of the ot-ester was still present, indicating 
that hydrolysis was incomplete. The i2C-NMR spectrum contained many aromatic signals at 
between 142.64 and 128.50 ppm, indicating that the pentafluorophenyl groups were still 
present. P. Hormozdiari had attempted a number of methods of hydrolysing off the
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pentafluorophenyl groups, using water, 5% NaHCOg, or an excess of base, but the reaction 
would not go to completion, even when an ethanolic solution of KOH and an organic base, 
pyridine/ H2O mixture was used.286
These two routes to the substrate appeared then to be unviable and the phosphate esters were 
not characterised further. Fortunately, the acid-lability of pentafluorophenol esters has been 
reported previously in the literature,288’289 and some success had been achieved in this group 
prior to these studies in the deprotection of such phosphates on the solid-phase, using acidic 
conditions.286 With this in mind the solution-phase protocol for the synthesis of (2S)-0- 
phosphohomoserine (32) was modified in order to apply it to the solid-phase.
2.5.2 19F Gel-phase NMR Spectroscopy
One drawback to solid-phase synthesis is that monitoring of reaction progress is problematic, 
unless one of the reagents in solution is a strong UV-chromophore. Often the compound must 
also be cleaved from the resin to allow proper characterisation. Conventional 1H- and 13C- 
NMR spectroscopy of compounds attached to solid supports (gel-phase NMR) usually requires 
prolonged spectral acquisition, gives broad resonances and is dominated by signals from the 
solid support.290 Various approaches to overcome these problems include magic angle 
spinning and the use of 13C-enriched building blocks, but these methods are expensive. 
Recently, however, it has been shown that 19F gel-phase NMR is a very sensitive technique 
for measuring transformations on solid-phase supports involving fluorine-containing 
compounds. 19F chemical shifts are spread over a wide frequency range and structural 
changes which are even quite distant from the fluorine atom will affect the position of the 
signal. Svensson and coworkers found that the correlation between the 19F chemical shifts for 
the support-linked compounds and the corresponding soluble references was excellent (< 0.1 
ppm difference) and that there was a significant change in the 19F chemical shift (> 1.0 ppm) 
for each transformation they carried out.290 Shapiro et ai. also reported the successful use of
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this technique for monitoring the time-course of nucleophilic displacement of fluorine from a 
solid-sup)p^ort2^(Ji In our experiments to perform the solid-phase synthesis of (2S)-0- 
phosphohomoserine, the presence of the A-trifluroacetyl group lent itself readily to the use of 
this technique, as well as FT-IR and 13C gel-phase NMR spectroscopy, for the characterisation 
of compounds on the solid support.
2.5.3 p-Benzyloxybenzyl Alcohol (Wang) Resin
Wang resin had previously been widely used in the group and was therefore an obvious first
choice as a solid support. The strategy developed for the solid-phase synthesis of (2SY0- 
phosphohomoserine (32, Scheme 2.8) was similar to the solution-phase procedure (see 
Scheme 2.3). The only major modification was that Wang resin was to be loaded with 
A-trifluoroacetyl-(25)-aspartate (86) by using the alcohol group on the resin, in the place of 
propan-2-ol, for the ring opening of the symmetric anhydride (73). It was hoped that, due to 
the bulky nature of the resin, the opening of the anhydride would proceed regioselectively as 
with isopropanol. The P-carboxyl group was to be reduced in the usual manner by mixed 
anhydride methodology and the resulting alcohol group phosphorylated using 
dipentafluorophenyl chlorophosphate (81). The phosphate group would then be deprotected 
using TFA/^O/TES (90:5:5) which would also cleave A-trifluoroacetyl-(2S)-<9- 
phosphohomoserine (90) from the resin. This would leave only the hydrolytic removal of the 
N-TFA-group using base to achieve the target compound. The solid-phase methodology also 
removes the need for time-consuming purification steps and hydrogenolysis of the phosphate 
benzyl protecting groups of 76, which often appeared to be inefficient.
O
u
F.C NH
H'/Aco2h
ho2c
N-trifluoroacetyl-(2S)-aspartate (86)
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Scheme 2.8: The proposed, solid-phase synthesis of (2S)-O-phosphohomoserme (32) on 
Wang resin.
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2.5.3.1 The Loading of Wang Resin With 2V-TrifluoroacetyI-(2S)-aspartate
When using propan-2-ol to selectively protect the a-carboxylic group of 73 the reaction was 
carried out at room temperature, after the addition of the alcohol at 4 “C (Scheme 2.3). 
Experiments to load 86 onto Wang were carried out as indicated in Scheme 2.8 and using the 
conditions listed in Table 2.5. A loading temperature of 4 °C was tested with Wang resin first 
of all (experiments 1-3, Table 2.5), as this low temperature might be expected to enhance the 
regioselectivity of the substitution. The reaction proceeded too slowly, however, to be useful 
at this temperature. Higher temperatures and catalytic amounts of DMAP were necessary to 
produce satisfactory loading within a reasonable time. Experiments 4-9 (Table 2.5) established 
that the optimum temperature for loading was probably between room temperature (23 0C) and 
45 °C. In most cases a reaction temperature of 30-35 aC was used, as the regioselectivity of 
the substitution was better at this temperature than at higher temperatures. IR spectroscopy 
indicated the formation of an ester linkage {omax(]KBr)/cm-1 1735 s (C=O, ester)} and both the 
13C and 19F gel-phase NMR spectra confirmed the substitution of 86 onto the resin: 5C(74.76 
MHz; DMSO) 171.33 (aCO2R), 162.48 (pCOoH), 130.02 (F3CCO), 117.84 (F3C), 49.40 
(«C), 34.81 (PC); 5p(282.2 MHz; DMSO) -74.91 (F3C on ct-ester). A portion of A-TFA- 
aspartate (86) was also cleaved from the resin using TFA/H2O/TES (90:5:5) and characterised. 
The i2C-NMR spectrum showed two signals for carboxylic groups {172.54 (aCO2H) and 
171.06 (pCO2H))} shifted downnield from die carbonnl ssggnll for 73 {{66.28 (0tC=O) aan 
167.61 (pC=O)}. There were also two quartets which corresponded to the A-trifluorocaetyl 
group (156.70 (q, 37.18, F3CCO) and 115.43 (q, f 285.26, F3C)}. The optical
rotation of the cleaved material was in good agreement with that obtained for the solution-phase 
product (-25.09 (c. 0.87, EtOH) compared to -24.35 for the solution-phase product}, 
indicating that the use of DMAP as an acylation catalyst does not cause significant 
racemisation, although P. Sieber found it did when attaching Fmoc-amino acids to Wang 
resin.292
The regioselectiv^y of substitution reactions under various conditions were determined by
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Table 2.5: Loading of Wang resin with N-TFA-asp under various conditions
Experiment Temperature Time (hours) Equivalents of
DMAP
Equivalents of
Anhydride
Stirring % Loadinga
1 4'C 15 none 10 X minimal
2 4"C 15 0.5 " X none
3 4'C 15 1.5 X none
4 O°C / rt 15/6 none " X none
5 O’C / rt 15/6 1 " X none
6 rt 19.5 none X none
7 rt 19.5 1 " X none
8 rt / 45'C 28.5 / 16 none " X 12
9 rt / 45°C 30 / 10.5 1 " X 62
10 rt / 60°C 55.5 / 8 1 " X 65b
11 rt 65 2 " J 31
12 rt 160 2 " J 82
13 30°C 118.5 2 J 100
14 25'C 36.5 1 •• J none
15 15°C / 35°C 48 / 116 1 J 75
16 rt ./ 30°C 14/49 1 " J 58
17 30’C 142 1 " J 46
18 30°C 1 5 J 56
19 30'C " 1 2.5 J 12
20 30°C " 2 10 J 79
21 30’C " 4 " J 81
a - loading was determined by comparing the mass of the resin before and after loading experiments (after careful 
washing and drying of loaded resin), values given are only approximate; b - a reaction was carried out using 1 eq. 
pyridine under similar conditions, giving a loading of 60%
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methylating the free acid group of 87 with diazomethane. The methyl-ester 91 was then 
cleaved from the resin using TFA/H2O/TES (90:5:5), and the ratio of a- vj 3~methyl ester 
peaks on iH-NMR spectra was determined {3.70 (3 H, s, aCO2CH3, 16%), 3.63 (3 H, s, 
PCO2CH3, 84%)}. 19F solution-phase NMR spectroscopy of the methyl ester 91 (6p(282.2 
MHz; C2HO3) -76.66 (F3C on P-ester)} and 14F gel-phase NMR spectroscopy on 77-TFA- 
asp-Wang (87) {8p(282.2 MHz; (C2H3)2SO) -74.27 (12%, F3C on P-ester), -74.91 (88%, 
F3C on ac-^c^^teM')} also confirmed the findings of these NMR experiments (Fig. 2.26 and Table 
2.8). This indicated that the lower temperatures produced better selectivity for a--substitution. 
An experiment left for a week at room temperature (12, Table 2.5) gave a high loading (82%) 
and one of the the highest regioselectivities achieved (a/p 5.2:1 as judged from the 1 H-NMR 
spectrum of the methyl ester (91)}.
The P-methyl ester (91) produced by diazomethane treatment of 87.
Some experiments were necessary in order to optimise the equivalents of anhydride and DMAP 
used in the reaction. It was also of interest to ascertain the effect of varying the number of 
equivalents of DMAP, with respect to the racemisation of the loaded amino acid and the 
regioselectivity of substitution. Experiments 17-20 (Table 2.6) show the effect of different 
quantities of anhydride and DMAP on the [a]]) values of 86 cleaved from the resin. Loading 
experiments 8, 9, 10, 12 and 22 - 27 (Table 2.7) show the effect of different temperatures and 
equivalents of DMAP on the regioselectivity of the nucleophilic substitution reaction. Although 
2.0 equivalents or more of DMAP gives a markedly faster loading of the resin compared to 1.0 
equivalents, this has an adverse effect on the regioselectivity and causes greater racemisation of 
86.
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Table 2.6: The racemisation effects of varying amounts of DMAP.
Experiment0 Ratio of Equivalents of 
DMAP vs. Anhydride
[of
17 1:10 -25.09
18 1:5 -20.25
19 2:5 - b
20 1:5 -18.91
21 2:5 -20.89
Solution phase
product‘
- -24.35
a - numbers refer to experiments listed in Table 2.5; b - insufficent 86 was loaded on the resin to obtain an 
[a]o reading; c - synthesised by hydrolysis of 78.
All reactions were carried out at 30 °C. N-TFA-asp (86) for these measurements was cleaved using 90:5:5 
TFA/H2O/TES and recrystallised from ether.
The use of sonication in the attachment of compounds to solid-supports has been reported in 
the liteLnt^i;rr<eJ2S>3 To pursue this method a loading experiment was carried out overnight at 
room temperature using 1 equivalent of DMAP and sonicating the reaction for three bursts of 
15 minutes. This produced a loading of 26%, which appeared quite efficient for a relatively 
short reaction time However, an attempt to repeat this method, sonicating the resin and 
anhydride for longer failed to produce any loading. There was insufficient time in these studies 
to optimise the amount of sonication that can be tolerated by the resin, before cleavage of the 
loaded amino acid occurs. No studies were made at this time of the regioselectivity and 
racemisation effects of this technique, but sonication remains a promising method for 
efficiently loading amino acids onto Wang resin.
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' Table 2.7: Effects of varying reaction conditions on the regioselectivity of Wang loading.
Experiment? Temperature Equivalents
of DMAP
Ratio of p- vs O-Me ester Ratio of a­
vs p-Wang
*H solution-
phase NMR2
l9F solution-
phase NMR2
19F gel-phase
NMRd
8 45 OC none 3.1:1 - -
9 45 °C 1 3.6:1 3.4:1 -
10 60 °C 1 4:1 - -
12 rt 2 5.2:1 - -
22 rt 1 4.1:1 3.5:1 4.6:1
23 rt 2 2.4:1 3.2:1 11.2:1
24 30 0C 1 3.8:1 3.6:1 4.1:1
25 30 °C 2 3.0:1 3.9:1 2.1:1
26 60 "C 1 4.3:1 3.5:1 8.6:1
27 60 °C 2 2.2:1 1.8:1 1.1:1
a- experiment number refers to the number in Table 2.5; b - calculated from the ratio of the two methyl peaks 
at 3.63 (3 H, s, fiC02CH3) and 3.70 (3 H, s, aCO2CH3); c - calculated from the relative integral values of,9F 
signals for 91 at -76.61 (F3C on a-ester) and -76.66 (F?C on P-esterf, d - calculated from the ratio of signals 
for 87 at -74.27 (F3C on p-ester), -74.91 (F3C on a-ester)
Fig. 2.26 gives some examples of NMR spectra comparing the ratios of a- vs P-substitution of 
86 on Wang resin at different temperatures and equivalents of DMAP. Solution-phase spectra 
(in C2HCl3) are of the methylation-product of N-TFA-asp-Wang after cleavage from the resin. 
Gel-phase spectra (in C62H6) are of iV-TFA-asp-Wang. The spectra shown are of top: 
experiment 22, middle: 24 and bottom: 25.
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Figure 2.26; Examples of NMR spectra comparing ratios of a-vs ^-substitution of 86 on Wang.
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Figure 2.27: 13C- gel-phase NMR spectra of top: Wang resin, bottom: 87, both in 
DMSO.
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2.S.3.2 p Resin
/*--rifluoroacetyl-(2S)-aspartate (86) was also successfully loaded onto p~ 
hydroxymethylpolystyrene resin (92) using the protocol developed for Wang resin. 
Preliminary small-scale experiments to optimise the loading temperature established that the 
reaction must be heated to 35 °C or above (Table 2.8). Unfortunately the nucleophilic 
substitution reaction appeared to proceed more slowly with this resin, so this route to the solid- 
phase synthesis of the substrate (32) was not pursued.
CH2OH
p-Hydroxymethylpolystyrene resin (92),
Table 2.8: Conditions for loading p-hydroxymethylpolystyrene resin.
Experiment Temperature Time (hours) Equivalents of
DMAP
Equivalents of
Anhydride
Stirring % Loading0
1 0 °C 170 none 5 X none
2 0 °C 1 X none
3 rt " none tl J none
4 rt 1 II
V none
5 35 °C none II J none
6 35 °C " 1 II J 36
a - calculated by comparing mass of resin before and after loading experiment (values are approximate)
The loading of 86 onto p-hydroxymethylpolystyrene resin was indicated by several new peaks 
on the IR spectrum: DjpaxCKBPrV^m’1 1735 s (C=O, aryl ester), 1541 (2° amide, solid state) 
and 1170 s (C-F or C-0 ester). 19F and 13C gel-phase NMR spectra showed several new 
signals compared to the resin alone, further indicating the loading of 86 onto the resin:
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(Sc(74.76 MHz; (C2H3)2SO) 171.37 (ocC02R), 162.58 (pCO2H), 157.00 (F3CCO), 117.87 
(F3C), 49.45 («C), 34.79 (PC); 6F(282.2 MHz; C2HC13) -74.87 (F3C)}.
2.5.3.3 Attempted Reduction of oc-p-Benzyloxybenzylpolystyrene-A-
trif!uoroacetyl-(2S)-aspartate
Once the procedure for loading 86 onto Wang resin had been established, attempts were made 
to reduce the free P-carboxylic group of 87 to an alcohol using the mixed anhydride 
methodology developed previously for the solution-phase synthesis of 75. The first attempt 
using this method led to cleavage of most of the A-trifluoroacetyl-(25)-aspartate (86) from the 
resin. The failure of this method, and a desire to avoid the awkward step of removing excess 
NMM and EBCF under nitrogenvza cannulae, led us to investigate a number of other methods 
for the selective reduction of carboxylic acid groups in the presence of both amide and ester 
functionalities.
The use of boranes in organic synthesis has been widely reported in the literature.294 Some 
borane complexes can selectively reduce carboxyl groups to primary alcohols in the presence of 
other functionalities, without the need for prior activation of the acid group. A popular reagent 
is diborane in THF, which, according to the literature, reacts extremely rapidly and selectively 
with acids.295-299 H. C. Brown et al. observed that aliphatic acids were reduced under mild 
conditions within 15-30 minutes and aromatic acids within 24 hours.295 In fact, the relative 
reactivity of this reagent with various functionalities is almost the reverse of that of alkali metal 
borohydrides.294 This is a result of the Lewis acid nature of diborane, which functions best as 
a reducing agent in attacking groups at positions of high electron density.295 Of particular 
interest was a carboxylic acid reduction carried out by Kluender and coworkers in the presence 
of A-trifluoroacetyl and methyl ester groups (Scheme 2.9).300
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Scheme 2.9: Selective reduction of carboxylic group in the presence ofNtrifiuoroacetyl and 
methyl ester functionalities.
Other reagents for the selective reduction of carboxylic acids to alcohols in the presence of 
esters and amides at low temperatures include sodium borohydride/ iodine, sodium 
borohydride/ catechol and sodium borohydride/ trifluoroacetic acid. 301-303 The latter could 
obviously not be used with Wang resin as TFA promotes the cleavage of compounds from the 
solid support. The action of diboranc has also bccn found to bc enhanced by thc presence of 
catalytic amounts of sodium borohydride.294
These reducing reagents were tested for their efficacy under a number of different reaction 
conditions (Table 2.9). Unfortunately, in many cases, the amino acid was merely cleaved from 
the resin. After each reaction, any material remaining bound to the resin was cleaved using 
TFA/H2O/TES (90:5:5) and analysed by spectroscopy. Neither the acid group or thc
A-rrifluoroaceryl amide group were reduced in any reaction as no H7 signals were observed 
and the NH doublet of 86 was still visible at 7.83 and 7.81 ppm in the 1H-NMR spectrum.
It seemed possible that the ester linkage to the resin was much more labile than the a-isopropyl
ester linkage of 74, and that reducing agents were preferentially attacking this function.
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Table 2.9: Conditions for attempted reductions of a-p-benzyloxybenzylpolystyrene-N- 
trlfluoroacetyl-( 2S faspartate.
Exp. Solvent Reducing Reagent Temp. Time
%
cleavage
1 DMF-THF
2.5 eq ea NMM and IBCF
2.5 eq NaBH4
-5 °C 
-5 ’C/ rt
30 min
2 h/O/N 65%
2
DMF/ THF
2.5 eq ea NMM and IBCF
2.5 eq NaBH
O°C
0 °C
2 h
24 h -
3 THF
1.1 eq ea NMM and IBCF
0.6 eq NaBH4
0 °C
0 *C/ rt
30 min
3 h/ 14 h 35%
4 DMF-THF
5 eq ea NmM and IBCF
2.5 eq NaBH4
0 °C
0 °C
30 min
6 h/ 1.5 h -
5 DME
5 eq ea NMM and IBCF
0.6 eq NaBH4
0 °C
O °C
0/N
5 h -
6
DME
5 eq ea NMM and iBCf
0.55 eq NaBH4
O°C
0 °C/ rt
0/N
1.5 h/ 1.5 h 13%
7 DMF-THF 1.1 eq BH3-THF 0 °C O/N 72%
8 DMF-THF l.l eqBH3-THF 0' °C/ rt 7h/0N -
9 Thf 1 eq BHg-THF, 0.1 eq NaBH4 0 °C 5 h -
10 DMF-THF 1.2 eq NaBH4, 0.5 eq I2 (dark) 0 °C 14 h 7%
11 DMF 1.2 eq NaBH4, 0.6 eq I2 0 °C/ rt 5 h/O/N -
12 THF/ EtOH 1.2 eq NaBH4, 0.5 eq I2 (dark) 0 °C 24 h -
13
DMF
2,5 eq ea NMM and IBCF
2.1 eq N-selecti'ide
0 °C
0 °C
30 min
2 h/ 30 min 39%
DMF was used in preliminary reactions due to its resin-swelling properties. When several 
reactions failed in this solvent, the solvent was changed to THF, as recommended in the 
solution-phase procedures. It was thought that the reducing reagents might be interacting with 
DMF, rendering them less effective. After reactions in THF also failed DME was selected as a 
possible alternative. Sodium borohydride is soluble in few organic solvents excepting alcohols 
and DME.294 Experiments to reduce the protected aspartate 74 using this reagent were 
successful in THF probably because it was less essential to solvate the sodium borohydride as 
74 was already in solution. In this case, however, the reaction was hindered by both the 
reducing agent and the substrate being in the solid-phase. DME also has the advantage of 
being slightly more dipolar than THF, and therefore has better resin swelling properties.
Reactions had been carried out successfully in the group previously using NMM and IBCF 
with compounds on Wang resin. The results obtained here were therefore difficult to explain.
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In order to better understand the mechanism by which 86 was being cleaved, a number of 
control experiments were carried out using just these two reagents (Table 2.10). Some of these 
reactions resulted in significant proportions of 86 being cleaved from the resin.
The washings from experiments 3-6 were analysed by OH- and 19F_NMR spectroscopy and all 
were found to contain at least some traces of 86. These findings, and the elimination of 86 
caused by NMM alone (experiments 2, 5 and 6, Table 2.10), indicated that the cleavage of 86 
from the resin could be induced by the presence of base. It was also noted that, in some early 
experiments using NMM and IBCF, the HH-NMR spectrum of material cleaved from the resin 
displayed multiplet signals at around 2 and 4 ppm, indicative of an isobutanol moiety derived 
from IBCF. On the basis of these findings the elimination mechanism shown in Scheme 2.10 
was proposed.
Table 2.10: Experiments to find the reagent(s) responsible for cleavage of 86 from the 
resin.
Exp. Reagent Equivalentsa Time % cleavage
1 NMM 5 3 h none
2 NMM 5 4 84.5
3 (i) NMM
(ii) IBCF
5
5
2 h
2.5 h
40
4 (i) NMM and IBCF
(ii) DIEA
5 of each
2
30 min
3.5 h
54.4
5 NMM 2.5 30 min 49.7
6 NMM 2.5 12 h 32
All reactions listed in this table were carried out at 0 °C in DME. a - relative to loading of 86 on the resin.
125
Results and Discussion- Soiid-phase Synthesis
Scheme 2.10: Proposed scheme for the reaction of 87 with NMM and IBCF.
The postulated elimination mechanism shown in Scheme 2.10 was confirmed when 
experiments were canied out to provide evidence for the activation of the carboxylic acid group 
(Section 2.5.3.4), It was found that if the bases used for these reactions were added gradually 
in dilute solution, this resulted in less compound being cleaved from the resin. IBCF or the 
coupling reagent PyBOP (93) were also added before any base. This meant that as small 
amounts of corboxylate ion were fonned, it reacted preferentially with the relative excess of 
activating agent, leaving little carboxylate available to cause elimination/ cleavage.
It was assumed that, because the formation of a carboxylate ion in 74 did not lead to cleavage 
of the ac-isopropyl group, the carboxylate ion formed by 87 would also not attack an ester
function. There ore two possible explanations for the difference in reactivity between these two 
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esters. Firstly it may be that the ester linkage is weaker in 87 than in 74. Another possible 
explanation is based on the different phases of 87 and 74. The carboxylate ion formed by 74 
is fully solvated. The carboxylate ion of 87, on the other hand, cannot interact to such an 
extent with the solvent, and is therefore much more nucleophilic towards the ester linkage.
BenzotriazolyZoxy-/ri‘s/pyrro/idin0/-phosphoni'umhexafZuorophosphate (PyBOP, 93)
Although the mechanism given in Scheme 2.10 could explain the cleavage of 86 in the 
presence of NMM, there was also significant cleavage of the compound in the presence of 
diborane. This cleavage must therefore occur via a different mechanism. One possibility is 
that, due to its Lewis acidic nature, diborane readily coordinates with the oxygen atom linking 
86 to the resin, which further weakens the ester bond (Scheme 2.11) One advantage of using 
p-hydroxymethylpolystyrene resin (92) instead of Wang resin, is that this elimination 
mechanism would not be possible.
O?h3 o
CH2-^6 'T CO2H 
HN CF3
If
o
Scheme 2.11; Proposed mechanism for the dlborane-lnduced cleavage of 86from Wang 
resin.
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2.S.3.4 Experiments to Confirm the Activation of the Carboxylic Group
Although the mixed anhydride methodology resulted in some cleavage of 86 from the resin, if 
fewer equivalents of IBCF and NMM were used, and the reaction time for the activation step 
was minimised to 15 minutes, then at least half of the N-TFA-asp would remain on the resin. 
In order to establish the reason why no reduction of the p-carboxylic acid group had occurred, 
it was necessary to determine whether the mixed anhydride was formed at all, or whether some 
other means were necessary to activate the P-CO2H group. To do this simple coupling 
experiments were devised, using diethylamine to attack any activated acid. Reactions were 
conducted in DME at 0 0C, and the bases used were diluted in DME and added slowly over 15 
minutes. These reactions are summarised in Scheme 2.12.
o-p
Wang\- CH3
H
©I
F3<C^NH o
0
O
94
Reagents and conditions: (i) 2 eq PyBOP, DME followed by slow addition of 1.05 eq 
DIPEA in DME, rt, 30 min; (ii) 2.5 eq IBCF, DME followed by slow addition of 2.5 eq 
NMM in DME, (-15 °C), 30 min ; (iii) 1.1 eq DEA, DME, rt, 30 min; (iv) 1.5 eq DEA, 
DME, -10 °C, 30 min.
Scheme 2.12; Coupling reactions with diethylamine.
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Both methods successfully produced the amide 94, although a consistent yield could not be 
obtained, and some cleavage still occurred in nearly all cases. A quantitative yield was 
obtained in one case using PyBOP. The PyBOP activation also produced the cleaner product: 
For characterisation the amide was cleaved from the resin using TFA/H2O/TES (90:5:5){m/z 
(El) 284 (42%, M+)}. The 'H-NMR spectrum showed signals for a carboxylic group {172.29 
(aCO2H)| and an amide {169.91 [pC(O)N)]} and two sets of signals corresponding to the 
ethyl groups {42.52 and 40.89 (CH3CH2N, 2 conformations) and 13.50 and 12.46 
(CH3CH2N, 2 conformations)}.
2.5.3.5 Reduction of a-/?-Benzyloxybeiizylpolystyrene-.A-trifluoroacetyl-(2S)-
aspartate
Having established two methods of activating the acid group and the way to minimise cleavage 
of 86 from the resin, a number of different reducing agents were tested (Fig. 2.28). Some 
more hindered reducing agents were tried, as these might have greater selectivity toward the 
activated acid rather than the ester linkage. PyBOP was used in most cases to activate the P~ 
carboxyl group, as indicated in Scheme 2.12. The results of these experiments are summarised 
in Table 2.11. The success or failure of the reduction reactions was monitored by cleaving any 
remaining material from the resin using TFA/H2O/TES (90:5:5), and examining the product by 
]1H-NMR spectroscopy. A successful reduction was indicated by an upfield shift in the signals 
for HP to approximately 1.9 ppm and the appearance of new signals for HYat around 3.3 ppm 
[cf. HH^NMR spectrum of 86, Fig. 2.29}. Although a number of reagents managed to 
produce some level of reduction, the amount of 86 eliminated from the resin was still too high. 
Any excess DIPEA and PyBOP or NMM and IBCF was removed prior to the addition of the 
reducing agent to reduce the opportunity for base-catalysed cleavage/ elimination of 86. It 
seemed, therefore, that there was another mechanism via which elimination could occur. 
Experiments were carried out in which Wang resin, or 87 were stirred overnight with 0.6 
equivalents sodium or lithium borohydride to check their stability towards these reagents.
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Figure 2.28; Hindered reducing agents.
Table 2.11; Reagents tried for the reduction of the activated p-carhoxyl group.
Reducing
Agent
Equivalents Temperature Time Reduction % ?
Cleavage
N-selectride 3 -15 °C/rt 1 h/16 h X 95
9-BBN 3 -15 °C/rt 20 min/ 25 h X 95
Super-Hydride 3 -15 °C/rt 30 min/ 11 h J -
Super-Hydride 2.5 0 "Cb rt 2.5 h/ 1 li - 100
BH3-THFa 1.1 - 10 °a rt 50 min/ 21 h X 47
NaBH4b 2.5 0 OC 12 h minor 24
NaBH4 2.5 0 °C/ rt 4 hb 10.5 - 92
NaBH4 0.6 rt/ 30 °C 11 h/ lOh 7 95
LiBH 4a 1.1 0 °C 1.5 h 7 27
L i BH 4 0.6 rt 18 h 7 13
LiBH 4 0.6 rtb 30 °C 10.5 hb 10 h 7 95
a - non-activated PCO2H, b - NMM/ IBCF activation
The results of the control experiments with sodium and lithium borohydride were not entirely 
conclusive. There was some loss of mass from both the Wang resin and 87, although some of 
this may be due to losses incurred during the washing procedure. At this stage attempts to 
synthesise 32 using Wang resin were abandoned in favour of searching for a new solid- 
support system which would prove more stable to reducing agents.
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9.09 45.77 8.12 31.41
8 7 6 5 4 3 2 ppm
Figure 2.29: Top: 1H-NMR spectrum of material cleaved from 87 (i.e. 86), bottom: lH- 
NMR spectrum of material cleaved from the resin after treatment of 87 with PyBOP/DIPEA 
then LiBH4.
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2.5.4 A New Solid Support
The problems encountered when trying to reduce the free acid group of 86 were mainly due to 
the ease with which the asparate moiety underwent base-catalysed elimination from the resin. 
A new linker, 95 was obtained for attachment to chloromethyllpolystyrene-diviTylbenzeTe 
(Memfield) resin (96) which would produce a resin similar to Wang, but with an ethyl rather 
than a methyl alcohol attachment (97). This would ensure that the ester linkage from, the resin 
to 85 would not be in conjugation with the aromatic ring system on the resin, and would leave 
the p-carboxyl group less hindered by the bulky resin. It was envisaged that the synthesis of 
32 using the new resin would proceed as originally intended with Wang resin (Scheme 2.8).
The new I'inker, 2~(^p~lvyd.r(ox-yp'heiryl)-eth-an.ol (95), Merrifield resin (96) and the new resin 
(97).
2.5.4.1 Attachment of 2-(^-Hydroxyphenyl)-ethanol to Merrifield Resin
A number of methods were tried for the attachment of the alcohol named above to Merrifield. 
These have been summarised m Table 2.12. It was preferable to keep the reaction temperature 
low to prevent damage to the resin. The best method was found to be the use of 2.5 
equivalents of the alcohol and 1 equivalent each of K2CO3 and potassium iodide in acetonitrile 
at room temperature (97% loading after approximately 40 hours). However the method most 
often used, for convenience, involved 2.5 equivalents each of the alcohol and powdered 
potassium hydroxide in acetonitrile at 35 “C (97% after 4 days, see Scheme 2.13). A catalytic 
amount of 18-crown-6 for solvating cations was essential for either method to succeed. 
Attempts were made to monitor the progress of reactions by UV, but it was found
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that the absorbance values of the various phenoxide species were too different from that of the 
phenol to produce coherent readings.
Table 2.12: Conditions used in experiments to load 95 onto Merrifield resin..
Equivalents
of (96)
Other Reagents Solvent Temp
CC)
Time
(hours)
h
Loading^
1 10 10 eq KOH (solid) DMSO 23 290 none
2 10 10 eq KOH DMSO 35 192 none
3 5 5 eq KOH DMSO 23/ 100 30/ 17.5 99
4 2.5 2.5 eq KOH, 18-crown-6 (cat) CH3CN 40 85.5 97
5 5 2 eq Et4NF DMF 40 46 none
6 5 2.5 eq CsF DMF 35 24 none
7 5 2.5 eq CsF DME 35 24 none
8 10 lOeq NaH DMF 23 290 none
9 10 2 eq NaH DMF 35 192 none
10 2.5 1 eq NaH, 18-crown-6 (cat) CH3CN 40 85.5 15
11 5 1 eq NaH, 18-crown-6 (cat) THF 40 160 21
12 5 1 eq NaH, 18-crown-6 (cat) THF 23/ 67 46/ 17.5 47
13 5 1.5 eq NaOEt/EtOH THF 40 42 none
14 5 1.5 eq NaOEt/ EtOH THF 23/ 67 30/ 10.5 none
15 2.5 1.5 eq NaOEt/ EtOH, 18-crown-6 (cat) CH3CN 40 85.5 none
16 5 1 eq K2CO3 DMF 40 46.5 69
17 2.5 1 eq K2GO3,  1 -eq KI 18^cjrown-6-- (cat) ch3cn 23 41.5 97
18 5 1 eq K2CO3 1 eq KI, 18-crown-6 (cat) CH3CN 23 41.5 70
19 2.5 1 eq K2CO3 1 eq KI, 18-crown-6 (cat) CH3CN 30 41.5 53
20 5 1 eq K2CO3 - 1 eq KI, 18-crown-6 (cat) CH3CN 30 41.5 50
21 5 1 eq K2CO3 - 1 eq KI, 18-crown-6 (cat) CH3CN 40 46.5 82
a - calculated by comparing the mass of the resin before and after loading experiments
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Scheme 2.13: The KOH-mediated loading of 95 onto Merrifield.
According to the literature, the best general method for the preparation of unsymmetrical ethers 
is the Williamson reaction, discovered in 1850. The normal method involves treatment of the 
halide with an alkoxide or aroxide ion derived from an alcohol or phenol. A variation on this 
procedure was reported in 1979 by Johnstone and Rose, involving the combination of the alky 
halide and alcohol with powdered potassium hydroxide in DMSO at room temperature.309 
Although they only describe a method involving alkyl bromides and iodides, it seemed 
plausible that Merrifield resin (an alkyl chloride) might also undergo reaction under these 
conditions. In our studies using Merrifield resin, however, no detectable reaction occurred at 
room temperature or 35 °C. It was necessary either to raise the reaction temperature to 100 °C 
or use a crown ether (18-crown-6) to solvate cations. A number of factors were producing this 
slow reaction. The chloride ion is a poorer leaving group than bromide or iodide ions. KOH is 
also only slightly soluble in DMSO, hence the need for the crown ether. This problem was 
alleviated by using acetonitrile as it is slightly more polar than DMSO. Another factor 
hindering the reaction is the bulky nature of the resin. It was noted in the paper that more 
hindered alkyl groups, not surprisingly, reacted more slowly and that this necessitated a higher 
reaction temperature.
Phase transfer catalysis has been shown to promote efficient reaction of alcohols and alkyl 
halides. Freedman and Dubois reported an improved Williamson ether synthesis using
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tetrabutylammonium bisulphate (TBAB)J305 McKillop et al. also used a quaternary 
ammonium salt as a phase transfer catalyst in the synthesis of phenol ethers.306 of particular 
interest was the reaction shown in Scheme 2.14, which is similar to what we were trying to 
achieve, which produced a yield of 86% of the desired product.
Scheme 2.14: McKillop's ether synthesis.
J. M. Miller et al. also reported on the use of a quaternary ammonium halide for the promotion 
of the synthesis of alkyl phenyl ethers, including thc product shown in Scheme 2.14.307 He 
used tetraethylammonium fluoride in DMF as a source of fluoride ions. The fluoride ion can 
act as a powerful hydrogen bond donor. In an article published in 1977 it was shown that 
phenol and fluoride can form a strong H-bond together, resulting in a large shift of thc 
hydroxyl stretching band in the IR spectrum (Aus(OH) ~ 1000 cm-1}.308 An attempt was 
made to use this reagent for promoting the alkylation (experiment 5, Table 2.12), but to no 
avail. Again steric hindrance may be the reason why this reaction failed and a higher reaction 
temperature may prove necessary. In the same paper Miller reports that the condensation of 
phenol with halogenoalkanes is promoted by the presence of KF.308 The reaction is 
accelerated by an order of magnitude if CsF is used instead. Although, in our hands, this 
reagent failed to produce a successful reaction, this may be attributed to the low solubility of the 
alkali metal fluoride in either of the solvents used. Again the use of 18-crown-6 and a higher 
reaction temperature would probaby have solved this problem. The use of fluoride-containing 
reagents was not pursued further, however, because other, more cost-effective methods had 
produced satisfactory results.
The use of sodium hydride to form an alkoxide ion which could react with benzyl bromide was 
reported by D. J. Hart et al. in their work on the total synthesis of lythrancepines.309 3.6
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equivalents of NaH were added to the alcohols in DMF at room temperature. After 1 hour 
benzyl bromide was added and the reaction left for 36 hours. Harsher reaction conditions were 
necessary here to produce a reaction between 95 and Merrifield resin (96). The best loading 
(47%) was obtained by refluxing the reagents in THF for over 60 hours in the presence of a 
catalytic amount of 18-crown-6. F. Kroll and D. Stones (unpublished results) have achieved 
some success with the loading of various phenols onto Merrifield resin using NaH in DMF at 
60 "C.
By far the best method found for loading 95 onto Merrifield was a protocol developed 
originally for the protection of phenols with a functionality that would be stable to 
hydrogenolysis at atmospheric pressure (Scheme 2.15).3i° This involved the use of potassium 
carbonate and potassium iodide in acetonitrile with a phenol and the alkyl chloride. The iodide 
replaces the chloride group on a small proportion of the alkyl chloride. This acts as a better 
leaving group when attacked by a phenoxide ion, thus accelerating the reaction. A reaction 
carried out using just K2CO3 produced a good loading of 95 on the resin (69%), but was not 
as efficient as the method using KI in conjunction with K2CO3.
Scheme 2.15: Mechanism for the reaction carried out by Davis and Muchowski.
The loading of 95 onto Merrifield was confirmed by the presence of several new peaks in the 
IR spectrum compared that for the resin alone: t)max(KBr)/cm'i 3453 hr m (O-H, alcohol), 
1517 m (aromatic C=C), 1500 (aromatic C=C), 1390 (O-H, alcohol). The 'I3C-NMR spectrum 
also showed the presence of several new signals: 6C(74.76 MHz; CgiHi) 158.55
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(Ar-CO, quaternary), 130.68 (Ar-CH), 115.52 (Ar-CH), 70.33 (PhCH2), 64.12 (CH2OH) 
(Fig. 2.30). The conditions for the loading of 95 onto Merrifield using potassium hydroxide 
were optimised, as summarised in Table 2.13.
Table 2.13: Optimisation of the conditions for the loading of 95 onto Merrifield using 
potassium hydroxide.
Equivalents
of (96)
Equivalents
of KOH
Temp
(°C)
Time
(hours)
h
Loading
1 1 1 23 41 none
2 1 1 35 41 22
3 1 1 60 41 none
4 2.5 2.5 23 41 50
5 2.5 2.5 35 41 22
6 5 5 23 41 none
7 5 5 35 41 24
8 5 5 60 41 none
All reactions were conducted in CH$CN with a catalytic amount of 18-crown-6. Equivalents given are with 
respect to the original loading of the resin (1.0 mmol/g).
2.5.4.2 Loading of the New Resin With A-trifluoroacety!-(2S)-aspartate
Before attempting to load 85 onto the new resin, 97, model reactions were carried out using 2- 
(4-methoxyphenyl)-ethanol (98) as a structural analogue of 97. Reactions were carried out as 
for the loading of Wang and 91 with the anhydride 73 using varying equivalents of DMAP at 
different temperatures to determine how this affected the regioselectivity of the substitution. 
The ratio of signals on the 19F-NMR spectra were used to determine the ratio of a- vs (-ester 
(Fig. 2.31 and Table 2.14).
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2l(4-methoxyphenyl)-ethanol (98)
Toble 2.14: Comparison of the regioselectivity of substitution reactions of 73 onto 98.
Experiment Equivalents
of DMAP
Temperature a- vs p-estera
1 0 0°C 72%
2 0.5 0°C 71%
3 1.0 ooc 67%
4 0 rt 58%
5 0.5 rt 65%
6 1.0 rt 58%
Reactions were carried out in DMF using 25 mg/ml 98 and 175 mg/ml 73.
Reactions 3, 5 and 6 (Table 2.14) appeared to be complete within 17 hours as shown by tic 
[band on baseline; eluant ethyl acctate-light petroleum (60%)], but reaction 2 took a few days to 
go to completion, and reactions 1 and 4 (no catalyst) were not completed even after 6 days. It 
was therefore obvious that the reaction to load 73 onto the new resin (97) would have to bc 
performed at room temperature or higher using a minimum of 0.5 equivalents of DMAP.
The first two loading experiments using the new resin were carried out at 0 °C and room 
temperature respectively using 5 equivalents of the anhydride 73 and 0.5 equivalents of 
DMAP. Both were left for three days, but no protected aspartate 85 had loaded onto the resin 
as determined by comparison of thc mass of the resin before and after the loading experiments. 
Both i9F gel-phase NMR and IR spectroscopy confirmed that no A^-t^'Tffl^coT^^^(^<ctyl-(25')- 
aspartate was present. A later experiment using the same equivalents of DMAP and 73 but 
increasing the temperature to 35 0C did not produce a significant loading after 4 days, by
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comparison of the mass of the resin at the start and end of the experiment. However, both 19F 
and 13C gel-phase NMR spectroscopy indicated that some of the protected asparate 85 had 
attached to the resin; 6C(74.76 MHz; C62H6) 34.09 (PC of aspartate), 48.42 (“C of 
aspartate), 117.44 (F3C), 169.11 (F3CCO), 173.77 (PCO2H of aspartate); 0p(282.2 MHz; 
(^^^SO) -74.81 (F3C). The IR spectrum showed the presence of an aryl ester linkage 
{1727 s (C=O)} and the W-trifluoroacetyl amide group {1653 m (2° amide, solid state)}. The 
most recent experiment was carried out using 1 equivalent of DMAP and 5 equivalents of 73 at 
35 0C. After 6 days the loading appeared to be quantitative, and the synthesis of 99 was 
confirmed by 19F and 13C gel-phase NMR and IR spectroscopy (Fig. 2.30 and 2.31). A 
method for cleaving 85 from the new resin has yet to be found. A number of methods for the 
selective cleavage of esters have been reported. Boron tribromide has been used for the 
deprotection of a number of ester protecting groups to the corresponding acids, without 
affecting amide bonds.iii Iodotrimethylsilane has also been shown to be a mild and effective 
reagent for the non-saponificative hydrolysis of esters under mild conditions.31^314 This can 
be synthesised in situ from chlorotrimethylsilane and sodium iodide.3 M This reagent does, 
however, also cleave ethers.
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2.6 Conclusions and Future Work
2.6.1 Substrate Synthesis
2.6.1.1 Solid-Phase Synthesis
The synthesis of both the non-labelled and [U-14C]-labelled substrate using previously 
established protocols has been reported here, N,N-diisoproTyl dibenzyl phosphoTamidite (79) 
has always been used in the past as a phosphorylating agent in this synthesis. However, 
problems can be encountered in the synthesis of this reagent, due to the instability of its 
precursor iV,N-diisoproppldichlooophosphoramidite (78). Two new reagents were therefore 
identified for the phosphorylation of 7/-trifluoroacety^(0-isopropyl-(25')-homoseriTe (75), one 
of which was available commercially (80), the other, 81, being synthesised easily from POCI3 
and pentafluorophenpl. These gave good clean yields of the phosphorylated compounds 83 
and 84. However, these phosphate groups could not be subsequently deprotected.
A/-trifluoroacetyl-(2S)-aspartatc (86) has been successfully loaded onto Wang, p- 
hydroxymethyl polystyrene (92) and polystyrene-4-pxymethyl-2-TheTylethaTol (97) resins 
during attempts to synthesise the substrate on the solid-phasc. The latter resin is a novel resin, 
which was synthesised by the base catalysed addition of 2-(T-hydroxyphenyl)-ethaTol (95) to 
Merrifield resin (96) in 97% yield. This was promoted by the use of KI to exchange chloride 
for the better leaving group, iodide, and by 18-ctowt-6 to solvate the ionic species. Both 
K2CO3 and powdered KOH could be used as bases for this reaction. Acetonitrile was found to 
be the best of the solvents tried in this reaction.
The nucleophilic addition reactions of each resin with 85 proceeded with good regioselectiv^y 
to favour protection of the a-carboxylic group of 86. Wang resin was the most selective for 
the ot-ester (84% a- vs. P-ester). This is due to the more hindered nature of the hydroxyl 
group on Wang compared to 92 and 97. This regioselectivity compares reasonably well with 
the ring opening of 85 by isopropanol, which produces a ratio of a- vs. P-ester of 95%. The 
ring opening of 85 using resins does, however, proceed much more slowly, and requires 
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heating of the reaction to at least 30-35 °C, which in turn lowers the regioselectivity.
The compound produced from the reaction of 85 with Wang resin, 87, was found to be 
unstable to reducing agents. It was thought that the compound produced using 
p-hydroxymethyl polystyrene (92) would also be unstable to reducing agents, as it resembles 
the structure of 87. Resin 92 was, in any case, less selective for the a-ester than Wang resin. 
The novel resin, 97, wos also less selective than Wang resin for the at-ester (72% a- vs. p­
ester), but it is hoped that 98 will prove more stable to reducing agents.
2.6.1.2 Suggestions for Future Synthetic Work
The conditions for the loading of 86 onto 97 have yet to be optimised, and a mild and selective 
method for the cleavage of the ester linkage must be developed. It would be preferable to find a 
method which would simultaneously deprotect the dipenlafIuorodiphenylphosphate triester to 
minimise the number of deprotection steps necessary in the solid-phase synthesis of 32. The 
possibility of reducing the p-carboxyl group on 99 using either the mixed anhydride or the 
PyBOP method of activation has yet to be explored, and it remains to be seen whether the new 
linker prevents the cleavage/elimination of 86 from the resin. It may be possible to use 
diborane with the new resin, as the ester linkage is no longer adjacent to a system of conjugated 
double bonds. If cleavage still occurs, more sterically hindered linkers such as 100 may be 
necessary, which resemble more closely the structure of the isopropyl group of 74, which is 
stable to reduction. A more hindered linker may also improve the regioselectivity of the 
nucleophilic addition reaction in favour of the a-ester.
If a resin is developed with enhanced stability towards reducing agents, this may have o wider
application for general use in the solid-phase synthesis of peptides and amino acid derivatives.
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2.6.2 A Viable Source of Threonine Synthase
2.6.2.1 The Tir8 Mutant
The mutant form of E. coli K-12 Tir8 is was first characterised by its resistance to 
thiaisoleucine (2-amino-3-methylthiobutyric acid).174 The growth of wild-type K-12 cells is 
prevented by the presence of this compound, due to the inhibition of threonine deaminase 
activity. The growth inhibition is reversed by isoleucine at a concentration one-tenth that of the 
inhibitor. Tir mutants have altered isoleucyl sRNA synthetases and derepressed levels of three 
of the five enzymes involved in the biosynthesis of isoleucine and valine. These mutants are 
also slower growing than wild-type cells.
In Section 2.2 it was reported that the Tir8 mutant might have reverted to wild-type during 
experiments to isolate TS and so that it longer over-expressed the enzymes coded for by the thr 
operon. One of the possible reasons for this is that wild-type cells are faster growing than Tii8 
cells and can rapidly overtake a growing culture. As Tir8 exhibits enhanced resistance to 
thiaisoleucine one method for detecting any remaining mutant cells is to plate out a fresh 
culture, grown from frozen glycerol stocks of Tir8, onto L-agar plates containing the 
compound and incubate these overnight. This would provide growth conditions selective for 
the mutant colonies, which could then be isolated and grown up in LB-medium for further 
attempts to isolate TS from this source. If this were still unsuccessful or if no mutants were 
isolated, then it would be necessary to immediately carry out more cloning work to insert thrC 
into a pET vector. Cloning the gene into such vectors does also have some advantages over the 
use of Tir8. Only thrC would be over-expressed in cells transformed with these constructs, 
facilitating the purification of the enzyme. A His-tagged version of the enzyme should also 
make the purification of TS much quicker and easier (see Section 1.117.
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2.6.2.2 Cloning Amplified77zrC Into pET Vectors
A protocol for the cloning of amplified gene fragments into pET vectors has been established 
and reported here. This involves cloning the gene first into pGEM-T from which it is 
subcloned into pET vectors. This first cloning step allows for the production of a large amount 
of the amplified gene DNA without the need for repeated PCR experiments, during which 
mutations can arise. Cloning of gene fragments with Nde I-sites at either terminus into pET 
vectors via ligation of cohesive termini does not appear to be possible, but fragments with a 
Nde I-site at one terminus and a BamY I site at the other can be ligated into pET vectors 
restricted with these two enzymes.
It has been found that ligations using pET-vectors have a specific temperature requirement of 
16 °C, whereas ligations into pGEM-T can tolerate warmer conditions (i.e. room temperature). 
The DNA insert must be extremely pure for ligation into pET expression systems. Successful 
results were obtained using PCR products and excised gene fragments which had been purified 
on Wizard Prep™ DNA purification columns and using recombinant plasmids which had been 
isolated using the QIAGEN maxiprep protocol and purified where necessary using Wizard™ 
DNA Clean-up Purification Resin.
Both the thrC gene and the gene coding for p-methylaspartase, containing Nde I-sites at each 
teimiinus, were amplified and cloned into the pGEM-T transcription vector. The identity of the 
gene inserts was identified by a number of means:
• Diagnostic PCR - whereby half as well as whole amplified gene fragments have been 
obtained using internal and external primers .
• Restriction analyses - carried out on the recombinant plasmids which gave distinct 
fragments of the predicted sizes.
• Subsequent di-deoxynucieotide sequencing of the recombinants which gave the sequence of 
the first 127 bases of the C-terminus of the thrC gene, including the Nde I-site, and the first
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120 bases of both the C- and N-termini of the gene for p-methylaspartase. These gene 
fragments could not be subcloned into pET vectors and the constructs were therefore discarded 
before full sequencing could be carried out.
The two genes were amplified again to produce gene fragments with an Nde I-site at the 
N-terminus and a BamH I-site at the C-tenninus. This also improved the efficiency of ligations 
into pET vectors, as the orientation of gene inserts in the vector could now be controlled. 
These PCR products were cloned into pGEM-T. Two recombinants for thrC (pGEM-TTSi and 
pGEM-TTSii) were identified by a number of restriction analyses. Preliminary sequencing 
experiments produced correct sequences for the two termini of the gene in both constructs. 
Subsequent sequencing of the whole thrC gene insert in both constructs has revealed one 
deletion and two mutations of the recombinant gene (Section 2.4).
The thrC fragment was excised from pGEM-TTSi and pGEM-TTSn for subcloning into the 
three pET-vectors pET-3a, -3b and -16b. Recombinants were identified by restriction analysis. 
Sequencing of these vectors was also carried out (Section 2.4) confirming the gene mutations 
observed in the pGEM-TTS constructs.
The asymmetric P-methylaspartase PCR product was also inserted into pGEM-T, and further 
cloning work has been carried out by other researchers to insert the gene fragment into pET- 
vectors (Section 2.3.2.3).
2.6.2.3 Future Work on ThrC
Since it has been determined that the recombinant thrC genes do not have the same sequence as 
the wild-type gene, if the Tir8 mutant is confirmed to have completely reverted to wild-type it 
will be necessary to repeat the cloning procedure which has been optimised during these 
studies.
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Taq DNA polymerase lacks a 3' - 5' exonuclease proofreading activity, and therefore has a 
relatively high error rate. The mutation frequency using this enzyme is 110 x IO’4 at lOmM 
MgCl2 and ImM dNTPs.244 A mutation is therefore highly likely to occur after relatively few 
cycles of PCR using this enzyme.265 Vent™ DNA polymerase has a fidelity 5-15 fold higher 
than that of Taq, having a mutation frequency of 190 x 10‘4, and is the only thermophilic 
polymerase with a 3' - 5' exonuclease proofreading activity.264’ 265 Therefore, in experiments 
to repeat the PCR amplification of thrC, it is obvious that Vent should be used instead of Taq. 
A new amplified thrC fragment should be produced with an Nde I-site at the N-terminus and a 
Bam H I-site at the C-terminus using this enzyme. As a precaution the PCR product(s7 should 
then be sequenced before undertaking any further work, to determine whether the PCR reaction 
has been successful. If a mutation occurs at an early stage in the PCR reaction, then that error 
will be amplified in subsequent cycles of PCR. If this is the case then in subsequent ligation 
experiments most of the recombinant plasmids will contain the mutant gene, and this is 
probably what happened when Taq was used in PCR reactions.
Many factors can affect the fidelity of Taq and these have been detailed by Eckert and 
Kunkel.2.5 A discussion of these may offer an explanation for the PCR errors encountered in 
this work. These factors may also affect the fidelity of other thermophilic polymerases, which 
have been less extensively studied.
• The concentration of dNTPs can have a detrimental effect on Taq fideltiy if too high. A 
1000 pM DNTP concentration causes the error rate to be doubled in comparison to using 1 pM 
dNTPs. In the work reported here the dNTP concentration was 125 pM, which gives a result 
very similar to that obtained for 1000 pM dNTPs. If a polymerase lacks an exonuclease to 
remove terminal mispairs, then unextended errors will be lost because they do not yield full- 
length DNA products for further amplification. At low dNTP concentrations the level of 
mispairing is reduced and the error discrimination is enhanced. The concentration of dNTPs 
should therefore be lowered in future PCR reactions.
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• The fidelity of Taq can be improved by decreasing the magnesium chloride concentration 
relative to the concentration of dNTPs present in the reaction. The concentration of MgCh 
should be equimolar with the dNTP concentration for optimum fidelity. The reactions reported 
here were carried out using 2.5mM MgCl2, as recommended by the manufacturer. In future 
reactions the concentration of MgCl2 relative to the dNTP concentration could be lowered to 
reduce the level of mutation.
• The error rate of Taq is reduced by decreasing the reaction pH to 5 - 6 and the frequency of 
mutations continues to increase as the pH is raised through 8.2. At pH 5.1, the error rate is 
reported to be 1/180 000 using 1000 pM dNTPs and 10 mM MgCh whereas at pH 8.2 the 
error rate is increased to 1/3 200 (both reactions at 70 °C). However, the incubation of DNA at 
high temperatures and low pH causes DNA damage, increasing the potential for mutations, so 
this must also been taken into consideration if lowering the reaction pH of PCR reactions in 
order to improve polymerase fidelity.
If the thrC gene is successfully cloned into pET vectors then it may prove possible to purify TS 
in a more efficient way than previously possible using the Tir8 mutant. If this were the case, it 
would then be useful to attempt the first X-ray crystallographic studies on the enzyme, 
particularly in order to elucidate the active-site structure of the enzyme. TS from either source 
could also be used, as originally intended, for product inhibition assays. The substrate 
analogues, which have been synthesised by G. Allan (these are discussed in Section 1.10), 
could also be tested as inhibitors of the enzyme or to further elucidate the TS reaction 
mechanism, as appropriate.
Site-directed mutagenesis experiments could later be carried out to monitor the effects of 
altering residues, which are conserved in all microbial TS sequences, on the structure and 
catalytic activity of the enzyme from E. coli. Mutant thrC genes produced via PCR could again 
be cloned into pET constructs using the established protocol.
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3.1 Synthesis
3.1.1 General Experimental Procedures
3.1.1.1 Compound Characterisation
Elemental microanalyses were performed in the departmental microanalytical laboratory.
NMR spectra were recorded on Varian Gemini 300 (.H, 300 MHz; 13C, 74.76 MHz; 31p, 
121.42 MHz; I9F, 282.2 MHz7, or Varian Gemini 200 (iH, 200 MHz; i.C, 50.31 MHz7 
spectrometers. .H- and .3C-NMR spectra are described in parts per million downfield shift 
from SiMe4 and are reported consecutively as position (8h or 5c7, relative integral, multiplicity 
(s = singlet, d = doublet, t = triplet, q = quartet, dd = double of doublets, dt = doublet of 
triplets, dq = doublet of quartets, sept = septet, m = multiplet, and br = broad7, coupling 
constant (7/Hz7 and assignment (numbering according to the lUPAC nomenclature for the 
compound7. .H-NMR spectra were referenced internally on 2HOH (5 4.80 ppm7, C2HC13 
(8 7.27 ppm7 or (C2H372SO (8 2.50 ppm7. 13C-NMR spectra were referenced on C2HC13 
(6 77.23 ppm7, C^H. (8 128.39 ppm7 or (CH^SO (6 39.51 ppm7. i.F-NMR spectra 
were referenced internally on CFCI3 and described in parts per million downfield shift from 
this compound. Aip-NMR spectra were referenced on external ^PO4.
IR spectra were recorded on a Perkin-Elmer 1710 FT-IR spectrometer. The samples were 
prepared as Nujol mulls, thin films between sodium chloride discs or as dispersions in 
potassium bromide discs. The frequencies (U as absorption maxima are given in 
wavenumbers (cnr^ relative to a polystyrene standard at 1603 cm-1. Signal strengths are 
reported as s = strong, m = medium, w = weak and br = broad.
Mass spectra and accurate mass measurements were recorded on VG 70-250 SE, Kratos 
MS-50, VG Platform E/S . Major fragments were given as percentages of the base peak 
intensity (100H7.
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UV data was obtained on Pye-Unicam SP8-500 or SP8-100 spectrophotometers.
Flash chromatography was performed according to the method of Still et al.3i5 using Sorbsil 
C60 (40-60 pm mesh) silica gel. Analytical thin layer chromatography (tic) was carried out on 
0.25 mm precoated silica gel plates (Macherey-Nagel SIL g/UV254) or 0.25 mm precoated 
cellulose plates and compounds were visualised using UV fluorescence, potassium 
permanganate solution, vanillin, or ninhydrin. Preparative tic was performed on glass-backed 
cellulose plates.
Melting points were taken on an Electrothermal or Gallenkamp melting point apparatus and are 
unconnected.
Optical rotations were measured at 23 °C on an Optical Activity AA-1000 polarimeter using 
10 cm path length cells. Readings are given in 10_1 deg cm2 g-2 and the solution concentration 
is given in g c^'3.
3.1.1.2 Reagent and Solvent Preparation
The solvents used were either distilled or of Analar quality and light petrol ether refers to that 
portion boiling between 40 and 60 “C. Solvents and bases were dried according to literature 
procedures, distilling under nitrogen. Ethanol and methanol were dried using magnesium 
turnings and iodine and stored over freshly activated Linde 4A molecular sieves. Isopropanol 
and acetonitrile were distilled over CoH^ and stored over activated Linde 4A molecular sieves. 
Toluene, CH^^ and diisopropylamine were distilled over Cal-L directly before use. 
Diisopropylethylamine was distilled from KOH. Triethylamine and N-methylmorpholine were 
distilled from ninhydrin, then KOH. THF and E^O were distilled from the sodium ketal of 
benzophenone directly before use, under nitrogen. DME was also distilled under nitrogen 
from the sodium ketal of benzophenone onto 4A molecular sieves. DMF and benzyl alcohol 
were distilled under reduced pressure onto activated Linde 4A molecular sieves.
Diazomethane preparation: Ntnitroso-N-methyIt4ttoIuene-suIphonamide (Diazald) (21 g,
150
Experimental- Synthesis
98 mmol) in ether (150 cm3) was added slowly to a solution of potassium hydroxide (4.8 g, 
86 mmol) in water (8 cm3) and isopropanol (12 cm3). The solution was heated in a clear 
jointed distillation apparatus and the ethereal diazomethane distilled into ether (10 cm3) at 0 °C. 
The yellow solution obtained was used in the synthesis of methyl ester derivatives.
3.1.1.3 Suppliers
2-(p-Hydroxyphenyl)-ethanol and 2-(4-methoxyphenyl)-ethanol were purchased from Aldrich. 
p-Benzyloxybenzyl alcohol (Wang), hydroxymethylpolystyrene and chloromethyllpolystyrene- 
divinylbenzene (Merrifield) resins were purchased from Novabiochem.
151
Experimental- -Synthesis
3.1.2 Synthetic Procedures and Characterisations
2V-Trifluoroacetyl-(2S)-aspartic anhydride 73.
O
A
F3C NH HB
71
O
o
o
To a stirred suspension of (25)-aspartate (500 mg, 3.76 mmol) in dry THF at -10 -* 0 °C 
was added dropwise trifluoroacetic anhydride (2.65 cm3, 18.8 mmol). The reaction was 
stirred under nitrogen at room temperature. The progress of the reaction was monitored by tic 
[7?f 0.38: ethyl acetate-light petroleum (3:2)]. Upon completion (48 h), the solvent was 
removed under reduced pressure to give 73 as a white solid (785 mg, 99%); mp 110-115 °C; 
'Umax(Nujol)/cm'1 3350 m (N-H stretching, 2° amide), 1886 m (C=O, anhydride), 1722 s 
(C=O, anhydride), 1556 m (C=O, 2° amide), 1371 s (C-F), 1342 s (C-F), 1225 s (C-F, C-O), 
1176 s (C-F, C-O) and 1083 m (C-F, C-O); 8H(200 MHz; C2HC13) 3.01 (2 H, dq, ABX, 
7ab 18.5, Jax 10.1,7Bx 6.8, HP), 4.85 (1 H, dt, 7nh,h 7.0, 7ax 10.1, 7b x 6.8, Ha) and 9.57 
(1 H, d, 7nh,h 7.0, amide NH); 8C(74.76 MHz; C2HC13) 34.09 (CP), 48.67 (C«), 115.34 (q, 
J FiC 285.28, F3C), 157.43 (q, 7 f3c,c 38.58, F3CCO), 167.61 (pC=O) and 169.28 (0tC=O); 
5f(282.2 MHz; C2HC13) -76.37 (F3C); m/z (CI) 230 (100%, [M + H + H2O]+) and 212 (14, 
[M + H]+).
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a-Isopropyl-AMrifluoroacetyl-(2S)-aspartate 74.
To a stirred suspension of (257-aspartic acid (1.15 g, 8.61 mmol7 in dry THF (30 cm37 at 
-5 °C was added dropwise (8 cmA, 56.7 mmol7 of trifluoroacetic anhydride. After 4 h the 
solvent was removed under reduced pressure, and the anhydride 73 was dissolved in dry 
isopropanol at room temperature. The progress of the alcoholysis was monitored by tic 
[Hf 0.46: ethyl acetate-light petroleum (3:27] and after 1 day the isopropanol was removed 
under reduced pressure, giving a clear yellow oil, which on standing formed a white solid. 
Recrystallisaton from ether gave a white crystalline solid (2.3Ig, 99H7, mp 92 "C (lit.,35 
91 °C7; [a]D -49.95 (c 1.0 in MeOH7, [lit.,35 -40.7 (c 1.0 in MeOH7]; Dmax(Nujol)/cm-i 3310 
s (N-H, 2° amide7, 3115s (OH, acid7, 1738 s (C=0, ester7, 1709 s (C=O, carboxylic7, 1566 s
(N-H, amide II7, 1467 s (CH2, CH3, C-H deformations7, 1390 and 1378 s (C-F7, 1313 s (C-
1
F7, 1280, 1236, 1208 and 1186 s (C-O and C-F stretching7 and 1106 s (C-F7; 0.(200 MHz; 
CTHCy 1.25 (6 H, d, JcH3,h 6-25, 2 x ' PrCH37, 3.08 (2 H, dq, ABX, Ab 17.83, Ax 4.42, 
Jbx 4.25. HP7, 4.21 (I H, br s, pCO2H7, 4.78 (1 H, dt, 7NH 6.60, ABX, ,/AX 4.42, 7Bx 
4.25, H“7, 5.11 (1 H, sep, Jch3,h 6.25, 'PrCH) And 7.38 (1 H, d, Jnh h 6.60, amide NH7; 
8(2(74.76 MHz; C2HC137 21.30 (‘PrCHj7, 35.06 (CP7, 48.80 (C°7, 70.96 ('PrCH7, 115.65 
(q, JF,c 285.28, F3C7, 157.19 (q, Jp,c,c 37,53, F3CCO7, 168.56 (ACO2'Pr7 and 175.54 
(PCO2H7; 8p(282.2 MHz; C4HCl37 -76.77 (F3C7; m/z (EI7 226 (4%, [M - CO4I]<). 212 (7, 
[M - CHaCO2H]+7, 184 (36, [M - CO.'Prn, 139 (35, [M - CO2'Pr and COaH]+7, 96 (22, 
F3CCO7, 88 (8, ['PrO2CH]+7, 69 (36, F3C+7, 59 (8, CH2CO2H+7, 43 {100, (CH372CH+7 and 
28 (35, CO+7.
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a:-IsopropyI’'A-^^r'inu(U'()accl5'l((2^^^^‘)-homoserine 75.
To a stirred solution of the isopropyl ester 74 (2.02g, 7.46 mmol) in dry THF (30 cm2) at 
-20 °C was added N-methyl morpholine (0.82 cm2, 7.46 mmol) and isobutylchloroformate 
(1.02 cm3, 7.46 mmol). After 20 min the solution was filtered into a suspension of sodium 
borohydride (0.169 g, 4.48 mmol) in dry THF at -20 °C. The solution was stirred for 2 h 
before being allowed to warm to room temperature and then stirred for a further 2 h. Excess 
borohydride was destroyed by the addition of water (5 cm2), and stirring continued for a 
further 30 min. The THF was removed under reduced pressure and the product extracted from 
the aqueous layer using ether (10 x 10 cm2). The combined organic extracts were washed with 
saturated NaHCOg solution (12 cm2) and saturated brine (12 cm2) and dried (MgS0>4). The 
ether was removed under reduced pressure giving the crude alcohol as a clear orange oil. 
Purification of the cmde oil by flash silica column chromatography [eluant DCM-EtOH (97:3) 
containing a few drops of acetic acid] gave the pure protected homoserine 75 as a clear yellow 
oil (0.672 g, 35%); umax(Nujol)/cm'i 3318 br m (OH and NH superimposed), 2923 m (OH, 
acid/ alcohol), 1723 s (C=O ester), 1560 w (NH), 1458 w (CH^ CH., C-H deformations), 
1377 m (CH3), 1184 bs (C-O, C-F) and 1106 m (C-O, C-F); 0H(200 MHz; C^HCI.) 1.29 
(6 H, d, 7cH3,h 6.25, 2 x 'PrCH3), 2.10 (2 H, m, HP), 3.73 (2 H, m, HY), 4.69 (1 H, dt, 
7Nh,h 4.35, AEX, 7ax 12.00, 7gX 3.20, H«), 5.09 (1 H, sept, 7ch3.h6.25, 'PrCH) and 7.82 
(1 H, d, 7Nh,h 4.35, NH); 0c(50.31 MHz; C2HCl3), 21.46 ('PrCH.), 32.90 (CP), 51.32 
(C«), 58.58 (CY), 70.17 ('PrCH), 115.74 (q, 7p,c 287.37, F3C), 157.09 (q, 7f3c,c 37.78, 
F.CCO) and 170.47 (oCC^Pi); 0p(282.2 MHz; C^HCl.) -76.74 (F3C); m/z (El) 258 (100%, 
[M + H]+), (17, [M - OH]+), 216 (33, [M - Tr + 2H]+), 198 (85, [M - 'PrO]+), 170 (80, [M 
- CO2'Pr]+), 140 (86, [M + H - CH^H and CO2'Pr]+), 69 (28, F3C+ and 57 (20, F.+).
154
Experimental- Synthesis
A,A-Diisopropyldichlorophosphamidite 78.
A
A- xCl“P
4^1V
To a vigorously stirred solution of PCI3 (11.62 g, 7.38 cm3- 85 mmol) in dry ether (75 cm3) at 
-20 °C under nitrogen was added dropwise via cannulae dry diisopropylamine (17.11 g, 23.7 
cm3, 169 mmol) dissolved in 75 cm3 dry ether. After 2 h the reaction was allowed to warm to 
room temperature and stirred for a further 1.5 h. The precipitated salts were removed by 
filtration under a nitrogen atmosphere, washing with dry ether (250 cm3). The solvent was 
then removed under reduced pressure to give a pale yellow liquid which was fractionally 
distilled. The product, 78, which was obtained as a colourless liquid at room temperature, 
solidified on cooling (13.78 g, 81%), bp 74-76 OC; 7 mm Hg (lit,^ 72-74 0C; 7 mm Hg) 
(HRMS: found: M+, 201.0235 Calc, for C6H14NPCl2: 201.0241); Tmax(thin film)/cm-l 
2374 s (C-H), 1664 w, 1462 m (CH3, C-H deformations), 1398 m and 1370 m (-CH(CH3)2), 
1202 m, 1171 m, 1155 m, 1123 s, 1027 m, 976 s and 882 w; 0H(200 MHz; C2HCl3) 1.27 
(6 H, d, 7cH3,h 6.83, 'PrCHg) and 3.92 (2 H, sept, 7ch3,h 6.83, 'PrCH); 0c(50.31 MHz; 
C2HCl3) 23.61 (d, 7c,p 8.54, 2 x 'PrCH3) and 48.35 (d, 7c,p 13.94, 2 x 'PrCH); 0p(121.42 
MHz; C2HCl3) 169.90 [lit,35 Sp 169.00]; m/z (El) 203 {5%, M+ (35C1, 37Ci)}, 201 (8, M+ 
(35C1)}, 186 {100, [M - CH3]+ (35C1)}, 168 {11, [M - Cl]+ (37C1)}, 166 {37, [M - Cl]+ 
(35C1)}, 148 (7, p'PrP37Cl2]+), 146 (24, ['PrP^Cl^Cir), 144 (42, ['PrP^C^]*), 88 (28, 
[PNPr]+), 43 (87, (CI^^CH*) and 32 (100, C2H8+).
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A,A-Diisopropylbis(benzyI)phosphoramidate 79.
To a stirred solution of the dichlorDFhosphamidite 78 (1.52 g, 7.51 mmol7 in dry DCM (5 
cm37 At -10 °C under a nitrogen atmosphere was added via cannulxe a solution of dry benzyl 
alcohol (2.13 g, 19.6 mmol7 and dry Et.N (2.8 cmA, 20.1 mmol7 in dry DCM (10 cm.7. After 
30 min the reaction was allowed to warm to room temperature and stirred for a further 4 H. 
The solution was then diluted with DCM (15 cm47, washed with NaHCO. solution (10 cm3 of 
5g w/w) and saturated brine solution (10 cm.7, and dried (MgSO47. The solvent was then 
removed under reduced pressure to yield the crude product as a pale yellow clear liquid. 
Purification of the crude oil by silica column chromatography on triethylamine-basified silica 
[eluant petroleum-ether/ethyl acetate 4:1] gave the phosphorA^niDate 79 as a colourless oil 
(2.19 g, 84%7, (HRMS: found: [M + H]+, 346.1600, Calc, for C20H29NO2P: 346.19357; 
3)max(thin film7/ cm-i 3070 m, 3060 s, 3010 s (triplet, C-H7, 2900 br s (CH2, CH3, C-H7, 
1930 w, 1860 w, 1780 w, 1600 m and 1580 m (doublet, Ar ring7, 1490 s and 1450 s (CH2, 
CH3, C-H deformations7, 1370 s (CH3 symmetrical deformation7, 1010 br s (P-O), 910 s xnd 
870 m (Ar C-H7, and 770 br s (CH-Ar out of plane7; 0.(200 MHz; C2HCl37 1.23 (6 H, d, 
7Ch3,h 6.84, 2 x 'PrCHy, 3.72 (2 H, m, 2 x 'PrCH), 4.75 (4 H, q, 7c,P 8.05, PhC/) and 
7.35 (10 H, m, Ar-H7; 0c(50.31 MHz; C2HCI3) 24.56 (d, J^H 7.22, 2 x 'PiCH3), 42.95 
(d, 7cH3,H 7.22, 'PrCH7, 64.30 (d, 7Ch2,op 10.88, 2 x OCH2Ph), 128.31, 127.41 and 126.87 
(Ar-C7, 138.06 (d, /p,c 4.89, Ar-C quaternary/ 8p(121.42 MHz; C4HCl37 140.01 [lit.,35 
6p(36.2 MHz; C^HC^ 148.10]; m/z (El7 346 (4%, [M + H]+7, 261 (3, [NH2P(OBn72]+7, 91 
(34, ['PrNHPH2]+), 86 (39, 'PiNCH2]+), 44 {100, (CH372CH2+7, 43 (27, 'Pr+), 42 {17, 
(CH37C+7 and 28 (16, C2H4+7.
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a-Isopropyl-iV-tri'fluoroacetyl-(2S)-FhosFhohomoserinebis(benzyI) ester 76.
O
X
F.c ^NH
CO2
TPr °"PC
o
II ..OBn
OBn
H
To a stirred mixture of the alcohol 75 (0.192 g, 0.75 mmol) and \-H tetrazole (157 mg, 2.24 
mmol) in dry DCM (12 cm2) Was added M,A^--^ii^c^l^l*<^l^^ll^i^(l^^l^:z^^)]phosphoramidite 79 
(388 mg, 1.13 mmol). The mixture was stirred at room temperature for 4.5 h then cooled to 
-40 °C. m-CPEA (258 mg, 1.50 mmol) in dry DCM (10 cm2) Was added dropwise to the 
reaction mixture and the resulting solution was stirred at 0 °C for 45 min before being diluted 
further with DCM (30 cm2), washed with NalSO3 (7 x 10 cm3 of 10% w/w ), NaHCO. (6 x 
10 cm3 of 5% w/w ), water (30 cm2) and saturated brine solution (15 cm2), and then dried 
(NalSO4). The solvent was removed under reduced pressure, giving the product as a clear 
yellow oil (0.244 g, 63%); Dmax(thin film)/cnri 1786 w, 1725 m (C=0, ester), 1560 w (2° 
amide), 1457 m (-CHl-, -CH., CH deformations), 1377 w (-CH., symmetrical 
deformations), 1262 m (C-F, C-O or P=0), 1215 m (C-O, C-F), 1182 m (C-F, C-O), 1106 w 
(C-O, C-F) and 1018 m (C-F); 6h(200 MHz; C2HCI3) 1.26 (6 H, m, 2 x 'PrCHg), 2.08 (2 H, 
m, HP), 3.75 (2 H, m, HY), 4.71 (IH, m, H«), 5.07 (5 H, m, 2 x PHCH and 'PrCH 
superimposed), 7.39 (10 H, m, Ar-H) and 7.62 (1 H, m, NH); 02(50.31 MHz; C2HCI.) 
18.99 ('PrCH3), 21.60 (PC), 47.28 («C), 68.39 (d, /c.op 5.49, YC), 69.46 (CH^h), 70.31 
('PrCH), 127.93 (10 x Ar-C), 135.33 (q, 7p,c 217.69, F.C) and 169.67 (pCO2'Pr); 
5p(121.42 MHz; dHCI.) -1.07 [lit.,35 6p 0.55].
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{2SyO -Phosphohomoserine 32.
To a stirred solution of phosphate triester 76 (0.201 g (0.39 mmol) in methanol (10 cm3) Was 
added 5% palladium charcoal (45 mg). The mixture was purged with hydrogen for 30 min and 
left to stir under a hydrogen atmosphere. After 4 days (when the reaction was judged to be 
complete by tic [eluant MeOH-DCM 19:1]), the mixture was filtered through a celite pad and 
concentrated under reduced pressure. The residue was dissolved in lM KOH (4 cm3) in 
ethanol (5 cm3) which resulted in the solution turning yellow. The mixture was left stirring for 
18 h and then concentrated under reduced pressure. The resulting pale brown solid was 
subjected to ion-exchange chromatography (Dowex 50-W H+> 200-400 mesh, 8% cross­
linked, 1cm x 6 cm) eluting with water. The ninhydrin positive fractions were combined and 
lypholized to yield 32 as a white crystalline solid (700 mg, 91%), mp 167-169 °C (lit.,
170 °C); 'OjmxxNujolj/cm"1 1733 w (C=0, saturated acid), 1462 m (C-H deformations), 1249 
w (P=O), 1020 w (C-O); 0h(200 MHz; ) 2.09 (2 H, m, HP), 3.93 (2 H, dq, 7cx 11-6,
7dx 5.4, HY) and 3.97 (1 H, dq, 7ax 7.6, 7bx 4.8, H«); 0C (50.31 MHz; CHgO) 33.40 and
33.25 (d, 7c,cop 7.63, PC), 54.19 and 54.03 (d, 7c,op 8.14, YC), 64.67 («C) and 175.09 
(aCO2H); 0p(121.42 MHz; %20) 0.59 [lit,35 8p 0.245]; m/z (El) 200 (5%, [M + H]+), 199
(5, M+), 181 (9, M - H2O]+), 119 (17, [M - HgPOgP), 104 (23, [M - POJ+l, 97 (15, 
[H2PO41U, 91 (73, [M - COPOgHH), 57 (23, [NH2CHCH2CH2H), 55 (37, [CgHsN]*) and 
44 (100, CO2+).
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[U-14C]]a-Isopropyl-"V-trifluoroacetyl-(25)-aspartate 74b
This compound was prepared in a manner identical to the unlxbelled ester 74 starting from 
[U-14C]-(2*07-xspartic acid (700 mg, 5.26 mmol7. THe reaction progress was monitored by tic 
[Rf 0.46: ethyl acetate-light petroleum (3:27]. Recrystallisation from ether-light petroleum gave 
the product as a white solid (1.0644g, 75%7l All spectroscopic and analytical data was
identical to that for 74.
[U-^Cba-Isopropyl-jV-trifluoroacetyl-^S^homoserine 75b
This compound was prepared in a manner identical to the alcohol 75 starting from 74 b 
(1.0644 g, 3.93 mmol7. Purification by silica column cHromatograpHy [eluant DCM-EtOH 
(97%7] gave the product as a yellow oil (0.518g, 51H7. All spectroscopic and analytical data 
was identical to that for 75.
[U-i4<C ]-x-Isopropyl-V-trifluoroacetyl-(2S)-phosphohomoserinebis(ben2yl)
ester 76b
This was prepared in a similar manner to the phosphate triester 76, starting from 75b (518 
mg, 2.02 mmol7. The reaction was monitored by tic [ethyl acetate-petroleum ether (1:47]. The 
crude product was obtained as a yellow oil (1.085g, >100% due to benzyl alcohol impurities7. 
All spectroscopic and analytical data was identical to that for 76.
[U-i4C]-(2S)“0 -phosphohomoserine 32b
This compound was prepared in a similar manner to 32, starting from 76b (1.085g, 2.1 
mmolf Any organic impurities were then removed by extraction with ether (3 x 10 cm47, and 
the product recrystallised from water-etHanol (346 mg, 83%7. All spectroscopic and analytical 
data was identical to that for 32.
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Dipentafiuorophenylphosphoro chloridate 81.
Using a modification of the procedure of EaerC27 freshly distilled POCI. (7.64 g, 50 mmol) 
and pentafIuiropheNil (17.41 g, 94.6 mmol) were refluxed at 140 °C under a nitrogen 
atmosphere for 48 h. The contaminants were distilled under reduced pressure to leave the 
product as a pale brown oil which solidified upon cooling (28.99 g, >100%), bp 181-183 °C, 
20 mm Hg; Dmax(lhm film)/cm-2 1346 m (C-F), 1318 m (C-F), 1239 m (C-O, C-F, P-O-aryl), 
1156 s (C-F, C-O), 1034 (C-F, C-O) and 1001 (C-F, C-O); 0c(74.76 MHz; dHClg) 136.75 
{meta Ar-CF), 139.70 {para Ar-CF), 140.13 (ortho Ar-CF), 143.01 (Ar-CO); 8p(121.42 
MHz; C2HC16) main signal -15.14; 6p(282.2 MHz; C^dg) -154.89 and -154.96 (4 F, d 
J 19.75, ortho Ar-CF), -157.96 (2 F, dt, 7 3.95, 7 21.73, para Ar-CF), -162.38 (4 F, t, 
meta Ar-CF); m/z (EI) 449 (40%, M +), 413 (30, [M - Cl]+), 265 (14, [M - OC^M and 249 
(17 [M - OoC^F5]U.
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A-TrifluoroacetyI-(2S)-aspartate 86.
AFaC NH H
CO,H
co2h
2
A solution of the anhydride 73 (0.555 g, 2.629 mmol) in distilled water (20 cm3) was stirred 
overnight at rt until a yellow oil crashed out of solution. THe mixture was extracted with ether 
(25 cm3), washed with water (2 x 10 cm3), 5% citric acid (10 cm3) and saturated brine
solution (10 cm3) and dried (MgSO3). The ether was removed under reduced pressure to give 
a white solid, which was recrystallised from ether-hexane to give the diacid 86 (0.147 g, 
25%); mp 132-134 °C; [at£> -24.35 (c 0.87 in EtOH); Dmaxxthin fUmycm! 2974 s (acid OH), 
2877 s (acid OH), 2604 w (acid OH), 1717 (C=0, saturated acid), 1566 m (NH, 2° amide), 
1371 m (C-F), 1303 m (C-F, C-O) and 1195 m (C-O, C-F); 0h(200 MHz; C4HC)3) 2.91 (2 
H, dq, ABX, 7Ab 17.47, 7Ax 4.76,7Bx 4.16, HP), 4.71 (1 H, dt, 7nh,h 7.65, 7Ax 4.76, JBx 
4.16, H“), 7.84 (1 H, d, 7Nh,h 7.65, amide NH) and 8.37 (2 H, br s, CO2H); 8C(74.76 MHz; 
C2HCl3) 34.90 (PC), 48.63 (“C), 115.43 (q, 7F.c 285.26, F3C), 156.70 (q, fj^C 37.18, 
F3CCO), 171.06 (pCOjH) and 172.54 ^^1); 8p(282.2 MHz; C2HCl3) -76.62 (FgChm/z 
(Cl) 230 (28%, [M - H20]+), 184 (100, [M - HCC^H]*), 114 (22, [F3CC(O)NHCH2]+), 69 
(35, F3C+) and 45 (32, CO2H+).
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a-p-Benzyloxybenzylpolystyrene-/V-trifluoroacetyl-(2S)-aspartate 87.
To a stirred suspension of Wang resin (200 mg, loading: 1.16 mmol/g) in dry DMF (5 cm3) 
under a nitrogen atmosphere was added the anhydride 73 (0.4897 g, 2.32 mmol) and DMAP 
(283 mg, 0.232 mmol). The reaction was warmed to 30-35 °C. After 1 week the resin was 
filtered, washed copiously with DCM, DMF, 5% citric acid-DMF and methanol, then dried 
under reduced pressure (248.9 mg, 99.9% loading, 0.931 mmol/g of A-TFA-asp); 
i)max(KBr)/crn-1 1735 s (C=O, ester linkage); 8C(74.76 MHz; (C2H3)2SO) 34.81 (PC), 49.40 
(«C), 117.84 (F3C), 130.02 (F3CCO), 162.48 (PCO2H) and 171.33 (aCO2R); SF(282.2 
MHz; (C2H3)2SO) -74.27 (12%, F3C on p-ester) and -74.91 (88%, F3C on a-ester).
A portion of 87 was treated with TFA/H2O/TES (90:5:5) for 2 h at room temperature to 
produce the free acid 86. All spectroscopic and analytical data was identical to that for 86, 
{[a]D -25.09 (c 0.87 in EtOH)}.
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a-p-BenzyIoxybenzylpolystyrene-A--rrifiuGroacetyI"(2S)-aspartate-P-methyl
ester 101.
To 87 (500 mg, loading: 0.913 mmol/g of A-TFA-asp) was added an excess of ethereal 
diazomethaNe (10 cm2). The mixture was left at room temperature until all bubbling Had 
ceased, and after the addition of another aliquot of diazomethane (5 cm2) the mixture was left 
for a futher 30 min. Excess diazomethane was removed by bubbling nitrogen through the 
solution and the resin was filtered and washed copiously with ether, DMF, 5% citric acid-DMF 
and methanol. THe resin was dried under reduced pressure (524 mg, 99%). THe ester was 
cleaved from the resin using TF^'H^O/TES (90:5:5) at room temperature for 2 H, filtered off 
and dried under reduced pressure, giving the monoester 91 as a yellow oil; t)max((hin film)/cnr 
2 3111 s and 2974 s (acid O-H), 2604 m (acid O-H), 1727 s (C=0, saturated acid), 1566 s 
(C=O, 2" amide), 1454 s (saturated C-H), 1298 s (C-O, C-F), 1240 (C-O, C-F), 1186 s (C-O 
ester, C-F); 0h(200 MHz; ^^2) 2.93 (2 H, dq, AEX, 7ob 17.3, Tax 5.02/Bx 4.74, HP), 
3.63 (3 H, s, PCO2CH3, 84%), 3.70 (3 H, s, oC02CH., 16%), 4.68 (1 H, dt, Jnh.h 7.2, 
7ax 5.02, 7bx 4.74, H«), 6.56 (1 H, br s, aCO2H) and 7.86 and 7.82 (1 H, d, 7NH)h 7.2, 
amide NH); 0C(74.76 MHz; C2HCI.) 34.85 (PC), 48.54 («C), 51.77 ^CO^H., major 
product), 52.71 (oCO2CH3, minor product), 115.43 (q, Jpc 285.28, F.C), 156.72 
(q, 7f3c.c 36.48, F.CCO) and 170.81 (aCO^); 0p(282.2 MHz; C2HC13) -76.66 (F.C); m/z 
(EI) 244 (17%, [M + H]+), 212 (27, [M - MeOH]+), 198 (100, [M - COgHl+j, 184 (55, [M - 
CO2Me]+), 139 (38, [M - CO^H and CO2Me]+), 114 (25, [F3CC(O)NH3]+), 99 (43, 
[F3CC(O)HJ+), 69 (47, F.C+) and 59 (41, [CO2Me]+).
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(X-p-Benzyloxyhtin.^yJ|)(‘Iys^l^ArenK’^^^^^^-rrtl3J(MrKKc.ety”i21S')-;^ispurtat.e-p-dicthyi
amide 94.
To a stirred suspension of 87 (250 mg, loading: 0.169 mmol of iV-TFA-asp) in dry DME 
(5 cm3) at room temperature under a nitrogen atmosphere was added via a cannula a solution 
of PyBOP (0.1756 g, 0.338 mmol) in DME (5 cm3) followed by the dropwise addition of 
DIPEA (30.9 mm3, 0.177 mmol) in DME (5 cm3). The resin was then stirred for 15 min and 
washed with portions of dry DME, DMF and DME again via cannulae to remove excess base 
and activating agent. A solution of diethylamine (19.3 cm3, 0.186 mmol) in DME (5 cm3) WaS 
then added slowly over 30 min and then the resin was filtered and washed excessively with 
DCM, DMF, 5% citric acid-DMF and methanol. The resin was dried under reduced pressure 
(254.9 mg, 53%); iDmax(KBr)/cm_1 1637 m (2" amide, solid state); 0^(74.76 MHz; 
(C2H3)2SO) 19.53 (CH2CH2N), 35.08 (PC), 49.55 («C), 52.03 (CHaCH2N), 130.48 
(F3CCO), 162.97 (PCONEt2) and 170.56 (aCO2R).
The amide was cleaved using TFA/H2O/TES (90:5:5) at room temperature for 2 h to give the 
free a-acid as a pale yellow oil which was dissolved in acetonitrile and purified by reverse- 
phase HPLC [eluant 0 - 30% acetonitrile in water, eluting at 15% acetonitrile]; 8H(200 MHz; 
C2HCl3) 1.19 (6 H, m., 2 x C7?3CH2N), 2.83 (2 H, m, HP), 3.36 (4 H, m, 2 x CH2N), 4.44 
(1 H, m, H«), 7.99 and 7.95 (1 H, d, /NH,H 7.0, NH) and 8.96 (1 H, br s, aCO2H); 
8C(74.76 MHz; C2HCy 13.50 and 12.46 (CH3CH2N, 2 conformations), 34.01 (PC), 42.52 
and 40.89 (CH3CH2N, 2 conformations), 49.01 (®C), 117.60 (q, F3C), 157.19 (q, 7f3c,c 
37.88, F3CCO), 169.91 (C(O)N) and 172.29 (aCO2H); Sp(282.2 MHz; C2HCl3) -76.72
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(F3C); m/z (El) 284 (42%, M+), 239 (15, [M - CO4C]+), 184 (14, [M - CON(CH2CH3)2]+), 
114 (29, [CH2CCO)N(CH2CH3)2] + ), 100 (59, [CON(CH2CH3)] + ), 74 (46, 
[(CH2CH3)2NH2]+), 72 (83, [(CH2CH3)2N]+), 58 (100, [CH3NCH2CH3]+) and 44 (36,
CO2+).
a"P-MethyIpolystyrene-N-trifIuoroacetyh(2S)-aspa.rtate 102.
----------—.......... ... ......................... ,
0
II
Merrifield —O ^'S-'-'^CChH
f3c nh3 ¥
0
To a stirred suspension of hydroxymethylpolystyrene resin (1.00 g, loading: 1.16 mmol/g) in 
dry DMF (10 cm3) under a nitrogen atmosphere was added the anhydride 73 (2.4487 g, 
11.60 mmol) and DMAP (0.1417 g, 1.16 mmol). The reaction mixture was left at 30 °C for 
10 days. THe resin was then filtered, washed as copiously in DCM, DMF, 5% citric acid- 
DMF and methanol and dried under reduced pressure (1.2450 g, 100% loading, 0.863 mmol/g 
of N-TFA-asp); 'Umax(KBr)/cm-1 1735 s (C=0, aryl ester), 1541 (2° amide, solid state), 1170 
s (C-F or C-O ester); 0c(74.76 MHz; (C^^SO) 34.79 (PC), 49.45 («C), 117.87 (F3C), 
157.00 (F3C<CO), (PCO2H) and 11^7.^37 (aCO2R); MHz; C23HCC3) -74M
(F3C on a-ester).
165
Experimental- -Synthesis
PoIystyrene”4-oxymethyl-2-phenyIethanol 97.
To a stirred suspension of cHloromethylipolystyrenetdivinylBenzene (Merrifield) resin (200 
mg, loading: 0.2 mmol) and 2-(pthydroxyphenyl)tethanol (0.0691 g, 0.5 mmol) in dry 
acetonitrile (5 cm2) was added powdered potassium hydroxide (0.0281 g, 0.5 mmol) and 
18-crownt6 (10 mg, 0.038 mmol). THe reaction was left for 3.5 days at 40 °C under a 
nitrogen atmosphere. The loaded resin was filtered and washed copiously with DCM, 5% 
citric acid-DMF, DMF and methanol and dried under reduced pressure (226.7 mg, 97% yield, 
0.859 mmol/g loading); ^^(KBO/cirr1 3453 br m (O-H, alcohol), 1517 m (aromatic C=C), 
1500 (aromatic C=C) and 1390 (O-H, alcohol); 02(74.76 MHz; Cg^g) 64.12 ((^OH), 
70.33 (PhCtf2), 115.52 (Ar-CH), 130.68 (Ar-CH) and 158.55 (Ar-CO quaternary).
a-[2-(4-Methoxyphenyl)-ethyl]-W-trifIuoroacetyl-(2S)-aspartate 103.
To a stirred solution of 2-(4-metHoxypheNyl)-etHanil (0.50 g, 3.29 mmol) In dry DMF (15 
cm2) under a nitrogen atmosphere was added the anhydride 73 (3.4676 g, 16.43 mmol) and 
DMAP (0.2007 g, 1.643 mmol). After 2 days the reaction was judged to Be complete by tic 
[/?f 0.0: ethyl acetate-light petroleum (3:2)]. THe solvent was removed under reduced pressure
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and the crude product redissolved in ether (20 cm3), washed with water (2x5 cm3), aqueous 
citric acid (25% w/w 5 cm3) and saturated brine (5 cm3) and dried (MgSO4) (1.98 g, >100% 
due to impurities). The crude product was purified by silica column chromatography [ethyl 
acetate-petroleum ether (3:1)] (1.09 g, 91%), mp 89-90 "C; (HRMS: found: 363.0930 
C15H16NO6F3 requires 363.2897); Dma/thin film^m! 1736 s (C==O, aryl ester), 1522 m 
(C=O, 2“ amide), 1259 s (C-O, C-F), 1229 s (C-O, C-F) and 1181 s (C-O, C-F), 03(200 
MHz; C4HCl)) 2.85 - 3.14 (4 H, m, HP and CH2O- overlapping), 3.77 (3 H, s, ArOCHg), 
4.33 (2 H, m, PhCH2), 4.82 (1 H, dt, /^.h 7.78, H«), 6.85 and 6.80 (2 H, d, / 8.45, Ar- 
H), 7.11 and 7.07 (2 H, d, J 8.45, Ar-H), 7.54 and 7.50 (1 H, d, JNH H 7.78, NH), 7.69 (1 
H, br s, CO2H); 0c(74.76 MHz; C4HCl)) 33.66 (PC), 34.88 (0^0-), 48.50 («C), 55.09 
(PhOCHg), 67.04 (PhCHz), 114.04 (Ar-CH), 115.46 (q, /p.c 287.65, F3C), 128.98 (Ar-C 
quaternary), 129.69 (Ar-CH), 157.05 (q, ^^,6 38.91, F3CCO), 158.42 (ArC quaternary) 
and 168.87 (CO2H); Sp(282.2 MHz; C4HCl)) -76.67 (F3C); m/z (El) 363 (11%, M+), 134 
(100, [NH3CH(C02H)CH2C02H]+).
a-(PoIystyrene-4..oxymethyl-2-Fhenylethyl)-,A-trifIuoroAcety^(21S)-aspartAte
99.
To a stirred suspension of 97 (1.50 g, loading: 1.431 mmol/g) in dry DMF was added the 
anhydride 73 (1.007 g, 4.77 mmol) and DMAP (0.0583 g, 0.477 mmol). THe reaction was 
stirred at room temperature for 10 days. The resin was filtered, washed copiously with DCM, 
5% citric acid-DMF, DMF and methanol and dried under reduced pressure (1.711 g, 97%,
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0.541 mmol/g in tV-TFA-asp); i)max(KBr)/cnr1 1727 s (C=O, aryl ester), 1653 m (2° amide, 
solid state) and 1078 w (C-O, C-F); 5C(74.76 MHz; C62H6) 34.09 (PC of aspartate),. 40.04 
(CH2O-), 48.42 («C of aspartate), 114.31 (Ar-CH), 117.44 (F3C), 129.35 (Ar-CH), 145.15 
(Ar-C quaternary), 157.08 (Ar-CO), 169.11 (F3CCO), 173.77 (CO2H of aspartate); 6p(282.2 
MHz; (C2H3)2SO) -74.81 (F3C).
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3.2 Molecular Cloning
3.2.1 Cloning Techniques
Bacterial Strains and Plasmids. Chromosomal DNA for the amplification of thrC was 
prepared from E. coli. strain TGI or XL 1-Blue. Minipreparation of the plasmid pSG4 
containing the gene for P-methylaspartase was from E. coli. strain TGI (K-12 A [lac-pro] supE 
thi hsdR5 / F'-traD36 proA+ B+ lac] Q lacZ A M15 .26° E. con strains JM83 and XL1-Blue 
were used as hosts for cloning experiments and BL21 (DE3) was used as the Host strain for 
analytical expression of recombinant proteins. Transcription vectors pGEM™-3Zf(+), 
pGEM™-5Zf(+) and pGEM-T™ and the expression vector pKK223-3 were purchased from 
Promega. The expression vectors pET-3a, pET-3b and pET-16b were purchased from 
Novagen, AMS Biotechnology. All vectors contain the ampicillin resistance gene (AmpR) and 
a multi-cloning site contained in the N-terminal region of the lacZ operon.
Isolation of chromosomal DNA from E. coli. This was performed either as described 
for the mimprepatation of plasmid DNA from E. coli, strain TGI (K-12 A [lac-pro] supE thi 
hsdRS / F'-traD36 proA+ 5+ lac] Q lacZ A Ml5 or using the SDS-Proteinase K method of 
large-scale chromosomal DNA preparation as follows:270
A starter culture of XLl-Blue cells in LB (10 cm2) was incubated at 37 °C for 3 h with 
shaking. Luria broth (200 cm2) was inoculated with 200 p,l of this starter culture and incubated 
overnight at 37 "C with shaking. Cells were pelleted by centrifugation (4 °C for 15 min at 
6, 000 xg) and stored at -20 °C for 2 h before resuspeNsion in 40 cm2 te (10 mM Tris. HCl 
(pH 8.0), 1 mM EDTA). The cell suspension was stored on ice for 10 min then centrifuged 
(4 °C for 45 min at 3, 000 rpm). The pellet was then resuspended in 3.2 cm2 50 mM 
Tris.HCl (pH 8.0) and 0.7 M sucrose. To this was added 0.6 cm2 lysozyme (20 mg/cm2) and 
the mixture was stored on ice for 5 min. 0.6 cm2 EDTA (pH 8.0) and 0.5 cm2 10%
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(w/v) SDS were added and the mixture stored on ice for a further 5 min The suspension was 
adjusted to 1% (w/v) SDS and 0.5 mg/cmC Proteinase K (Promega) and incubated at 55 °C for
7.5 h. The reaction was halted by the addition of 5 cm3 phenol (pre-equilibrated with 1 M 
Tris.HCl (pH 8.0)) and mixed for 3 h. The mixture was transferred to a Falcon tube and 
centrifuged (25 °C, 10 min at 4, 000 rpm), discarding the lower phenol layer. 1.0 vol 
phenol/ chloroform was added to the aqueous layer, mixed gently and the mixture centrifuged 
at room temperature (10 min at 3, 000 rpm). The upper aqueous layer was transferred to a 
fresh tube and stored on ice for 5 min before the addition of 2.5 cm3 7.5 m ammonium acetate 
and 10 cm3 ethanol to precipitate the DNA. The mixture was stored at -20 °C for 30 min after 
which the DNA was pelleted by centrifugation at room temperature (10 min at 3, 000 rpm), 
rinsed with 70% (v/v) ethanol and air-dried for 2 min. The DNA was dissolved in H2O and 
stored at -20OC before further use.
Restriction enzyme digestions. Restriction enzymes and buffers were purchased from 
Promega or New England Biolabs. All plasmid DNA or gene fragment digestions with 
restriction enzymes were carried out under the conditions specified by the supplier. In general 
lpg of DNA was digested with 1 unit of restriction enzyme in the appropriate buffer in a total 
volume of 20 jxl. DNA was purified by phenol/chloroform extraction.
CIAP-digestions. In general lpg of DNA was digested with 1 unit of calf intestinal 
alkaline phosphatase (CIAP, Promega) in the appropriate buffer in a total volume of 20 pi 
incubating at 37 °C for 1 h.. The plasmid DNA was purified by extraction 3 times with 
phenol/chloroform, precipitation using 2.5 volumes ethanol and 1/20 volumes of 4M sodium 
acetate and the mixture was stored at -20 OC for a minimum of 20 min. The DNA was pelleted 
by centrifugation (13, 000 rpm for 15-20 min and redissolved in H2O to a final concentration 
of 1 pg/pl.
Agarose gel electrophoresis. Flat bed 1% agarose gels were prepared using 1 x TAE 
(0.04M Tris-acetate, 0.00 IM EDTA) containing 0.2 pg/cmC ethidium bromide. A 1 kb DNA
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ladder (Gibco) was run against DNA fragments to determine their approximate size.
«
Gel purification of DNA fragments. To isolate DNA fragments from low melting point
(LMP) agarose the following methods were used:
(i) Phenol/acetate method. THe slice of LMP agarose containing the DNA fragment to 
be isolated was placed in 500 pi of phenol/acetate (phenol equilibrated with 0.3 M sodium 
acetate) and heated at 70 °C until the agarose was melted. After vortexing the tube was 
incubated on ice for 10 min and then spun in a microfuge (10 min at 13, 000 rpm). The upper, 
aqueous layer was removed to a fresh tube and subjected to a further extraction with 
phenol/acetate. DNA was precipitated from the resulting aqueous fraction by ethanol 
precipitation, dried in a vacuum dessicator and then redissolved in TE (10 mM Tris. HCl (pH 
8.0), 1 mM EDTA) or HgO as appropriate to give an approximate concentration of 1 mg/cm3 
DNA.
(ii) WIZARD™ Prep DNA Purification System. DNA was isolated from a section of 
LMP agarose using the WIZARD™ Prep DNA purification system (Promega) according to the 
manufacturer's instructions.
(Hi) Seaplaque™ agarose. THe desired DNA fragment was run into a section of 
Seaplaque agarose (PMC Bioproducts) which was then excised, melted by incubation at 70 °C 
and used directly for in-gel ligations according to the manufacturer’s instructions.
Blunt-end repair of overhangs. 5'-OverHangs were filled in to produce blunt ends using 
T4 DNA polymerase. 1 jig of plasmid DNA was incubated for 5 min with 5 units of T4 DNA 
polymerase (Promega), 100 |LM of each dNTP in T4 polymerase buffer (33 mM Tris.acetate 
(pH 7.9), 66 mM potassium acetate, 10 mM magnesium acetate, 0.5 mM DTT, 0.1 mg/cmP 
BSA). The reaction was halted by Heating to 75 °C for 10 min.
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Ligations. Ligation reactions were routinely carried out with 0.5 - 1 |xg of vector DNA, 1.5 
jxg of insert DNA, 4 Weiss units of T4 DNA ligase (Promega) In a total of 25 pl of T4 DNA 
ligase buffer [30 mM Tris.HCl (pH 7.8), 10 mM MgClg, 10 mM DTT, 0.5 mM ATP]. THe 
reactions were incubated at room temperature or 16 0C overnight. Ligation reactions for the 
insertion of gene fragments into pGEM-T were carried out using 50 ng pGEM-T vector 
(Promega), with vector:iNsert ratios ranging from 1:1 and 1:10 using 1 unit T4 DNA ligase in 
a total volume of 10 pi. THe concentration of cloned DNA and plasmid DNA solutions were 
estimated from their luminescence on agarose gels. The following formula was used to 
calculate the amount of insert needed for a ratio of 1:1 insert: vector:
ng of vector x kb size of insert
------------------------------------------------------- x insert : vector molar ratio = ng of insert
kb size of vector
In-gel ligations were performed using Seaplaque™ agarose according to the manufacturer's 
instructions.
Transformation of E. coli, E. coli was transformed with plasmid DNA after making 
competent cells using the calcium chloride method (adapted from CoHen et al.2®1). 10 cm2 
cultures of cells were grown to exponential phase in Luria Bertam broth [LB brotH: 1% (w/v) 
bacto-tryptone, 0.5% (w/v) barto-yeast extract, 1% (w/v) NaCl, pH 7.5] cooled to 4 °C for 10 
min and pelleted by centrifugation (4 °C for 10 min at 4, 000 rpm). Each pellet was 
resuspended in 10 cm2 of ice-cold 0.1 M CaC^, stored on ice for 10 min and pelleted again as 
before. Cells were then suspended in 200 pl 0.1 M CaC^ per pellet and stored at 4 °C for at 
least 30 min to attain competency. Cells could be stored in CaC^ solution at 4 0C for 24 - 48 H 
before losing competency.266 200 pi of competent cells were gently mixed with plasmid DNA 
(up to 50 ng In 10 cm2 or less of solution) in sterile eppendorfs and the mixture stored on ice 
for 30 min. The tubes were transferred to a circulating water batH preheated to 42 °C for 
exactly 90 sec and then rapidly transferred to an ice-BatH for 1-2 min. 800 pi of LB was added 
to each tube which were then incubated at 3°C for 45 min. Up to 200 pi of each culture was
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then transferred to L-agar plates coated with 40 pi of X-gal (20 mg/ml in DMF) and 4 pi IPTG 
(200 mg/ml in DMF) for overnight incubation at 37 OC. •
Minipreparation of plasmid DNA. 10 cm3 of LB containing 10 pg/cm3 ampicillin was 
inoculated with a single colony of transformed E. coli JM83 or XL 1-Blue and incubated 
overnight at 37 °C with shaking. The cells were pelleted (4 °C, 4, 000 rpm, 10 min) and the 
supernatant removed. Pellets were resuspended in 700 pi of STET buffer (0.1 M NaCl, 
10 mM Tris.HCl (pH 8.0), 1 mM EDTA (pH 8.0), 5% (v/v) Triton X-100), containing 
1 mg/cmC lysozyme, and incubated at room temperature for 10 min. 30 pi of 10% (w/v) SDS 
was added and mixed in then 75 cm3 of 4 m potassium acetate was added and mixed. After 
incubation on ice for 15 min the mixture was spun in a microfuge for 15 min at 13, 000 rpm. 
The supernatant was transferred to a fresh tube, 1 pi of 1 mg/cmC RNase A (Sigma) was added 
and the mixture incubated at room temperature for 15 min before repeated extraction with 
phenol/chloroform. The aqueous phase was removed to a fresh tube, and the DNA ethanol 
precipitated twice. The DNA precipitate was washed with 70% (v/v) ethanol and resuspended 
in 100 cm3 H2O.
Maxipreparation of plasmid DNA. This was performed according to the QI'AGEN 
maxiprep plasmid purification protocol. LB was inoculated with a single colony of E. coli 
XL 1-Blue, or with a starter culture of XL 1-Blue cells which had been transformed with 
miniprep plasmid DNA isolated as above, and grown overnight at 37 °C with shaking. For 
high copy number plasmids (pGEM vectors) 150 cm3 cultures were used, for low copy 
number plasmids such as pET vectors 500 cm3 cultures were grown. 10 cm3 starter cultures in 
LB were incubated at 37 °C for 3 or 4 h.
3.2.2 Polymerase Chain Reaction
Standard PCR Protocol. Sequences encoding thrC or the gene for p-methylaspartase were 
amplified from chromosomal DNA via PCR. Reactions were carried out in TAQ DNA
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polymerase buffer [50 mM KCl, 10 mM Tris.HCl (pH 9.0), 0.1% (v/v) Triton X-100, 2.5 
mM MgCl2] with 1 mM DTT, 0.125 mM of each dNTP, 200 pmol of each primer and up to 
1 |ig of template DNA in a total 100 |xl reaction volume. Reactions were overlaid with 
100 cm3 mineral oil (Sigma), heated to 94 °C for 5 min and then Held at 85 0C whilst 2.5 units 
of TAQ DNA polymerase (Boehringer Mannheim or Promega) were added to the aqueous 
phase of each reaction.
PCR was carried out using the following programs:
For gene fragments with Nde l-sites at each terminus: 1: 94 °C, 2 min; 2: 42 °C, 1 min; 3: 
72 °C, 2 min; 4: 94 0C, 1 min; 5: Cycle of steps 2-4, x 20; 6: 72 °C, 5 min; 7: Hold at 
4 °C indefinitely.
For gene fragments with Nde l-sites at the N-terminus, BamH l-sites at the C-terminus: as 
above except step 2: 40 °C, 1 min.
Products of PCR reactions were extracted against phenol/chloroform and ethanol precipitated 
before further use.
Overlap PCR. THe reaction conditions were as stated above except that Half-gene fragments 
were produced using either the external forward primer and the internal reverse primer, or the 
external reverse primer and the internal forward primer. These were gel-purified and used as 
the template for a PCR reaction using outside primers only to produce a whole gene fragment.
Cycle Sequencing. Plasmid DNA sequencing was carried out using the fmol™ kit 
(Promega) according to the supplier's instructions. Sequencing gels were made using 31.5 g 
urea, 15 cm3 Sequagel™ Concentrate (National Diagnostics), 15 cm3 x5 TEE [x5 composition: 
54 g Tris base, 27.5 g boric acid, 0.5 M EDTA (pH 8.0) and dH2O to 11], making up to a total 
volume of 75 cm3. To 68 cm3 of this was added 300 pi 10% APS solution and 100 pi 
TEMED. Gels were preheated to 44 0C before applying samples for separation, run at 
200 Vand dried under vacuum on a slab-gel drier for 2 H at 80 °C. Dried gels were exposed 
on X-Ray photographic film overnight.
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3.2.3 Oligonucleotides
Oligonucleotides were synthesised using phisphotamidite chemistry on an oligonucleotide 
synthesizer In the Division of Cell and Molecular Biology at the University of St. Andrews or 
obtained from Oswel. These oligonucleotides are listed in Table 3.1 and 3.2.
Table 3.1: Oligonucleotides used for amplification of gene fragments.
TSl. Forward primer at IN-terminus of thrC. Nde I-site
Met Lys Leu Tyr Asn Leu 
5•-tTTT CAT ATG AAA CTC TAC AAT CTG- 3'
_______________________________Nde I_______________________________________________
TS2. Reverse primer at C-terminus of thrC. Stop codon, Nde I-site.
Met * Glu His Asn Met Met 
5' -AAAA CAT ATG TTA CTG ATG ATT CAT CAT- 31 
_____ __ _____________________ Nde I_______________________________ _________________
TS3. Forward primer from Base 643 on thrC
His Gin Pro Phe Ala
________________________ 5' - AA CAT CAG CCG TTT GCT G - 3 1________________ ________
TS4. Reverse primer from Base 660 on thrC
________________________ 5 ' - CAG CAA ACG GCT GAT GTT - 3 '__________ __ _____ ______
TS5. Forward primer at ^terminus of thrC . Nde I-site.
Met Lys Leu Tyr Asn Leu
5' - GTCA GTC AGT CAT ATG AAA CTC TAG AAT CTG - 3' 
___________________________________ Nde I___________________________________________
TS6. Reverse primer at C-terminus of thrC. Stop codon, BamH I-site.
Met * Glu His Asn Met Met 
5■ - ATGC GGA TCC TTA CTG ATG ATT CAT CAT - 3'
_______ _ ___________________ BamH I_____________________________________ ________ __
MAI. Forward primer at ^terminus of the gene coding for P-metHylaspartase. Nde I-site.
Met Lys lie Val Asp Val 
5.-TTTT CAT ATG AAA ATT GTT GAG GTA- 3’
_______________________________Nde I_______________________________________________
MA2. Reverse primer at C-terminus of the gene coding for PtmetHylaspartase. Stop codon, Nde I-site.
Met * Lys Arg Arg Gly Val 
5‘ -AAAA CAT ATG TTA TTT TCT TCT TCC TAG- 3' 
_____________________________ Nde I_________________________________________________
MA 3. Forward primer from Base 640 of the gene coding for ptmetHyiaspartase
Arg * Met Val Lys
________________________ 5 1 - TA CGT TAA ATG GTT AAG A - 3 '________________________
MA4. Reverse primer from Base 657 of the gene coding for PtmetHylaspartase
________________________ 5 ' - TCT TAA CCA TTT AAC GTA - 3 ' _______ _________ _____
MAS. Forward primer at N-terminus of the gene coding for PtmetHylasparlase. Nde I-site 
Met Lys lie Val Asp Val
51 - GTCA GTC AGT CAT ATG AAA ATT GTT GAC GTA - 3'
Nde I
MA6. Reverse primer at C-terminus of the gene coding for ptmetHylospartase. Stop codon, BamH I-site.
Met * Lys Arg Arg Gly Val 
5' - ATGC GGA TCC TTA TTT TCT TCT TCC TAG - 3'
BamH I
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Oligonucleotide primers were designed to contain restriction sites to enable PCR products to be
easily cloned. For forward coding sense primers the encoded amino acid sequence is shown - *
above the nucleic acid sequence. Stop codons are indicated on the complementary strand by
a *.
Table 3.2: Oligonucleotides used in sequencing experiments.
SP6 promoter primer.
5' - d(GAT TTA GGT GAC ACT ATA G) - 3’
T7 promoter primer.
5' - d(TAA TAC GAC TCA CTA TAG GG) - 3'
Primer concentrations were calculated from their A260 values using the following formula:
Concentration (pmol pl-1) = Amo x dilution factor
(nA x 1.52) + (nC x 0.75) + (nG x 1.17) + (nT x 0.92)
3.2.4 Expression in E. colt
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The discontinuous buffer 
gel system based on that of Laemmli was used.317 All gels were constructed with a 4% 
stacking gel and a polyacrylamide resolving gel. Gels were run at 40 mA upper current 
limit and 250 V upper voltage limit. Generally proteins were run through the stacking gel at 
120 V and run through the resolving gel at 225 V. Gels were stained overnight in Coomassie 
blue according to the method of Sambrook et al.,266 destained in destaining buffer (5% 
methanol, 10% acetic acid in aqueous solution) and dried under vacuum on a slab-gel drier at 
60 OC for 2 h.
Analytical expression of proteins. 10 cm3 cultures of LB-ampicillin (LB with 100 
pg/cmC ampicillin) were inoculated with single colonies ofE coli BL21(DE3) transformed
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with pTN-TS expression vectors and grown overnight at 37°C with shaking. 2 x l cm3 of 
each overnight culture was transferred to 2 x 9 cm3 of fresh LB-ampicillin (one culture for 
induction and one as a control) and incubated at 37 °C for 3 h with shaking. To the cultures to 
be induced was added 100 pi of 100 mM 1PTG and all cultures were incubated for a further 2 H 
at 37 °C with shaking. The cultures were then kept at 4 °C for a short time before the cells 
were pelleted (4°C, 4, 000 rpm, 10 min), resuspended in 500 pi chilled PBS buffer containing 
12 mg/cm3 lysozyme and transferred to sterile eppendorfs. THe cells were then lysed using a 
probe sonicator in several 10 sec bursts resting on ice in between. Insoluble material was 
removed by centrifugation in a microcentrifuge (4 °C, 10, 000 rpm, 30 min) and 20-40 pi of 
the lysate was subjected to SDS-PAGE analysis using molecular weight markers of 66 and 45 
kDa. The total protein concentration of the lysates was measured using the BCA protein assay 
(Pharmacia) as recommended by the manufacturer, using a BSA calibration curve for 
comparison. Varying amounts of two of the lysates were applied to a gel first of all in order to 
determine what protein concentration would produce the clearest results. Approximately 50 pg 
of protein from each sample was loaded onto gels.
Analytical purification of His-tagged proteins. Ni-NTA Resin synthesised by C. 
Botting at the Division of Cell and Molecular Biology was prepared for use by equilibrating 
with 10 volumes of the sonication buffer desribed above for 1 H. 250 pi of the cell lysate from 
cells transformed with vectors pTN-TS5 - 8 were stirred with between 100 and 140 pi of a 
50% Ni3+ resin slurry at room temperature for 1 h. The slurry was pelleted by centrifugation 
on a microfuge (10, 000 rpm, 10 min) and the supernatant retained for analysis. THe resin was 
then washed with 150 pi TBS (20 mM Tris, 0.3 M NaCl, pH 8.0), centrifuged as before and 
the supernatant retained for analysis. THe protein was then eluted from the resin by washing 
with 150 cm3 of elution buffer (250 mM imidazole, 20 mM Tris, 0.3 M NaCl, pH 7.5). This 
was centrifuged and the supernatant containing the His-tagged proteins removed. THe 
supernatant from each of the Ni3+ treatment steps was analysed by SDS-PAGE.
Plasmid Stability Test, E. coli BL21(DE3) freshly transformed with pTN-TS vectors 5-8
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were grown in 5 cmC portions of LB-medium containing lOOmg/cm3 ampicillin overnight at
37 °C with shaking. A small subculture was transferred into 500 cm3 of fresh LB medium - «
containing 100 mg/cmC ampicillin and allowed to grow at 37 °C to an ODeoo reading of 0.6. 
Three aliquots of 1,000 mmC, 147 mm3 and 135 mm3 of LB were transferred to three sterile 
eppendorfs. A primary dilution of bacteria was prepared by transferring 1 mmC of log phase 
culture into 1 cm3 of LB. Two secondary dilutions were prepared by transferring 3 mm3 and 
15 mmC of the primary dilution into tubes containing 147 mm3 (dilution A) and 135 mmC 
(dilution B) of LB, respectively. Bacteria were plated onto L-agar plates containing no 
additives, lOOgg/ml ampicillin only, 0.4 mM IPTG only or both lOOgg/ml ampicillin and 
0.4mM IPTG., as indicated in Table 2.6. The plates were incubated overnight at 37 "C.
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Appendix 1
CLUSTAL W( 1.60) Multiple Sequence Alignment of fi-family Enzymes.
Q A representation of the ClustalW alignment of ^-family enzymes from various organisms generated using 
SeqVu. Homologous residues are shaded and identical residues are boxed.
The lysine residue responsible for binding to PLP is at the following positions in each enzyme;
Cysteine synthase: B. subtilis - 44; E. coli - 41; yeast - 86
D-serine dehydratase: B. subtilis - 117
L-serine dehydratase: yeast - 39
Threonine dehydratase: B. subtilis - 60; E. coli - 62; yeast - 109 
Tryptophan synthase (p-subunit): B. subtilis - 90; E. coli - 86
Threonine synthase: B. subtilis - 59; E. coli - 107; yeast - 124
CS_B. subtilis 1
CS_E. coli 1
CS_Yeast I
DSDHT_B. subitlis 1
LSDHTBYeast 1
TD_B. subtilis 1
TD_E. coli 1
TDjYeast 1
TrS_B. subtilis 1
TrS_E. coli 1
TS_B. subtilis 1
TS_E. coli 1
TS_Yeasi 1
CS_B. subtilis 1
CS_E. coli 1
CSjYeast 1 9
DSDHTJ. subitlis 4 3
LSDHT BYeast 1
TD_B. subtilis 1
TD_E. coli 1
TDjYeast 4 5
TrS_B. subtilis 2 5
TrS_E. coli 2 2
TS_B. subtilis 1
TS_E. coli 2 9
TSjYeast 4 3
________________________________________________________________________  o
_________________________________________________________________________ o
------------------------------------------ MSCSQNKTSVSLAWRECI 18
--MSVHSEVLHALLKDPFIQKLIDAEPVFWANSGKKEGPLPRAD 42
_________________________________________________________________________ 0
________________________________________________________________________  0
________________________________________________________________________  0
MSATLLKQPLCT V ' V RQGKQSKVSGLNLLRLKAHLHRQHLSPSLI 44
-------------------------------- M Y P Y P N E I G R Y G D F G G K F V P E T L M 24
------------------------------------- TTLLNPYFGEFGGMYVPQILM 21
_________________________________________________________________________ 0
--------------------------M K L Y N L K D H N E Q V S F A Q A V T Q G L G K N Q G 28
--MPNASQVYRSTRSSSPKTISFEEAIIQGLATDGGLFIPPTIP 42
-------------------------------- VRVAN------ S IT E L I G
-------------------------------- SKIFE------ DNSLTIG
SIASVLIGAYASYKYYKLFKTRDIPRPKEGVEELIG
ewateiaeaekrmqrfapyiaevfp----- etkga kIgJi I
_________________________________________________MEMTHYE--------MWKG L I H Q YKE F L P VTDQT P------ ALTL H eJg]- -
-MADSQPLSGAPEG - -AEYLRAVLR----- A^IPVYEAAQ-
KLHSELKLDELQTDNTPDYVRLVLR----- SSVYD N -
R - 
R -
T P 
T P
T P
E^gjp
T P
ES
T P 
T P
-IV
IL Q 
I S
QPLDEIQTAFKQIKDDPAFREEYYK----- LLKDYSG
PELRQLEEEFVSAAKDPEFQAQFND----- LLKNYAG
-------MWKGLIHQYKEFLPVTDQTP------ ALTLHEG
LFFPHDLPEFSLTEIDEMLKLDFVTRSAKILSAF I [CL --““riQVDQATLFNDWSKLSFQDLEFEIMRQLYIAQEEIPDEQDLK d[l]i
A - 
A- T Pl-
GjD - E ijp]LPJQ E I
1 - 
1 -
5 - 
8 1 
1 2 
3 - 
3 5 
8 2
6 2 
5 - 
3 -
7 -
8 -
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CS_B. subtilis 
CS_E. coli 
CS_Yeast 
DSDHTJ. stAitlis 
LSDHT _Yeast 
TD_B. subtilis 
TD_E. coli 
TDJYeast 
TrS_B. subtilis 
TrS_E. coli 
TS_B. subtilis 
TS_E. coli 
TSJYeast
CS_B. subtilis 
CS_E. coli 
CS_Yeast 
DSDHTJ . subitlis 
LSDHTJYeast 
TD_B. subtilis 
TD_E. coli 
TDJYeast 
TrS_B. subtilis 
TrS_E. coli 
TS_B. subtilis 
TS_E. coli 
TS_Yeast
CS_B. subtilis 
CS_E. coli 
CSJYeast 
DSDHTJ3. subitlis 
LSDHT_Yeast 
TD_B. subtilis 
TD_E. coli 
TDJYeast 
TrS_B. subtilis 
TrS_E. coli 
TS_B. subtilis 
TS_E. coli 
TS_Yeast
CS_B. subtilis 
CS_E. coli 
CS_Yeast 
DSDHTJ. subitlis 
LSDHT_Yeast 
TD_B. subtilis 
TD_E. coli 
TD_Yeast 
TrS_B. subtilis 
TrS_E. coli 
TS_B. subtilis 
TS_E. coli 
TS_Yeast
CS_B. subtilis 
CS_E. coli 
CS_Yeast 
DSDHTJ. subiilis 
LSDHTJYeast 
TD_B. subtilis 
TD_E. coli 
TD_Yeast 
TrS_B. subtilis 
TrS_E. coli 
TS_B. subtilis 
TS_E. coli 
TS Yeast
1 8 
1 8 
6 0 
8 2 
1 3 
3 3 
3 6 
8 3
6 3 
6 0
3 3
7 2
8 5
4 7 
4 4
8 9 
120
4 2 
6 2 
6 5
1 1 2
9 3 
8 9 
6 2
1 1 0
127
6 9 
6 6
1 1 3 
1 64
6 6 
8 1 
8 4
1 3 1 
1 1 2 
108 
8 1 
1 3 1 
1 5 8
108 
105 
1 52 
203 
103 
1 1 8 
124 
17 1 
152 
148 
1 1 8 
1 7 2 
200
142 
14 1
191 
237 
139 
14 8 
1 5 2 
19 9
192 
1 8 8 
1 4 8 
206 
234
KLNRLADENS 
RLNRIGN----
EVQHMKGKLE
RQVFNNGKTN
HLPKLSEQLG
KMEKLSSRLD
QGVGLSSRLN
YADRVTEYLG
KCQNITAGTN
HLPKLSEQLG
- -ADVYL K L E YMN------------ P G - S S V K D R
- - GRI LA K V E S RN------------ P S - F S V K C R
- -VNIYA K L E L E N------------ P A - G S A K D R
- - A A Y Q Q P F P G RWLLKCDHEL P I S G S I K A R
- - SWFY V K H E I l Q------------ P G - G S F K S R
- - IELH V K T E GVN------------ P T - G S F K D R
-- NVILV K R E DRQ------------ P V - H s F K L R
--TNVIL K R E dll------------ P V - F s F K L R
- GAKIYL K R E DLN------------ H T - G s H K I N
-- TTLYL K R E dll------------ H G - G A H K T N
-- IELHV 0 T E GVN------------ P T - gOSJf K d|rJ
-FPAPVANV E SDVGCLELFHG P T - L A F K D F
LVQNVTGDK E NLHILELFHG- P T - Y A F K D V
I-GLAMIEAAE------KEGKLKAGNT---------------------------- II
I-GANMIWDAE------KRGVLKPGVE---------------------------- LV
V-ALNIIKTAE------ELGELVRGEP-------------------------GWVF
GGIYEVLKYAENLALQEGMLQETDDYRILQEERFTGFFSRYSIA
G-IGHLIRKSN------QQPLSEGSGK-------------------------LAVF
G-MVMAVAKAK------EEGNDTI---------------------------------MC
G-AYAMMAGLT----- EEQKAHG-----------------------------
G-AYNMIAKLD----- DSQRNQG
N-ALGQALLAK----- KMGKTKI
V I
V I 
I A
Q-VLGQALLAK----- RMGKTEI---------------------------------IA
MVMAVAKAK----- EEGNDTI M C
G-GRFMAQMLT----- HIAGDKP---------------------------- VTIL
A-LQFVGNLFE----- YFLQRTNANLPEGEKK-------------QITVV
E P T S 
E P T S 
E G T S 
V S S T 
S S S G
N T 
N T 
S T 
N L 
N A
IG L AMVAAAKG-LKAILVM P 
I A L AYVAAARG-YKLTLTM A I S I^Jv VCNALG-YRAHIS L^jD - 
L SIGIIGAALG-FRVTVHMSA-
DT--MSMERR--NLLR 
ET--MSIERR--KLLK 
--DTSLEKLALLE 
--DAKQWKKDLLR
LA A
A S T G - N T S A A A
T A S A A 
A C S A A 
E T G A A
NHAQGV 
NHAQGV Q hIgIv A P
E T G A£J Q h[gJV A S 
ASTG-NTSAAA TAT sfGlD tIGIa A V
TACRSMA-LNCSVVV 
AYAARAN-MKCIVII 
F S S A R L GiV KA LIVM 
FAAKHLK-IPATIVM
A K----- TTKP R--MVKK
PN----GKIAFG--KLAQ
ATA-TADIKVD-- A V R E 
EJV C-TPSIKYQ--NVSR
TVAAKFG-FSCTVFMGE----EDVARQSLNVFR
LASALLG-LKCRIY MAGA----KDVERQSPNVFR
AYAARAN-MKCIVII Jhafyglpnvkvvily 
GAT S|GJD t|gJs AAIYGLRGKKDVSVFILY;|gJi
A - - Y 
A - - L 
S - - L 
Q - - K 
I Q S A 
A VM Y 
F - - 
L - - 
M K L L 
M S L S 
A VM Y
A E L V i L T P PGa EG----- M K G
A N L V - L T e|gJa KG----- M K G
ATVNKVKPASIVDPNQYVN 
V E V M i E Y ETA---------Y S E
AKVI--IH 
AEII-AID 
GEVL - - LH 
SQVV - - LY 
AEVVPVTS 
AEVIPVHS 
AEII-AID
TLGGNIETV-AID 
VPDENVQTLS - V E
D S W E
N---------FDD
A iN-----FDE
N i E------- FD E
N G E----- L K D
S A E----- L K D
N---------FDD
N----GKIAFG--KLAQ
R----GKISPLQEKLFC
TGRISPIQEE- -QMTT
IKKAEELAEKHG 
IQKAEEIVASNP 
AKKACNELKKSG 
AJVNE GRRQAEQDP
- Y F V P 
E - K Y L L L
----- N G I R
- F C Y F I D
- - EADEYLRHKLMAQESQ----H G S K
ALKIVRSICEKSP 
AKAKAIELSQQQG 
AKAECAKLAEERG 
ATNEA I RYWVQ H C 
ACNEALRDWSGSY 
pL KIVRSICEKSP
D---------FDACQALVKQAFDDEE
T---------FDNCQDIVKAIFGDKE
QQFNNPS-NPEIH----R Q
QQFSNPA-NPEIH----EK
AVFADQFENEANWKVHYQ
T G K 
T G P 
T G P
----F----
----L----
E D H F Y M I 
E T A S Y M L
----- L K V A
----- F N S K
A IV E0F G------ DD-QLDAFVAG
AIWEDT--------DG-QVDVFIAGEJI A h|Ht--------- KGNIDAFIAG
DEHSRQLFLGYAVAASRLKTQ LDCM NIK P----- SLETPLFVYLP
TLYVHPFDNETIWEG-HSTIVD 
IALVNSV-NPYRIEG-QKTAAF 
-TWVPPFDHPMVIAG-QGTLAL 
-TNIPPFDHPYVIAG-Q g|tJv A M 
GSVVGPHPYPQVVREFQKMIGE 
GTAAGPHPYPTIVREFQRMIGE IALVNSV-NPYRIEG-Q K0A A S 
LGLNSANSINISRLLAQ ICYY S
I I E 
V E E 
L L Q 
I L R 
A K D 
T K A 
VC E 
AVAHNVGAVNSINWARILAQ M0Y Y F Y H H H
ALKENDISLPRVKALVCS
AL--------- GEAPDVLAIP
AD----------- AHLDRVFVP
AV R------ TANKIGAVFVP
AL K R-- IEGTMPDKVVAC
AILE--REGRLPDAVIAC
AL--------- GEAPDVLAIP
QL P-QETRNQLVVSVP
'QJA TN - - GKDSKKVKFVVP
4 6 
4 6 
8 6 
1 1 6 
4 1 
6 1 
6 6 
1 1 1 
9 I 
8 6 
6 1 
109 
126
6 8 
6 5 
1 1 2 
1 63 
6 6 
8 0 
8 6 
130 
1 1 1 
107 
8 0 
130 
1 67
107 
104 
1 6 1 
202 
102 
117 
123 
1 7 0 
1 6 1 
147 
1 1 7 
1 6 1 
199
1 6 1 
140 
190 
236 
138 
147 
1 6 1 
198 
1 9 1 
1 87 
147 
205 
233
176 
174 
228 
276 
1 8 1 
1 63 
1 86 
236 
233 
229 
1 83 
246 
27 5
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CS_B. subtilis 
CS_E. coli 
CS_Yeast 
DSDHTJ. subitlis 
LSDHTJYeast 
TD_B. subtilis 
TD_E. cali 
TDJYeast 
TrS_d. subtilis 
TjS_E. coli 
TS_B. subtilis 
TS_E. cali 
TS_ Yeast
CS_B. subtilis 
CS_E. cali 
CS_Yeast 
DSDHTJJ. subtilis 
LSDHT_Yeast 
TD_B. subtilis 
TD_E. caei 
TD_Yeast 
TrS_B. subtilis 
TrS_E. cali 
TS_B. subtilis 
TS_E. cali 
TS_ Yeast
CS_B. subtilis 
CS_E. cali 
CSJYeast 
DSDHTJ. subtilis 
LSDHTJYeast 
TD_B. subtilis 
TD_E. cali 
TD_Yeast 
TjS_B. subtilis 
TjS_E. cali 
TS_d. subtilis 
TS_E. cali 
TS Yeast
m
175
229 
27 7 
1 8 2 
184 
187 
237 
234
230 
184 
247 
276
202 
202 
257 
305 
209 
21 1 
224
274 
264 
26 1 
2 1 1
275 
320
223 
229 
286 
335 
234 
237 
266 
3 1 6 
298 
295 
237 
302 
358
CS_B. subtilis 250
CS_E. cali 256
CS_Yeast 322
DSDHTJJ subitlis 369
LSDHTJYeast 269
TD_B. subtilis 270
TD_E. coli 300
TDJYeast 350
TjS_S. subtilis 336
TrS_E . cali 33 3
TS_d. subtilis 270
TS_E. caei 337
TSJYeast 402
- T
- T
- T
- V
- G
G G 
G G 
G G 
G G 
G G
- N "AG
T 6 T 
T L T 
T 6 T 
G P G 
L F S
AGEVLK----EAYPSIKIYA
VSRYIKG-TKGKTDLISVA 
VAKFLKERAKIPCHVVLAD 
VAFGLKLLYGDDVHVFFAE 
IIKGLDR-NHLAEKIPVVA
NITAYWKGFKEYHE-KNGTGLPK
- G G G LAAGVAVLIKQLMPQIKVIAVEAE---------DSACLKAA
- G GGj L IAGIGAYLKRVAPHIKIIGVETY---------DAATLHNS
- G GSNAMGMFQAFLN- ED - VELIGAEAA---------G---------------- KG
- gig s n a iIg]m fadfin-etnvgligvepg---------G--------HG
- N A F]n FTAYWKGFKEYHE - KNGTGLPK------------------------
N f|g D L T aIGIl LAKSLG - LPVKRFIAATN------------------------
N FIgJd f l a[gJy fakkmglpieklaiatnendildrflksglyer
VE----PSDSP---- V - LSGG---------- KPGPHKIQG---------------
V E----PTDSP---- V - IAQALAGEEI-KPGPHKIQG--------------
-------PQGSGFYNR -VNYGVMYDYVEKEGTRRRHQ--------------
-------PTHSPCMLLGLYSGLHEKISVQDIGLDNQT---------------
----VETAGCD---- V-LNKSLKKG---- SPVTLEKLT---------------
MR----GFEAE--------GAAAIVRNEV- IENPETIAT--------------
LDAGHPVDLPRVGL-FAEGVAVKRI -GDETFRLCQEYLDDI ITV 
LQRNQRTPLPVVGT-FADGTSVRMI-GEETFRVAQQVVDEVVLV
IDT--PLHAA----T - ISKGTVGVIH-GSLTYLIQDEFG---- QII
IET--GEHGA----P-LKHGRVGIYF-GMKAPMMQTEDG---- Q I E
MR----GFEAE--------GAAAIVRNEV-IENPETIAT--------------
VN----- DTVPR - -F-LHDGQWSPKA-TQATLSNAM--------------
SDKVAATLSPAMDI -LISSNFERLLWYLAREYLANGDD------- L
IGAGF - VPDILNTEVYDEIFP------------------- VKNEEAF
IGAGF - IPANLDLKLVDKVIG--------------------ITNEEAI- V D tJ EGIGLNRITHNFHMGEKFID----------- ESIRVNDNQAI
AADGLAVGR-PSGFVGKLIEPLLSG--------------CYTVEDNTLY
----SJVA TSLASPYIASFAFEEFNKYEC---------- KSVVLSDQDVL
----A
D 6 D A 
N T D E 
E P Y S 
E S Y E 
----A
RIGNPASWDKAVKAAEESNGK-------------IDEVTDDEIL
CAAM-KDLFEDVRAVAEPSG-------------- ALALAGMKKY
CAAV - KDIFEDTRSIVEPSG-------------- ALSVAGMKKY
SAGLDYPGIGPEHAYLHKSGRV--------- TYDSITDEEAV
SAGLDFPSVGPQHAYLNSTGRA--------- DYVSITDDEAL
RIGNPASWDKAVKAAEESNGK-------------IDEVTDDEIL
DVSQPNNWPRVEELFRRKIWQLKE LGYAAVDDETT
K A E E10V NNWFQELKTNGKFQVDKSIIEGASKDFTSERVSNEETS
2 0 1 
20 1 
256 
304 
208 
2 1 0 
223
273 
263 
260 
2 1 0
274 
3 1 5
222
228
285
334 
233 
236 
265 
3 1 5 
297 
294 
236 
30 1 
357
249
255
321
368
268
269
299
349
335 
332 
269
336 
40 1
EYARRAAREEG------ILGGISSGAAIYAALQVAKKL------------G 282
STARRLMEEEG------ILAGISSGAAVAAALKLQEDE------------S 288
RMAKYLSVNDG------LFVGSSTAINAVAAIQVAKTL------------P 354
TLLHMLAVSED------KYLEPSALAGMFGPVQLFSTEEGR-------R 404
ATCLRYADDYN----FIVEPACGASLHLCYHPEILED----------- I 302
HAYQLIARVEG------VFAEPGSCASIAGVLKQVKSG------------E 302
IALHNIRGER------- LAHILSGANVNFHGLRYVSER------------C 33 1
ISTVHPEIDHTK- NTYVPILSGANMNFDRLRFVSER---------- A 385
DALKLLSEKEG------ILPAIESAHALAKAFKLAKG------------- M 367
EAFKTLCLHEG------IIPALESSHALAHALKMMREN------------ P 365
HAYQLIARVEG----- VFAEPGSCASIAGVLKQVKSG------------ E 302
QQTMRELKELG----- YTSEPHAAVAYRALRDQLNPGEYG------- L 372
ETIKKIYESSVNPKHYILDPHTAVGVCATERLIAKDNDKSIQYI 445
CS_a. subtilis 283 KGKK--------VLAIIPS---- NG
CS_E. cali 289 FTNKN------ IVVILPS-----SG
CSJYeast 355 HGSN--------IVIIACD---- SG
DSDHTJ. subtilis 405 YAQKYKMEHAVHVVWGT - - GG
LSDHT_Yeast 303 LEQKIYEDDIVIIIAC-----GG
TD_d. subtilis 303 IPKGSK---- VVAVLTG----- NG
TD_E. cali 332 ELGEQREALLAVTIPEE - - KG
386 VLGEGKEVFMLVTLPDV - - PG 
TrS_a. subtilis 368 DRGQL - - - - ILVCLSG 5 - - RG
TrS_E. cali 366 DKEQL------LVVNLSG----- RG
TS_B. subtilis 303 IPKGSK---- VVAVLTG----- NG
TS_E. cali 373 FLGTAHPAKFKESVEAI- - l[g
TS Yeast 446 SLSTAHPAKFADAVNNALSGF
ERYLSTPLYQFD----------------- 307
ERYLSTALFADLFTEKELQQ---- 322
SRHLSKFWKEAKEIDHDVSLEEV 390 
SMVPKDEMAAYNRIGADLLKKRN 446
SCMTYEDLVK^SSTLNVS------- 338
LKDPNTAVDISEIKPVTLPTDED 340 
SFLKFCQLLGGRSVTEFNYRFAD 373 
AFKKMQKIIHPRSVTEFSYRYNE 427
DKDVNTLMNVLEEEVKRHV-----  400
DKDIFTVHDILKARGEI---------396
LKDPNTAVDISEIKPVTLPTDED 340 
ETLDLPKELAERADLPLLSHNLP 416 
SNYSFEKDVLPEELKKLSTLKKK 489
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CSjB. subtilis 0
CS_E. coli 0
CS_Yeast 3 9 1
DSDIH'Jl. subitlis 447
LSDHTjYeast 0
TD_B. subtilis 341
TD_E. coli 374
TD_Yeast 428
TrSjB. subtilis 0
TrS_E. coli 0
TS_B. subtilis 34 1
TS_E. coli 4 1 5
TSjYeast 490
CS_B. subtilis 0
CS_E. coli 0
CSjYeast 0
DSD1H'_B. subitlis 0
LSDHT_Yeast 0
TDjB. subtilis 0
TD_E. coli 4 1 0
TDjYeast 472
TrS_B. subtilis 0
TrS_E. coli 0
TS_B. subtilis 0
TS_E. coli 0
TS_Yeast 0
CS_B. subtilis 0
CS_E. coli 0
CS_Yeast 0
DSIDH:_B. subitlis 0
LSDHTjYeast 0
TD_B. subtilis 0
TD_E. coli 454
TDjYeast 515
TrS_B. subtilis 0
TrS_E. coli 0
TS_B. subtilis 0
TS_E. coli 0
TSjYeast 0
________________________________ ______ ________________________________  307
_____________________________ ___  ____________________ ______ ______ _____ 3 2 2
I N --------------------------------------------------------------------- 393
G k--------------------------------------------------------------------- 448
---------------    338
S5LEYVKGEERV---------------------------------------------------- 352
A KN------------ ACIFVGVRLSRGLEERKEILQMLNDGGYSVVDL 409
HRHESSSEVPKAYIYTSFSVVDREKEIKAVMAALNELGFEAVDI 471
40 0
___________-_____- -- --------------------- ------ --------- -  ---- -----3 96
SILEYVKGEARV---------------------------------------------------- 352
ADFAALRKLMMNH Q------------------------------------------------  428
L K F - E R A D V E L V K N A - E E E L A KM K L------------------------------ 514
------------ ---------------- ------------------- ---- ------------------ 3 07
________________________________________________________________________ 322
________________________________________________________________________ 393
________ ________ _  --- ----- ---- ----- ----------------------------- - 4 4 8
----------------- ------------------------------------------------------  3 38
----------------- -----------------------------  ---------- ------------- 352
SDDEMEKLHVRYMVGGRPSHPLAERLYSFEFPESPGALLRFLNT 453 
SDNELAKSHGRYLVGG-ASKVPNERIISFEFPERPGALTRFLGG 5 - 4 
------------------------------------------------------------------------ 400
------------------------------------------------------------------------ 396
________________________________________________________________________ 352
_ ------- ------------- --------------------- ---- - --------------------- 4 28
---------- --------------------- - --------- ---------------------------- 514
---------- - ------------------ ----------------------------- ----------- 30 7
________________________________ _____________________ _  __________  __  - 3 2 2
----- ------------------------------------ -  _-------------------- -----39 3
------- -------------------------- -  -------------------- ------ ------ - 44 8
__________ ______  - ---------------------- ---- --------- --------- ----- 3 3 8
•___ ______________________________________ _ ________ -■ - - ------ -  -----  3 5 2
LGTYWNISLFHYRSHGTDYGRVLEEFELGQDHEPDFETRLNELG 496 
LSDSWNLTLFHYRNHGADIGKVLEGISVPPRENLTFAKFLEDLG 558
4 00
______________ ___________ __________ ______________ _________ ___________ 396
_______ ______ ___ ______ ________________________ ____ _______ ______ _____ 3 5 2
________________________________________________________________________ 428
________________________________________________________________________ 5 - 4
Abbreviations given are as follows:
es - cysteine synthase (O-acetylserine sulfhydrolase); dsdht - D-serine dehydratase; lsdht - L-serine dehydratase; td 
- threonine dehydratase (threonine deaminase); trs - tryptophan synthase ((---ubunit); ts - threonine synthase.
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Appendix 2
Table of Reactions Catalysed by Threonine Synthase.
SUBSTRATE TYPE OF REACTION PRODUCT
(2S)-homoserine half-transamination PMP (from PLP) a
(2S)-serine deamination (P-elimination) pyruvate
(2S)-0 -phosphohomoserine p, y-replacement (2S,3/?)-threonine
DL-0 -methylserine half-transamination PMP (from PLP) »
(2S,3j?)-threonine deamination (p-elimination) a-ketobutyrate
{2S)-allo -threonine deamination (p-elimination) a-ketobutyrate
DL-vinylglycine P - (25,3/R)-threonine
DL-allylglycine half-transamination PMP (from PLP) a
(2S)-alanine half-transamination PMP (from PLP) a
DL-3-chloroalanine deamination (p-elimination) pyruvate
DL-3,3,3-trifluoroalanine half-transamination PMP (from PLP) a
(2S)-norvaline half-transamination PMP (from PLP) »
DL-3-hydroxynorvaline deamination (P-elimination) a-ketovalerate
(2S)-2-aminobutanoic acid half-transamination PMP (from PLP) a
{2S)-threo - 2-amino- 3 -chlorobutanoic acid deamination (p-elimination) a-ketobutyrate
DL-2-amino-5-phosphonopentanoic acid half-transamination PMP (from PLP) »
a - for the structure of PMP (pyridoxamine-5'-phosphate) see Scheme 1.2
b - (2S)-vinylglycine is an intermediate in the synthesis of (2S,3j?))-hreonine from (2S)-0 -phosphohomoserine (see
Schemes 1.16 - 1,18)
-AppsndiBss-
Appendix 3
Wild-type tryptophan synthase stJCBtcJss, highlighting residues involved in mutation 
experiments discussed in Section 1.3.
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Appendix 4
Table of Amino Acid Codes
Amino Acid Code Side-Chain Structure
Alanine Ala, A -CH3
Arginine Arg, R
Nh2
JJ '
h2n n^^
H
Asparagine Asn, N
H2 Ny^
0
Aspartic acid Asp, D ho2c""x
Cysteine Cys, C HSCH2-
Glutamic acid Glu, E HO2C'ZXX
Glutamine Glu, Q
O
Glycine Gly, G -H
Histidine His, H
Isoleucine He, I Me(Et)CH-
Leucine Leu, L (Me)2 CHCH2
Lysine Lys, K H3^
Methionine Met, M MeSxx"X
Phenylalanine - Phe, F PhCH2 
Proline Pro, P N^CO2 H
H
Serine Ser, S HOCH2 -
Threonine Thr, T
Me.
CH
HO'
/=\/C"2-
Tryptophan Trp, W
v/1
H
Tyrosine Tyr, Y HO 2 -
Valine Val, V (Me)2CH-
■AppsndtBss
Appendix 5
The Genetic Cade
5-OH
Terminal
Base
Middle Base
3'-OH
Terminal
Basej
u c A G
Phe Ser Tyr Cys U
U Phe Ser Tyr Cys c
Leu Ser STOP1 STOP 2 A
Leu Ser STOP 3 Trp G
Leu Pro His Arg UC Leu Pro His Ai'g C
Leu Pro Gin Arg A
- -- Leu Pro Gin Arg G
De Thr Asn Ser U
A De Thr Asn Ser c
He Thr Lys Arg A
Met 4 Thr Lys Arg G
Val Ala Asp Gly U
G Val Ala Asp Gly c
Val Ala Glu Gly A
Val Ala Glu Gly G
I - Ochre; 2 - Opal; 3 - Amber; 4 - chain-initiating N-formIl-msthtonine
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Appendix 6
V
Sequence alignments for threonine synthase from various microorganisms.
@ A representation of the Clustal W alignment of TS enzymes from various microorganisms generated using 
SeqVu. Homologous residues are shaded and identical residues are boxed.
S. cerevisiae 1
S. pombe 1
C. glutamicum 1
M. glycogenes 1 
E. coli t
P. aeruginosa 1
S. marcescens 1
H. influenzae 1
M. leprae 1
M. tuberculosis 1
B. subtilis t
Br. lactofermentum 1
MPNASQVW R STRSSS?Kt 
-MSSQVSVLS ARG GSS-N
----------M 13 Y I S TR D A S R TP
-------MK1^ISTRGQS-PA
------- M K L Y N TI E H N E - Q
------- M RY I S TRG Q AP - a|-------MKLYN L# DHN#-Q
-------MN L Y N I R h’IeB - Q-
S E I 
AT Y 
EQY 
IHDL 
EN L 
Il d l
YRDRi
Y K E F
Y ASY
AjE E A I I q|gI 
FEEAVLKGI
IIatdgIg 
Ja N D G G
FISDILL G GIJa p d g g LY
F|S E I L L GIG IjIA p d gig LIY
FA Q A V T QlG IJg K N Q G
F|E D V L L AIG I LIY
F A Q, A I K QlG IJg k q q Jg
fejs Q A V R QGIJg rdqIs.
T T H Q P W PIGp|I A A - - - -
q P Wi 
- MW. 
-MY
4 4 
4 2 
3 9 
3 8 
3 8 
3 8 
3 8 
3 6 
2 4 
2 4 
1 4 
1 4
S. cerevisiae 
S. pombe 
C. glutamicum 
M. glycogenes 
E. coli 
P. aeruginosa 
S. marcescens 
H. influenzae 
M. leprae 
M. tuberculosis 
B. subtilis 
Br. lactofermenlum
4 5 
4 3 
4 0 
3 9 
3 9 
3 9 
3 9 
3 7 
2 5 
2 5 
1 5 
1 5
YQATjLFNYWeKLg 
PSG-WJEAWKPKS 
DI DA - QLSKWREVL 
SAD-AIiSAMRGHNS L T - EIDEM L'i# D 
T L E - EpP S 1Wv Gj 
E E T i E...
Bln- N 
-----------(g1
-----
----- VT DQT P At.T
----- VN EKT PDV
L L
----- ETDLAFAIMRLY
----- FPEIAFEVMSLYIPRS
ANEG TAAPAREVI S-DFV - - T----- YRDLAFTTLSRLI--J
----- AV T RS A KI * S A F* G-ft
----- Y.HELAFRV.MRP FVAG -
----- A VT R S S RIL SAFIG
----- SVigRSQKISGALID-G
----- %L#GGTPLIA APR---- L----- &LRGGTPLI AA N---- L
----- L H E GNTpLiHL-P K---- L
-----L MEGNTPLI PLlN------ I
I
V
A I T 
II V 
riv 
3PL 
K RV 
T L D A Mt V 
S E.Q:TGGTIHL 
SKQTGCTIHL 
SEQLGIEL HV 
S KQ -LHVQ L YG
S A D
V E
AD
8 4 
8 1 
8 0 
7 5 
7 6 
7 6 
7 6 
7 4 
5 7 
5 7 
4 7 
4 7
S. cerevisiae 
S. pombe 
C. glutamicum 
M. glycogenes 
E. coli 
P. aeruginosa 
S. marcescens 
H. influenzae 
M. leprae 
M. tubercuuosis 
B. subtilis 
Br. laclofermentum
8 6 
8 2 
8 1 
7 6 
7 7 
7 6 
7 7 
7 5 
C 8 
5 8 
4 8 
4 8
K R--------------5YSTFRSDEVT|
DR--------------SYE TFRHI ET T
Aj|-------------- A YlTa|^K#))[4*^W$V
JDKT YR AD V Y A YARGQEABAEDIT
R A--------------------AFAFR--A
JE1 TYG--------- VFAHDASGAAA
q A------------------- aFUfII i - a
KN------------------- AFTF>--a|
K----------------------------------------------------------
K----------------------------------------------
K----------------------------------------------
K----------------------------------------------------------
|l V-Q N V T G D K E N-L-.H-.I LJE L F H
Ik s lkng---------- LNVm
^ILEDN----------XY&G
|T Y R L E D D---------- L Y LLS
' AN V E S D----------VG C
>e|»t h %---------- --- - cv|e
HAD 
---------V
------- V
------- T
----Y
G - DN 
G L N - 
GVN - 
CAN -b
VAKVTDD----------VS CL SYFH
LeKVEEN-------
1 1 9 
1 1 2 
1 1 3 
1 1 5 
102 
108 
102 
100 
6 4 
6 4 
5 4 
5 4
S. cerevisiae 120
S. pombe 11 3
C. glutamicum 1 1 4
M. glycogenes 1 1 6
E. coli 103
P. aeruginosa 109
S. marcescens 103
H. influenzae 1 0 1
M. leprae 6 5
M. tubercubsis 6 5
B. subtilis 5 5
Br. lactofermentum 5 5
MAQMLAEyAGE 
MEQ ALA AVRGD 
MTMAVTDALAR 
MTMJAlfT DAL AH 
M VMAVAKAKEE M V mEIE A K A K E H
RAVL T 
R ApII- C 
D tE|M C
|i c(Ss tUn
KH TN K TE EE R ■ DW LT
rW-----------------e tsn
kg----------------ettn
GDKP-------------------- VTXLT
ARRG-------------ERVVi
-------------VT
TS GD 
T S G D 
T S GD 
AT S GD 
AT S G D 
AT SG D 
ATSGD 
A^LSGD 
GN 
A ST GN 
TGN
163 
1 56 
149 
1 5 1 
1 36 
1 44 
1 36 
1 34 
9 5 
9 5 
8 5 
8 5
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S. Bsrsvistas 
S. pombe 
C. glutamicum 
M. geIBogsnss 
E. cali 
P. aeruginosa 
S. maJCssBsns 
H. infecsnzas 
M. leprae 
M. tuberculosis
B. subtilis 
Bj. laBtofeJmsntcm
S. csJSvtstas 
S. pombe
C. glutamicum 
M. glycogenes 
E. coli 
P. aeruginosa 
S. maJCssBsns 
H. influenzae 
M . leprae 
M. tcbeJcub)sts
B. subtilis 
Bj. lactofsrmentcm
S. BSJsvtstas 
S. pombe
C. glutamicum
M . glycogenes 2 3 9
2 2 3 
2 3 2 
223 
22 1 
174 
174 
163 
163
E. coei 
P. aeruginosa 
S. maJcescens 
H. influenzae 
M . leprae 
M . ttbeJcutbsis 
B. subtilis 
Bj. bli:lofsJmentum
S A A A
iS A A A
G K K D ' V . S V FI LYP 
GKKDVSVFILFP 
RGREGIRVFM LTP 
MlRjG KQGVKVFM L S P 
FYGL PNVKVViy|Y 
AAVADNVDIFIID 
F Y G L K NV R VV I l|y 
F^G L ENINVVILYP 
-AGITCAVLIP 
- AGITCAvtJl 
-ANMKCIVIIS A AjA A A
s aIs a AlAlY AlAlRl- -lgmkcnnvn
F DyC 3D IV K A IFG 
fddcqdok OICG 
F DDC Q p V VKAVS A 
F D D C QP I VK AV S N 
F P0C QALV KQAFD 
FDDCQFmVKASFA 
F DIaI CQ A L V K Q A F D 
F d|AcPJA L1V.K1O A 'F D 
FDDqLELARKMAA
T GR0S ■ P NGF E L MTTV P D E 
NG A'V F P I Q E A L MTTVTDP 
a|g IRMTPFQQA QMFGL DDP 
hqHm s r p q t aIajm F S L Q D D 
rIgkUs F L Q E KL F C T ..L G G - 
H nF-VS- eve; r-rIQIm t ti hg d
VQ 
VH 
1 F
N I F
I E 
N H 
I H 
I R
p
l£lE
S PLQEKLJFCpfrQG - 
KI SR L Q SR L C. c CTG G -
KIA MIK L A QAVM HG A-----K
K IAMGKLA SiVMHG A----K
G K I A F GK LAQAVMYGA----- ERFKiRa H G K L AjQJA VAYGA----E
KEFNIKHNVGA VSfMkKhHI
a.efkkdnriga \ 
DHA^CAK^-RIGAh 
D E El# K V A L G ■ L N . S Al 
DQGFLKGTRLVaFnSI
Q E L K DALHLNSANSIN
VELRQAIGLN S AJN SIN
VNSINWARILA 
VNEI N
F PM - I SL VN S V|N
V NS VN
V N S V NI
F D I DAL I L AR I I A I |gF P T------------ISL
F D d|a L K IMR I I C E K S P-----------I AL
R N I A A E E P - -F D DlA I K A
GF FQ A TNGKD S KK V KF 
S Y L S V ■ Y K , Q G 16 A D D V R F 
" WI I I R T T I IS I R I IK V S F S| 
KI Y F 11JAT AD-NAQGV SF A
E AVAG 
H HAL Q 
E A VA 0 
E A VA Q 
E I V D A 
E I V D V 
E VI E Q
K I A aIeJe I C D GRi
ARILS 
RLNA 
FAIR VAA 
RL L A 
RIMA 
RL L A 
DLA I E G 
R I E G 
I E G
----- IT LlV N .SiVlNiP Y|RJI E G
FQ E-T RNQLVVS 
GAP - - HRSVAFS 
PGE- A RN Q L VI S 
PKE-KRDNVVVS
II A----- PHVHAL
IT A----- PDVHALP
IE A----- PDVLAI
QN A----- PDVLAI
L P
L L AKSL G L P 
RNNGLP
A G|L IlAIK T LlGJLP 
A - YWKIYTEYH 
YWKIYTEYH 
YWKIFKEYH 
YWKIFCEYE
S. BSJsvistas 2 9 5
SO pombe 2 8 8
C glutamicum 2 8 0
M. glycogenes 2 8 2
2 6 6 
2 7 4 
2 6 6 
2 6 4 
2 1 3 
2 1 3 
2 0 2 
202
E . coli 
P. aeruginosa 
S. majcescens 
H. influenzae 
M. leprae 
M . tcbeJcclvsis
B. subtilis 
Bj. lbcofsJmentlC3
S. csJSvtstas 3 2 9 
S. pombe 3 3 2
C. glutamicum 3 1 6
M. glycogenes 3 1 8 
E. coli 2 9 9
P. aeruginosa 3 0 7 
S. majcescens 2 9 9 
H. influenzae 2 9 7 
M. leprae 2 4 8 
M. tcbsrcuh>sis 2 4 8 
B. subtilis 2 3 6 
Bj. lbC0)fsJmentc3l 2 3 6
IEKLAIATNE 
TKQLV I ATLE 
IDRLIVATNF 
I AKLVVATNE 
VKRFIAATLV 
VSQLIVAR Hl 
VKRI IAATNA
ND 
ND 
ND 
ND 
N D 
ND 
ND
ILDRFLKSG 
ILNR FFKTG 
VLDEFFRTG
LYERSD-------------------------- KVAA
RYEKADSTQVSPSIPISAKE 
DYR V R IS------------ A D T H E
VLQECFKCG VYRPRIS------------ANTYH
TVPRFLHD L 
ILHRFMI I L 
T V I R I L I I L
QWSPKA----------------- TQ AlTJL
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I K R F V A I TCiJAliejT V P R Y L R S|gN WD P K T
Q WQ I H A----------------- TVA
TVA 
H P E 
H P E 
N I E
ADILIDRL PRMLITQAAIAAP LVLIEPVS----------
Q L I L I D K L P R M I I TQ A A I A A ' FL V I I E P V I----------
E KIN G TIL PR mRgFEAEIAA AIVAN EVIE----------
KE-KIYKK PRIHGF'EAEGAAAIVKIHVIE--------------E P E
I A 
I A 
I A 
:U|I a
P|A MD I 
pk N D I 
P Si ND I 
P S|N D I 
N D E 
p"sJn D 
N 
N 
T 
T 
T 
T
AND V S Q P N 
ANDVS R P N
N FE R
N F B R
N F B R
N F E R
N W P R
N FF R
N WF R
N W P R
IRI 
I R I 
I RI 
I RI
G S P A S W T S 
GSPASWTS 
G N P A S WDR 
INPASWSY
LLWYLAREYLANIGD-LKAGEIVNNWFQELK 
YDWYLALATEAPNHTPAEAVEILSRWMNEFK 
FIFLLLIRLATRVND - - LFGTQVRQGIFSLA 
FVFLLVGRLAAKVRE--LWGKVLAIGSFLLN
---------------------------- VEEL FRRKIWQLK
LlfDLHGR---------------- N GK AVASLLDAFK
----------------------------
---------------------------- v eBLFkrngwdlt
--------------------------------^V^E a|I Q-------- Q
--------------------------------------- ^V^E^ Q---------Q
--------------------------------A v KAAE------- 'E
--------------------------------aVeaae---------Q
206 
1 99 
1 92 
194 
178 
1 87 
178 
176 
134 
134 
1 24
1 24
250 
243 
236 
238 
222 
23 1 
222 
220 
173 
173 
162 
1 62
294 
287 
279 
28 1 
265 
273 
265 
263
2 1 2 
2 1 2 
20 1 
20 1
328 
33 1 
3 1 5 
3 1 7 
298 
306 
298 
296 
247 
247 
235 
235
37 1 
375 
357 
359 
324 
340 
324 
322 
267 
267 
255 
255
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S. cerevisiae 3 7 2
S. pombe 3 7 6
C glutamicum 3 5 8
M. glycogenes 3 6 Q
E. coli 325
P. aeruginosa 341
S. marcescens 325
H. influenzae 323
M. leprae 268
M. tuberculosis 268
B. subtilis 256
Br. lactofermentum 256
S. cerevisiae 416
S. pombe 416
C. glutamicum 393
M. glycogenes 394
E. coli 347
P. aeruginosa 38 1
S. marcescens 347
H. influenzae 345
M. leprae 292
M. tuberculosis 292
B. subtilis 280
Br. lactofermentum 2 8 Q
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li RYRALRtDQ.LQ 
FI r Y Q V L K-D Q L K 
|R SIAGlJkAI D
IaR iJg vlkqVk 
in ais'BAg V iKHVe
FIK e s 
fJk e s
G S T V 
G S T V 
GSKV 
G E T V
K
T
459 
459 
433 
433 
386 
421 
386 
384 
322 
322 
3 10 
310
S. cerevisiae 4 6 Q
S. pombe — 4 6 Q
C glutamicum 4 3 4
M. glycogenes 4 3 4
E. coli 3 8 7
P. aeruginosa 4 2 2
S. marcescens 3 8 7
H. influenzae 3 8 5
M. leprae 3 2 3
M. tubercubsis 3 2 3
B. subtilis 311
Br. bctofementum 31 1
E A I 
ER I
C T I Tl 
C T VT 
av| 
a vHt
N
II 
veA 
V E A 
E A I
EKA^IjS Q AR A -
Y N
JQ E lM L 
11 Q LPL 
ING LKD 
In g l'k d 
In GL K D 
IN G LKD
OD G.$ LD EE R T CIF S G K 
R F RRIMDRPFKVSDLPN 
SLEGLESLPQRFFVMER 
EL A , E R A D L P LL S H N L P A 
ADD F E R E E EGT V L P N 
AL ALRAELPLLS H TLPA 
TLDKHNQLPLLSLEMDE 
t||li-em- -psISS P mfi 
TA LK -DM--P SVS PVFI 
\^DIS E - - I%P VTLPT 
ISSNQ--LDIASVSNI
IDILKQ
TDAVKQ
R R VIK Q 
fi|F A A L R K 
E L A K VQ A 
SF G E L R K 
DJF AQLRA
A VA VVE
P V i AV V E
E D SIL E 
[fill E Q i K D
503 
503 
469 
469 
422 
458 
4 22 
420 
355 
355 
344 
344
S. cerevisiae 5 Q 4
S. pombe 5 Q 4
C glutamicum 4 7 Q
M. glycogenes 4 7 Q
E. coli 4 2 3
P. aeruginosa 4 5 9
S. marcescens 4 2 3
H. influenzae 4 2 1
M. leprae 3 5 6
M. tubercubsis 3 5 6
B. subtilis 3 4 5
Br bctofementum 3 4 5
rieeelrvkm-kl - 
I I EVT.L SReWa - 
Y I VD Ajl dkDQ T S VK
nvDDi------------
L M M Ktt Q------- --- - -
VD I D'H G NP gV P L
D0MGLP&----------
YIl&s--------------
Q%G L V---------------------
kSgla---------------------
YVKGAARV-----------
HIKG vImS-----------
5 1 4 
5 1 4 
48 1 
475
428 
47Q
429 
425 
36Q 
36Q 
352 
352
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Protein sequences for TS were obtained from the SwissProt database (web-site: http://expasy.hcuge.ch/cgi- 
bin/sprot-search-de) under the following accession numbers:
No. Organism Accession Number
1 B. subtilis P04990
2 B. lactofermentum P09123
3 C. glutamicum P23669
4 E. coli P00934
5 H. influenzae P44503
6 M. glycogenes P37145
7 M. leprae P45837
8 M. tuberculosis Q10610
9 P. aeruginosa P29363
10 S. pombe Q42598
11 S. marcescens P27735
12 S. cerevisiae (yeast) P16120
Percentage identities between the various threonine synthase enzymes (organisms are numbered 
as in the table above).
1 2 3 4 5 6 7 8 9 10 11
2 68
3 17 15
4 17 12 28
5 18 16 28 66
6 10 11 57 29 28
7 55 53 18 16 16 17
8 55 55 18 14 13 16 93
9 18 11 36 31 27 40 15 15
10 17 13 33 28 30 37 13 16 37
11 17 13 25 83 66 27 14 15 33 28
12 13 12 35 31 30 33 13 12 35 55 30
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Comparison between the threonine synthase enzymes quoted in reference 170.
P. aeruginosa B. subtilis C. glutamicum Br. lactofermentum S. cerevisiae
E. coli 34.9 24.2 30.2 21.9 37
43 47.5 48.8 40.8 56
261.8 137.7 229.5 131.4 252.9
P. aeruginosa 25.9 40.4 16.8 40.8
48.7 56.8 30.2 59.7
145.1 311.6 129.7 332.5
B. subtilis 22.5 67.8 24.5
49.5 79.8 47
139 397.4 143.3
C. glutamicum 17.4 39.4
36.3 58.4
134.3 324.1
Br, lactofermentum 16.1
33.2
143.5
i
First line, percentage of identity; second line, percentage of similarity; third line, quality scores.
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Appendix 7,
Gene Sequence and Translation of ThrC from E. coli.
1/1
ATG AAA gtg TAG AAT GTG AAA GAT GAG AAG
M K L Y N L K D H N
61/21 
GAG GGG TTG GGG AAA AAT GAG CCC GTG TTT
0 G L G K N Q G L F
121/41 
ACT GAA ATT GAT GAG ATG GTG AAG GTG GAT
T E I D E M L K L D
181/61 
GCG TTT ATT ggt GAT GAA ATG GGA GAG GAA
A F I G D E I P Q E
241/81 
GGG TTG ggg GGT CCC gig CCC AAT GTT GAA
A F P A P V A N V E
301/101 
GGG GGA AGG gtg GGA TTT AAA GAT TTG GGG
G P T L A F K D F G
361/121 
ATT GGG GGT GAT AAG GGA GTG AGG ATT GTG
I A G D K P V T I L
421/141 
GTG GGT GAT GGT TTG TAG GGT TTA ggg AAT
V A H A F Y G L p N
481/161
AAA ATG AGT GGA GTG GAA GAA AAA GTG TTG
K I S P L Q E K L F
541/181 
GGG ATG GAG GGG GAT TTG GAT Grc TGT GAG
A I D G D F D A G Q
601/201
GAA GTG AAA GTG CCC GTA Grc TTA AAG TGG
E L K V A L G L N S
661/221 
GGG GAG ATT TGG TAG TAG TTT GAA GGT GTT
A Q I G Y Y F E A V
721/241 
GTG GTT GTG TGG GTG GGA AGG GGA AAG TTG
L V V S V P S G N F
781/261 
TGA dG GGT GTG GGG GIG AAA ggt TTT ATT
S L G I, P V K R F I
841/281 
GGT TTG GTG GAG GAG GGT GAG TGG TGA GGG
R F L H D G Q W S P
901/301 
ATG GAG GTG AGT GAG CCC AAG AAG TGG GGG
M D V S Q P N N W P
961/321 
TGG GAA GTG AAA GAG gtg GGT TAT GGA GGG
W Q L K E L G Y A A
1021/341
GGT GAG TTA AAA GAA GTG GGG TAG AGT TGG
R E L K E L G Y T S
1081/361
GTG GGT GAT GAG TTG AAT GGA GGG GAA TAT
L R D Q L N P G E Y
1141/381
AAA TTT AAA GAG AGG GIG GAA GGG ATT GTG
K F K E S V E .A I L
31/11
GAG GAG GTG AGG TTT GGG GAA GGG GTA AGG
E Q V S F A Q A V T
91/31 
TTT GGG GAG GAG GTG GGG GAA TTG AGG GTG
F P H D L P E F S L
151/51 
TTT GTG AGG GGG AGT GGG AAG ATG GTG TGG
F V T R S A K I L S
211/71 
ATG GTG GAA GAG GGG GTG GGG GGG GTC Ttt
I L E E R V R A A F
271/91 
AGG GAT GTG GGT TGT GTG GAA TTG TTG GAG
S D V G G L E L F H
331/111 
GGT GGG TTT ATG rcA GAA ATG GTG AGG GAT
G R F M A Q M L T H
391/131 
AGG GGG AGG tgg GGT GAT AGG GGA GGG GGA
T A T S G D T G A A
451/151 
GTG AAA GIG GTT ATG GTG TAT GGA GGA GGG
V K V V 1 L Y P R G
511/171 
TGT AGA TTG GGG GGG AAT ATG GAA AGT GTT
G T L G G N I E T V
571/191 
GGG GTG GTG AAG GAG GGG TTT GAT GAT GAA
A L V K Q A F D D E
631/211 
GGT AAG TTC ATT AAG ATG AGG ggt TTG GTG
A N S I N I S R L L
691/231 
GGG GAG GTG GGG GAG GAG AGG GGG AAG GAG
A Q L P Q E T R N Q
751/251 
GGG GAT TTG AGG GGG GGT GTG GTG GGG AAG
G D L T A G L L A K
811/271 
GGT GGG AGG AAG GTG AAG GAT AGG GIG GGA
A A T N V N D T V P
871/291 
AAA GGG AGT GAG GGG AGG TTA TGG AAG GGG
K A T Q A T L S N A
931/311 
GGT GTG GAA GAG TTG TTG Grc GGG AAA ATG
R V E E L F R R K I
991/331 
GTG GAT GAT GAA AGG AGG GAA GAG AGA ATG
V D D E T T Q Q T M
1051/351
GAG GGG GAG GGT GGG GTA GGT TAT GGT GTC
E P H A A V A Y R A
1111/371
GGG TTG TTG GTG GGG AGG GGG GAT GGG GGG
G L F L G T A H P A
1171/391
GGT GAA AGG TTG GAT GTG GGA AAA GAG GTG
GET L D L P K E L
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1201/401 1231/411
GCA GAA CGT GGT GAT TTA CGC TTG CTT TGA GAT AAT GTG GGG GGG GAT TTT GGT GGG TTG
A E R A L P L L S H N L P A D F A A L
1261/421
GGT AAA TTG ATG ATG AAT CAT GAG TAA
R K L M M N H Q ★
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Appendix 8,
Positions of Common Restriction Endonuclease Sites on ThrC from E. coli.
Fsp I
1
ATGAAACTCTACAATCTrcAAAGA^TKACAA^^GCA^GGTCAGCmraC^GCAAGCCGTAACCCAGGGGTTGGO^^AAAATCA 8 0 
TACTTTGAGATGTTAGACTTTCT1A^G^T:GT?Trac:TCG^TC^CAG^TCGAAACGCGTTCG^<^.ATTGG^,r'CiC(^(^.A^^iC(^<^^TrTTTAGT
• • • • | • • • •
45
EcoR I
I
(GGGGCTGTTTTTTCCGCACGACCTGCCGGAATTCAGCCTGACTGAAATTGATGAGATGCTGAAGCTGGATTTTGTCACCC 160 
CCCCGAC^AAAAAG(G^GGK^(^'rc(^7^^CGG^Crr^^jA^^^^(^iG7^C^CT37^C^^TAJACTACTCTACGACTTCGACCT^AAAA^C:A^^TGGG
• • | • • • • • •
109
BssH II
I
GCAGTGC^^aATCCTCTCGGCGnTDAWnKXT^JWKAyyTC^C(A^CAG^?yy«C^<T^GaAG^^GCGTCCGICGCGGCGPrT 240 
C^TCAC^CTTCTAG^^J^SCGC^rAACCACTACTTT?A^GGGTGTCCm^AGGA^CCTTCTC^:^^CGC:GCGCCGCAAA
• • • • • * | • •
228
_ Mcr I Dra I
’ I I
GCCTTCCCGGCTCCGGTCGCCAATGTTGAAAGCGATGTCGGTTGTCTGGATTGTTCCACGGGCC.AACGCT<GGC ATTTTAA 320 
CGGAAG^(^(^*G^^C^iACG^CG^TT^T^C^.^<^'rrrC^'rACAGCC.AACAGAC^TTAACAAG^TG^(CC<G^,^T^^G.^^<^^'^^^TT
• | • » • • • • | *
254 316
Mcr I
1
AGAT'raC^GGCGGTCGCTTT^^T^^^C^^^TrcC^T^^^C^CC^^T^AkT^T^C^^^TC^l^^GCCAGTGACCATTCTGACCGCGACCT 400 
TCTAAAGCC^CAG(^iG^^^;^(^(^'Gr^(^TTTACGACTGa^TATAACGCCCACTATTCGGTCACTGGTAAGACTGGC^TCGA
i1 • •••*••
330
CCGGTGATACCGGGCCGGAGTTGGCCArcGCTrTCTACGSTOTACCGAATGTGAAAGTGSTTATCCTCTATCCACGAGGC 480 
GGCCACTATGGCCTCGCCGTCACCGAGTACGAAAGATGCCAAATGGCTTACACTTTCACCAATAGGAGATAGGTGCTCCG
• •••«•••
Bspl407 T
I
GGGGTAAGTAAGATGCGGGGGGAGATGTTCCGTAAGTraGCGGAGGTGTAGGGACCGTTGCAGTCGGAGGAGATCTCGG 560
C,CTCGGCCGGGTGGCGTTACCCTCGACGGGGCGCGC,GG.ACCGAAGTCGCGCATCCX3GCGGCGGCGGCC,GCCGCCGGGGCC
• • • | • • • • •
511
CGCCCGTCAGGCGATGGCGGGGAGGGAGTTTGGCGGTGAGGAACCGGGGGTGGAGACAGGTTAAAATCGGCTAGATCGA 640 
GCGGACAGTGC(GCGAGCACCCCCGTCCGCCGGGCTAGTAGTTCC,TGGCCCCAACCGCGACACCGG.TCC1GAGCAGATTGGGCC
• •••*• • ©
Pvu II
Fsp I JPvu II
I I I
CCGACACAGGCCGTCCGCTGGAGCAGACTCGCCGCTAATTTCGG(GCTGTC^GCGCAGCCGACGCGGGGGGCGCGCAGCCAG 720 
AGCTGTGGTCGGCGGGCGAACGAGCCTGGACGGTGATGGGAATTCGGAGACGCGTAGGCGG CGTCATACGAGAG'TTGGTC
• • • • II* * I *
690 718
694
Pspl406 I
I
ATGGCTGCCTAGGTGACGAGCGGAGACTCAGGAGGCCTGGCGGAGGGTATGATGGAG;AGGTAAATCGGTCCGCCGGTGAA 800 
GGCCGACAGAGCGAGGSTCGGCGTCTGGAGCCGGTGGGATGACGCCCAGGCGACAGGTCAGGTGGGCCAGACGGGGAACC
800
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SsTE ii
I
ACGTTTTATTCCTCCGACCAACGTGAACGATACCGTGCCACGTTTCCTGCACGACGGTCAGTGGTCACCCAAAGCGACTC
TGCAAAATAA^CGACGCTGGTTGCA^C^TTG^T^A^^GG^A^C^CGT^C^TAA^^A^CGTGCTGCCAGTCACCAGTGGGTTTCGCTGAG
• • • • • • j • •
863
SsTX I PsU. I
I I
AG^OAOOTTATCCAACG^SATGGACGTGAGrCAO^^^CAACTGG^CaCGro'R^JAASA^TKGTPCC^C^^AAATC
TCCGCTGCAATAGGTTGCGCTACCTGCACTCAGTCGGCTTGTTGACCGGCGCACACCTTCTCAACAAGGCGGCGTTTTAG
«
893 904
TGGCAACTGAAAGAGCTaGGTTATGCAGCCGTGGATGATGAAACCACGCAACAGACAATGCGTGAGTTAAAAGAACTGGG
ACCGTTGACTTTCTCGACCCAATACGTCGSCACCTACTACTTTrcGIGCGTTGTCTGTTACGCACTCAAT'rTTCTTGACCC
• •••••••
ScI I
I
CTACACTTCGGAG(^(^(G J^AC(G^'TG^(^(Gr^iA(G^'rrATCGTGCG^rrG<^^rT^2^rT^^^T'T^^r CC^G^<^(^JA^^^iATG(^^T'rGTTCC
GATGTGAAG^^TCG^<G'TC(^(^^C^<GG^C^^^(^(^^^^i^^(^.^^(^(^G2^C^C^(CAC^C^^^C^^CA^^Tr^2AG(^,T^<^(G^TTATACCGAACAAGG
• • • • | • • • •
I086
Dra I Xnrn I Psp4006 I
I I I
TCGGCACCGCGCATCCGGCG7CACT^TAAAGAGAGCGT(G3AAGCGAT^CTCGGTG7CACCG^T^GGATCTGCCAAAAGAGCTG
AGCCGTGGCOCGTAaXZCGCCTTAAATTTCTCTCGCACCTTCGCTAAGAGCCACTTTGCAACCTAGACGGTTTTCTCGAC
• |. « •
1144 1159 1176
GCAGAACG'KGCCX3ATTrACCC'Pr<GCTTTCACATAATCTGCCCGCCGATTTTGCTGCGTTGCGTAAATTGATGATGAATCA
CGTCTTGCACGACTAAATGGGACCGAAAGTGTATTAGACGG<GCG<GCTAAACGAC(GCAC(GATf]TrACCTACTACTTAGT
880
960
I040
1120
I200
I280
TCAGTAA 1287
AGTCATT
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Appendix 9.
Accession numbers for vector DNA sequences.
Full sequences for the pET-expression vectors can be obtained via e-mail on the Internet al the following address: 
novalech@novagen.coim. The sequences for pBR322 and pKK223-2 are available from the EMBL database under 
the following accession numbers:
pBR322 VB(00O4a
pKK223-2 M77749
a - also in the following journal: Gene, 1982, 9, 287 - 305.
Full sequences for the cloning vectors pGBM-3Zf(+), pGEM-5Zf(+) and pGEM-T are available from the EMBL 
database under the following accession numbers:
pGEM-3Zf(+)
pGEM-5Zf(+)
pGEM-T
X65304
X55008
X63088
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Appendix 10,
Positions of Common Restriction Endonuclease Sites on the Gene for fi-Methylaspartase.
Hinc II Bspl407 I
ATGAAAATTGTTCACCTACTTTGTACACCA(CATTAACCTGCA^TFCTATTTTGATGACC7AAG3AGCAATr ’CAAAAACCGAGC
TACTTTTAACAACTGCATGAAACATCTGCTCCTAATTGACCTAAGATAAAACTACTGCT^TCTCCTTACTTTTT'CCCTCC
8 0
a
10 22
AGCACATCATCCATTTACATATAC^CCC:TCTACTGTAACACAAGCATTTACTCAAGTAACACAAAAAGGTCAATCAATAT
TCCTGTACTACCTAAATCTATATCACCGAGATCACAATGTCT^CCTrAAATGAGTTCATTCTCTT^TTCCACTTACTTATA
160
Pst I Sea I
CTGTATTATTAGTTCTTCAAWAI,CG,CAGCT]TCCTrcAC(GAGA^TG^GCTGCAGTTCACT?A<TrcJGGACCACCCCGAACA
CACATAATAATCAAGAACTTCTACCAGTCCAACCACTGCCTCTAACACCACGTCAACTCATCACTCCTCCTCCCCCTTCT
a
240
209 218
CATCCATTATTCTTACCTAAACATTTTATACCTGTTATAG7AAAAC/AATAGCTCCAAAATTCATT’GCAACACAAATAAC
CTAG^r^J^^J^r^.AA(^^zA^T^^(^C^zA]^^^r^(^r^IA^JA^rIT^rT(^<^7^C^CA^7^T^l^T^T^l^l^vTTCrTTvTATCG^(^C^GTTTz^^,^j^(^rlT^j^(^^^^"^(^'TC'TT'TATTG
320
Dra I EcoR I
TAACTTTAAACCAATGGCACAACAATTCCACAAAATCACTCTAAATCGTAATAGATTACATACTCCTATCACATATGCTA
ATTGAAATTTCCTTACCCTCTTCTTAACCTCTTTTACTCACATTTACCATTATCTAATCTATCACCATACTCTATACCAT
400
325 3 33
TAACTCAGCCTATACTTCATCC:ACTACCTAAAACTACAAAACTAACTATGGCTCAAGTAATCAGACATCAATACAATCCA
ATTCACTCCCATATGAAC^ACGTCATCGATT'TTCATCTT,TTCATTGATACCCACTTCATTACTCTCTACTTATCTTAGCT
480
Pspl406 I
GCAGGAGA?AATCAATCCAGTTCCTCTATTTGCTCACTCAGCTGATGATACATACCATAACGTTCATAACATGATAATTAA
CCTCCTCTTTACTTACGTCAAGCACATAAACG&GTCAGTCCACTACTATCTA,T3CTAT'T3C7AACTA,T^GTACTATTAATT
560
538
Xmn I
AGAAGCTCATGTTTTACCACATGCTTTAAT,CAACAATGTTCAAGAAAAATTAGGACTTAAACCACAAAAACTTCTTGACT
TCTTCCACTACAAAATGCTCTACCCAA\TTAG^T^GTTACAC'TTC'TTTTTAATCCTCAATTTCCTCTTTTTC;AACAACTCA
* * a a a a | a a
625
Ssp I
640
ACCTTAAATGCTTAACACATACAATAATCAAATTAACACTAACACAAGACTATG<C^CCAATATTCCACATCCACGTATAT
TGCAATTTACCAATTCTCTATCTTATTACTTTAATTCTCATTCTCTCCGGATACGAGCTTATAAGCTCTAGCTCCATATA
720
699
Hinc 11
CGAACAA,TCGGT<C3TCGCATTTCATGTTCACATCAAGGC^TATGGCTGATTACATTCACACTTTAGCTGAAGCTCCTAAGCC
CCTTGTRACCCACGACCTAAACTACAACTCTACTTCCCATACCGACTAATGTAAGTCTCAAATCGACTTCCACGATTCGC
Afl II Afl 11
ATTCCACTTAMGAA^TCAyGCAC(:AA^CCACCTTGAACSATAGACAJAAACAAATGCAAGCTATCACACACTT,AAGACCTG
TAAGCTCAATTCTTAACTTCCTGCTTACCTCCAACTTCTATCTCTTTTTGT ,TTACCTTCGATACTCTCTGAATTCTCCAC
807 870
a a ♦ a I
9 I a
800
745
880
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Acc I
I
TTAATCTGCCTTCTCCTCATCTGCGTCTTAATCAACGACTACTTACCACATTATGTCAACTTCTACAATTTAAGAAGTGA
• | • • • •'• • .
898
Hpa I 
Hinc II
I
GATAACAAAGCTGGACACATGGTTCAGATCAAAACTCCAGACCTTGGTGGAGTTTAACTAATATAGCAGA'KGCrATTATGTA
CTATTGTTTCGACCTGTGTACCAAGTCTAGTTTTCAGGTCTGGAACCACCTCAATTGTTATATCGTCTACGATAATACAT
• • • • • | « • •
1012
1012
CTGTAAA^TAACG<^^rT^<GG(G^CTjATT^,T^(^2^CG^2A^C^CTrc^iA^^<^iAA^( r^TA^(C^(G^TK^(^(^(^^T^JA(^rT^i^^AAC'^JAACJA
GACATTTCGATTGCCTTACCCTCGAATAACACCTCCTTGAACATTGCTTTGATTGTCTAGGCGACTTCAATGTTGATTGT
• ••••«••
Hinc II
I
TAGGTATGGCTTGTGGAGCTAGACAGGTTCTTGCTAAA.CCAGGTATGGGTGTTGACGAAGGAATGATGATCGTTAAGAAC
ATCCATACCGAACACCTCGATCTGTCCAAGAACGATTTGGTCCATACCCACAACTCGCTTCCTTACTACTAGCAATTCTTG
• • • • • I • • «
1171
960
1040
1120
1200
GAAATGAACAGAGTTTTAGCTCTTGTAGGAAGAAGAAAATAA 1242 
CTTTACTTGTCTCAAAATCGAGjaACATCCCPTCTTCTTTTATT
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Appendix 11.
The Sequence Data. Obtained far the ThrC Recombinant Gene in pGEM-TTSrand pGEM-TTSn
1. pGEM-TTSlX SP6:
Sense strand sequence from N-terminus of thrC (first codon underlined in red) to base 568. Primer sequence 
is given in red at start of sequence. Mutations (underlined in the main sequence): 319-321 (deletion of A);
340 (A to G).
GTCAGTCAGT CATATGAAAC
TGGGCAAAAA TCAQGGGCTC
GATTTTGTCA CCCGCAGTGC
GCGCGCGGCG TTTGCCTTCC
CGCTG^LATT TMGATTTCG
TGACCGCGAC CTCC^TGAT
TATCCACGAN GCAAAATCAG
CGOCG^'TTTC NATGCCTGTC
TCTACAATCT GZGA^CA^^KT^C
TTTTTTCCGC ACXCGC<CCTGC
GAANATCCTC TCTCGGCmTT
CGGCTCCGGT C(CG^C^rK^rn’
GCGGTCGCTT TG'QTCGCCCCG
ACCGGAGCGG CAGrGTG3rCTC
TCCACTGCAA GA^AA^(^rCTr
CA^C^fGC^CjAC^ TTCGCCTTTC
OGATTCACG CCrCC'CGCGG
CTTCGITCC^TCC 2GGrCCAGAA
rCAGGCCCGTC ,rcCC;GTTCTA,
ATGCTCACCC ATA,CTTCCCCr
TaCrTTCTAC GCCTrT^AC<CC<
TCTCTACA'TT (C;CCCCCCGG
CCCGGCCCCA ACCC^OGG^'T
^ITTCG[GAGCG, CCTCAACC,TC
GCAAGTZC^TCr AACGCCGCGT
(GCGGTTGTr CGCCCCCCGA
rITCCGTAGGCCA GT^^CC^'TTC
A^]TC^TG7AGCGT G^TTATCCTC
A^TCCVGCCTC TTGCCATCNA
2. pGEM-TTTSx T7:
Anti-sense strand sequence from C-terminus of thrC (stop codon shown in blue) to base 899. Primer 
sequence is given in red at start of sequence.
ATCCCCGTCC TTGCTCATCA NNCAATAATC ATTTACGCAA CCCGCCGNGG TC<C:CCCCCAC CGTTGTCTCG GGCCGGCCCT
GAGTCGCCAC CTTATCACGC CATCTTTTCC AGATJCAACG TTTAGCCCGC .?ACGTCr:CTT:C GCCCTCTC^TT TAGATTTACC
CCCGTCCNCC CTCCCCGCCG AGAAACCAAA TTAGGCTCGT CA(CC:CGJCCCC ACNGTAGCCT ACCCAGCCCT
CCCCCTCCCN GCTCTGCCCA AACTTCTTTA NCTCACGCAI’ TCTCTCTTCA G^TCCITTTACT CG,TACGCCCC TCCGTAGCCC
Appendices
3. pGEM-TTSi x TS3:
Sense strand sequence from base 683 to base 1191. Mutations (underlined): 716 (A to G); 944 (T to C).
AAGCTGTTGC GCAGCTGCCG GCAACCAGCT CGGTGTCTCG GTT3<^CCA^CXC3 GGAACTTTA<r CGATTTGACG
GCGG^TCTGC TCCCCAACTT AC^TCGGCTG CTTGGGGAAC GGTTr^T^rTKC: ^TCA<CTAAC G<TGACAGTA CCTCTC:CAAC
TTTAATCAAA GACG^'T^.AGT CC;<TACCCTA ACCACCTTAG CCAG.CTCTAT CCTACAr'TGT (:CGCTCGGGC CACTAGAACA
ACTCCTACTG TGTCCAAGAC ']TQCT^CA3CC GGAAAATCTTr CCAA.CATCAA <:GAGATCG^C^? A^XGACCTAG CCATCATCAA
ACAAACTAAC ACACAATCTG TGGGGTTAAA. CCACCTCCCA’ ACAAA7TTCCr (C^CTCA^CCCA’ <CTAGACCAT ATTCTGCCCT
^G'BG^^T^.AN GTTCAATTAA GGCACATATCr ^rTTCCTCTA' CAGCACCTCT CATC<ACCTGr .GGiTiT .'AA'AG NACTCTCGAA
CAGATTCTCC C,TCAAACGTT GCCTCTGrCT
4. pGEM-TTSi x TS4:
Anti-sense strand sequence from base 605 to base 25. Mutations (underlined): 340 (T to C); 319-321
(deletion of T).
AGTTCTTCAT
TGTCGTCCAA
CCTAAAACCT
TCAAATATCC
ATAACACAAA
CTCGGA,T^TC
TCACTCACGT
CATCAAACCT
TCTACAGAAC
ANAAACCATC
GTAA<CTA^TTT
TACTTTTAAA
ATTACCAATA
TCAATTCCCC
^^INTGAAACC
AGTGTT’TC'n’
AGccAT■'^c;cc
G^CTCTCAQAr
CATATX:CCA<r
AAC<ACTT<A<
CACAcrGACxr
AAKGTG^T^TTQr
CGAGGCCCAA
TCATCTCr,AT
GrCCACCAeCG
TT<CA<CTC<<
C<GTC^TXACT
CCCAAGAACAr
TAG<CTATCGA
GA,TT’T■TCACT
AATCCCA(CC^
AAATCHAAA
AACGGGAAAN
AATCTCCCTC
GCACCTGA,TT,
AATACTCCTT
TGTCCATAGA
CGACCITAAGA
TCAAACCGT^
CCCAGACTAC
ACAAAATAAA
TTTCACTANC
GATCGCAACA
CCATAACCAT
ATCCTCAATG
CCACCGTCCA
CA<CTTCTTTC
GATTAACTAT
CTTTCCCTTA
GTTTAGATAT
TTTAACATTA
CTTTATTAAC
ACAATTCCAG
AGCA'TTTCTT
CTCATCAATT
CCCCTTGCCT
AAACTTCAAA TGATTGTTCT
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5. pGEM-TTSn x SP6:
Anti-sense strand sequence from C-terminus of thrC (stop codon is shown in blue) to base 786. Primer 
sequence is shown in red. Mutations (underlined in main sequence): 944 (A to G), 785 (A to G, not confirmed 
in other sequencing experiments).
ATGCaGATCC
AAATCAGCAC
AACNTGAAAA
AAAACTACAN
ANCTCTTTCA
CTTQ^ATAAC
NCGCAGC^T
TTACTGATGA
ATTATCACNA
ATAAAGNACT
AGTGTANCCC
ATTGACNAAT
ATACCCTGNA
AAAACGTTTC
TTCATCATCA
ATATTTTACA
ACAAGCCATA
ACTTCTTTTA
TTTAAGAAGC
TCACTTTGGC
ACCGGCAGAC
ArTT^ACGCAA
AGATCCAACG
TTCAAATAGN
ACTCACG^T
AAC^CTCTT
TGACCACTCA
CGCAGCAAAA
TTTATACAAA
TTCAACTGAT
TGTCTGTTGC
ACNCNCAAGC
CCATCATAAA
TACAAGAGAT
TNTAAATTCC
GAGGC^^^
GTGGTTTCAT
C^CTTCTTC
ACTTNCATGC
ANTTTTCTCN
ACG^TCT^TT
ACGATAAGCT
CATC'CAlCGGC
GGCTGACTCA
CACGGTATCG
TNAANAGAAT
TAAATTTCGC
NAAAANACAT
TGCATAACCC
ACTACNTAAA
TTANCATTAC
6. pGEM-TTShx T7:
Sense strand sequence from N-terminus of thrC (first codon is underlined in red) to base 348. Primer 
sequence is shown in red. Mutation (underlined in main sequence): 319-321 (deletion of A).
GTCNATATAT CATATGAAAC rT^TJ^(CArT^^r GAAAGATCAC /TTCCTGATA3 T^^^TTTGC GCAAGCCGTA ACCCACCCGT
TGGGCAAAAA TCAGGGGCTG 'TriTlTCOGC ACGACCrT3CC GG;AATTTANC C'TG^^f^TG.AAA TTCTTATCTT ACTGATAATG
CATTTTCTCA AACAANCTGA GAACGATCCrT'' 'TC<GCAGTT^A ^ITTAATA^TTG. AATCCCACAG ATTATCCTGA ATCTAACCGT
AAACCCGAAA TTTGCATTAC C(AACTCC<CAT C(AA<ANTrArT^ <GTNTGCCTT TCCG^TTGTA^ GGNTCTGTIA AAAAACCCAA
CAATACAATT TMGNTTTAA <GAGCTAA:AT TA'TAGATANC
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7. pGEM-TTSn x TS3:
Sense strand sequence from base 671 on thrC to base 1220 . Mutation (underlined): 944 (C to T). Note a 
mutation at 785 was not found in this sequencing experiment {cf. pGEM-TTSn x SP6).
GCTGCTGCTT
CGCGATTTGA
TGCCGTCCCG
CTCAGCCGGA
GTGGGTGGTC
TTATAGTGCG
GNGGCGTGGG
TGGGGCTGTT
CGCCCCGTCT
CGTTTCCTGC
CAGCTGGCCG
AGACCGCGAG
CTGCGTGATC
GGC(GCTTCTC
GCNCGGCTGC
GCTCGCGGAG
GCCACCCTCG
CGTGTCGGGG
GCGGGCGATG
GGTTGAGTCC
CGTGAAACGT
CGCANGAGAC
TCACTCCGTC
GTCGTAACCC
AGTCGT^CG
CGTGGGTTGA
GGGACAATGT
TGCATCTCCC
GCGCGACCGG
TGCCCGTGAA
AAAGCGACTC
CCGCAGGATC
GAGGACTGGG
GGCTTGTTCC
GGGAGANCTC
CTOGTTGTCT
AC<CiTTTATT
ACGCGACGTT
TGGCGACTCA
CTGCGCTTCG
TCCGCGCCGC
GCGNGGCGTG
CGGTCCCAGG
GCTGCGGCCG
ATCCAACCAG
AGGAGCTGGG
GGGCCGCGCG
NCGTACGGOG
CTCmTACC
CGG^CTTC
ACGTGAACGA
GTGGGCGTCG
TTGTGAGGCC
CTCCCGTANC
GAGTTTAGAG
8. pCEM-TTSo it TS4:
Anti-sense strand sequence from base 611 on thrC to base 252. Mutation (underlined): 319-321 (deletion of
T).
ACT'rTCAGT'T
CGATATTGCC
GAGTTCGGTG
ATCACCCGCA
C^IAATCATA
GCCCAGTGTG
GGCCGTGGGA
GTATGGGTCA
7AGcccrc^rTr
CAGCG.GAGCT’
AtGC^ATG^^
GGArTTTCTCC
TTTACCAGCK
TTTTATTCCAG
7A’.ATG’c.c^CiT'c
CATJAAGGCGC
GCCTGGCGGG
TGGACTGATT
CGCrA'I'CACC
CCGCCGAAAT
CA,TCGCGGCTC
TTGCCTCGTC
(GGAGCCTCCGCC
C:EGGGTG<CC
GCCACrTCGArTC
(G^^TWG^^TT
GrTC^CGA^'TQC
ACGCGTTGGCC
GCAACAGTTT
AACAACT^
TCACTCGATT
CGTGGAACAG
TTCCGGGCAG CCGGCGTAGC rTTTCCGCCAGT CGCGACCGGG
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Appendix 12.
The Sequence Data Obtained for the ThrC Recombinant Gene in pTN-TS Constructs./
The results for pTN-TS3, pTN-TS5 and pTN-TS6> should be compared with those for pGEMd-TT'Sp all others
should be compared with those for pGEM-TTSn.
1. pTN-TSl x TS3:
Sense strand from base 712 on thrC to base 1287. Mutation (underlined): 944 (C to T).
AGCAACCAGA
GCCCCTCAAA
AACTGACTCA
TCAAAAATAT
ACAACTCCGT
CTTTCTTCAT
AAACACTTCC
GATCAATTAT
TCCTTCTTTA
CGTTTTATTC
NCTGACGTTA
CCTAACTCAA
TACAATTACG
CCCAACCCTC
AAGAACCTGT
CAGTNA
CCTGTCAAGT
CTCTGACAAA
TTCAATCTCA
ACACATCGCT
AGACCTACCT
CATCCCCACA
TCATTAAAAT
CCAAATTTTG
CCTCAACCAT
TCCAAGTGAG
TATCAAGCCG
TCTCCTAGAT
AATTTAAAGA
TCTTTTCACA
GACATTTCAT
ACCGTCTCAC
TAACTTCAAA
TCCATCATCA
TATTGTCTCT
GACACTCCAA
TAATATCACC
CGACC^TCTC
GTTTTCTCTA
AACTCGTCCT
AACAACCAAA
TGO^^l^TCA
CCGATTCTTG
GACGATTTTG
CTCGTGAACT
CGAACCTCAG
CTCTCCAAGA
TAGACAATCT
GTTGAATCCA
GTCAAAAGTT
CTCACTTCAA
AACTACCTTT
TCGTAACACA
GTCCTTAACA
GTGAGTTAAA
CGCGAATATC
CCATCTCTCA
GTAAATTGAT
2. pTN-TSl x TS4:
Anti-sense strand sequence from base 588 of thrC to base 28. Mutation (underlined): 319-321 (deletion of 
T).
CTCTCCTTCA CAACCCCCTC A(A^CACC^TXX5 rW\TCCC:CG^ CGATGCTAAC AGrT^rc(C\TA ^TTGAC(CAC<Ar. ATGTATACAA
CAGCTTTIAT TGAAGTCGAC TGArnTTKTCC TCG^TCCrTAG ACCATAACCA CTTTCACATTT C<CCTTAArCCT< TAGAAAGCAT
CAGACACTCT CGATTCCCTA TCACCGGC<^G T<CCACGIXTAG AATCCTAACT CCCAT?A^TAC CC<CTAA?ATC <CCrTTAGTATT
TCTCAAATAA AGTCAACCTC G.AAATCTITTA A^G'C'AGCGT TCCACCCTCG 2A^CAAr^]7^C(Ar GAC?AACC(G\C ATAGATTTAA
AAATTCCTGA CCCGAGTCCG G7C\aCCTAAr GCCCCA<CGCA. ACTGCTAT^C CT^CCG^A^TKCA 'KC]TTCCCATT? TATTATCAAT
AAACCCCCAG ACCATTTTCC CACTWaGGr AGCTTCAGrA rTCTCArKCA\T T^AAG^.TCA<CC CTCAATTACG
CAACCTCGTC ACCAAAAAAC ACAZCCCTCAT rTT^CTCAAA CACATCCCTT AC<CG2TTCAC CCAAr<CT]TCAC ATCATCGTT
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3. pTN-TSl x T7:
Failed to produce a readable sequence.
4. pTN-TSl x T7T:
Anti-sense strand sequence from base 1284 of thrC to base 770. Mutation (underlined): 944 (A to G).
CTCATGC^TC ATCATCAATT TGCGCAGCGC GGCGAAATCG GCGGG^.AGAT TATGTGGGAG CAGGGGTAGG TCAGCACGTl
CTCCCAGCTC TTTTGGAAGG TCCAACG'TTT CGCCGAGGGT CGCTTCCACG CTCTCTTTGG ATTrAGACGG ATGACC2CCTTC
CCGGGGGACG GGCCGTGTTC GCCTGGATTC AACTCATCGC GCAGCGCACG GTAGGCTACG GCACCGlCGAG GCTCCGAAGT
GTGGCCAGGT TC^llTTAACT CACGCCTTCT CTGTTGCGT3 G^^TCATCAT CAACGGATGC GTAGCCCGGC IX'-ITTCA/CTT
GCCA^'TlTl' GCGGCGGAAC GGCTCT,TCGC GCGCGGCCGG TTGTTCCGCT GACTCACGTC CATCGCG'^lG GATGACGTAC
CCTCAGTCGC TTTGGGTGAC CACTCACCGT CGTCAGCGGG GCGTGGAGCG GTATCGTlCA CGTTGGTCCC AGCAATAGAA
CGT^lCACCG GCAGGCCGGG TGACTTAGNC AGCA
5. pTN-TS2 x TS3:
Sense strand from base 717 on thrC to base 1110. Mutation (underlined): 944 (T to C).
CGCGCCGGCT GGTTGTCTCG GTOGCCWAGC G^TAA^C^rTTC(GC CGATTTCACG GCCCGGVClGc IGGCGAAGTA ACTCCGTCTG3
CCGGlGAAAC GTTTTATTGC TCTCCCC<AAGC G^TGGCCGATA CC<GTGCCA<AC TTTTCCTGrAC GACCGTCAGT GCTAGACCCGG.
AGCGGCTTAG GCG.CCCTTAT CCAAC(CC(CCT (GG^C(^^TG<CT CA«CAGG«CC ACTGCCOGAC TGT^C^^G TGTTACOCCC
CCAAGATCTG GCAGCTGGGG GAGCATGCCG ATGCACACGr CG.G^rTG^^lG^ ACCACGCAAC ^GACA^T^^ (CGAGrTCAGGA
GCACTTNGGG GCCrACACACG (GGTGGAGGCT ATCGN(GC<GCT (G2G^TGGNCAG TTGGGTACGG CAGGGlTAT
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6. pTN-TS2 x TS4:
Anti-sense strand sequence from base 637 of thrC to base 30. Mutation (underlined): 319-321 (deletion of
T).
TTTAAACCTA AAACGTCITIT ANC'TTATTAT TAATAAAACA
ANTAAAANCN ATTTCAATNT TAACAAACTA TATNCNAAAC
GCTTTAACAC TTTATCTTTA ACTTTNCCAT AAATAAANTG
ATACTCNATC ACTTNTANCA CAAANTNTAC ATCAACAT^T^
ACCCACTGAA AAATTTCATA TCNTAAAAAN TCACTTTATA
AAGATCTTAA NACATTTCCT ATGAGNTTTA NTANAATNTN
AATTANAATT CTATTCNTTT TANGTANACA TAAATTAAAC
CCTQCCTTTA AGATTGAACT TAAATACCTA ATAA
7. pTN-TS2x T7:
Failed to produce a readable sequence.
8. pTN-TS2 x T7T:
Anti-sense strand sequence from base 1283 of thrC
TAATGTTTAN TANTAAT^TTT ACCACNTC<CCT GCA7GAANTN
TAAAAACTCT TTTCCAAAAT <ACTTAATrc ACCGNCNA^A
CCTAATTCNC CNGAGACTGT CNCAAATCAT AATAGACATC
NAITTTTTCTT ACTCTCATCT GNTTTTAAAT CATACATAAA
AAAAACTGCC AATAAACTNT CNAAACAAAT CCAAGTCNCA
ATAACNTTTN AAAAACCAAC NTATC2^TNN TGACNAAATT
CNTTGGAATC AACTAACGAC NAGAATAAAG CAGAAACCAC
ANCAACGNAT GAATCTTAAA NCTGCAACTA NCTAAATAAN
CNAATCATGA CATNTTTTCA AACAATATTT TTCACCANAA
to base 1044. Mutation (underlined): 1051 (C to T).
CCCCCAAATA TTGTNTGTAN TAGGGTAAAT CGTNNTTATrc
(A:A^rc(ATCCA TCTATTTNTT ^rTACAAC(GN TACCAACTCC
ACTGGNTATN AAANTTTTAC CCrTA3ATTTiA ACTGAATANG CAAATAACAA ATAGCTAC(TT CAGCGTGATC GTGAAACTTA
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9. pTN-TS3 x TS3:
Sense strand sequence from base 686 on thrC to base 1045. Mutations (underlined): 716 (A to G); 944 (T
to C).
CTG^TTCAGAA
CGTTTCATCC
CATCTAAGAA
CCCCGCCTCT
AACTAACACA
CTTCACCTAT
CGAAGTCACT
CCTCACTCGT
CCAA^tAGT£C
AAATCTGTCA
GA<A<AACTCC
CCACCTAX2<A
CACCCATACAr
'^rc(AT:cGTCA
GKAAAAGAA
ACCAGCTGGT
CGGCAACGG^
GGCATAGCCG
AAAACAGGCC
CTQCGCTACC
TCTTTCCGTC
TIAT-reCTOC
ACGTrATCC
ACTCAAAGAG
CCCAA:CTCCA
GAC<AACG^IG
ACAGTCArKGG
CTCCC^7AT3
A(ATRCCCACr
/ArCAATACCT<
CGTCCGCTAG
CAC<:CGTC<Gr.
TTTCACCCTC
TCTCACCT^T
CAGAACAACT
TCATCAAACA
10. p'P^^-'IT^3x TS4:
Anti-sense strand sequence from base 589 of thrC to base 80. Mutations (underlined): 319-321 (deletion of 
T); 340 (T to C)
AAGTCTCTTT
AACAG'T'T’TTT
ATCAGTTAAT
TTTCTCCCAC
CAAAATTGGC
ATAAAACACG
CACCACTCTA
CTTCTACTCC
CTCGCTCCCC
AAACTGAACG
CACCCCACTC
AGACGATCrTT
TGACACACCC^
ACKTGnTTTT
TA'ATTCCGGC
CCGJCATCTA
GCGGC^GAG^<Ar
CCACCCrATCCTC
CCCAA^[TACAC
CCTCGTGAT
rGCTTCTCGTC
AAArTCA2AGC
AC<CTCCACCC
GCTCCTAAAk^T
GTACATCCAA
ACACGATAAC
ACAATCGTTA
GTTCCTCCGT
CACGCGCTCT
AAACTTTAAG
ACAGmTCCG
CACrTTGACA
CTXGC?ATTX^TC
(CGACAATT-
^rccCACCAT[T
CATCCTA^XAr
TATTTG2CCGXC
TTITAGC?^AAAT
AC<TCGAATA
CA(Cr(AA\CCA
CC^KGKCCGT
A,^^^<AArTTr
CAATCTACAG
CGTANAAACT
TCCGTCACAA
ACATCG^TTT
TTCATNACCA
CGCTCAATTA
TCCAACGTTG TCACGAAAAA ACACACCCTC
A pp en die es
11. pTN-TS3x T7:
Sense strand sequence from N-terminus of thrC {Nde I site shown in red, start codon underlined) to base 443. 
Mutations (underlined in the main sequence): 319-321 (deletion of A); 340 (A to G).
CNTTTGANTA TATNAANTAT GAAAGA^AACCNTAAGCAGC TCTAATTTGA GCTAAGCCGTA AAAAAGAGAT TAAAAATTNT
TANAAAGATA TTTTTTA?AAA ACTAGTAATGA GCCNTTTJACA CTANATATAT TTGATCAGAT GCTGAAGCTG AATTTTGTAAA
CCGCAGTGCG ANCTTCATAT COAACGTAT 11001 0^^ ATACCNCNGG ^^TNCTGSZr NCTCCACCTC CACAAAGAGTT
TAACTTAAAA AATCCAATCA C<AAT^TTCTTC ^<0(0^01:: GATTGTATCC ANT^G'TTC(AT CCAAACAACC A'TGAANTTTM
CTTTTAGCAC AT^?G^'^TTGT G<A?ACAAATN <ATCATAAATA TTACCCATGN TAAGCCAGTG ACANTTATGN CCCACAACTAA
ACTGTTNCAA ATCCGCONAL' GiCGATATTcL• 'J^rT^-T^i^^i.G^CT^’' TA
12. pTN-TS3x T7T:
Anti-sense strand sequence from C-terminus of thrC {BamH I site shown in red, gene stop codon in blue) to base 
813. Mutation (underlined in the main sequence): 944 (A to G).
GGTTAATTNC
CAGCACGTTC
TAAGCACTAA
ATCCCANCTA
CTTTANATTA
GATAACG'ICG
TGNTATTTCA
TAACTACTAT
AANGATAATA
TNAACANC,TT
AATCT,^^iTG
CCTGAGTCGC
TTATTAATTT
GGAANTTTTA
CATTTTT^<AT:
CACAAGGATA
1'T'TGG^j.IGAC
NAGATAAGAA
CANTCCTTTA
ACTGCTTTCA
NCAAATTGTA
CACTGACCGT
GCA.NTNTAAC
AC(CCAGCTTrA
ACTAATATAC
TG^TTGAGTAG
ACGAGCAGTG
CGTGCAGGAA
CCGGCAAATT
(ACTT'CACCA
CATGACATAG
^ITTTATCATT
ttt3ttt^^^^:^c:c’
AGG CIGAA■NAc
A^TGTGNTTC:
^T2^T:ATT^ZATT
TrAGC-rACCAC
(CACGGCKGCA
GATACACGrIT
NAAAATTANT
TTTAGACCAA
CNGACTGAAC
TNTCACNAAT
CNTAAAATTA
CGTTGGTCGC
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13. pTN-TS4x TS3:
Sense strand sequence from base 687 on thrC to base 1239. Mutation (underlined): 944 (T to C).
TGTNGCGCAG
GTCTGCTGGC
CTICACIACI
GCCGCITGTG
CGCAACAGAC
GATCAGTTGA
TCTCGGTGAA
CTGCCGCAGG
GAAGTCACTC
ITCAITGITC
iaagaitagt
AATGCITGAI
ATCCAIICIA
ACITTGIATC
AIACGCICAA
IITCTGCCII
ACCCAAAICI
TCCICCICAA
TTAAAAIAAC
ATATGGCTTI
TINCAAAAIA
CCAICTGITT
TIAAACITTT
ACTCAIICIA
AATCTCGCAA
TIIICTACAC
TTCCTCIGCA
ICTIGCAIAA
ITCTCIITGC
TATTICTGCI
CITTATCCAA
CTIAAAIAIC
TTCIIAICCI
CCICICATCC
CITGCTGATT
CAAICIIAAA
ACCAACITIA
CICIATGIAC
TGGGTTATCC
GACICTICCI
IICIAAATTT
TACCCTNICT
CTTCGICIAT
ACIATACCIT
ITGAITCAIC
AGCCITIIAT
TAICTTATCI
AAAIAIAICG
TTCACATAAT
TTIACIICII
GCCACITTTC
CIAACAACTI
IATIAAACCA
TICICTICIT
TIIAAICIAT
CTG
14. pTN-TS4 x TS4:
Anti-sense strand sequence from base 657 of thrC to base 85. Mutation (underlined): 319-321 (deletion of
T).
ICCTGCTTCA CCAICGCCTI ACAIICATCI AAATCICCIT CIATIICAAC AITTTCGATA TT3CCICCCA ATGTACAIAA
CAITTTTTCT TICAITGIAC TIATTTTGCC TCGTGIATAI AIIATAACCA CTTTCACATT CIITAAACCI TAIAAAICAT
IAICCACTGC CICTCCIITA TNACCKIAII TCICIITCAI AATIITCACT GGCTTATT4AC CCICAATATG IITCAICATT
TGTICCATAA AGCIACCICC IAAATC2TAA ATICCAICGT TGICCCGTGI AACAATTNCA IACAACCIAC ATCICTTTCA
ACATTGICIA CCIIAICCII IAAIICAAAC ICCGNICICA CGCGCTCTTT CAIIANTTCC TINIGIAATT CATCACCAAT
AAACGCCIAI AGGATCTTCI CACTGCIIIT GACAAAATNC AICTTCAICA TCTCATCAAT TTCAITCAII CTIAATTCCI
ICAGITCITI CGIAAAAAAC AI
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15. pTN-TS4x T7:
Sense strand sequence from bases 70 to 408 on thrC . Mutations (underlined); 88 (T to G); 106 (C to T); 
282-284 (deletion of T); 395-396 (CG to TN). The sequence above (pTN-TS4 x TS4) does not confirm any 
of these alterations, and shows a mutation at 319-321 not found in this sequencing experiment.
GGCAAAAATC ANGGGCTGGT TTTTCCGCAC GACCTGTOr AATTCAGCCT GACTGAAAtTTT QATGAGATGC TGAAGCTGGA
TITIGTCACC CGATGTCAGA ACATCCTCTC GGCGTTTATT GCCGAATAAA TarACAGGA AATNCTCGAA GTCACAGTCA
CAGACAAGTT TACATTCACG CATAACATAA CCAATJT3;^TIA ATTGCATGGC C<GyTATC1CC TT'TTCM'^ICCT CCGGACTTAG
CTCGATTTTT TCTTTTANCA CATCGCTTTT TCTGAATATTT GCA3ATAAAT ATT3C^CGCTC ATAAGCCAINT GTCCTTTATG
TAAGTNTACT NCCATGTT
16. pTN-T44x T^T:
Anti-sense strand sequence from base 1283 on thrC to base 786. Mutation (underlined in the main sequence): 
944 (A to G).
TGTTCTTTCT
TCAATGATCT
CATGGTTATT
TTGAACTGTT
AATGTNTTTC
ACTATATCCA
TCA'TCAATTT
TTTCGATGTT
CAATTTTTCG
CTTITAACTN
ACGACGTTCg
TTTACATCTC
ACCGATTAGA
CCATTCGG^TN
CCrraGGArTMA
AC(AAT^lTrcNC
ACTCTTCraC
CACTCACCGT
(ACTTTT]TAGG
A<AAGTATTlr^
AC^XCTrlTNTCG
,KA^TCTC'rcC5
A<ACACCNT.G
CG^TGTTJGCT
GAA^rcCACCA
(ATGACCTAAl
OTTCAATATC
,]TTA^TAA3CA,
ACCCTAGATAC
ATCTCAAAGC
TCTCTTrAAA
TAAGCTACAG
ATAGCATCCT
GACTNACGTN
GNATCG'TTCA
7TTGCC^/TTT
^mTCAACGA
CATGACrcCAA5
TTTT^A^CCTCA?
CC^rITTG^rlT^CG?
NAGCACGTTC
TAACAGATCA
ATNCGAAGTC
A,TT^NTGTTC
GATAACGTCG
AGCAATAAAA
AGTTINTAAA CATGTCCATA TCACC7TCG
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17. pTN-TS5 x TS3:
Sense strand from base 680 on thrC to base 1182. Mutation (underlined): 944 (T to C).
CTITTICICA
GITCTICTII
CCTICACIAC
IICCGCITIT
ACICAACAIA
TCA^TCCGGTTC
TLCNNSGLTA
ICTGCCICAI
CIAAITCACT
IITCAITGIT
CICCICLTCI
CAATICITIA
AATCCAIICI
CCCLTTCGAC
GALACICLCA
CGGNITICCI
CACCCAAALC
TTCCLCCLCA
ITTCCCACCC
AATATLICTT
TTT
ACCAGLTGIL
GLTIAACGLT
GLCTCLCLGC
ACCATGGCCG
CGGLLIGTCG
GCTGCGGGLC
IGTCTCGGIT
ITAT'IGCTGC
ICGTTATCCA
ICTGAAACAG
ITTCGGAGGG
FCCGCGCCGG
CCAAGCGGAA
TLAGGGCCGG
AC<TCGA^CGLC
CTACCCCATC
CLACGGLGCC
CGGCGCAAGC
ACTCCGGCGA
AACGACAGCG
CG1CCGTCAG
CAOCCGTCGA
GTGGCCTACG
CCAAGTGCGC
ICGCACGGCG
TGCCACGACC
CCCALCCCCCT
TGATGAAACC
TCGGFCTIGL
GTCGAAGCGA
18. pTN-TS5 x TS4:
Anti-sense strand sequence from base 609 of thrC to base 100 . Mutation (underlined): 319-321 (deletion of
T).
TTICCGTTCT TGATGCTCAC ACCAIGCA,’IA, GACCGACCGA TGCCAGICCT CC^7CA^rT^CG^C G'GALCTLCGC ACALTTTGGC
TAT7II?(CCGCC CACTGTACAL AACTJLTi’IT'T CCTT^G^T^ AGTLC'IG'T,IG CCTTCGTLGCT AdACGATTCCC CAATTTCACA
TTCILTCCCC GLTALCCCLG ATAT^GACC^CC? TGCGCCTGGG TCTCACCLLC CLGTCCCZCCGT ACLCCTLTTA CTQCGTTATG
ACGGLGCATA 'TCGCTACLGA TTy^TCT^C^CVTP TCCACCIC^C^G NGGCCATANT AACCTACAGC GTTCCCCCGT CCCCCCCTTC
CCICCACCGI CCCTGLGTTT CAC^CA^CA^^ GGCCCICCIC CICCACIGAC ACGACCCGNIC H^jAC^G^G^'TC TTCCACICTT
TCGTCNCGCC TTGGATGACC AiAC^CTC^C^CCL: CCkC^ZVCLL^C^CT TGCGACTCGI (LGTGACCCCCC TNCAGATTSN LGATCTCAT,N
cAGTGAAIGC AICCTGCATT GGccGAcGTG
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19. pTN-TS5 x T7:
Sense strand sequence from N-terminus of thrC {Nde I site shown in red, start codon underlined) to base 440.
Mutations (underlined in the main sequence): 278 (T to A); 319-321 (deletion of A).
CATATGAAAC TCTACAATCT GAAAGATCAC CAAGGAGCACG TCAGCTTTGC (GCAAGCCGTA ACCCAGGGGT TGGGCAAAAA
TCAGGGGCTG N'lTiTlCCCC ACGAGC^CXA GGACCrTGACA CTGACTGAAA ^ATACAAACAAC^ ACTAAAGCTA GATnTG:^TNA
CCCGCAAAAC GAAGAT^JCTC rKACAA3ANTA TITAAXACIAG\ AATCCCACAG GAAATCC^AGA AANAGCACAT GCGCACGACA
ATAACCTTCC CAACTCCGAT CCCGCTCTIG AGAAACACA;AC CAGATATCTG GTA^’TT^'TT^C ACAAGCCAAC GCTG^CATTT
AAGTNNNCNG CGGNCGCTTT ATATGGCACAA TGCTCACCCCA TATTGCGGGT GATAAGCCAG tgaccattct gaccgcnacc
IVAAjLjlVaH'lH. C/ikjIUjV 1VH IVaVX’l'XVlMU
20. pTN-TS5x T7T:
Anti-sense strand sequence from base 1283 on thrC to base 1134. No mutations noted.
AAATAATACA TCATCAAATA ACGCAACGCA ACAAAAACGA CGGACAAATA ATATGAAAGC AAAGATAAAT NAACACATAC
AGNCAACACT ATTAACAAAN NCAACGTTTN ACCAAAAATN ATTANCACGC TNTNTTTAAA ATTCGCCGAA
21. pTN-TS6x TS3:
Sense strand sequence from base 716 on thrC to base 1056. Mutation (underlined): 944 (T to C)
AACCAACAAA
GATGAAACAT
CAACTCAGAC
AAAAACAAAC
TTAACTCAAT
TTAATTACTA
AACATAATCC
AACTAAAAGA
GACAA.AGGAG
CCG^C^CA^C^C^
AACGAGACGG
GG^A^AAATAT
GcCCTAC(AACG
GAACGATACC
GCGTGAGTCA
GCAGCCG^AAA
AATTGACAGC
ATACCACATA
GCCGAACAAC
ATGATAAAAC
GAAGATGATC
TCCTAAACCA
TAAACGAGAG
CACCAAACAA
GCGAAGTCAC
CAGTCAGTAG
AGAAAAAAT£
ACAATACATA
TCGGTC'TGCC
TCACCCAAAG
ATACCACCGC
AGTTAAAAGA
ACAAGACTAC ACTTCAGAGC CG.
Appendices
22. pTN-TSl> x TS4:
Anti-sense strand from base 583 to base 103. Mutation (underlined): 321-319 (deletion of T).
CATTCTCCTG ACACTCTCTG GCTTAGTTTT <ACAA^^K:<G^^T <GGCTTAGCT TCGATATTGC CGCCCAATGT TATATTCTGT
TTTTATTCAT TTTAACTCGT (GC^TQTA^CCAt T7TTTAACATT CA(AT^rcCCCT AAACCGTAA TTCATTGTGC
ATCTCAAGAT CCGATTTATA AGGTCGTCGC GrrcATTCACA TArTCTCCC(CA AATA,TCACTC TCTTTTTATC
AATTTTTGCA TAAGAAATTT TC;EETT.^GT CAGC'G^T!TGGC' CATr!rCGTT?A ATTCGAGACA ACCGACATC CTTTATTATT
TCGCATCAGA TCAAGGGTTG CATTTCCACG CGC^ACGGC?, CATATYCTTAJ ATTR^CTCrC (GGATTrCATC TAATTTTTTC
CACATGTCGT TTTTAGATAT CACGATGTCT 2TTTTAATAT TTCTCCT^XTC ATTTT^TR.A GTATGGCTCA TTTAACCTTA
23. pTN-TS6x T7:
Sense strand sequence from N-terminus of thrC {Nde I site shown in red, start codon underlined) to base 460
Mutations (underlined in the main sequence): 319-321 (deletion of A); 340 (A to G).
ATTTTCTTTA TCTTCTTTAT GAAAGATNAC ATTAGTGATA TCATCA^TTA G<:ATTCC:AA,A ACCCANGGGT TGCGATTTTT
TNTNGGGATC NTTTTTCACA ACGANCTGCC GCCTTTTATK? CAGCTAGCTT ,^rcATTATAT GCTGAAAATC CTTTTTCTCT
AAAGATATCA CTTGTTAATC TCGGCGTTTA TrrcCGXATTA AATCACACAT GCTTTTCAGG AAGAGCGCGT GCGCACCGAA
TSTCXCTTCC CGGATCAGGT CTCCAATGA^ GCTTTCACTT; TCCGCI^TCTT GCCT^TTT^CTTA CTCGCGAATT CCATCCATTT
TAA(TN^TAG CACGNAGATT TGAGGCAC'AA A,]TA'TCGTCC ATAT]TCAGG; ^TGATAATCAA GTCTCATT^C TCTCACAGTC
V X X IV kjdN X X/H-VAxrtM XbXbnfinb X^ V
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24. pTN-TTS x T7T:
Anti-sense strand sequence from C-terminus of thrC {BamH I site shown in red, gene stop codon in blue) to
base 770. Mutation (underlined); 944 (A to G).
CLCTGCTTAG TCCTCCT^A TCACATAACT ACCCGCCGIA LCACAATCII CdCCCAGATT A'TLTyCCCGC CACCITCCAT
CALGCGGTTC TCCGCLGTCT TTTTTICAGAT GGCAACGITGA ACCCAIGCATA GCTTCCACGC 1GC,TATTGA2CC TGAGLGGCIA
TCGGGLIGGC CICLGAACAC GC<ATAGAGT CCCGLLCIGTA ACTIATAAGG CGCGCACGA TAAGCTACGG AACGLGCGLI
CACGGAALTL TAGCCCAITT C,IGGTGGJCrAG ACdACTTCT GITG,LGGGLL 'TTTCATCATC C.A<^CII^rT^<CA TCACCGAIGT
CTTTCALTTC CCAICTTTGC C<GIIGGIAAS ACTT'CTCCAC AAGAGGNCAG TTGTTCGICT GACTCACGTC CATGGGLGGC
CATCAGLTGI GCTCCCTCCG TTTTTGGIAI CC^CCT^G^CCC^TT CITGCA^CLAC ACGTCCGC^CCG GTATCGTTCA CCGTCcTGGG
CICCATCACC CLTTTCACGL <2GCAICGAG GTACCTTCI'C ACCA
25. pTN-TS7 x TS3:
Sense strand sequence from base 712 on thrC to base 1287 (gene stop codon shown in blue). Mutation
(underlined): 944 (T to C)
CLCAACCALG TCLTGITCTG GGG^C^CCL G(ACACGTTA ICGATTTGAC 1CIACGCrAC^TC CTCQGCGAACCT CACTCCITCT
LGCCLTCAAA GCTTTTATT3 CTAGLAICAG CGr[GIACGIC ACCCCTGCCAC GTTTCCTGCA CGACCCLTAG TCLTAACCGA
AALCLACTCA CIGIACCTTA TCCAACGCCG ATIACGCTCcG TCAGCCGAAC AACTGGCCGC GTCTILAACA (^TVC^TGC^C^
GLGCAAAGGT GGCGGCTGGG ACAd^CGGTTA^[TGACIGA ITCGCTGATGA AACCACGCAA CAAICCAATIC ITICITTAAA
AGAAGTGCIG TGAGATTCGG ACAI^^^^C^C^C'C^': GACCATTCGA IATCGTGCGC TGCGTGATCA GTTGAATCCA CGCIAATATC
IGTTGNGCCT CCLGAGCICI CATCGCGGLA CACTTAAACI IAGCGTGGAA GCGATTCTCG GTGAAACGTT GCATCT3CA
AGGGGGATGG GAIACCITCG TGACATATCC GTTCATTTAC ATAATCTCCC GCCGACNTTTC CTKCLTTICG TAAATTIATI
ATCAATGCTC ALTAC
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26. pTN-TS7 x TS4:
Anti-sense strand from base 602 to base 169. Mutation (underlined): 321-319 (deletion of A).
ACAA’CAACAA
ACCCAAAATA
AACCATAAAA
ATAAAGAACA
CCAACATNAC
AATATCAAA'A
CAAACACCAA
CAAAACAAAT
AGCAAAAACC
ACAAATATAC
TATNAACATA
CCAATAAACG
CATCACCAAC
A’TTCTTACAA
ACTACCGCTC
CATAAAGCAA
AACGACCGAA
CCAAAAGAAT
ACCAAACAAA
A,GAACAAAAT
CAATATNACC
CCACCAAAAT
ACCAGAAAAA
CTT
CATCGAAATC
ATACCTCAAA
GAAAAACGCA
NTTAAATGCC
CAAACGCCAC
ACCAACAAAA
AATAAAGAAT
AACAAAATAA
AGCGTTAACC
ACGCACACGC
ACAACAAAAT
AACCACTTTC
TCACAAACTA
CAAAAAACAA
TCTnCAGGA
CAATAATACC
ACAATCAATA
ATNACCCGCA
TTCCAGACAA
ATTCCAAAAG
27. pTrCTST x T7:
Sense strand sequence from N-terminus of thrC (Nde I site shown in red, start codon underlined) to base 273.
CATATGAAAC TCTACANTCT
TCAGAGGCTA AAAA'i,ACCAC
CCCACAANAC AAAAAACCAC
NTAACCTTCC CGACTCCAAT
GAAA.GA^A7AC AACCAGCA<A3
ACGACCTCCC (AAACATCGKC
TCACGZ('dAA^/A CATAGTACCTA
C(C:CCCAAAA^ GAGGGCGArCG
ACAACATTAC <ACGCCACCTA
CTAACTAAAA
G^ATCCCACAG g ,AAGC’CCr^AG;
TCCGNT
ACCaC GAGGCAAAAA
CA,'rTAACGC'IG GATTTTATCA
GACNCAGGGGr^ GCGCACGGCG
28. pTN-TS7x T7T:
Anti-sense strand sequence from C-terminus of thrC (gene stop codon in blue) to base 910. Mutation
(underlined): 944 (A to G)
ATACTAAAAA
CAATCTGCCA
AATGCCAAGA
AAAAATAGCC
ATTCATCATC
GCTCTTTTAA
AACAAGCCAT
CAAATCTATA
AATATACGAA
CAGGTC'CAAC
ATTAGACTGG
AAOTNACGCA
ACGAAAAACN
GATAAJAeCGA
ACTACA^C^IAA.
TAAAJCTCAAA
AACAACAAGC
AAATCACA'TC
TCACGCAGCG
CAAAATTTCA
AGArA^A^AA^AA
CACCA?r c^AC^
CAO:ACCACC<A
^^NCTCCACCAA
GCACCA7GAAA
GAKGGC^^IAC
TAa.GACA<AG
CfIAACAAGCCX:
TAAATNAGCA
CCAAAAACAC
AACAACTCCG
CAACTCAATC
AAATACCAAA ATTTGCAACA GAACGACTAT TTCACACCAG ANCAAATAAT CAACTAACT
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29. pTN-TS4 x TS3:
Sense strand sequence from base 712 on thrC to base 1184 . Mutation (underlined): 944 (T to C).
CATTAATGAT CATTCTCTAC GTGCCTTCAG ATTTCTTCCA CGTTTTCTAA GCCGATCTCA 7CCAGTTGTC TCTAGATATA
CCGCTGTTTA GTTTTTTTCA TGCGACCAAC ATGTTCGTTT CCCTCAATCG TTTACTGATC GTAGATATCT CATCTCAATT
AGCGACTNAG CAATCGTTTT CATTAGAGTT CGTAGTCTGT CTGACATTCT TCTCGAAACG tgtggaagag Tlgttccgcc
CATTTTTATC GCTTCTCTTT GTGTTCGATT TTCATGCCGT CGTTGTTGTT TCCTCACTTC TATCTTTACC TCTGTTTTTT
ATTCTCGGAT TATCTTCCGT CACGNTCGAT CACGTTGCTT TTAATGCGAT GAGTGTTATC TTGTTTNATG GAATTTTTAA
CTTCNTACTC CGTTCCCAGA TTNCGGAGTT TT^ TTTCGAG TCAGTGGTTG AGTTTCTNGA TCTTTCCTTC GA
30. pTN-TS8x TS4:
Anti-sense strand from base 587 to base 88. Mutation (underlined): 321-319 (deletion of T)
CAATCATTCT CCTCAAACTC AGA^CA'Ar; ATTTCAGAAG A(GTTGGATTC AGTTTCGATA ^T7A?C(A?CCAT TTATTATGTT
CTGTTTTTAT TCATGTCGTA TGATTTCCC TCAA3AGTAT AGGATAACCA CTTTATATTT 03317^002 TTGTTTGATT
GTCACTCTCA CGATACGATT T^T\CC<ACA(TC TCAGAAGCAT AA^TCCr cACT GGCTTATTAC CC(AATTTATC CATATCATTT
TCTCAATTTT TGAAAACGAA G.AAT]TTAAT ATGCAATCAG TCcCACCG'TAC TTCTTTTNAT GACATTAAGTC TTNCATTTNT
TCTTTCAAGT CCGGTGAACG G^CTTCGAT^CT GGAAAGCACA A(CTA^^TA^TKA TCGTTTTTCT G'TGG^TA'TTTrc: TTTTCATTTT
TTCCACGTGT CGTTATTNGA AC,A7GAGAiG ATATTTTTCA GCTTAGCAT CTNATNAATT rrcAG^TTTGGA TGTTTTCAGA
CTCATCATCA CATTTTTT
31. pTN-TS4 x TT:
Failed to produce a readable sequence.
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32. pTN-TSSx T7T:
Anti-sense strand sequence from C-terminus of thrC (gene stop codon in blue) to base 694. Mutation 
(underlined): 944 (A to G)
TAAC’AAATGA ATCATCAACA ATTTTCGAAA GCCAC/AGCA ^rcG«AACAA GAGAAAGCAA.. AGC(GACGGAA TGA,TCCGAAC
AATCAACCAG CTCA,1,^,1AGC AGATACCACG GTTCACCGAG ACATCGC^ArcC ACGATCTCTT TAAA\rAIAAAA CGGA^AAC(AAC
GAACCAAGAA ACAAACCATA ^ TAGGCTGAG GTCAACTCAT CACTG'3AGC<G? AC(GC^AGA:AC^ ACCCAAGAAT GCQCGCrC<CT
AAAATAACCC AAATCAA,i,i,A ACTAACGAAA GG'^CAAA^A'A Gr]CA3rAAreAT CATCCACGC T(AATCACC<X AGCTCTTrcA
AA^ACCAAAT ATAACGACAA AACCACTATTNCA<NCCXCC NAAG1CAAA^A AGGAAACGCA CATAAATCAC GGrrcGT\TAACC
GTCGCCAAAA AGGCAATAGA TGACCACTAA GCGTCGAACA <CGAGCCCCKA CAGXATAAAC:3 TGGGAC^iCA^T
AAAACATTTN ACCGACAGAC CGGGATGCTA GGCCC^CCC^CGC CCCX3CCGACA AA^ATCG.JAA GATnCO:rICr TGGGACCCACC
ACAACCAGCT AAATACACAA CTTCTAAXAN AGCTC
